{"title": "PDF", "author": "PDF", "url": "https://publikationen.sulb.uni-saarland.de/bitstream/20.500.11880/28785/1/Dissertation%20Clemens%20Ziller.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Aus \u00a0dem \u00a0Institut \u00a0f\u00fcr \u00a0Sport-\u00ad \u00a0und \u00a0Pr\u00e4ventivmedizin \u00a0Bereich \u00a0Klinische \u00a0Medizin \u00a0der \u00a0Medizinischen \u00a0Fakult\u00e4t \u00a0der \u00a0Universit\u00e4t \u00a0des \u00a0Saarlandes, \u00a0Homburg/Saar \u00a0\u00c4rztlicher \u00a0Direktor: \u00a0Univ.-\u00adProf. \u00a0Dr. \u00a0med. \u00a0T. \u00a0Meyer \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Impfen \u00a0im \u00a0Leistungssport: \u00a0Abh\u00e4ngigkeit \u00a0des \u00a0Impferfolges \u00a0und \u00a0der \u00a0Nebenwirkungsrate \u00a0vom \u00a0Impfzeitpunkt \u00a0nach \u00a0der \u00a0letzten \u00a0Trainingseinheit \u00a0 \u00a0 \u00a0Dissertation \u00a0zur \u00a0Erlangung \u00a0des \u00a0Grades \u00a0eines \u00a0Doktors \u00a0der \u00a0Medizin \u00a0der \u00a0Medizinischen \u00a0Fakult\u00e4t \u00a0 \u00a0der \u00a0UNIVERSIT\u00c4T \u00a0DES \u00a0SAARLANDES \u00a02018  \u00a0 \u00a0 \u00a0 \u00a0vorgelegt \u00a0von: \u00a0Clemens \u00a0Ziller \u00a0 \u00a0geboren \u00a0am \u00a010.11.1990 \u00a0in \u00a0Pfaffenhofen \u00a0a. \u00a0d. \u00a0Ilm \u00a0 \u00a0\t\r \u00a02\t\r \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Meinen \u00a0liebevollen \u00a0Eltern \u00a0Frau \u00a0Edith \u00a0Ziller \u00a0M.A. \u00a0und \u00a0 \u00a0Herrn \u00a0Dr. \u00a0med. \u00a0dent. \u00a0Josef \u00a0Ziller \u00a0gewidmet. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a03\t\r \u00a0Inhaltsverzeichnis\t\r \u00a0Abbildungsverzeichnis\t\r \u00a0........................................................................................................\t\r \u00a05\t\r \u00a0Tabellenverzeichnis\t\r \u00a0............................................................................................................\t\r \u00a06\t\r \u00a0Abk\u00fcrzungsverzeichnis\t\r \u00a0.......................................................................................................\t\r \u00a07\t\r \u00a01.\t\r \u00a0Zusammenfassungen\t\r \u00a0..................................................................................................\t\r \u00a08\t\r \u00a01.1.\t\r \u00a0Deutsch\t\r \u00a0...........................................................................................................................\t\r \u00a08\t\r \u00a01.2.\t\r \u00a0Englisch\t\r \u00a0.........................................................................................................................\t\r \u00a010\t\r \u00a02.\t\r \u00a0Einleitung\t\r \u00a0.................................................................................................................\t\r \u00a012\t\r \u00a02.1.\t\r \u00a0Physiologische\t\r \u00a0Grundlagen\t\r \u00a0...........................................................................................\t\r \u00a012\t\r \u00a02.1.1.\t\r \u00a0Die\t\r \u00a0\u201eopen\t\r \u00a0window\u201c-\u00ad\u2010Theorie\t\r \u00a0........................................................................................\t\r \u00a012\t\r \u00a02.1.2.\t\r \u00a0Die\t\r \u00a0\u201ej-\u00ad\u2010shaped-\u00ad\u2010curve\u201c-\u00ad\u2010Theorie\t\r \u00a0......................................................................................\t\r \u00a014\t\r \u00a02.2.\t\r \u00a0Impfungen\t\r \u00a0im\t\r \u00a0Leistungssport\t\r \u00a0........................................................................................\t\r \u00a015\t\r \u00a02.2.1.\t\r \u00a0Bestehende\t\r \u00a0Impfempfehlungen\t\r \u00a0..................................................................................\t\r \u00a015\t\r \u00a02.2.2.\t\r \u00a0Nutzen-\u00ad\u2010Risikoverh\u00e4ltnis\t\r \u00a0von\t\r \u00a0Impfungen\t\r \u00a0f\u00fcr\t\r \u00a0Athleten\t\r \u00a0.................................................\t\r \u00a016\t\r \u00a02.2.3.\t\r \u00a0Impfreaktionen\t\r \u00a0............................................................................................................\t\r \u00a017\t\r \u00a02.2.4.\t\r \u00a0Zeitpunkt\t\r \u00a0der\t\r \u00a0Impfung\t\r \u00a0................................................................................................\t\r \u00a019\t\r \u00a02.3.\t\r \u00a0Indikationen\t\r \u00a0der\t\r \u00a0jeweiligen\t\r \u00a0Impfungen\t\r \u00a0.........................................................................\t\r \u00a020\t\r \u00a02.3.1.\t\r \u00a0Spezielle\t\r \u00a0Impfindikationen\t\r \u00a0bei\t\r \u00a0Sportlern\t\r \u00a0....................................................................\t\r \u00a020\t\r \u00a02.3.2.\t\r \u00a0\u00dcberblick\t\r \u00a0\u00fcber\t\r \u00a0die\t\r \u00a0Impfempfehlungen\t\r \u00a0.......................................................................\t\r \u00a022\t\r \u00a02.4.\t\r \u00a0Besonderheiten\t\r \u00a0der\t\r \u00a0Influenzaimpfung\t\r \u00a0..........................................................................\t\r \u00a023\t\r \u00a02.4.1.\t\r \u00a0Epidemiologie\t\r \u00a0und\t\r \u00a0Klinik\t\r \u00a0der\t\r \u00a0Influenza\t\r \u00a0.......................................................................\t\r \u00a023\t\r \u00a02.4.2.\t\r \u00a0Indikationen\t\r \u00a0f\u00fcr\t\r \u00a0die\t\r \u00a0Impfung\t\r \u00a0.......................................................................................\t\r \u00a024\t\r \u00a02.4.3.\t\r \u00a0Impfstoffe\t\r \u00a0und\t\r \u00a0Applikationsverfahren\t\r \u00a0........................................................................\t\r \u00a025\t\r \u00a02.4.4.\t\r \u00a0H\u00e4ufige\t\r \u00a0Nebenwirkungen\t\r \u00a0und\t\r \u00a0Methoden\t\r \u00a0zur\t\r \u00a0Reduktion\t\r \u00a0...........................................\t\r \u00a028\t\r \u00a02.4.5.\t\r \u00a0Influenzaimpfrate\t\r \u00a0bei\t\r \u00a0Sportlern\t\r \u00a0..................................................................................\t\r \u00a030\t\r \u00a02.5.\t\r \u00a0Einfl\u00fcsse\t\r \u00a0k\u00f6rperlicher\t\r \u00a0Aktivit\u00e4t\t\r \u00a0auf\t\r \u00a0Impfungen\t\r \u00a0..............................................................\t\r \u00a031\t\r \u00a02.5.1.\t\r \u00a0Effekte\t\r \u00a0auf\t\r \u00a0den\t\r \u00a0Impferfolg\t\r \u00a0..........................................................................................\t\r \u00a031\t\r \u00a02.5.2.\t\r \u00a0Effekte\t\r \u00a0auf\t\r \u00a0das\t\r \u00a0Nebenwirkungsprofil\t\r \u00a0..........................................................................\t\r \u00a033\t\r \u00a02.6.\t\r \u00a0Studienziel\t\r \u00a0und\t\r \u00a0Hypothesen\t\r \u00a0..........................................................................................\t\r \u00a034\t\r \u00a03.\t\r \u00a0Material\t\r \u00a0und\t\r \u00a0Methoden\t\r \u00a0............................................................................................\t\r \u00a035\t\r \u00a03.1.\t\r \u00a0Studiendesign\t\r \u00a0...............................................................................................................\t\r \u00a035\t\r \u00a03.2.\t\r \u00a0Probanden\t\r \u00a0und\t\r \u00a0Probandenrekrutierung\t\r \u00a0........................................................................\t\r \u00a037\t\r \u00a03.3.\t\r \u00a0Testdurchf\u00fchrung\t\r \u00a0.........................................................................................................\t\r \u00a040\t\r \u00a03.3.1.\t\r \u00a0Standardisierung\t\r \u00a0.........................................................................................................\t\r \u00a040\t\r \u00a03.3.2.\t\r \u00a0Zeitpunkte\t\r \u00a0der\t\r \u00a0Impfungen\t\r \u00a0und\t\r \u00a0Nachkontrollen\t\r \u00a0..........................................................\t\r \u00a040\t\r \u00a03.3.3.\t\r \u00a0Probenmaterial\t\r \u00a0und\t\r \u00a0Erfassungsb\u00f6gen\t\r \u00a0........................................................................\t\r \u00a041\t\r \u00a03.3.4.\t\r \u00a0Studienablauf\t\r \u00a0..............................................................................................................\t\r \u00a043\t\r \u00a03.4.\t\r \u00a0Messmethodik\t\r \u00a0..............................................................................................................\t\r \u00a045\t\r \u00a03.4.1.\t\r \u00a0Anthropometrische\t\r \u00a0Daten\t\r \u00a0...........................................................................................\t\r \u00a045\t\r \u00a03.4.2.\t\r \u00a0Routine\t\r \u00a0Laborparameter\t\r \u00a0.............................................................................................\t\r \u00a045\t\r \u00a03.4.3.\t\r \u00a0Immunologische\t\r \u00a0laboranalytische\t\r \u00a0Methoden\t\r \u00a0.............................................................\t\r \u00a046\t\r \u00a03.5.\t\r \u00a0Statistische\t\r \u00a0Analysen\t\r \u00a0....................................................................................................\t\r \u00a051\t\r \u00a04.\t\r \u00a0Ergebnisse\t\r \u00a0................................................................................................................\t\r \u00a053\t\r \u00a04.1.\t\r \u00a0Immunologische\t\r \u00a0Auswertung\t\r \u00a0........................................................................................\t\r \u00a053\t\r \u00a04.1.1.\t\r \u00a0Blutbildver\u00e4nderungen\t\r \u00a0...............................................................................................\t\r \u00a053\t\r \u00a04.1.2.\t\r \u00a0CD4+-\u00ad\u2010T-\u00ad\u2010Zell-\u00ad\u2010Frequenzen\t\r \u00a0...............................................................................................\t\r \u00a055\t\r \u00a04.1.3.\t\r \u00a0Antik\u00f6rpertiter\t\r \u00a0............................................................................................................\t\r \u00a058\t\r \u00a04.1.4.\t\r \u00a0Neutralisationstests\t\r \u00a0....................................................................................................\t\r \u00a062\t\r \u00a0\t\r \u00a04\t\r \u00a04.2.\t\r \u00a0Nebenwirkungen\t\r \u00a0..........................................................................................................\t\r \u00a066\t\r \u00a04.2.1.\t\r \u00a0Lokale\t\r \u00a0Reaktionen\t\r \u00a0.......................................................................................................\t\r \u00a066\t\r \u00a04.2.2.\t\r \u00a0Allgemeine\t\r \u00a0Reaktionen\t\r \u00a0...............................................................................................\t\r \u00a068\t\r \u00a04.2.3.\t\r \u00a0Besonderheiten\t\r \u00a0im\t\r \u00a0Trainingsablauf\t\r \u00a0............................................................................\t\r \u00a070\t\r \u00a05.\t\r \u00a0Diskussion\t\r \u00a0.................................................................................................................\t\r \u00a072\t\r \u00a05.1.\t\r \u00a0Ergebnisbewertung\t\r \u00a0.......................................................................................................\t\r \u00a072\t\r \u00a05.1.1.\t\r \u00a0Abh\u00e4ngigkeit\t\r \u00a0des\t\r \u00a0Impferfolges\t\r \u00a0vom\t\r \u00a0Impfzeitpunkt\t\r \u00a0....................................................\t\r \u00a072\t\r \u00a05.1.2.\t\r \u00a0Abh\u00e4ngigkeit\t\r \u00a0der\t\r \u00a0Nebenwirkungen\t\r \u00a0vom\t\r \u00a0Impfzeitpunkt\t\r \u00a0.............................................\t\r \u00a075\t\r \u00a05.2.\t\r \u00a0Methodenkritik\t\r \u00a0.............................................................................................................\t\r \u00a077\t\r \u00a05.2.1.\t\r \u00a0Timing\t\r \u00a0der\t\r \u00a0Impfung\t\r \u00a0und\t\r \u00a0der\t\r \u00a0Blutentnahmen\t\r \u00a0..............................................................\t\r \u00a077\t\r \u00a05.2.2.\t\r \u00a0Einschlusskriterien\t\r \u00a0der\t\r \u00a0Probanden\t\r \u00a0und\t\r \u00a0Probandenzahlen\t\r \u00a0.........................................\t\r \u00a078\t\r \u00a05.2.3.\t\r \u00a0Verst\u00e4ndlichkeit\t\r \u00a0und\t\r \u00a0Zuverl\u00e4ssigkeit\t\r \u00a0der\t\r \u00a0Nebenwirkungserhebung\t\r \u00a0...........................\t\r \u00a079\t\r \u00a05.2.4.\t\r \u00a0Probentransport\t\r \u00a0..........................................................................................................\t\r \u00a080\t\r \u00a05.3.\t\r \u00a0Schlussfolgerung\t\r \u00a0...........................................................................................................\t\r \u00a081\t\r \u00a0Literaturverzeichnis\t\r \u00a0..........................................................................................................\t\r \u00a082\t\r \u00a0Anhang\t\r \u00a0.............................................................................................................................\t\r \u00a094\t\r \u00a0Danksagung/\t\r \u00a0Publikation\t\r \u00a0.................................................................................................\t\r \u00a099\t\r \u00a0  \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a05\t\r \u00a0Abbildungsverzeichnis \u00a0 \u00a0 \u00a0Abbildung \u00a01: \u00a0\u201eopen \u00a0window\u201c-\u00adTheorie.\t\r \u00a0................................................................................\t\r \u00a013\t\r \u00a0Abbildung \u00a02: \u00a0\u201ej-\u00adshaped-\u00adcurve\u201c-\u00adTheorie\t\r \u00a0..............................................................................\t\r \u00a014\t\r \u00a0Abbildung \u00a03: \u00a0Studienverlauf\t\r \u00a0................................................................................................\t\r \u00a044\t\r \u00a0Abbildung \u00a04: \u00a0Lymphozytenverlauf\t\r \u00a0......................................................................................\t\r \u00a054\t\r \u00a0Abbildung \u00a05: \u00a0Leukozytenverlauf\t\r \u00a0.........................................................................................\t\r \u00a054\t\r \u00a0Abbildung \u00a06: \u00a0Verlauf \u00a0der \u00a0Influenza-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten\t\r \u00a0............................\t\r \u00a056\t\r \u00a0Abbildung \u00a07: \u00a0Verlauf \u00a0der \u00a0SEB-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten\t\r \u00a0....................................\t\r \u00a057\t\r \u00a0Abbildung \u00a08: \u00a0Verlauf \u00a0des \u00a0IgG-\u00adLevels\t\r \u00a0.................................................................................\t\r \u00a059\t\r \u00a0Abbildung \u00a09: \u00a0 \u00a0Verlauf \u00a0der \u00a0IgM-\u00adRatio\t\r \u00a0...................................................................................\t\r \u00a060\t\r \u00a0Abbildung \u00a010: \u00a0Verlauf \u00a0der \u00a0IgA-\u00adRatio\t\r \u00a0..................................................................................\t\r \u00a061\t\r \u00a0Abbildung \u00a011: \u00a0Titerverlauf \u00a0des \u00a0H1N1-\u00adStammes\t\r \u00a0...............................................................\t\r \u00a063\t\r \u00a0Abbildung \u00a012: \u00a0Titerverlauf \u00a0des \u00a0H3N2-\u00adStammes\t\r \u00a0...............................................................\t\r \u00a064\t\r \u00a0Abbildung \u00a013: \u00a0Titerverlauf \u00a0des \u00a0Brisbane-\u00adStammes\t\r \u00a0.........................................................\t\r \u00a064\t\r \u00a0Abbildung \u00a014: \u00a0Titerverlauf \u00a0des \u00a0Phuket-\u00adStammes\t\r \u00a0............................................................\t\r \u00a065\t\r \u00a0Abbildung \u00a015: \u00a0Schmerzintensit\u00e4t\t\r \u00a0........................................................................................\t\r \u00a066\t\r \u00a0Abbildung \u00a016: \u00a0Gr\u00f6\u00dfe \u00a0und \u00a0Dauer \u00a0der \u00a0R\u00f6tung\t\r \u00a0....................................................................\t\r \u00a067\t\r \u00a0Abbildung \u00a017: \u00a0Gr\u00f6\u00dfe \u00a0und \u00a0Dauer \u00a0der \u00a0Schwellung\t\r \u00a0............................................................\t\r \u00a067\t\r \u00a0Abbildung \u00a018: \u00a0Maximale \u00a0Muskelschmerzintensit\u00e4t\t\r \u00a0..........................................................\t\r \u00a068\t\r \u00a0Abbildung \u00a019: \u00a0Muskelschmerzintensit\u00e4t \u00a0\u00fcber \u00a0sieben \u00a0Tage\t\r \u00a0............................................\t\r \u00a069\t\r \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a06\t\r \u00a0Tabellenverzeichnis \u00a0 \u00a0Tabelle \u00a01: \u00a0 \u00a0Impfempfehlungen\t\r \u00a0............................................................................................\t\r \u00a022\t\r \u00a0Tabelle \u00a02: \u00a0Sportart \u00a0und \u00a0Kaderstatus\t\r \u00a0..................................................................................\t\r \u00a038\t\r \u00a0Tabelle \u00a03: \u00a0Anthropometrische \u00a0Daten\t\r \u00a0.................................................................................\t\r \u00a039\t\r \u00a0Tabelle \u00a04: \u00a0T-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung\t\r \u00a0................................................................................\t\r \u00a046\t\r \u00a0Tabelle \u00a05: \u00a0B-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung\t\r \u00a0...............................................................................\t\r \u00a047\t\r \u00a0Tabelle \u00a06: \u00a01. \u00a0F\u00e4rbung \u00a0der \u00a0Stimulation\t\r \u00a0...............................................................................\t\r \u00a048\t\r \u00a0Tabelle \u00a07: \u00a02. \u00a0F\u00e4rbung \u00a0der \u00a0Stimulation\t\r \u00a0...............................................................................\t\r \u00a048\t\r \u00a0Tabelle \u00a08: \u00a0Influenza-\u00adreaktive-\u00adCD4+-\u00adT-\u00adLymphozyten\t\r \u00a0.......................................................\t\r \u00a055\t\r \u00a0Tabelle \u00a09: \u00a0IgG-\u00adLevel\t\r \u00a0.............................................................................................................\t\r \u00a058\t\r \u00a0Tabelle \u00a010: \u00a0IgM-\u00adRatio\t\r \u00a0...........................................................................................................\t\r \u00a059\t\r \u00a0Tabelle \u00a011: \u00a0IgA-\u00adRatio\t\r \u00a0...........................................................................................................\t\r \u00a061\t\r \u00a0Tabelle \u00a012: \u00a0Neutralisationstiter\t\r \u00a0...........................................................................................\t\r \u00a062\t\r \u00a0Tabelle \u00a013: \u00a0Gruppenvergleich \u00a0der \u00a0Neutralisationstiter\t\r \u00a0....................................................\t\r \u00a062\t\r \u00a0Tabelle \u00a014: \u00a0Art \u00a0anderer \u00a0Allgemeinreaktionen.\t\r \u00a0..................................................................\t\r \u00a070\t\r \u00a0Tabelle \u00a015: \u00a0Trainingsausf\u00e4lle\t\r \u00a0..............................................................................................\t\r \u00a071\t\r \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a07\t\r \u00a0Abk\u00fcrzungsverzeichnis \u00a0\n \u00a0STIKO \u00a0St\u00e4ndige \u00a0Impfkommission \u00a0des \u00a0RKI \u00a0RKI \u00a0Robert-\u00adKoch-\u00adInstitut \u00a0HAV/HBV/HCV \u00a0Hepatitis \u00a0A/B/C \u00a0Virus \u00a0HbsAG \u00a0Hepatitis \u00a0B \u00a0surface \u00a0Antigen \u00a0ZNS \u00a0Zentralnervensystem \u00a0JE \u00a0Japan-\u00adB-\u00adEnzephalitis \u00a0HPV \u00a0Humanes \u00a0Papillomavirus \u00a0BCG \u00a0Bacillus \u00a0Calmette-\u00adGu\u00e9rin \u00a0HA \u00a0H\u00e4magglutinin \u00a0NA \u00a0Neuraminidase \u00a0COPD \u00a0Chronic \u00a0obstructive \u00a0pulmonary \u00a0disease \u00a0WHO \u00a0World \u00a0Health \u00a0Organisation \u00a0CD \u00a0Cluster \u00a0of \u00a0Differentiation \u00a0OSP \u00a0Olympiast\u00fctzpunkt \u00a0EDTA \u00a0Ethylendiamintetraessigs\u00e4ue \u00a0CRP \u00a0C-\u00adreaktives \u00a0Protein \u00a0i.m. \u00a0intramuskul\u00e4r \u00a0BE \u00a0Blutentnahme \u00a0MCV \u00a0Mean \u00a0Corpuscular \u00a0Volume \u00a0GOT \u00a0Glutamat-\u00adOxalacetat-\u00adTransaminase \u00a0GPT \u00a0Glutamat-\u00adPyruvat-\u00adTransaminase \u00a0Gamma-\u00adGT \u00a0g\uf067-\u00adGlutamyltransferase \u00a0rpm \u00a0rounds \u00a0per \u00a0minute \u00a0FACS \u00a0Fluorescence-\u00adactivated \u00a0cell \u00a0sorting \u00a0PFA \u00a0Paraformaldehyd \u00a0PBS \u00a0Phosphate \u00a0buffered \u00a0saline \u00a0SEB \u00a0Staphylococcus \u00a0aureus \u00a0Enterotoxin \u00a0B \u00a0Ig \u00a0Immunglobulin \u00a0MW \u00a0Mittelwert \u00a0SD \u00a0Standardabweichung \u00a0PR\u00c4 \u00a0Messzeitpunkt \u00a0vor \u00a0der \u00a0Impfung \u00a0NSAID \u00a0Non-\u00adsteroidal \u00a0anti-\u00adinflammatory \u00a0drugs \u00a0IE/L \u00a0Internationale \u00a0Einheiten \u00a0pro \u00a0Liter \u00a0ELISA \u00a0Enzyme \u00a0linked \u00a0immunosorbent \u00a0assay \u00a0EMEM \u00a0Eagle\u00b4s \u00a0Minimum \u00a0Essential \u00a0Medium \u00a0FFU \u00a0Focus \u00a0forming \u00a0unit \u00a0MDCK \u00a0Mardin-\u00adDarby \u00a0canine \u00a0kidney \u00a0RDE \u00a0Receptor \u00a0destroying \u00a0enzyme \u00a0RE/ml \u00a0Relative \u00a0Einheiten \u00a0pro \u00a0Milliliter \u00a0\t\r \u00a08\t\r \u00a01. \u00a0Zusammenfassungen \u00a0 \u00a01.1. \u00a0Deutsch \u00a0 \u00a0\u201eImpfen \u00a0 im \u00a0 Leistungssport: \u00a0 Abh\u00e4ngigkeit \u00a0des \u00a0 Impferfolges \u00a0 und \u00a0 der \u00a0Nebenwirkungsrate \u00a0vom \u00a0Impfzeitpunkt \u00a0nach \u00a0der \u00a0letzten \u00a0Trainingseinheit\u201c \u00a0 \u00a0Ziel \u00a0dieser \u00a0Studie \u00a0war \u00a0es, \u00a0anhand \u00a0eines \u00a0ad\u00e4quaten \u00a0Leistungssportlerkollektivs \u00a0den \u00a0Einfluss \u00a0eines \u00a0vorangehenden \u00a0Trainings \u00a0auf \u00a0eine \u00a0Impfung \u00a0zu \u00a0dokumentieren. \u00a0Das \u00a0Augenmerk \u00a0 lag \u00a0 hier \u00a0 insbesondere \u00a0 auf \u00a0 der \u00a0 Induktion \u00a0der \u00a0Immunantwort \u00a0 und \u00a0inwieweit \u00a0diese \u00a0im \u00a0Rahmen \u00a0des \u00a0\u201eopen \u00a0windows\u201c \u00a0(Kakanis \u00a0et \u00a0al. \u00a02010) \u00a0reduziert \u00a0sein \u00a0k\u00f6nnte. \u00a0 Zudem \u00a0 wurde \u00a0 die \u00a0 Impfvertr\u00e4glichkeit \u00a0 charakterisiert, \u00a0 da \u00a0ein \u00a0 vermehrtes \u00a0Auftreten \u00a0vor \u00a0 allem \u00a0von \u00a0 lokalen \u00a0 Nebenwirkungen \u00a0 mit \u00a0 einer \u00a0 vorangehenden \u00a0physischen \u00a0Belastung \u00a0assoziiert \u00a0sein \u00a0kann \u00a0(Havas \u00a0et \u00a0al. \u00a01997, \u00a0Swartz \u00a0et \u00a0al. \u00a02008). \u00a0 \u00a0Hierzu \u00a0wurden \u00a0 45 \u00a0 Leistungssportler \u00a0 randomisiert \u00a0 auf \u00a0zwei \u00a0 Gruppen \u00a0 verteilt \u00a0 und \u00a0innerhalb \u00a0von \u00a0zwei \u00a0Stunden \u00a0nach \u00a0einer \u00a0Trainingseinheit \u00a0(n=24) \u00a0oder \u00a0nach \u00a0einem \u00a0Tag \u00a0Pause \u00a0(n=21) \u00a0gegen \u00a0Influenza \u00a0immunisiert. \u00a0Der \u00a0Nachweis \u00a0der \u00a0Immunantwort \u00a0erfolgte \u00a0anhand \u00a0zellul\u00e4rer \u00a0und \u00a0humoraler \u00a0Parameter, \u00a0welche \u00a0nach \u00a0einer, \u00a0zwei \u00a0und \u00a026 \u00a0 Wochen \u00a0erhoben \u00a0 wurden. \u00a0Neben \u00a0 der \u00a0 Quantifizierung \u00a0 und \u00a0 Charakterisierung \u00a0Influenza-\u00adspezifischer-\u00adCD4+-\u00adT-\u00adZellen \u00a0\u00fcber \u00a0 die \u00a0 Aktivierung \u00a0 und \u00a0 Zytokininduktion, \u00a0wurden \u00a0neutralisierende \u00a0Antik\u00f6rper \u00a0gegen \u00a0die \u00a0Impfst\u00e4mme \u00a0sowie \u00a0IgG-\u00ad, \u00a0IgM-\u00ad \u00a0und \u00a0IgA-\u00adAntik\u00f6rper \u00a0 gegen \u00a0die \u00a0Impfantigene \u00a0 bestimmt. \u00a0Nebenwirkungen \u00a0 und \u00a0Trainingseinschr\u00e4nkung \u00a0 wurden \u00a0 innerhalb \u00a0 von \u00a0 zwei \u00a0 Wochen \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0anhand \u00a0standardisierter \u00a0B\u00f6gen \u00a0erfasst. \u00a0 \u00a0 \u00a0In \u00a0dieser \u00a0Erhebung \u00a0konnte \u00a0keine \u00a0verringerte \u00a0Immunogenit\u00e4t \u00a0in \u00a0Abh\u00e4ngigkeit \u00a0von \u00a0physischer \u00a0Bet\u00e4tigung \u00a0 festgestellt \u00a0 werden. \u00a0Es \u00a0 zeigten \u00a0 sich \u00a0 f\u00fcr \u00a0 keinen \u00a0 der \u00a0Parameter \u00a0 und \u00a0 zu \u00a0 keinem \u00a0 Zeitpunkt \u00a0 statistisch \u00a0 zu \u00a0 sichernde \u00a0 Unterschiede \u00a0zwischen \u00a0beiden \u00a0Gruppen. \u00a0Die \u00a0Anstiege \u00a0der \u00a0Influenza-\u00adspezifischen-\u00adCD4+-\u00adT-\u00adZellen, \u00a0der \u00a0Neutralisationstiter, \u00a0als \u00a0auch \u00a0der \u00a0Antik\u00f6rper \u00a0waren \u00a0innerhalb \u00a0der \u00a0ersten \u00a0beiden \u00a0Wochen \u00a0nach \u00a0der \u00a0Impfung \u00a0in \u00a0beiden \u00a0Gruppen \u00a0signifikant \u00a0(p<0,01). \u00a0 \u00a0\t\r \u00a09\t\r \u00a0Sowohl \u00a0im \u00a0Hinblick \u00a0auf \u00a0die \u00a0lokalen \u00a0als \u00a0auch \u00a0auf \u00a0die \u00a0allgemeinen \u00a0Nebenwirkungen \u00a0konnten \u00a0 keine \u00a0 signifikanten \u00a0 Unterschiede \u00a0 zwischen \u00a0 beiden \u00a0 Gruppen \u00a0 festgestellt \u00a0werden. \u00a0Auch \u00a0auf \u00a0die \u00a0Einschr\u00e4nkung \u00a0der \u00a0Trainingsleistung \u00a0schien \u00a0der \u00a0Zeitpunkt \u00a0der \u00a0Impfung \u00a0keinen \u00a0Einfluss \u00a0gehabt \u00a0zu \u00a0haben. \u00a0 \u00a0Eine \u00a0 Anpassung \u00a0 des \u00a0 leistungssportlich \u00a0orientierten \u00a0 Trainings \u00a0an \u00a0 den \u00a0 Zeitpunkt \u00a0einer \u00a0Impfung \u00a0scheint \u00a0im \u00a0Hinblick \u00a0auf \u00a0diese \u00a0Studie \u00a0als \u00a0nicht \u00a0notwendig. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a010\t\r \u00a01.2. \u00a0Englisch \u00a0 \u00a0\u201eVaccination \u00a0 in \u00a0 competetive \u00a0 sport: \u00a0dependence \u00a0 of \u00a0 the \u00a0vaccination \u00a0 succes \u00a0and \u00a0the \u00a0side \u00a0effect \u00a0rate \u00a0from \u00a0the \u00a0time \u00a0of \u00a0vaccination \u00a0after \u00a0the \u00a0last \u00a0training \u00a0session \u00a0\u201c \u00a0 \u00a0The \u00a0aim \u00a0of \u00a0this \u00a0study \u00a0was \u00a0to \u00a0document \u00a0the \u00a0influence \u00a0of \u00a0a \u00a0previous \u00a0training \u00a0on \u00a0a \u00a0vaccination \u00a0by \u00a0means \u00a0of \u00a0an \u00a0adequate \u00a0competitive \u00a0sports \u00a0collective. \u00a0In \u00a0particular, \u00a0the \u00a0focus \u00a0was \u00a0on \u00a0the \u00a0induction \u00a0of \u00a0the \u00a0immune \u00a0response \u00a0and \u00a0how \u00a0much \u00a0it \u00a0could \u00a0be \u00a0reduced \u00a0in \u00a0the \u00a0context \u00a0 \u00a0of \u00a0 \u00a0\u201copen \u00a0window\u201d \u00a0(Kakanis \u00a0et \u00a0al. \u00a02010). \u00a0In \u00a0addition, \u00a0the \u00a0vaccination \u00a0 compatibility \u00a0 was \u00a0 characterized \u00a0  \u00a0 as \u00a0 an \u00a0 increased \u00a0 occurrence, \u00a0especially \u00a0of \u00a0local \u00a0side \u00a0effects, \u00a0maybe \u00a0associated \u00a0with \u00a0a \u00a0previous \u00a0physical \u00a0strain \u00a0(Havas \u00a0et \u00a0al. \u00a01997, \u00a0Swartz \u00a0et \u00a0al. \u00a02008). \u00a0 \u00a0For \u00a0 this \u00a0 purpose \u00a045 \u00a0 competitive \u00a0 athletes \u00a0 were \u00a0randomized \u00a0 into \u00a0 two \u00a0 groups \u00a0 and \u00a0immunized \u00a0against \u00a0influenza \u00a0within \u00a0two \u00a0hours \u00a0after \u00a0a \u00a0training \u00a0session \u00a0(n=24) \u00a0or \u00a0after \u00a0a \u00a0 one-\u00adday \u00a0 break \u00a0 (n=21). \u00a0 The \u00a0 detection \u00a0 of \u00a0 the \u00a0 immune \u00a0 response \u00a0 was \u00a0 based \u00a0 on \u00a0cellular \u00a0 and \u00a0 humoral \u00a0 parameters, \u00a0 which \u00a0 were \u00a0 collected \u00a0after \u00a0 one, \u00a0 two \u00a0 and \u00a0 26 \u00a0weeks. \u00a0In \u00a0addition \u00a0to \u00a0the \u00a0quantification \u00a0and \u00a0characterization \u00a0of \u00a0influenza-\u00adspecific-\u00adCD4+-\u00adT \u00a0cells \u00a0via \u00a0activation \u00a0and \u00a0cytokine \u00a0induction, \u00a0neutralizing \u00a0antibodies \u00a0against \u00a0the \u00a0vaccine \u00a0strains, \u00a0as \u00a0well \u00a0as \u00a0IgG, \u00a0IgM \u00a0and \u00a0IgA \u00a0antibodies \u00a0against \u00a0vaccine \u00a0antigens \u00a0were \u00a0determined. \u00a0Adverse \u00a0reactions \u00a0and \u00a0exercise \u00a0limitations \u00a0were \u00a0recorded \u00a0within \u00a0two \u00a0weeks \u00a0after \u00a0the \u00a0vaccination \u00a0by \u00a0means \u00a0of \u00a0standardized \u00a0arches. \u00a0 \u00a0In \u00a0this \u00a0survey, \u00a0no \u00a0reduction \u00a0in \u00a0immunogenicity \u00a0depending \u00a0on \u00a0physical \u00a0activity \u00a0could \u00a0be \u00a0found. \u00a0There \u00a0were \u00a0no \u00a0statistically \u00a0significant \u00a0differences \u00a0between \u00a0the \u00a0two \u00a0groups \u00a0for \u00a0any \u00a0of \u00a0the \u00a0parameters \u00a0and \u00a0at \u00a0any \u00a0time. \u00a0Increases \u00a0in \u00a0influenza-\u00adspecific-\u00adCD4+-\u00adT \u00a0cells, \u00a0neutralization \u00a0titer \u00a0and \u00a0antibodies \u00a0were \u00a0significant \u00a0in \u00a0both \u00a0groups \u00a0within \u00a0the \u00a0first \u00a0two \u00a0weeks \u00a0after \u00a0vaccination \u00a0(p<0.01). \u00a0There \u00a0were \u00a0no \u00a0significant \u00a0differences \u00a0between \u00a0the \u00a0two \u00a0groups \u00a0in \u00a0terms \u00a0of \u00a0both \u00a0local \u00a0and \u00a0general \u00a0adverse \u00a0effects. \u00a0Also \u00a0on \u00a0the \u00a0limitation \u00a0of \u00a0the \u00a0training \u00a0performance \u00a0the \u00a0time \u00a0of \u00a0vaccination \u00a0seemed \u00a0to \u00a0have \u00a0had \u00a0no \u00a0influence. \u00a0 \u00a0\t\r \u00a011\t\r \u00a0An \u00a0adaption \u00a0of \u00a0the \u00a0performance-\u00adoriented \u00a0training \u00a0to \u00a0the \u00a0time \u00a0of \u00a0vaccination \u00a0seems \u00a0to \u00a0be \u00a0unnecessary \u00a0in \u00a0view \u00a0of \u00a0this \u00a0study. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a012\t\r \u00a02. \u00a0Einleitung \u00a0 \u00a0Neben \u00a0der \u00a0sportlichen \u00a0Leistung \u00a0selbst \u00a0spielt \u00a0die \u00a0Gesundheit \u00a0im \u00a0Leistungssport \u00a0eine \u00a0gro\u00dfe \u00a0Rolle. \u00a0Nur \u00a0Sportler, \u00a0die \u00a0Ihre \u00a0Gesundheit \u00a0aufrechterhalten \u00a0k\u00f6nnen, \u00a0sind \u00a0in \u00a0der \u00a0Lage, \u00a0konstant \u00a0zu \u00a0trainieren \u00a0und \u00a0sich \u00a0stetig \u00a0zu \u00a0bessern. \u00a0Neben \u00a0 allgemeing\u00fcltigen \u00a0 prophylaktischen \u00a0Ma\u00dfnahmen \u00a0wie \u00a0 Hygiene, \u00a0sportgerechtem \u00a0Lebensstil \u00a0(ausreichend \u00a0Schlaf, \u00a0ausgewogene \u00a0Ern\u00e4hrung) \u00a0und \u00a0der \u00a0Expositionsprophylaxe \u00a0 sind \u00a0 Impfungen \u00a0 bei \u00a0 der \u00a0Vermeidung \u00a0 von \u00a0Infektionskrankheiten \u00a0relevant \u00a0(Gabriel \u00a02004). \u00a0Hierbei \u00a0sollte \u00a0bedacht \u00a0werden, \u00a0dass \u00a0nicht \u00a0nur \u00a0Sportler \u00a0selbst \u00a0immunisiert \u00a0werden, \u00a0sondern \u00a0 im \u00a0 Optimalfall \u00a0 auch \u00a0 Familienmitglieder, \u00a0 Trainer \u00a0 und \u00a0 Betreuer, \u00a0um \u00a0 eine \u00a0bestm\u00f6gliche \u00a0Herdenimmunit\u00e4t \u00a0zu \u00a0erreichen \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0Nur \u00a0wenn \u00a0hierf\u00fcr \u00a0Verst\u00e4ndnis \u00a0vorliegt \u00a0und \u00a0die \u00a0Unsicherheiten \u00a0in \u00a0Bezug \u00a0zum \u00a0Thema \u00a0impfen \u00a0 beseitigt \u00a0 werden, \u00a0 lassen \u00a0 sich \u00a0 solche \u00a0 Vorhaben \u00a0 auch \u00a0 in \u00a0die \u00a0Realit\u00e4t \u00a0umsetzen. \u00a0 \u00a02.1. \u00a0Physiologische \u00a0Grundlagen \u00a0 \u00a0 \u00a02.1.1. \u00a0Die \u00a0\u201eopen \u00a0window\u201c-\u00adTheorie \u00a0 \u00a0Die \u00a0 \u201eopen \u00a0 window\u201c-\u00adTheorie \u00a0 geht \u00a0 davon \u00a0 aus, \u00a0 dass \u00a0 es \u00a0 ein \u00a0 Zeitfenster \u00a0 nach \u00a0sportlicher \u00a0 Aktivit\u00e4t \u00a0 gibt, \u00a0 in \u00a0 welchem \u00a0 es \u00a0 zu \u00a0 einer \u00a0 kurzfristigen \u00a0und \u00a0vor\u00fcbergehenden \u00a0 Abschw\u00e4chung \u00a0der \u00a0 Immunfunktion \u00a0 kommt. \u00a0 In \u00a0 diesem \u00a0Zeitraum \u00a0 lassen \u00a0 die \u00a0 Immunparameter \u00a0 erh\u00f6hte \u00a0Infektraten, \u00a0 insbesondere \u00a0 der \u00a0oberen \u00a0Atemwege, \u00a0vermuten \u00a0(Gabriel&Kindermann \u00a01997, \u00a0Kakanis \u00a0et \u00a0al. \u00a02010). \u00a0 \u00a0Physiologisch \u00a0 l\u00e4sst \u00a0 sich \u00a0 dies \u00a0 in \u00a0 eine \u00a0 Sofortreaktion \u00a0 und \u00a0 eine \u00a0 verz\u00f6gerte \u00a0Reaktion \u00a0einteilen. \u00a0Die \u00a0Sofortreaktion \u00a0setzt \u00a0bereits \u00a0wenige \u00a0Minuten \u00a0nach \u00a0dem \u00a0Beginn \u00a0einer \u00a0Belastung \u00a0ein. \u00a0Nach \u00a0dem \u00a0Anstieg \u00a0der \u00a0Neutrophilen, \u00a0Lymphozyten \u00a0und \u00a0nat\u00fcrlichen \u00a0Killerzellen \u00a0fallen \u00a0diese \u00a0nach \u00a0Belastungsende \u00a0rasch \u00a0wieder \u00a0ab. \u00a0Nat\u00fcrliche \u00a0Killerzellen \u00a0und \u00a0Lymphozyten \u00a0erreichen \u00a0meist \u00a0innerhalb \u00a030 \u00a0Minuten \u00a0wieder \u00a0 ihre \u00a0 Ausgangswerte. \u00a0Im \u00a0 Rahmen \u00a0 der \u00a0 verz\u00f6gerten \u00a0 Immunreaktion \u00a0werden \u00a0innerhalb \u00a0von \u00a0vier \u00a0bis \u00a0acht \u00a0Stunden \u00a0nach \u00a0Belastungsende \u00a0erniedrigte \u00a0\t\r \u00a013\t\r \u00a0Zellkonzentrationen \u00a0 an \u00a0 nat\u00fcrlichen \u00a0 Killerzellen \u00a0 und \u00a0 Lymphozyten \u00a0 gemessen, \u00a0wohingegen \u00a0 die \u00a0 Leukozytose \u00a0 in \u00a0 diesem \u00a0 Zeitraum \u00a0 durch \u00a0 einen \u00a0 Anstieg \u00a0 der \u00a0Neutrophilen \u00a0 bedingt \u00a0 ist. \u00a0 Ursache \u00a0 dieser \u00a0 Neutrophilie \u00a0 ist \u00a0 die \u00a0 stressbedingte \u00a0Cortisolaussch\u00fcttung \u00a0(Gabriel&Kindermann \u00a01997, \u00a0Scharhag \u00a0et \u00a0al. \u00a02002). \u00a0Vor \u00a0allem \u00a0die \u00a0Zahl \u00a0der \u00a0nat\u00fcrlichen \u00a0Killerzellen \u00a0scheint \u00a0hier \u00a0deutlich \u00a0herabgesetzt \u00a0und \u00a0 niedriger \u00a0 als \u00a0 der \u00a0 Vorbelastungswert \u00a0 zu \u00a0 sein, \u00a0 aber \u00a0 auch \u00a0 eine \u00a0 verringerte \u00a0Funktion \u00a0neutrophiler \u00a0Granulozyten \u00a0wurde \u00a0festgestellt \u00a0(Pedersen&Ullum \u00a01994, \u00a0Niemann \u00a02007, \u00a0Kakanis \u00a0et \u00a0al. \u00a02010) \u00a0Der \u00a0Zeitraum, \u00a0in \u00a0dem \u00a0sich \u00a0Bakterien \u00a0und \u00a0Viren \u00a0 leichter \u00a0 im \u00a0 K\u00f6rper \u00a0 ausbreiten \u00a0 k\u00f6nnen, \u00a0 betr\u00e4gt \u00a0 abh\u00e4ngig \u00a0 von \u00a0 den \u00a0Messwerten \u00a0zirka \u00a0zwischen \u00a0drei \u00a0und \u00a072 \u00a0Stunden \u00a0(Niemann&Pedersen \u00a01999). \u00a0In \u00a0diesem \u00a0Kontext \u00a0werden \u00a0zahlreiche \u00a0Mechanismen \u00a0diskutiert, \u00a0die \u00a0hierbei \u00a0eine \u00a0Rolle \u00a0spielen. \u00a0Unter \u00a0anderem \u00a0scheinen \u00a0Stress-\u00adHormone, \u00a0Zytokine, \u00a0der \u00a0Wechsel \u00a0der \u00a0 K\u00f6rpertemperatur \u00a0 als \u00a0 auch \u00a0 Dehydratation \u00a0 einen \u00a0 Einfluss \u00a0 auf \u00a0 die \u00a0Immunfunktion \u00a0zu \u00a0nehmen \u00a0(Niemann \u00a02007). \u00a0 \u00a0Inwieweit \u00a0 auf \u00a0 Einzelzellebene \u00a0 tats\u00e4chlich \u00a0 eine \u00a0 Funktionsbeeintr\u00e4chtigung \u00a0vorliegt \u00a0ist \u00a0nicht \u00a0abschlie\u00dfend \u00a0gekl\u00e4rt \u00a0(Gabriel&Kindermann \u00a01997) \u00a0und \u00a0auch \u00a0ein \u00a0experimenteller \u00a0Nachweis \u00a0einer \u00a0erh\u00f6hten \u00a0Akquisition \u00a0von \u00a0Infekten \u00a0w\u00e4hrend \u00a0des \u00a0\u201eopen \u00a0windows\u201c \u00a0ist \u00a0noch \u00a0f\u00e4llig. \u00a0 \u00a0 \u00a0 \u00a0\n \u00a0Abbildung \u00a01: \u00a0Modellhafte \u00a0 Darstellung \u00a0 des \u00a0 \u201eopen \u00a0 window\u201c. \u00a0 Biphasige \u00a0belastungsinduzierte \u00a0 Leukozytose \u00a0 mit \u00a0 anschlie\u00dfender \u00a0 Lymphozytopenie \u00a0 und \u00a0Neutrophilie \u00a0(gestrichelte \u00a0Linie) \u00a0(aus \u00a0Gabiel \u00a02004). \u00a0\n\t\r \u00a014\t\r \u00a02.1.2. \u00a0Die \u00a0\u201ej-\u00adshaped-\u00adcurve\u201c-\u00adTheorie \u00a0 \u00a0Die \u00a0 Unterschiede \u00a0 der \u00a0 langfristigen \u00a0 Infektanf\u00e4lligkeit \u00a0 versucht \u00a0 die \u00a0 \u201ej-\u00adshaped-\u00adcurve\u201c \u00a0zu \u00a0beschreiben \u00a0(Niemann \u00a0et \u00a0al. \u00a01990). \u00a0Hierbei \u00a0ergaben \u00a0epidemiologische \u00a0Studien, \u00a0dass \u00a0Leistungssportler \u00a0scheinbar \u00a0die \u00a0h\u00f6chste \u00a0Anf\u00e4lligkeit \u00a0gegen\u00fcber \u00a0Infektionen \u00a0der \u00a0oberen \u00a0Atemwege \u00a0haben \u00a0(Niemann \u00a01994, \u00a0Baum&Liesen \u00a01997). \u00a0Niedriger \u00a0ist \u00a0sie \u00a0bei \u00a0Personen, \u00a0die \u00a0keinen \u00a0Sport \u00a0betreiben \u00a0und \u00a0am \u00a0niedrigsten \u00a0bei \u00a0all \u00a0denen, \u00a0die \u00a0sich \u00a0m\u00e4\u00dfig \u00a0sportlich \u00a0bet\u00e4tigen \u00a0(Niemann \u00a0et \u00a0al. \u00a01990, \u00a0Niemann \u00a01994). \u00a0 Es \u00a0 stellt \u00a0 sich \u00a0 also \u00a0 so \u00a0 dar, \u00a0 als \u00a0 g\u00e4be \u00a0 es \u00a0 eine \u00a0 Minderfunktion \u00a0 des \u00a0Immunsystems \u00a0 bei \u00a0 Athleten. \u00a0 Die \u00a0 Ursache \u00a0 hierf\u00fcr \u00a0 k\u00f6nnte \u00a0 in \u00a0 dem \u00a0 h\u00e4ufigen \u00a0Aus\u00fcben \u00a0 eines \u00a0 sehr \u00a0 anspruchsvollen \u00a0 k\u00f6rperlichen \u00a0 Trainings \u00a0 mit \u00a0 der \u00a0darauffolgenden \u00a0 supprimierten \u00a0 Funktion \u00a0 der \u00a0 NK-\u00adZellen \u00a0 liegen, \u00a0 wohingegen \u00a0moderate \u00a0 regelm\u00e4\u00dfige \u00a0 sportliche \u00a0 Bet\u00e4tigung \u00a0 einen \u00a0 stimulierenden \u00a0 Effekt \u00a0 auf \u00a0das \u00a0 Immunsystem \u00a0 zu \u00a0 haben \u00a0 scheint \u00a0 (Niemann \u00a0 et \u00a0 al. \u00a0 1990, \u00a0 Pedersen&Ullum \u00a01994). \u00a0 \u00a0 \u00a0 \u00a0\n \u00a0Abbildung \u00a02: \u00a0 Graphische \u00a0 Darstellung \u00a0 der \u00a0 \u201ej-\u00adshaped-\u00adcurve\u201c \u00a0modifiziert \u00a0 nach \u00a0Niemann \u00a01994 \u00a0(aus \u00a0Gabriel \u00a02004). \u00a0 \u00a0    \n\t\r \u00a015\t\r \u00a02.2. \u00a0Impfungen \u00a0im \u00a0Leistungssport \u00a0 \u00a02.2.1. \u00a0Bestehende \u00a0Impfempfehlungen \u00a0 \u00a0In \u00a0 der \u00a0 Regel \u00a0 werden \u00a0 die \u00a0 Empfehlungen \u00a0 der \u00a0\u201eSt\u00e4ndigen \u00a0 Impfkommission \u00a0 am \u00a0Robert-\u00adKoch-\u00adInstitut \u00a0 \u201c \u00a0 (STIKO) \u00a0 als \u00a0 Grundlage \u00a0 f\u00fcr \u00a0 die \u00a0 Impfempfehlungen \u00a0verwendet. \u00a0Diese \u00a0gelten \u00a0jedoch \u00a0f\u00fcr \u00a0die \u00a0Allgemeinbev\u00f6lkerung \u00a0und \u00a0haben \u00a0unter \u00a0anderem \u00a0auch \u00a0 \u00f6konomische \u00a0 Interessen \u00a0 im \u00a0 Blick. \u00a0 Es \u00a0 ist \u00a0 also \u00a0 m\u00f6glich, \u00a0 dass \u00a0Impfungen, \u00a0die \u00a0 durchaus \u00a0 sinnvoll \u00a0 f\u00fcr \u00a0 ein \u00a0 Individuum \u00a0 sein \u00a0 k\u00f6nnten, \u00a0 von \u00a0 der \u00a0STIKO \u00a0 nicht \u00a0 empfohlen \u00a0 werden, \u00a0 da \u00a0 der \u00a0 Nutzen \u00a0 auf \u00a0 die \u00a0 Gesamtgesellschaft \u00a0bezogen \u00a0 in \u00a0 keinem \u00a0 Verh\u00e4ltnis \u00a0 zu \u00a0 der \u00a0 finanziellen \u00a0 Belastung \u00a0f\u00fcr \u00a0 das \u00a0Gesundheitswesen \u00a0steht. \u00a0Bei \u00a0der \u00a0Frage, \u00a0ob \u00a0und \u00a0wie \u00a0ein \u00a0Sportler \u00a0geimpft \u00a0werden \u00a0sollte, \u00a0sollten \u00a0diese \u00a0Interessen \u00a0nicht \u00a0im \u00a0Vordergrund \u00a0stehen \u00a0(Black \u00a02013). \u00a0 \u00a0Einerseits \u00a0die \u00a0 intensive \u00a0 k\u00f6rperliche \u00a0 Belastung, \u00a0 die \u00a0 m\u00f6glicherweise \u00a0Auswirkungen \u00a0auf \u00a0die \u00a0Immunfunktion \u00a0hat, \u00a0andererseits \u00a0der \u00a0Alltag \u00a0der \u00a0Sportler \u00a0selbst, \u00a0 zu \u00a0welchem \u00a0h\u00e4ufiges \u00a0 Reisen \u00a0 ins \u00a0 Ausland \u00a0 und \u00a0 enger \u00a0 Kontakt \u00a0 mit \u00a0Mannschaftskollegen \u00a0 oder \u00a0 Gegnern \u00a0geh\u00f6rt, \u00a0 schr\u00e4nken \u00a0 die \u00a0 Anwendbarkeit \u00a0universeller \u00a0Impfpl\u00e4ne \u00a0ein. \u00a0In \u00a0diesem \u00a0Zusammenhang \u00a0besitzen \u00a0manche \u00a0Richtlinien, \u00a0wie \u00a0die \u00a0STIKO, \u00a0eine \u00a0\u201e\u00d6ffnungsklausel\u201c, \u00a0 bei \u00a0 der \u00a0 neben \u00a0 den \u00a0 empfohlenen \u00a0 Impfungen \u00a0 zus\u00e4tzliche \u00a0Indikationen \u00a0zur \u00a0Impfung \u00a0gegeben \u00a0sind \u00a0(Schmolz \u00a0et \u00a0al. \u00a02016). \u00a0Unter \u00a0 den \u00a0 Mannschafts\u00e4rzten \u00a0 und \u00a0 Sportmedizinern \u00a0 selbst \u00a0 herrscht \u00a0ebenfalls \u00a0eine \u00a0gewisse \u00a0Unsicherheit \u00a0bez\u00fcglich \u00a0der \u00a0Impfschemata \u00a0f\u00fcr \u00a0die \u00a0Athleten. \u00a0 \u00a0Forciert \u00a0 wird \u00a0 diese \u00a0 durch \u00a0anekdotische \u00a0 Berichte \u00a0 \u00fcber \u00a0 eine \u00a0 eingeschr\u00e4nkte \u00a0Immunreaktion \u00a0 nach \u00a0 sportlicher \u00a0 Bet\u00e4tigung \u00a0 sowie \u00a0 die \u00a0 Vermutung, \u00a0 dass \u00a0Impfnebenwirkungen \u00a0 im \u00a0 Zusammenhang \u00a0 mit \u00a0 physischer \u00a0 Belastung \u00a0 st\u00e4rker \u00a0ausfallen \u00a0k\u00f6nnten. \u00a0Dies \u00a0 alles \u00a0 beeinflusst \u00a0 die \u00a0 Entscheidung, \u00a0ob \u00a0 und \u00a0 zu \u00a0 welchem \u00a0 Zeitpunkt \u00a0Impfungen \u00a0durchgef\u00fchrt \u00a0 werden \u00a0 sollten \u00a0und \u00a0 zeigt \u00a0 die \u00a0 Notwendigkeit \u00a0 einer \u00a0Anpassung \u00a0der \u00a0empfohlenen \u00a0Impfpl\u00e4ne \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0 \u00a0Es \u00a0 mangelt \u00a0 weiterhin \u00a0an \u00a0Forschung \u00a0 im \u00a0 Bereich \u00a0 der \u00a0 Impfpraktiken \u00a0 bei \u00a0professionellen \u00a0 Sportlern. \u00a0 Dabei \u00a0 sollte \u00a0 man \u00a0 bedenken, \u00a0 dass \u00a0 man \u00a0 mit \u00a0 korrekt \u00a0durchgef\u00fchrten \u00a0 Impfungen \u00a0 ein \u00a0 starkes \u00a0 und \u00a0 langwirksames \u00a0 Mittel \u00a0 hat \u00a0 um \u00a0Krankheiten \u00a0 zu \u00a0 vermeiden. \u00a0 Durch \u00a0 eine \u00a0 geringere \u00a0 Zahl \u00a0 krankheitsbedingter \u00a0\t\r \u00a016\t\r \u00a0Ausf\u00e4lle \u00a0k\u00f6nnen \u00a0sportliche \u00a0Leistungen \u00a0gesteigert \u00a0werden \u00a0und \u00a0zudem \u00a0geht \u00a0man \u00a0mit \u00a0 positivem \u00a0 Beispiel \u00a0 f\u00fcr \u00a0 die \u00a0 gesamte \u00a0 Bev\u00f6lkerung \u00a0 voran \u00a0(Signorelli \u00a0 et \u00a0 al. \u00a02016). \u00a0Dies \u00a0ist \u00a0gerade \u00a0in \u00a0einer \u00a0Zeit \u00a0relevant \u00a0in \u00a0der \u00a0das \u00a0Vertrauen \u00a0in \u00a0Impfungen \u00a0und \u00a0die \u00a0Impfbereitschaft \u00a0immer \u00a0weiter \u00a0sinken \u00a0(Kata \u00a02010, \u00a0Odone \u00a0et \u00a0al. \u00a02015). \u00a0 \u00a0 \u00a02.2.2. \u00a0Nutzen-\u00adRisikoverh\u00e4ltnis \u00a0von \u00a0Impfungen \u00a0f\u00fcr \u00a0Athleten \u00a0 \u00a0Sportler, \u00a0 die \u00a0 intensive \u00a0 Trainingseinheiten \u00a0 absolvieren, \u00a0k\u00f6nnten \u00a0 wohl \u00a0ein \u00a0h\u00f6heres \u00a0Erkrankungsrisiko \u00a0als \u00a0vergleichbare \u00a0Personen \u00a0haben, \u00a0die \u00a0nur \u00a0moderat \u00a0oder \u00a0 gar \u00a0 keinen \u00a0 Sport \u00a0 betreiben \u00a0 (Pyne&Gleeson \u00a0 1998). \u00a0 Nichtsdestotrotz \u00a0werden \u00a0 sie \u00a0 in \u00a0 den \u00a0 STIKO \u00a0 Empfehlungen \u00a0 nicht \u00a0 als \u00a0 gesonderte \u00a0 Risikogruppe \u00a0gef\u00fchrt. \u00a0Zudem \u00a0ist \u00a0zu \u00a0bedenken, \u00a0dass \u00a0bereits \u00a0milde \u00a0Erkrankungen \u00a0bei \u00a0Athleten \u00a0deutlich \u00a0gr\u00f6\u00dfere \u00a0Auswirkungen \u00a0haben \u00a0k\u00f6nnen \u00a0als \u00a0in \u00a0der \u00a0Normalbev\u00f6lkerung. \u00a0Diese \u00a0scheinbar \u00a0trivialen \u00a0Infektionen \u00a0k\u00f6nnen \u00a0dazu \u00a0f\u00fchren, \u00a0dass \u00a0sich \u00a0ein \u00a0Sportler \u00a0in \u00a0 seinem \u00a0 Wohlbefinden \u00a0 oder \u00a0 dem \u00a0 Gef\u00fchl \u00a0 perfekt \u00a0 vorbreitet \u00a0 zu \u00a0 sein \u00a0beeintr\u00e4chtigt \u00a0 f\u00fchlt \u00a0oder \u00a0 es \u00a0 krankheitsbedingt \u00a0 sogar \u00a0 zu \u00a0 Wettkampf-\u00ad \u00a0und \u00a0Trainingsausf\u00e4llen \u00a0kommt. \u00a0Auch \u00a0Trainer \u00a0neigen \u00a0dazu, \u00a0Sportler, \u00a0die \u00a0sie \u00a0aufgrund \u00a0einer \u00a0 trivialen \u00a0 Infektion \u00a0 als \u00a0 krank \u00a0 einsch\u00e4tzen, \u00a0nicht \u00a0in \u00a0 Wettk\u00e4mpfen \u00a0einzusetzen. \u00a0Neben \u00a0den \u00a0teilweise \u00a0langandauernden \u00a0Krankheitsperioden \u00a0kann \u00a0auch \u00a0die \u00a0Rekonvaleszenz \u00a0nach \u00a0einer \u00a0Krankheit \u00a0zu \u00a0einer \u00a0reduzierten \u00a0Leistung \u00a0oder \u00a0sogar \u00a0weiteren \u00a0Ausf\u00e4llen \u00a0f\u00fchren \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0Ein \u00a0weiteres \u00a0Problem \u00a0ist, \u00a0dass \u00a0bei \u00a0einer \u00a0fehlenden \u00a0\u201eHerdenimmunit\u00e4t\u201c \u00a0innerhalb \u00a0einer \u00a0Mannschaft \u00a0 oder \u00a0 Trainingsgruppe \u00a0bereits \u00a0 besiegt \u00a0 geglaubte \u00a0Erkrankungen \u00a0jederzeit \u00a0wieder \u00a0auftreten \u00a0k\u00f6nnen \u00a0(Furian&G\u00e4rtner \u00a02014). \u00a0Auch \u00a0scheint \u00a0die \u00a0Rate \u00a0an \u00a0schweren \u00a0Komplikationen, \u00a0die \u00a0durch \u00a0Krankheiten \u00a0mit \u00a0eigentlich \u00a0 mildem \u00a0Verlauf \u00a0 ausgel\u00f6st \u00a0 werden \u00a0k\u00f6nnen, \u00a0bei \u00a0 Sportlern \u00a0erh\u00f6ht \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0Ein \u00a0Beispiel \u00a0hierf\u00fcr \u00a0w\u00e4re \u00a0die \u00a0Myokarditis. \u00a0Obwohl \u00a0dies \u00a0haupts\u00e4chlich \u00a0in \u00a0Tierversuchen \u00a0nachgewiesen \u00a0wurde, \u00a0scheint \u00a0es \u00a0auch \u00a0auf \u00a0den \u00a0Menschen \u00a0 \u00fcbertragbar \u00a0 zu \u00a0 sein. \u00a0 Es \u00a0 zeigte \u00a0 sich, \u00a0 dass \u00a0 nach \u00a0 k\u00f6rperlicher \u00a0Belastung \u00a0die \u00a0Schwere \u00a0der \u00a0akuten \u00a0Phase \u00a0inklusive \u00a0Virusreplikation, \u00a0Nekrose \u00a0und \u00a0Letalit\u00e4t \u00a0gesteigert \u00a0waren \u00a0(Gatmaitan \u00a0et \u00a0al. \u00a01970, \u00a0Illb\u00e4ck \u00a0et \u00a0al. \u00a01989). \u00a0Ein \u00a0weiterer \u00a0Aspekt \u00a0in \u00a0dem \u00a0sich \u00a0die \u00a0Athleten \u00a0von \u00a0Nicht-\u00adSportlern \u00a0unterscheiden \u00a0ist \u00a0 das \u00a0 Erregerspektrum. \u00a0 Aufgrund \u00a0 der \u00a0 Tatsache, \u00a0 dass \u00a0 im \u00a0 Rahmen \u00a0 von \u00a0\t\r \u00a017\t\r \u00a0Wettk\u00e4mpfen \u00a0 h\u00e4ufig \u00a0 Reisen \u00a0 ins \u00a0 Ausland \u00a0 unternommen \u00a0 werden, \u00a0 sind \u00a0 die \u00a0Sportler \u00a0 zus\u00e4tzlich \u00a0 Erregern \u00a0 ausgesetzt, \u00a0 die \u00a0in \u00a0 ihrem \u00a0 Heimatland \u00a0 nicht \u00a0endemisch \u00a0 sind. \u00a0 Auch \u00a0 der \u00a0 Kontakt \u00a0 zu \u00a0 fremden \u00a0 Sportlern \u00a0 und \u00a0 deren \u00a0Keimspektrum \u00a0 stellt \u00a0 eine \u00a0 Herausforderung \u00a0 an \u00a0 das \u00a0 Immunsystem \u00a0 dar. \u00a0 Der \u00a0Kontakt \u00a0gilt \u00a0vor \u00a0allem \u00a0dann \u00a0als \u00a0riskant, \u00a0wenn \u00a0der \u00a0Abstand \u00a0von \u00a0einer \u00a0Armesl\u00e4nge \u00a0unterschritten \u00a0 wird. \u00a0 (G\u00e4rtner&Meyer \u00a0 2014). \u00a0Hierbei \u00a0 spielen \u00a0 vor \u00a0 allem \u00a0Atemwegsinfektionen \u00a0eine \u00a0gro\u00dfe \u00a0Rolle, \u00a0w\u00e4hrend \u00a0f\u00fcr \u00a0durch \u00a0Blut \u00a0\u00fcbertragbare \u00a0Krankheiten \u00a0ein \u00a0deutlich \u00a0geringeres \u00a0Risiko \u00a0vorzuliegen \u00a0scheint \u00a0(Kordi&Wallace \u00a02004). \u00a0Zu \u00a0guter \u00a0Letzt \u00a0sollten \u00a0auch \u00a0die \u00a0Inkubationszeiten \u00a0nicht \u00a0aus \u00a0den \u00a0Augen \u00a0verloren \u00a0werden. \u00a0Sportler, \u00a0die \u00a0Kontakt \u00a0zu \u00a0Infizierten \u00a0hatten, \u00a0k\u00f6nnen \u00a0den \u00a0Erreger \u00a0schon \u00a0\u00fcbertragen, \u00a0obwohl \u00a0sie \u00a0klinisch \u00a0gesund \u00a0sind. \u00a0In \u00a0Anbetracht \u00a0dieser \u00a0Tatsache \u00a0ist \u00a0auch \u00a0ein \u00a0Ausschluss \u00a0aus \u00a0dem \u00a0Training \u00a0oder \u00a0dem \u00a0Wettkampf \u00a0denkbar, \u00a0wenn \u00a0die \u00a0Gefahr \u00a0einer \u00a0\u00dcbertragung \u00a0besteht. \u00a0 \u00a0 \u00a02.2.3. \u00a0Impfreaktionen \u00a0 \u00a0Nebenwirkungen \u00a0sind \u00a0bei \u00a0 Leistungssportlern \u00a0 von \u00a0deutlich \u00a0 gr\u00f6\u00dferer \u00a0 Relevanz \u00a0als \u00a0f\u00fcr \u00a0die \u00a0Grundgesamtheit \u00a0der \u00a0Menschen. \u00a0Aufgrund \u00a0 der \u00a0 aktuellen \u00a0 Datenlage \u00a0 l\u00e4sst \u00a0 sich \u00a0 feststellen, \u00a0 dass \u00a0 hierbei \u00a0gr\u00f6\u00dftenteils \u00a0 nur \u00a0 Impfreaktionen \u00a0 beachtet \u00a0 werden \u00a0 m\u00fcssen, \u00a0 die \u00a0 kurz \u00a0 nach \u00a0 der \u00a0Vakzination \u00a0auftreten \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0Hierzu \u00a0z\u00e4hlen \u00a0lokale \u00a0Reaktionen, \u00a0also \u00a0solche \u00a0die \u00a0geh\u00e4uft \u00a0innerhalb \u00a0von \u00a0sechs \u00a0bis \u00a072 \u00a0Stunden \u00a0nach \u00a0der \u00a0Impfung \u00a0auftreten \u00a0(Vilella \u00a0et \u00a0al. \u00a02000). \u00a0Abh\u00e4ngig \u00a0vom \u00a0Applikationsweg \u00a0k\u00f6nnen \u00a0dies \u00a0nach \u00a0intranasaler \u00a0Anwendung \u00a0eine \u00a0laufende \u00a0Nase \u00a0oder \u00a0ein \u00a0rauer \u00a0Hals \u00a0sein. \u00a0Nach \u00a0intradermaler \u00a0Applikation \u00a0treten \u00a0vor \u00a0allem \u00a0Juckreiz, \u00a0Angio\u00f6deme, \u00a0Erytheme \u00a0und \u00a0Schwellungen \u00a0 auf. \u00a0Diese \u00a0meist \u00a0 unmittelbar \u00a0nach \u00a0 der \u00a0 Impfung \u00a0 auftretenden \u00a0Reaktionen \u00a0sind \u00a0IgE-\u00advermittelt \u00a0und \u00a0bergen, \u00a0bei \u00a0einer \u00a0erneuten \u00a0Gabe \u00a0desselben \u00a0Impfstoffes, \u00a0die \u00a0Gefahr \u00a0schwerer \u00a0anaphylaktischer \u00a0Reaktionen \u00a0(Wood \u00a02013). \u00a0Juckende \u00a0 subkutane \u00a0 Granulome \u00a0 hingegen \u00a0 sind \u00a0 vor \u00a0 allem \u00a0 mit \u00a0aluminiumgebundenen \u00a0Impfstoffen \u00a0assoziiert \u00a0(Lidholm \u00a0et \u00a0al. \u00a02013). \u00a0Verz\u00f6gerte \u00a0Reaktionen \u00a0hingegen \u00a0k\u00f6nnen \u00a0Stunden \u00a0bis \u00a0Tage \u00a0nach \u00a0der \u00a0Impfung \u00a0auftreten \u00a0 und \u00a0entsprechen \u00a0Hypersensitivit\u00e4tsreaktionen \u00a0 auf \u00a0 den \u00a0 Wirkstoff. \u00a0\t\r \u00a018\t\r \u00a0Diese \u00a0 umfassen \u00a0 Fieber, \u00a0 M\u00fcdigkeit, \u00a0 Kopfschmerz \u00a0 und \u00a0Lymphknotenschwellungen \u00a0 (Wood \u00a0 2013). \u00a0Diese \u00a0 Allgemeinreaktionen \u00a0 sind \u00a0sowohl \u00a0f\u00fcr \u00a0Sportler \u00a0als \u00a0auch \u00a0f\u00fcr \u00a0Nicht-\u00adSportler \u00a0von \u00a0Relevanz. \u00a0Zu \u00a0 guter \u00a0 Letzt \u00a0 k\u00f6nnen \u00a0 auch \u00a0 Impfstoff-\u00adspezifische \u00a0 Reaktionen \u00a0 auftreten. \u00a0 Dies \u00a0beruht \u00a0auf \u00a0der \u00a0Tatsache, \u00a0dass \u00a0sich \u00a0die \u00a0abgeschw\u00e4chten \u00a0Viren \u00a0und \u00a0Bakterien \u00a0im \u00a0K\u00f6rper \u00a0vermehren \u00a0und \u00a0somit \u00a0Symptome \u00a0verursachen \u00a0k\u00f6nnen, \u00a0die \u00a0denen \u00a0der \u00a0Krankheit \u00a0\u00e4hneln, \u00a0vor \u00a0der \u00a0die \u00a0Impfung \u00a0sch\u00fctzen \u00a0soll \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0Sollte \u00a0 es \u00a0 zu \u00a0 Nebenwirkungen \u00a0 kommen, \u00a0 so \u00a0 ist \u00a0 im \u00a0 Falle \u00a0 von \u00a0 leichten \u00a0Impfreaktionen \u00a0keine \u00a0Sportpause \u00a0n\u00f6tig. \u00a0Bei \u00a0schweren \u00a0Impfreaktionen \u00a0oder \u00a0bei \u00a0Verschlechterung \u00a0der \u00a0Symptomatik \u00a0hingegen \u00a0ist \u00a0sowohl \u00a0eine \u00a0symptomatische \u00a0Therapie \u00a0als \u00a0auch \u00a0eine \u00a0vor\u00fcbergehende \u00a0Einstellung \u00a0der \u00a0k\u00f6rperlichen \u00a0Aktivit\u00e4t \u00a0indiziert \u00a0 (Furian&G\u00e4rtner \u00a0 2014). \u00a0 Bei \u00a0 Nichtbeachtung \u00a0 kann \u00a0 dies \u00a0 neben \u00a0 einer \u00a0Mitbeteiligung \u00a0 innerer \u00a0 Organe \u00a0 (v.a. \u00a0 des \u00a0 Herzens) \u00a0 zu \u00a0 einem \u00a0\u00dcbertrainingssyndrom \u00a0 f\u00fchren, \u00a0 aus \u00a0 welchem \u00a0 eine \u00a0 wochen-\u00ad \u00a0bis \u00a0 monatelange \u00a0Leistungseinschr\u00e4nkung \u00a0resultieren \u00a0kann \u00a0(Gabriel \u00a02004). \u00a0Insgesamt \u00a0l\u00e4sst \u00a0 sich \u00a0 jedoch \u00a0 sagen, \u00a0 dass \u00a0 die \u00a0 Datenlage \u00a0 im \u00a0 Hinblick \u00a0 auf \u00a0k\u00f6rperliche \u00a0Aktivit\u00e4t \u00a0 und \u00a0 Pr\u00e4vention \u00a0 im \u00a0 Sinne \u00a0 von \u00a0 Impfungen \u00a0 noch \u00a0 nicht \u00a0ausreichend \u00a0gekl\u00e4rt \u00a0ist \u00a0(Furian&Rolirad \u00a02009). \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a019\t\r \u00a02.2.4. \u00a0Zeitpunkt \u00a0der \u00a0Impfung \u00a0 \u00a0Der \u00a0 Zeitpunkt \u00a0 einer \u00a0 Impfung \u00a0sollte \u00a0sorgf\u00e4ltig \u00a0 gew\u00e4hlt \u00a0 werden. \u00a0Zwar \u00a0legten \u00a0Studien \u00a0dar, \u00a0dass \u00a0innerhalb \u00a0von \u00a0zwei \u00a0Stunden \u00a0nach \u00a0sportlicher \u00a0Bet\u00e4tigung \u00a0eine \u00a0verringerte \u00a0Immunzellenzahl \u00a0und \u00a0\u2013funktion \u00a0vorzuliegen \u00a0scheint \u00a0(Kakanis \u00a0et \u00a0al. \u00a02010), \u00a0eine \u00a0 verringerte \u00a0 Zell-\u00advermittelte \u00a0 Immunit\u00e4t \u00a0konnte \u00a0jedoch \u00a0 nicht \u00a0festgestellt \u00a0 werden \u00a0(Campbell \u00a0 et \u00a0 al. \u00a0 2010). \u00a0 Bei \u00a0 manchen \u00a0 Personen \u00a0scheint \u00a0k\u00f6rperliche \u00a0 Aktivit\u00e4t \u00a0 sogar \u00a0 als \u00a0 Adjuvans \u00a0auf \u00a0 die \u00a0 Immuninduktion \u00a0wirken \u00a0zu \u00a0k\u00f6nnen \u00a0(Shi&Rock \u00a02002, \u00a0Edwards \u00a0et \u00a0al. \u00a02007). \u00a0 \u00a0Auch \u00a0 gibt \u00a0 es \u00a0keine \u00a0 generellen \u00a0 Bedenken, \u00a0Impfungen \u00a0in \u00a0 Phasen \u00a0 erh\u00f6hter \u00a0Belastung, \u00a0sei \u00a0sie \u00a0physischer \u00a0oder \u00a0psychischer \u00a0Natur, \u00a0durchzuf\u00fchren, \u00a0jedoch \u00a0sind \u00a0Nebenwirkungen \u00a0hiernach \u00a0immer \u00a0m\u00f6glich. \u00a0Um \u00a0weder \u00a0Leistungseinbr\u00fcche \u00a0noch \u00a0Ausf\u00e4lle \u00a0zu \u00a0riskieren \u00a0sind \u00a0Impfungen \u00a0insbesondere \u00a0vor \u00a0Wettk\u00e4mpfen \u00a0und \u00a0der \u00a0 Vorbereitung \u00a0 darauf \u00a0 zu \u00a0 vermeiden \u00a0 (Furian&G\u00e4rtner \u00a0 2014). \u00a0 Die \u00a0 Impfung \u00a0sollte \u00a0deshalb \u00a0nach \u00a0M\u00f6glichkeit \u00a0in \u00a0einer \u00a0trainingsfreien \u00a0Zeit \u00a0w\u00e4hrend \u00a0der \u00a0Winter-\u00ad \u00a0oder \u00a0 Sommerpausen \u00a0 appliziert \u00a0 werden, \u00a0 um \u00a0 die \u00a0 Auswirkung \u00a0 der \u00a0Nebenwirkungen \u00a0m\u00f6glichst \u00a0gering \u00a0zu \u00a0halten. \u00a0Prinzipiell \u00a0ist \u00a0auch \u00a0eine \u00a0Applikation \u00a0direkt \u00a0nach \u00a0einem \u00a0Wettkampf \u00a0denkbar, \u00a0um \u00a0einen \u00a0m\u00f6glichst \u00a0langen \u00a0Zeitraum \u00a0bis \u00a0zum \u00a0n\u00e4chsten \u00a0zu \u00a0gew\u00e4hrleisten \u00a0(Furian \u00a02000). \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a020\t\r \u00a02.3. \u00a0Indikationen \u00a0der \u00a0jeweiligen \u00a0Impfungen \u00a0 \u00a02.3.1. \u00a0Spezielle \u00a0Impfindikationen \u00a0bei \u00a0Sportlern \u00a0 \u00a0Prinzipiell \u00a0gelten \u00a0f\u00fcr \u00a0Leistungssportler \u00a0grunds\u00e4tzlich \u00a0die \u00a0gleichen \u00a0Impfrichtlinien \u00a0wie \u00a0 f\u00fcr \u00a0 die \u00a0Allgemeinbev\u00f6lkerung. \u00a0 Dennoch \u00a0sollten \u00a0 speziell \u00a0 bei \u00a0 bestimmten \u00a0Sportarten \u00a0und \u00a0unter \u00a0bestimmten \u00a0Umst\u00e4nden \u00a0einige \u00a0Besonderheiten \u00a0bedacht \u00a0werden. \u00a0So \u00a0ist \u00a0es \u00a0gerade \u00a0bei \u00a0Sportarten \u00a0wie \u00a0Rugby, \u00a0Fu\u00dfball \u00a0und \u00a0Outdoor-\u00adSportarten, \u00a0bei \u00a0denen \u00a0 es \u00a0 h\u00e4ufig \u00a0 zu \u00a0 Verletzungen \u00a0 und \u00a0Verunreinigungen \u00a0 der \u00a0 Haut \u00a0 kommt, \u00a0wichtig, \u00a0auf \u00a0 einen \u00a0 g\u00fcltigen \u00a0 Impfschutz \u00a0gegen \u00a0 Tetanus \u00a0 zu \u00a0 achten \u00a0(G\u00e4rtner&Meyer \u00a0 2014). \u00a0Ebenso \u00a0 sollten \u00a0alle \u00a0 Athleten, \u00a0 wie \u00a0 auch \u00a0 die \u00a0Allgemeinbev\u00f6lkerung, \u00a0gegen \u00a0 Masern \u00a0immunisiert \u00a0 werden. \u00a0Das \u00a0 Masernvirus \u00a0wird \u00a0aufgrund \u00a0seiner \u00a0hohen \u00a0Kontagi\u00f6sit\u00e4t \u00a0extrem \u00a0schnell \u00a0und \u00a0bereits \u00a0bei \u00a0kurzem \u00a0Kontakt \u00a0 von \u00a0 einem \u00a0 auf \u00a0 ein \u00a0 anderes \u00a0 Individuum \u00a0 \u00fcbertragen, \u00a0 weshalb \u00a0gerade \u00a0Sportveranstaltungen \u00a0aufgrund \u00a0der \u00a0gro\u00dfen \u00a0Menschenmenge \u00a0und \u00a0dem \u00a0engen \u00a0Kontakt \u00a0 der \u00a0 Personen \u00a0 untereinander \u00a0 pr\u00e4destiniert \u00a0 f\u00fcr \u00a0 einen \u00a0Masernausbruch \u00a0sind \u00a0(Caseris \u00a0et \u00a0al. \u00a02014). \u00a0 \u00a0Gr\u00f6\u00dfere \u00a0Masernausbr\u00fcche \u00a0werden \u00a0in \u00a0der \u00a0Literatur \u00a0immer \u00a0 wieder \u00a0 beschrieben \u00a0 (Takla \u00a0 et \u00a0 al. \u00a0 2014). \u00a0 Beispiele \u00a0 hierf\u00fcr \u00a0 w\u00e4ren \u00a0 im \u00a0Bereich \u00a0 des \u00a0 Fu\u00dfballs \u00a0 die \u00a0 Weltmeisterschaften \u00a0 in \u00a0 Deutschland \u00a0 2006 \u00a0 und \u00a0S\u00fcdafrika \u00a02010 \u00a0sowie \u00a0die \u00a0Europameisterschaft \u00a0in \u00a0der \u00a0Schweiz \u00a0und \u00a0\u00d6sterreich \u00a02008. \u00a0Der \u00a0Krankheitsverlauf \u00a0ist \u00a0oftmals \u00a0sehr \u00a0schwer \u00a0und \u00a0h\u00e4ufig \u00a0kommt \u00a0es \u00a0zu \u00a0schwerwiegenden \u00a0 Komplikationen \u00a0 wie \u00a0 einer \u00a0 Hepatitis, \u00a0 Enzephalitis \u00a0oder \u00a0Pneumonie \u00a0(Caseris \u00a0et \u00a0al. \u00a02014). \u00a0Neben \u00a0 den \u00a0 Standardimpfungen \u00a0 sind \u00a0 f\u00fcr \u00a0 Leistungssportler \u00a0 weitere \u00a0 Impfungen \u00a0empfehlenswert: \u00a0Da \u00a0 gerade \u00a0 Trainingslager \u00a0 oft \u00a0 in \u00a0 Regionen \u00a0 mit \u00a0 moderatem \u00a0 Klima \u00a0 und \u00a0schlechteren \u00a0 hygienischen \u00a0 Bedingungen \u00a0 stattfinden \u00a0 (G\u00e4rtner&Meyer \u00a0 2014), \u00a0spielt \u00a0die \u00a0Prophylaxe \u00a0der \u00a0Hepatitis \u00a0A \u00a0eine \u00a0entscheidende \u00a0Rolle. \u00a0Zwar \u00a0wird \u00a0die \u00a0Hepatitis-\u00adA-\u00adVakzination \u00a0 in \u00a0 Deutschland \u00a0 f\u00fcr \u00a0 Erwachsene \u00a0 nicht \u00a0 generell \u00a0empfohlen \u00a0 (STIKO \u00a0 2017), \u00a0 aber \u00a0 eine \u00a0 akute \u00a0 Hepatitis \u00a0 kann \u00a0 einen \u00a0 Ausfall \u00a0 von \u00a0mehreren \u00a0 Monaten \u00a0 verursachen. \u00a0 Zudem \u00a0 ist \u00a0 eine \u00a0 alleinige \u00a0Expositionsprophylaxe \u00a0 der \u00a0f\u00e4kal-\u00adoral \u00a0\u00fcbertragenen \u00a0 Krankheit \u00a0schwierig \u00a0(Martin&Lemon \u00a02006). \u00a0 \u00a0\t\r \u00a021\t\r \u00a0Ebenso \u00a0wie \u00a0bei \u00a0der \u00a0HAV-\u00adImpfung \u00a0wird \u00a0auch \u00a0die \u00a0Hepatitis \u00a0B-\u00adImpfung \u00a0von \u00a0der \u00a0STIKO \u00a0nicht \u00a0generell \u00a0empfohlen \u00a0(STIKO \u00a02017). \u00a0Da \u00a0die \u00a0Hepatitis \u00a0B \u00a0zu \u00a0den \u00a0durch \u00a0Blut \u00a0und \u00a0K\u00f6rperfl\u00fcssigkeiten \u00a0\u00fcbertragenen \u00a0Krankheiten \u00a0geh\u00f6rt, \u00a0ist \u00a0eine \u00a0Impfung \u00a0vor \u00a0allem \u00a0bei \u00a0Kontaktsportarten \u00a0sinnvoll. \u00a0Aufgrund \u00a0der \u00a0hohen \u00a0Virulenz \u00a0reichen \u00a0bereits \u00a0 wenige \u00a0 Milliliter \u00a0 eines \u00a0 infekti\u00f6sen \u00a0 Agens \u00a0 aus \u00a0 um, \u00a0sich \u00a0 zu \u00a0 infizieren \u00a0(Guiterrez&Decker \u00a02010). \u00a0Es \u00a0wird \u00a0sogar \u00a0vermutet, \u00a0dass \u00a0das \u00a0Trinken \u00a0aus \u00a0dem \u00a0gleichen \u00a0Beh\u00e4lter \u00a0ausreicht \u00a0um \u00a0aufgrund \u00a0kleiner \u00a0Blutungen \u00a0in \u00a0und \u00a0um \u00a0den \u00a0Mund \u00a0das \u00a0Virus \u00a0zu \u00a0\u00fcbertragen \u00a0(Kordi&Wallace \u00a02004). \u00a0Die \u00a0Pr\u00e4valenz \u00a0ist \u00a0vor \u00a0allem \u00a0in \u00a0Afrika, \u00a0S\u00fcdostasien \u00a0und \u00a0S\u00fcdamerika \u00a0sehr \u00a0hoch, \u00a0weshalb \u00a0man \u00a0aufgrund \u00a0h\u00e4ufiger \u00a0Aufenthalte \u00a0 im \u00a0 Rahmen \u00a0 von \u00a0 Wettk\u00e4mpen \u00a0 und \u00a0 Trainingslagern \u00a0 von \u00a0 einem \u00a0erh\u00f6hten \u00a0Infektionsrisiko \u00a0ausgehen \u00a0muss \u00a0(Furian&Rolirad \u00a02009). \u00a0F\u00fcr \u00a0die \u00a0Impfung \u00a0empfiehlt \u00a0sich \u00a0ein \u00a0Impfstoff \u00a0mit \u00a0einem \u00a0hohen \u00a0Gehalt \u00a0an \u00a0HbsAg \u00a0(20\u00b5g) \u00a0und \u00a0eventuell \u00a0eine \u00a0Titerkontrolle \u00a0nach \u00a04 \u00a0Wochen \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0Bei \u00a0Non-\u00adRespondern \u00a0kann \u00a0die \u00a0Gabe \u00a0eines \u00a0adjuvantierten \u00a0Impfstoffes \u00a0deutlich \u00a0effektiver \u00a0sein \u00a0und \u00a0die \u00a0gew\u00fcnschte \u00a0Immunantwort \u00a0bewirken \u00a0(Hoebe \u00a0et \u00a0al. \u00a02012). \u00a0F\u00fcr \u00a0alle \u00a0 Athleten, \u00a0 die \u00a0in \u00a0 der \u00a0 freien \u00a0 Natur \u00a0 trainieren \u00a0 (z. \u00a0B. \u00a0 L\u00e4ufe \u00a0 im \u00a0 Wald \u00a0absolvieren), \u00a0 ist \u00a0 zudem \u00a0eine \u00a0 Impfung \u00a0 gegen \u00a0 die \u00a0 Fr\u00fchsommer-\u00adMeningoenzephalitis \u00a0(FSME) \u00a0sinnvoll. \u00a0Diese \u00a0ist \u00a0vor \u00a0allem \u00a0in \u00a0Nord-\u00ad, \u00a0Mittel, \u00a0und \u00a0Osteuropa, \u00a0aber \u00a0auch \u00a0in \u00a0Teilen \u00a0Asiens \u00a0endemisch. \u00a0\u00dcbertragen \u00a0wird \u00a0sie \u00a0durch \u00a0Zeckenbisse. \u00a0Nach \u00a0 dreimaliger \u00a0 Grundimmunisierung \u00a0 sollte \u00a0 alle \u00a0 3 \u00a0 drei \u00a0Jahre \u00a0eine \u00a0Auffrischungssimpfung \u00a0erfolgen \u00a0(RKI \u00a02012). \u00a0 \u00a0Auf \u00a0 die \u00a0 Influenzaimpfung \u00a0 wird \u00a0 aufgrund \u00a0 der \u00a0 besonderen \u00a0 Relevanz \u00a0 f\u00fcr \u00a0 diese \u00a0Arbeit \u00a0in \u00a0einem \u00a0gesonderten \u00a0Kapitel \u00a0eingegangen. \u00a0\t\r \u00a022\t\r \u00a02.3.2. \u00a0\u00dcberblick \u00a0\u00fcber \u00a0die \u00a0Impfempfehlungen \u00a0 \u00a0F\u00fcr \u00a0alle \u00a0Athleten \u00a0Aufgrund \u00a0geographischer \u00a0Gegebenheiten \u00a0Aufgrund \u00a0k\u00f6rperlicher \u00a0Gegebenheiten \u00a0Umstrittenes \u00a0Nutzen-\u00adRisikoverh\u00e4ltnis \u00a0Irrelevant \u00a0f\u00fcr \u00a0Athleten \u00a0Tetanus/Diphterie \u00a0(Td) \u00a0 \u00a0 \u00a0Virusenzephalitiden \u00a0(z. \u00a0B. \u00a0FSME) \u00a0H\u00e4mophilus \u00a0influenzae \u00a0B \u00a0(HiB) \u00a0Papillomavirus \u00a0(HPV) \u00a0Tuberkulose \u00a0(BCG) \u00a0Pertussis \u00a0(aP) \u00a0Gelbfieber \u00a0Pneumokokken \u00a0R\u00f6teln \u00a0(R) \u00a0Rabies \u00a0Influenza \u00a0Japan-\u00adB-\u00adEnzephalitis \u00a0-\u00ad \u00a0-\u00ad \u00a0Herpes \u00a0Zoster \u00a0Hepatitis \u00a0A \u00a0(HAV) \u00a0Poliomyelitis \u00a0(P) \u00a0-\u00ad \u00a0-\u00ad \u00a0Cholera \u00a0Hepatitis \u00a0B \u00a0(HBV) \u00a0Typhus \u00a0-\u00ad \u00a0 \u00a0 \u00a0Masern \u00a0(M) \u00a0bakterielle \u00a0Meningitis \u00a0-\u00ad \u00a0-\u00ad \u00a0-\u00ad \u00a0Mumps \u00a0(M) \u00a0-\u00ad \u00a0-\u00ad \u00a0-\u00ad \u00a0-\u00ad \u00a0Varizellen \u00a0(V) \u00a0-\u00ad \u00a0-\u00ad \u00a0-\u00ad \u00a0-\u00ad \u00a0Tabelle \u00a01: \u00a0 \u00a0\u00dcberblick \u00a0\u00fcber \u00a0die \u00a0verf\u00fcgbaren \u00a0Impfungen \u00a0und \u00a0Unterteilung \u00a0anhand \u00a0ihrer \u00a0Relevanz \u00a0f\u00fcr \u00a0Athleten \u00a0(G\u00e4rtner&Meyer \u00a02014). \u00a0 \u00a0\t\r \u00a0                   \t\r \u00a023\t\r \u00a02.4. \u00a0Besonderheiten \u00a0der \u00a0Influenzaimpfung \u00a0 \u00a02.4.1. \u00a0Epidemiologie \u00a0und \u00a0Klinik \u00a0der \u00a0Influenza \u00a0 \u00a0Das \u00a0 Influenzavirus \u00a0 ist \u00a0 ein \u00a0 hochkontagi\u00f6ser \u00a0 Erreger \u00a0 aus \u00a0 der \u00a0 Gruppe \u00a0 der \u00a0Orthomyxoviridae, \u00a0 von \u00a0 dem \u00a0 drei \u00a0 Serotypen \u00a0 (A, \u00a0 B \u00a0 und \u00a0 C) \u00a0 bekannt \u00a0 sind \u00a0(P\u00f6hlmann&Schmitt \u00a0 2016). \u00a0 Zu \u00a0 den \u00a0 Symptomen \u00a0 der \u00a0 Influenza \u00a0 z\u00e4hlen \u00a0 unter \u00a0anderem \u00a0Fieber, \u00a0Kopfschmerz, \u00a0Gliederschmerzen, \u00a0Husten \u00a0sowie \u00a0eine \u00a0laufende \u00a0Nase. \u00a0Husten \u00a0 und \u00a0 Abgeschlagenheit \u00a0 k\u00f6nnen \u00a0 \u00fcber \u00a0 Wochen \u00a0 persistieren. \u00a0Es \u00a0kann \u00a0zu \u00a0Komplikationen \u00a0wie \u00a0Otitis \u00a0media, \u00a0Pneumonie, \u00a0Fieberkr\u00e4mpfen, \u00a0Reye-\u00adSyndrom \u00a0oder \u00a0Myokarditis \u00a0kommen. \u00a0Es \u00a0gibt \u00a0\u00fcber \u00a0200 \u00a0Viren, \u00a0die \u00a0eine \u00a0Influenza \u00a0oder \u00a0 eine \u00a0 der \u00a0 Influenza \u00a0 \u00e4hnlichen \u00a0 Erkrankung \u00a0 (\u201eInfluenza-\u00adlike-\u00adIllness\u201c) \u00a0hervorrufen \u00a0 k\u00f6nnen. \u00a0 Die \u00a0 Influenza \u00a0 A-\u00ad \u00a0und \u00a0 B-\u00adViren, \u00a0 gegen \u00a0 welche \u00a0sich \u00a0 der \u00a0Impfstoff \u00a0 richtet, \u00a0machen \u00a0 nur \u00a0 circa \u00a0 10% \u00a0 der \u00a0 Gesamtheit \u00a0 dieser \u00a0 Viren \u00a0 aus \u00a0(Demicheli \u00a0 et \u00a0 al. \u00a0 2014). \u00a0 Zudem \u00a0 zeigen \u00a0 die \u00a0 Influenza \u00a0 A-\u00adViren \u00a0eine \u00a0 hohe \u00a0genetische \u00a0Variabilit\u00e4t. \u00a0Einzelne \u00a0Mutationen \u00a0auf \u00a0dem \u00a0Genom, \u00a0der \u00a0sogenannte \u00a0\u201eAntigendrift\u201c, \u00a0 sorgen \u00a0 daf\u00fcr, \u00a0 dass \u00a0 die \u00a0 Immunit\u00e4t \u00a0 aus \u00a0 dem \u00a0 Vorjahr \u00a0gegen \u00a0 das \u00a0Virus \u00a0m\u00f6glicherweise \u00a0keine \u00a0Wirkung \u00a0zeigt. \u00a0Dies \u00a0f\u00fchrt \u00a0dann \u00a0zu \u00a0den \u00a0j\u00e4hrlichen \u00a0Grippewellen. \u00a0 Zudem \u00a0k\u00f6nnen \u00a0 die \u00a0 Viren \u00a0 Genomsegmente \u00a0 austauschen, \u00a0wodurch \u00a0v\u00f6llig \u00a0neue \u00a0antigene \u00a0Eigenschaften \u00a0auf \u00a0eine \u00a0f\u00fcr \u00a0dieses \u00a0Antigen \u00a0naive \u00a0Bev\u00f6lkerung \u00a0 treffen. \u00a0 Dies \u00a0 bildet \u00a0 die \u00a0 Grundlage \u00a0 f\u00fcr \u00a0 den \u00a0 Ausbruch \u00a0 einer \u00a0Pandemie. \u00a0 Werden \u00a0 im \u00a0 Rahmen \u00a0 dieses \u00a0 Genomaustausches \u00a0Oberfl\u00e4chenproteine \u00a0 ausgetauscht, \u00a0 die \u00a0 f\u00fcr \u00a0 das \u00a0 H\u00e4magglutinin \u00a0 (HA) \u00a0 oder \u00a0 die \u00a0Neuraminidase \u00a0(NA) \u00a0kodieren, \u00a0spricht \u00a0man \u00a0von \u00a0einem \u00a0Antigenshift. \u00a0Bleiben \u00a0HA-\u00ad \u00a0und \u00a0 NA-\u00adSubtyp \u00a0 erhalten, \u00a0 von \u00a0 einer \u00a0 intrassubtypischen \u00a0 Reassortierung \u00a0(P\u00f6hlmann&Schmitt \u00a02016). \u00a0 \u00a0Jede \u00a0 Influenzasaison \u00a0 f\u00fchrt \u00a0 zu \u00a0 zahlreichen \u00a0 gesundheitsbedingten \u00a0 Ausf\u00e4llen, \u00a0einhergehend \u00a0mit \u00a0einer \u00a0hohen \u00a0Morbidit\u00e4t \u00a0und \u00a0Mortalit\u00e4t \u00a0und \u00a0somit \u00a0auch \u00a0einem \u00a0enormen \u00a0wirtschaftlichen \u00a0Schaden \u00a0f\u00fcr \u00a0die \u00a0Allgemeinbev\u00f6lkerung. \u00a0J\u00e4hrlich \u00a0sind \u00a0circa \u00a05-\u00ad10% \u00a0der \u00a0weltweiten \u00a0Population \u00a0jeder \u00a0Altersgruppe \u00a0durch \u00a0die \u00a0Influenza \u00a0betroffen, \u00a0mit \u00a0h\u00f6heren \u00a0Infektionsraten \u00a0in \u00a0der \u00a0Wintersaison \u00a0(St\u00f6hr \u00a02002, \u00a0Grande \u00a0et \u00a0al. \u00a02016). \u00a0Alleine \u00a0in \u00a0Italien \u00a0kam \u00a0es \u00a0in \u00a0Saison \u00a02014/15 \u00a0zu \u00a06,3 \u00a0Millionen \u00a0F\u00e4llen \u00a0von \u00a0Influenzainfektionen, \u00a0was \u00a011% \u00a0der \u00a0Bev\u00f6lkerung \u00a0entspricht \u00a0(Odone \u00a0et \u00a0al. \u00a02015). \u00a0 In \u00a0 Deutschland \u00a0 lag \u00a0 die \u00a0 gesch\u00e4tzte \u00a0 Zahl \u00a0 der \u00a0 Influenza-\u00adassoziierten \u00a0\t\r \u00a024\t\r \u00a0Arbeitsunf\u00e4higkeiten \u00a0w\u00e4hrend \u00a0der \u00a0Influenzawelle \u00a02016/17 \u00a0bei \u00a03,4 \u00a0Millionen. \u00a0Die \u00a0Mortalit\u00e4t \u00a0f\u00fcr \u00a0Berlin \u00a0betrug \u00a026,2 \u00a0Todesf\u00e4lle \u00a0auf \u00a0100.000 \u00a0Einwohner. \u00a0Am \u00a0Ende \u00a0dieser \u00a0Saison \u00a0dominierten \u00a0mit \u00a093% \u00a0die \u00a0Influenza \u00a0A(H3N2)-\u00adViren, \u00a0wohingegen \u00a0die \u00a0Influenza \u00a0 B-\u00adViren \u00a0 nur \u00a0 6% \u00a0 ausmachten \u00a0(RKI \u00a0 2017). \u00a0 In \u00a0 der \u00a0aktuellen \u00a0Influenzasaison \u00a0(KW12/ \u00a02018) \u00a0sind \u00a0mit \u00a070% \u00a0Influenza \u00a0B-\u00adViren \u00a0der \u00a0dominierende \u00a0Subtyp. \u00a0 Influenza \u00a0 A(H1N1) \u00a0pdm09 \u00a0 liegen \u00a0 mit \u00a0 27% \u00a0 an \u00a0 zweiter \u00a0 Stelle, \u00a0wohingegen \u00a0Influenza \u00a0A(H3N2) \u00a0nur \u00a03% \u00a0ausmachen \u00a0(RKI \u00a02018). \u00a0 \u00a0Hierin \u00a0zeigt \u00a0sich \u00a0 auch \u00a0 die \u00a0 Problematik \u00a0 der \u00a0 Auswahl \u00a0 eines \u00a0 geeigneten \u00a0 Impfstoffes, \u00a0 auf \u00a0welche \u00a0sp\u00e4ter \u00a0noch \u00a0genauer \u00a0eingegangen \u00a0werden \u00a0soll. \u00a0 \u00a0 \u00a0 \u00a02.4.2. \u00a0Indikationen \u00a0f\u00fcr \u00a0die \u00a0Impfung \u00a0 \u00a0Aufgrund \u00a0der \u00a0hohen \u00a0Kontagi\u00f6sit\u00e4t \u00a0aber \u00a0auch \u00a0aufgrund \u00a0des \u00a0Umstandes, \u00a0dass \u00a0der \u00a0 Krankheitsverlauf \u00a0 mitunter \u00a0 sehr \u00a0 schwerwiegend \u00a0 ausfallen \u00a0 kann, \u00a0 gibt \u00a0 es \u00a0zahlreiche \u00a0Indikationen \u00a0f\u00fcr \u00a0eine \u00a0Influenzaimpfung. \u00a0Personen, \u00a0die \u00a0laut \u00a0STIKO-\u00adEmpfehlung \u00a0gegen \u00a0Influenza \u00a0geimpft \u00a0werden \u00a0sollten, \u00a0sind \u00a0alle \u00a0Menschen \u00a0\u00fcber \u00a060 \u00a0Jahren \u00a0sowie \u00a0Bewohner \u00a0von \u00a0Pflege-\u00ad \u00a0oder \u00a0Altenheimen \u00a0und \u00a0auch \u00a0Menschen \u00a0mit \u00a0 einer \u00a0 erh\u00f6hten \u00a0 Expositionsgefahr \u00a0 (z. \u00a0B. \u00a0 medizinisches \u00a0 Fachpersonal). \u00a0Zudem \u00a0 auch \u00a0 Schwangere \u00a0 ab \u00a0 dem \u00a0 2. \u00a0 Trimenon \u00a0 bei \u00a0 gesteigerter \u00a0Gesundheitsgef\u00e4hrdung \u00a0 aufgrund \u00a0 eines \u00a0 Grundleidens \u00a0 im \u00a0 1. \u00a0 Trimenon. \u00a0 Auch \u00a0Kinder, \u00a0Jugendliche \u00a0und \u00a0Erwachsene \u00a0mit \u00a0bestimmten \u00a0Grundleiden \u00a0wie \u00a0COPD, \u00a0Immunschw\u00e4che, \u00a0 Stoffwechselerkrankungen, \u00a0 Leber-\u00ad, \u00a0 Nieren-\u00ad \u00a0oder \u00a0 Herz-\u00adKreislauferkrankungen \u00a0sollten \u00a0eine \u00a0Influenzaimpfung \u00a0erhalten \u00a0(STIKO \u00a02017). \u00a0 \u00a0Athleten \u00a0sollten \u00a0ebenfalls \u00a0eine \u00a0j\u00e4hrliche \u00a0Impfung \u00a0gegen \u00a0das \u00a0Influenzavirus \u00a0in \u00a0Erw\u00e4gung \u00a0ziehen \u00a0(Trabacchi \u00a0et \u00a0al. \u00a02015). \u00a0Gr\u00fcnde \u00a0hierf\u00fcr \u00a0sind \u00a0unter \u00a0anderem \u00a0die \u00a0zahlreichen \u00a0Reisen, \u00a0die \u00a0Sportler \u00a0unternehmen \u00a0um \u00a0zu \u00a0ihren \u00a0Veranstaltungen \u00a0zu \u00a0kommen \u00a0sowie \u00a0die \u00a0Tatsache, \u00a0dass \u00a0Atemwegsinfektionen \u00a0neben \u00a0der \u00a0hohen \u00a0Exposition \u00a0 bei \u00a0 Kontaktsportarten \u00a0in \u00a0 \u00fcberf\u00fcllten \u00a0 Umgebungen \u00a0wie \u00a0Umkleidekabinen \u00a0und \u00a0Mannschaftsr\u00e4umen \u00a0besonders \u00a0leicht \u00a0\u00fcbertragen \u00a0werden \u00a0k\u00f6nnen. \u00a0Auch \u00a0die \u00a0scheinbar \u00a0herabgesetzte \u00a0Aktivit\u00e4t \u00a0des \u00a0Immunsystems \u00a0nach \u00a0intensiver \u00a0 k\u00f6rperlicher \u00a0 Belastung \u00a0 k\u00f6nnte \u00a0solche \u00a0 Infektionen \u00a0 beg\u00fcnstigen \u00a0(Signorelli \u00a0et \u00a0al. \u00a02015). \u00a0Zus\u00e4tzlich \u00a0sollte \u00a0noch \u00a0bedacht \u00a0werden, \u00a0dass \u00a0abh\u00e4ngig \u00a0von \u00a0der \u00a0Hemisph\u00e4re \u00a0in \u00a0der \u00a0man \u00a0sich \u00a0aufh\u00e4lt, \u00a0unter \u00a0Umst\u00e4nden \u00a0Erregerantigene \u00a0\t\r \u00a025\t\r \u00a0aus \u00a0der \u00a0aktuellen \u00a0Saison \u00a0oder \u00a0aus \u00a0dem \u00a0Vorjahr \u00a0kursieren \u00a0k\u00f6nnen. \u00a0Bei \u00a0Reisen \u00a0in \u00a0die \u00a0andere \u00a0Hemisph\u00e4re \u00a0kann \u00a0die \u00a0Influenza \u00a0folglich \u00a0ein \u00a0ganzj\u00e4hriges \u00a0Risiko \u00a0darstellen \u00a0und \u00a0unterschiedliche \u00a0Influenzaimpfstoffe \u00a0k\u00f6nnten \u00a0angebracht \u00a0sein. \u00a0In \u00a0diesem \u00a0 Falle \u00a0 w\u00e4re \u00a0 eine \u00a0 Impfung \u00a0 zweimal \u00a0 im \u00a0 Jahr \u00a0 indiziert \u00a0 (G\u00e4rtner&Meyer \u00a02014). \u00a0Eine \u00a0 Kontraindikation \u00a0 gegen \u00a0 die \u00a0 Influenzaimpfung \u00a0 gibt \u00a0 es \u00a0 f\u00fcr \u00a0 Personen, \u00a0 die \u00a0allergisch \u00a0auf \u00a0die \u00a0orale \u00a0Aufnahme \u00a0von \u00a0H\u00fchnereiwei\u00df \u00a0reagieren, \u00a0da \u00a0Influenza-\u00adImpfstoffe \u00a0meist \u00a0H\u00fchnereiwei\u00dfe \u00a0enthalten \u00a0(STIKO \u00a02017). \u00a0 \u00a0 \u00a02.4.3. \u00a0Impfstoffe \u00a0und \u00a0Applikationsverfahren \u00a0 \u00a0Aufgrund \u00a0der \u00a0bereits \u00a0genannten \u00a0genetischen \u00a0Variabilit\u00e4t \u00a0des \u00a0Influenzavirus \u00a0ist \u00a0eine \u00a0j\u00e4hrliche \u00a0Impfung \u00a0mit \u00a0der \u00a0von \u00a0der \u00a0WHO \u00a0empfohlenen \u00a0Antigenkombination \u00a0erforderlich. \u00a0 Diese \u00a0 ist \u00a0 nach \u00a0 M\u00f6glichkeit \u00a0 bereits \u00a0 im \u00a0 Herbst \u00a0 durchzuf\u00fchren \u00a0 und \u00a0auch \u00a0 dann, \u00a0 wenn \u00a0sich \u00a0 die \u00a0 Antigenzusammensetzung \u00a0 nicht \u00a0 von \u00a0 der \u00a0 der \u00a0vergangenen \u00a0Saison \u00a0 unterscheidet \u00a0 (STIKO \u00a0 2017), \u00a0 da \u00a0 der \u00a0 Impfschutz \u00a0 mit \u00a0zunehmender \u00a0Dauer \u00a0nachl\u00e4sst \u00a0und \u00a0nach \u00a0dem \u00a0Ablauf \u00a0eines \u00a0Jahres \u00a0vermutlich \u00a0kein \u00a0ausreichender \u00a0Schutz \u00a0mehr \u00a0besteht. \u00a0Die \u00a0Erhebung \u00a0der \u00a0WHO, \u00a0welche \u00a0Virenst\u00e4mme \u00a0in \u00a0den \u00a0Impfstoff \u00a0der \u00a0n\u00e4chsten \u00a0Saison \u00a0 aufgenommen \u00a0 werden \u00a0 sollen, \u00a0bedarf \u00a0 gro\u00dfer \u00a0 wissenschaftlicher \u00a0 und \u00a0logistischer \u00a0 Anstrengungen. \u00a0Es \u00a0 gibt \u00a0 hierbei \u00a0 verschiedene \u00a0 Impfstoffe \u00a0 mit \u00a0unterschiedlichen \u00a0 Anwendungsgebieten, \u00a0 die \u00a0 im \u00a0 Folgenden \u00a0 erl\u00e4utert \u00a0 werden \u00a0sollen. \u00a0Zum \u00a0einen \u00a0gibt \u00a0es \u00a0Influenza-\u00adTotimpfstoffe. \u00a0Hierbei \u00a0werden \u00a0die \u00a0Erreger \u00a0mit \u00a0einem \u00a0chemischen \u00a0Mittel \u00a0abget\u00f6tet \u00a0und \u00a0k\u00f6nnen \u00a0entweder \u00a0als \u00a0komplettes \u00a0Virus, \u00a0 als \u00a0 Subunit-\u00ad \u00a0oder \u00a0 als \u00a0 Spaltimpfstoff, \u00a0bei \u00a0 dem \u00a0nur \u00a0 noch \u00a0 der \u00a0 aktive \u00a0 Teil \u00a0vorhanden \u00a0 ist, \u00a0 verabreicht \u00a0 werden. \u00a0 Meist \u00a0 werden \u00a0 diese \u00a0 intramuskul\u00e4r \u00a0verabreicht \u00a0(Demicheli \u00a0et \u00a0al. \u00a02014). \u00a0Ob \u00a0in \u00a0den \u00a0Musculus \u00a0glutealis \u00a0oder \u00a0Musculus \u00a0deltoideus \u00a0 geimpft \u00a0 wird \u00a0 ergibt \u00a0 sich \u00a0f\u00fcr \u00a0 Sportler \u00a0aus \u00a0 der \u00a0 Art \u00a0 der \u00a0 Belastung. \u00a0W\u00e4hrend \u00a0 Fu\u00dfballer \u00a0 oder \u00a0 L\u00e4ufer \u00a0 lokale \u00a0 Nebenwirkungen \u00a0 im \u00a0Oberarm \u00a0 eher \u00a0tolerieren \u00a0 k\u00f6nnen, \u00a0 ist \u00a0 f\u00fcr \u00a0 Speerwerfer \u00a0 oder \u00a0 Kugelsto\u00dfer \u00a0 eher \u00a0 ein \u00a0 glutealer \u00a0Zugang \u00a0zu \u00a0bevorzugen. \u00a0Seit \u00a0 2009 \u00a0 ist \u00a0 in \u00a0 der \u00a0 Europ\u00e4ischen \u00a0 Union \u00a0 auch \u00a0 die \u00a0 intradermale \u00a0 Applikation \u00a0zugelassen. \u00a0Diese \u00a0Art \u00a0der \u00a0Applikation \u00a0hat \u00a0ihre \u00a0Vorteile \u00a0vor \u00a0allem \u00a0in \u00a0Hinblick \u00a0auf \u00a0\t\r \u00a026\t\r \u00a0eine \u00a0h\u00f6here \u00a0Immunogenit\u00e4t, \u00a0Dosisersparnis \u00a0und \u00a0gr\u00f6\u00dfere \u00a0Akzeptanz \u00a0durch \u00a0den \u00a0Patienten. \u00a0 Zudem \u00a0 ist \u00a0 das \u00a0 Risiko \u00a0 einer \u00a0 Nadelstichverletzung \u00a0 f\u00fcr \u00a0 das \u00a0medizinische \u00a0Fachpersonal \u00a0durch \u00a0nadelfreie \u00a0Injektionsm\u00f6glichkeiten \u00a0verringert \u00a0(Pileggi \u00a0 et \u00a0 al. \u00a0 2015). \u00a0In \u00a0Bezug \u00a0 auf \u00a0 die \u00a0 Effektivit\u00e4t \u00a0 scheint \u00a0 die \u00a0 intradermale \u00a0Anwendung \u00a0 in \u00a0 der \u00a0 Gruppe \u00a0 der \u00a0 18-\u00ad \u00a0bis \u00a0 60-\u00adj\u00e4hrigen \u00a0 vergleichbar \u00a0 mit \u00a0 der \u00a0intramuskul\u00e4ren \u00a0Applikation \u00a0zu \u00a0sein, \u00a0bei \u00a0den \u00a0\u00fcber \u00a060-\u00adj\u00e4hrigen \u00a0teilweise \u00a0sogar \u00a0\u00fcberlegen \u00a0(Young&Marra \u00a02011). \u00a0Bei \u00a0immungeschw\u00e4chten \u00a0Patienten \u00a0stellte \u00a0sich \u00a0ebenfalls \u00a0eine \u00a0vergleichbare \u00a0Wirksamkeit \u00a0heraus \u00a0(Pileggi \u00a0et \u00a0al. \u00a02015). \u00a0Allerdings \u00a0 treten \u00a0 Nebenwirkungen \u00a0 wie \u00a0 Schwellung, \u00a0 Erytheme, \u00a0 Juckreiz \u00a0 und \u00a0Indurationen \u00a0 innerhalb \u00a0 der \u00a0 ersten \u00a0 Tage \u00a0 geh\u00e4uft \u00a0 auf, \u00a0 wohingegen \u00a0Muskelschmerzen \u00a0geringer \u00a0zu \u00a0sein \u00a0scheinen \u00a0(Young&Marra \u00a02011). \u00a0Zum \u00a0 anderen \u00a0 gibt \u00a0 es \u00a0 attenuierte \u00a0Influenza-\u00adLebendimpfstoffe \u00a0 die \u00a0intranasal \u00a0verabreicht \u00a0werden \u00a0k\u00f6nnen. \u00a0Die \u00a0Viren \u00a0werden \u00a0in \u00a0Zellkulturen \u00a0so \u00a0gez\u00fcchtet, \u00a0dass \u00a0sie \u00a0sich \u00a0prim\u00e4r \u00a0zwar \u00a0in \u00a0der \u00a0nasopharyngealen \u00a0Schleimhaut \u00a0vermehren \u00a0k\u00f6nnen, \u00a0um \u00a0eine \u00a0Immunantwort \u00a0zu \u00a0induzieren, \u00a0jedoch \u00a0nicht \u00a0mehr \u00a0unter \u00a0den \u00a0w\u00e4rmeren \u00a0Temperaturen \u00a0der \u00a0tiefen \u00a0Atemwege \u00a0und \u00a0der \u00a0Lunge \u00a0(Ambrose \u00a0et \u00a0al. \u00a02008). \u00a0Diese \u00a0Lebendimpfstoffe \u00a0 k\u00f6nnen \u00a0 auch \u00a0 bei \u00a0 Kindern \u00a0 \u00fcber \u00a0 zwei \u00a0 Jahren \u00a0 angewandt \u00a0werden \u00a0(Heikkinen&Heinonen \u00a02011) \u00a0und \u00a0wiesen \u00a0in \u00a0dieser \u00a0Population \u00a0sogar \u00a0eine \u00a0gr\u00f6\u00dfere \u00a0Effektivit\u00e4t \u00a0auf \u00a0als \u00a0andere \u00a0Applikationsarten \u00a0sowie \u00a0eine \u00a0Reduktion \u00a0der \u00a0Influenza-\u00adassoziierten \u00a0 Otitis \u00a0 media \u00a0 um \u00a0 51% \u00a0 (Ambrose \u00a0 et \u00a0 al. \u00a0 2008). \u00a0 Mit \u00a0zunehmendem \u00a0Alter \u00a0sinkt \u00a0die \u00a0Effektivit\u00e4t \u00a0jedoch \u00a0und \u00a0zeigt \u00a0teilweise \u00a0sogar \u00a0eine \u00a0geringere \u00a0als \u00a0die \u00a0intramuskul\u00e4re \u00a0Anwendung \u00a0(DiazGranados \u00a0et \u00a0al. \u00a02012). \u00a0Eine \u00a0\u00dcbertragung \u00a0des \u00a0Virus \u00a0von \u00a0einem \u00a0Geimpften \u00a0auf \u00a0eine \u00a0nichtgeimpfte \u00a0Person \u00a0ist \u00a0zwei \u00a0bis \u00a0drei \u00a0Tage \u00a0nach \u00a0Impfung \u00a0zwar \u00a0prinzipiell \u00a0m\u00f6glich, \u00a0aber \u00a0unwahrscheinlich \u00a0und \u00a0ohne \u00a0klinische \u00a0Konsequenz \u00a0(Ambrose \u00a0et \u00a0al. \u00a02008). \u00a0Die \u00a0Wahrscheinlichkeit \u00a0einer \u00a0\u00dcbertragung \u00a0nach \u00a0einem \u00a0Kontakt \u00a0mit \u00a0einem \u00a0geimpften \u00a0Kind \u00a0liegt \u00a0bei \u00a0circa \u00a00,5% \u00a0(Vesikari \u00a0et \u00a0al. \u00a02006). \u00a0Die \u00a0 Effektivit\u00e4t \u00a0 des \u00a0 Impfstoffes \u00a0 korreliert \u00a0 jedoch \u00a0 auch \u00a0 stark \u00a0 mit \u00a0 der \u00a0\u00dcbereinstimmung \u00a0zirkulierender \u00a0Virusst\u00e4mme \u00a0mit \u00a0denen, \u00a0die \u00a0durch \u00a0die \u00a0Impfung \u00a0abgedeckt \u00a0werden. \u00a0Die \u00a0Zusammensetzung \u00a0der \u00a0trivalenten \u00a0Impfstoffe \u00a0umfasste \u00a0bisher \u00a0 immer \u00a0 einen \u00a0 A(H1N1)-\u00ad \u00a0und \u00a0 A(H2N3)-\u00adStamm \u00a0sowie \u00a0 einen \u00a0 B-\u00adStamm \u00a0(Greenberg \u00a0et \u00a0al. \u00a02013). \u00a0Bei \u00a0den \u00a0B-\u00adSt\u00e4mmen \u00a0koexistieren \u00a0die \u00a0B/Victoria/2/87-\u00adLinie \u00a0sowie \u00a0die \u00a0B/Yamagata/16/88-\u00adLinie \u00a0(McCulers \u00a0et \u00a0al. \u00a02004). \u00a0Obwohl \u00a0die \u00a0A-\u00adSt\u00e4mme \u00a0f\u00fcr \u00a0einen \u00a0Gro\u00dfteil \u00a0der \u00a0Infektionen \u00a0verantwortlich \u00a0sind, \u00a0tritt \u00a0die \u00a0Influenza \u00a0\t\r \u00a027\t\r \u00a0B \u00a0geh\u00e4uft \u00a0bei \u00a0Kindern \u00a0und \u00a0Jugendlichen \u00a0auf \u00a0und \u00a0verursacht \u00a0alle \u00a02 \u00a0bis \u00a04 \u00a0Jahre \u00a0eine \u00a0 Epidemie. \u00a0 Es \u00a0 besteht \u00a0 keine \u00a0 Kreuzreaktion \u00a0 zwischen \u00a0 den \u00a0 B-\u00adLinien, \u00a0 was \u00a0bedeutet, \u00a0dass \u00a0der \u00a0Schutz \u00a0nur \u00a0bei \u00a0\u00fcbereinstimmender \u00a0Linie \u00a0gew\u00e4hrleistet \u00a0ist \u00a0(Belshe \u00a0 2010). \u00a0 Die \u00a0 Zugabe \u00a0 eines \u00a0 vierten \u00a0 Stammes \u00a0 bei \u00a0 den \u00a0 quadrivalenten \u00a0Impfstoffen \u00a0 bietet \u00a0 daher \u00a0 einen \u00a0 breiteren \u00a0 Schutz \u00a0 gegen \u00a0 die \u00a0 Influenza. \u00a0 Eine \u00a0Auswirkung \u00a0 auf \u00a0 die \u00a0 Immunantwort, \u00a0 die \u00a0 die \u00a0 drei \u00a0 urspr\u00fcnglichen \u00a0 St\u00e4mme \u00a0 der \u00a0trivalenten \u00a0Impfung \u00a0hervorgerufen \u00a0haben, \u00a0wurde \u00a0dabei \u00a0nicht \u00a0beobachtet \u00a0(Beran \u00a0et \u00a0al. \u00a02013, \u00a0Greenberg \u00a0et \u00a0al. \u00a02013). \u00a0Seit \u00a011. \u00a0Januar \u00a02018 \u00a0wird \u00a0von \u00a0der \u00a0STIKO \u00a0auch \u00a0 die \u00a0 Verwendung \u00a0 eines \u00a0 quadrivalenten \u00a0 Impfstoffes \u00a0 empfohlen \u00a0 (STIKO \u00a02018). \u00a0Da \u00a0 die \u00a0 B-\u00adSt\u00e4mme \u00a0 vor \u00a0 allem \u00a0 eine \u00a0 signifikante \u00a0 Morbidit\u00e4t \u00a0 bei \u00a0 Kindern \u00a0verursachen \u00a0und \u00a0bei \u00a0diesen, \u00a0wie \u00a0oben \u00a0erw\u00e4hnt, \u00a0eine \u00a0h\u00f6here \u00a0Effektivit\u00e4t \u00a0mittels \u00a0intranasaler \u00a0Anwendung \u00a0erzielt \u00a0werden \u00a0kann, \u00a0ist \u00a0die \u00a0Gabe \u00a0eines \u00a0quadrivalenten \u00a0Lebendimpfstoffes \u00a0sinnvoll. \u00a0Auch \u00a0hier \u00a0zeigte \u00a0sich \u00a0in \u00a0Studien, \u00a0dass \u00a0trivalente \u00a0und \u00a0quadrivalente \u00a0 Lebendimpfstoffe \u00a0 bez\u00fcglich \u00a0 ihrer \u00a0 Sicherheits-\u00ad \u00a0und \u00a0Vertr\u00e4glichkeitsprofile \u00a0bei \u00a0 einer \u00a0 breiteren \u00a0 Abdeckung \u00a0 gegen \u00a0 B-\u00adSt\u00e4mme, \u00a0\u00e4quivalent \u00a0sind \u00a0(Toback \u00a0et \u00a0al. \u00a02012). \u00a0Zu \u00a0der \u00a0gro\u00dfen \u00a0Anzahl \u00a0an \u00a0verschiedenen \u00a0Impfstoffen \u00a0sind \u00a0in \u00a0einigen \u00a0L\u00e4ndern \u00a0auch \u00a0sogenannte \u00a0adjuvantierte \u00a0Impfstoffe \u00a0zugelassen. \u00a0Diese \u00a0mit \u00a0dem \u00a0MF59-\u00adAdjuvans \u00a0 kombinierten \u00a0 Vakzine \u00a0 versprechen \u00a0 eine \u00a0 h\u00f6here \u00a0 Potenz \u00a0 und \u00a0Antik\u00f6rper-\u00adTiter \u00a0 bei \u00a0 einer \u00a0 gleichzeitigen \u00a0 Dosisersparnis \u00a0 (O\u00b4Hagan \u00a0 2007). \u00a0 Bei \u00a0Gabe \u00a0 des \u00a0 adjuvantierten \u00a0 Impfstoffes \u00a0 zeigten \u00a0 sich \u00a0 im \u00a0 Vergleich \u00a0 mit \u00a0 anderen \u00a0allerdings \u00a0signifikant \u00a0 mehr \u00a0 unerw\u00fcnschte \u00a0 Wirkungen. \u00a0 Fast \u00a0 doppelt \u00a0 so \u00a0 h\u00e4ufig \u00a0traten \u00a0 hierbei \u00a0 Lokalreaktionen \u00a0 wie \u00a0 Schmerzen, \u00a0 R\u00f6tung, \u00a0 Schwellung \u00a0 und \u00a0Indurationen \u00a0auf \u00a0(Gysling \u00a02007). \u00a0Die \u00a0verbesserte \u00a0Wirkung \u00a0zeigte \u00a0sich \u00a0jedoch \u00a0vor \u00a0allem \u00a0 bei \u00a0 alten, \u00a0 chronisch \u00a0 kranken \u00a0 und \u00a0 immunsupprimierten \u00a0 Patienten \u00a0(Banzhoff \u00a0et \u00a0al. \u00a02003). \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a028\t\r \u00a02.4.4. \u00a0H\u00e4ufige \u00a0Nebenwirkungen \u00a0und \u00a0Methoden \u00a0zur \u00a0Reduktion \u00a0 \u00a0Die \u00a0 Influenzaimpfung \u00a0 gilt \u00a0als \u00a0 eine \u00a0 nebenwirkungsarm. \u00a0 So \u00a0 konnte \u00a0 gezeigt \u00a0werden, \u00a0 dass \u00a0 systemische \u00a0 Nebenwirkungen \u00a0 wie \u00a0 Fieber, \u00a0 Myalgien, \u00a0 M\u00fcdigkeit \u00a0oder \u00a0 Kopfschmerz \u00a0 nach \u00a0 Injektion \u00a0 des \u00a0 Impfstoffes \u00a0 bei \u00a0 jungen \u00a0 gesunden \u00a0Erwachsenen \u00a0nicht \u00a0h\u00e4ufiger \u00a0auftraten \u00a0als \u00a0in \u00a0der \u00a0Placebo-\u00adGruppe \u00a0(Nichol \u00a0et \u00a0al. \u00a01996). \u00a0 Lokalreaktionen \u00a0 wie \u00a0 Schwellung, \u00a0 R\u00f6tung, \u00a0 Juckreiz, \u00a0 Indurationen \u00a0 oder \u00a0Schmerz \u00a0an \u00a0der \u00a0Einstichstelle \u00a0hingegen \u00a0kamen \u00a0bei \u00a0den \u00a0Geimpften \u00a0h\u00e4ufiger \u00a0vor \u00a0als \u00a0in \u00a0der \u00a0Placebo-\u00adGruppe. \u00a0Diese \u00a0treten \u00a0meist \u00a0bereits \u00a0kurz \u00a0nach \u00a0der \u00a0Injektion \u00a0auf \u00a0und \u00a0dauern \u00a0etwa \u00a0ein \u00a0bis \u00a0zwei \u00a0Tage \u00a0an \u00a0(CDC \u00a02017). \u00a0Allerdings \u00a0fielen \u00a0sie \u00a0mild \u00a0aus \u00a0(Govaert \u00a0et \u00a0al. \u00a01993). \u00a0Bei \u00a0Gabe \u00a0des \u00a0intranasalen \u00a0Lebendimpfstoffes \u00a0werden \u00a0zudem \u00a0 Nebenwirkungen \u00a0 wie \u00a0 eine \u00a0 laufende \u00a0 Nase, \u00a0 Niesen, \u00a0 Husten \u00a0sowie \u00a0abdominelle \u00a0 Beschwerden \u00a0 mit \u00a0 \u00dcbelkeit \u00a0 und \u00a0 Erbrechen \u00a0 beschrieben \u00a0 (CDC \u00a02017). \u00a0Einige \u00a0der \u00a0systemischen \u00a0Nebenwirkungen \u00a0wie \u00a0Fieber \u00a0und \u00a0Kopfschmerz \u00a0k\u00f6nnen \u00a0zwar \u00a0 durch \u00a0 die \u00a0 begleitende \u00a0 Gabe \u00a0 von \u00a0NSAIDs \u00a0 wie \u00a0 Paracetamol \u00a0reduziert \u00a0werden, \u00a0allerdings \u00a0besteht \u00a0die \u00a0Gefahr, \u00a0dass \u00a0es \u00a0dadurch \u00a0bei \u00a0einigen \u00a0Impfstoffen \u00a0zu \u00a0 erniedrigten \u00a0 Antik\u00f6rpertitern \u00a0 kommt \u00a0 (Prymula \u00a0 et \u00a0 al. \u00a0 2009). \u00a0 F\u00fcr \u00a0 die \u00a0Influenzaimpfung \u00a0 hingegen \u00a0 scheint \u00a0 kein \u00a0 supprimierender \u00a0 Effekt \u00a0 zu \u00a0 bestehen \u00a0(Gross \u00a0 et \u00a0 al. \u00a0 1993). \u00a0 Auch \u00a0 bezieht \u00a0 sich \u00a0 dieser \u00a0 Effekt \u00a0 auf \u00a0 die \u00a0 prophylaktische \u00a0Gabe \u00a0von \u00a0Paracetamol, \u00a0also \u00a0innerhalb \u00a0der \u00a0ersten \u00a0sechs \u00a0Stunden \u00a0nach \u00a0Impfung, \u00a0wohingegen \u00a0 die \u00a0 therapeutische \u00a0 Gabe \u00a0 keine \u00a0 Auswirkungen \u00a0 zu \u00a0 haben \u00a0 scheint \u00a0(Doed\u00e9e \u00a0et \u00a0al. \u00a02014). \u00a0Lokalreaktionen \u00a0k\u00f6nnen \u00a0durch \u00a0die \u00a0richtige \u00a0Injektionsmethode \u00a0verringert \u00a0werden. \u00a0Wie \u00a0 oben \u00a0 bereits \u00a0 erw\u00e4hnt \u00a0 treten \u00a0 lokale \u00a0 Reaktionen \u00a0 bei \u00a0 intradermaler \u00a0 Gabe \u00a0h\u00e4ufiger \u00a0auf \u00a0als \u00a0bei \u00a0intramuskul\u00e4rer \u00a0Gabe \u00a0(Young&Marra \u00a02011). \u00a0Im \u00a0Falle \u00a0einer \u00a0intramuskul\u00e4ren \u00a0Anwendung \u00a0sollte \u00a0der \u00a0Muskel \u00a0des \u00a0sitzenden \u00a0oder \u00a0liegenden \u00a0Impflings \u00a0komplett \u00a0entspannt \u00a0sein. \u00a0Auch \u00a0die \u00a0Verwendung \u00a0einer \u00a0l\u00e4ngeren \u00a0Nadel \u00a0(25mm) \u00a0(Davenport \u00a02004) \u00a0und \u00a0der \u00a0WHO-\u00adTechnik, \u00a0bei \u00a0der \u00a0die \u00a0Haut \u00a0zwischen \u00a0Daumen \u00a0und \u00a0Zeigefinger \u00a0gespannt \u00a0und \u00a0ein \u00a0Einstichwinkel \u00a0von \u00a090\u00b0 \u00a0angestrebt \u00a0wird \u00a0 reduzierten \u00a0 Schmerzen \u00a0 und \u00a0 andere \u00a0 unerw\u00fcnschte \u00a0 Nebenwirkungen \u00a0(Cook&Murtagh \u00a0 2005). \u00a0 Zudem \u00a0 zeigte \u00a0 sich, \u00a0 dass \u00a0 eine \u00a0 z\u00fcgige \u00a0 Injektion \u00a0 (1-\u00ad2 \u00a0Sekunden) \u00a0weniger \u00a0schmerzhaft \u00a0ist \u00a0als \u00a0eine \u00a0langsamere \u00a0(Ipp \u00a0et \u00a0al. \u00a02007). \u00a0Lange \u00a0Zeit \u00a0 galt \u00a0 die \u00a0 Aspiration \u00a0 zur \u00a0 Vermeidung \u00a0 einer \u00a0 akzidentiellen \u00a0 intravasalen \u00a0\t\r \u00a029\t\r \u00a0Injektion \u00a0als \u00a0notwendig. \u00a0Mittlerweile \u00a0ist \u00a0ihr \u00a0Nutzen \u00a0jedoch \u00a0umstritten \u00a0(Ipp \u00a0et \u00a0al. \u00a02006) \u00a0und \u00a0wird \u00a0von \u00a0der \u00a0STIKO \u00a0nicht \u00a0mehr \u00a0empfohlen, \u00a0da \u00a0durch \u00a0die \u00a0zur \u00a0Injektion \u00a0verwendeten \u00a0 Muskeln, \u00a0 keine \u00a0 gro\u00dfen \u00a0Blutgef\u00e4\u00dfe \u00a0 ziehen \u00a0(STIKO \u00a0 2017). \u00a0Zus\u00e4tzlich \u00a0wird \u00a0ein \u00a0schmerzreduzierender \u00a0Effekt \u00a0bei \u00a0Verzicht \u00a0auf \u00a0die \u00a0Aspiration \u00a0wird \u00a0diskutiert \u00a0(Petousis-\u00adHarris \u00a02008). \u00a0Bez\u00fcglich \u00a0 allergischer \u00a0 Reaktionen, \u00a0 insbesondere \u00a0 der \u00a0 Kontaktallergie \u00a0 mit \u00a0Aluminium, \u00a0 ist \u00a0 die \u00a0 Verwendung \u00a0 von \u00a0 zwei \u00a0 verschiedenen \u00a0 Nadeln \u00a0 notwendig. \u00a0Eine \u00a0um \u00a0den \u00a0Impfstoff \u00a0aufzuziehen \u00a0und \u00a0die \u00a0andere \u00a0f\u00fcr \u00a0die \u00a0Injektion \u00a0(Lidholm \u00a0et \u00a0al. \u00a02013). \u00a0Auch \u00a0sollte \u00a0das \u00a0Desinfektionsmittel \u00a0auf \u00a0der \u00a0Haut \u00a0vor \u00a0dem \u00a0Einstich \u00a0vollst\u00e4ndig \u00a0 getrocknet \u00a0 sein \u00a0 (G\u00e4rtner&Meyer \u00a0 2014). \u00a0Eine \u00a0 schwerwiegende, \u00a0jedoch \u00a0 sehr \u00a0 seltene \u00a0 Komplikation \u00a0 ist \u00a0 das \u00a0 Auftreten \u00a0 eines \u00a0Guillan-\u00adBarr\u00e9 \u00a0Syndroms \u00a0 (GBS) \u00a0 nach \u00a0 der \u00a0Gabe \u00a0 des \u00a0 inaktivierten \u00a0 Influenza-\u00adTotimpfstoffes. \u00a0Allerdings \u00a0 ist \u00a0 dies \u00a0 extrem \u00a0 selten \u00a0 und \u00a0 tritt \u00a0 nur \u00a0 in \u00a0 ein \u00a0 bis \u00a0 zwei \u00a0 F\u00e4llen \u00a0 pro \u00a0 eine \u00a0Million \u00a0Geimpfte \u00a0auf \u00a0(CDC \u00a02017). \u00a0 \u00a0Ein \u00a0weiterer \u00a0Punkt, \u00a0der \u00a0zu \u00a0beachten \u00a0ist, \u00a0ist \u00a0die \u00a0Gefahr \u00a0des \u00a0Synkopierens \u00a0des \u00a0Impflings \u00a0und \u00a0die \u00a0damit \u00a0einhergehenden \u00a0potenziellen \u00a0Verletzungen \u00a0durch \u00a0den \u00a0Sturz. \u00a0Vor \u00a0allem \u00a0Jugendliche \u00a0und \u00a0Frauen \u00a0synkopieren \u00a0h\u00e4ufiger \u00a0nach \u00a0Impfungen \u00a0als \u00a0 andere \u00a0 Gruppen \u00a0 (Braun \u00a0 et \u00a0 al. \u00a0 1997, \u00a0 Halsey \u00a0 et \u00a0 al. \u00a0 2013). \u00a0In \u00a0 Erhebungen \u00a0f\u00fchrten \u00a0 in \u00a0 diesem \u00a0 Zusammenhang \u00a0 nahezu \u00a0 14% \u00a0 der \u00a0Synkopen \u00a0 zu \u00a0Hospitalisierungen \u00a0 (Kroger \u00a0 et \u00a0 al. \u00a0 2006). \u00a0 Die \u00a0 Tatsache \u00a0 das \u00a0 die \u00a0 vasovagal-\u00adinduzierte \u00a0Synkope, \u00a0insbesondere \u00a0nach \u00a0einer \u00a0Trainingseinheit, \u00a0ein \u00a0bei \u00a0Athleten \u00a0nicht \u00a0selten \u00a0beobachtetes \u00a0Ph\u00e4nomen \u00a0ist \u00a0(Hastings&Levine \u00a02012), \u00a0verst\u00e4rkt \u00a0die \u00a0Notwendig \u00a0 auf \u00a0 pr\u00e4synkopale \u00a0 Anzeichen \u00a0 zu \u00a0 achten \u00a0 und \u00a0 eine \u00a0 ausreichende \u00a0Nachbeobachtungszeit \u00a0nach \u00a0der \u00a0Impfung \u00a0einzuhalten \u00a0(Braun \u00a0et \u00a0al. \u00a01997). \u00a0 \u00a0Da \u00a0 die \u00a0 meisten \u00a0 Vorf\u00e4lle \u00a0 innerhalb \u00a0 der \u00a0 ersten \u00a0 15 \u00a0 Minuten \u00a0 nach \u00a0 Impfung \u00a0stattfinden, \u00a0 sollte \u00a0 eine \u00a0 Nachbeobachtungszeit \u00a0 von \u00a0 mindestens \u00a0 15 \u00a0 Minuten \u00a0eingehalten \u00a0werden \u00a0(CDC \u00a02008). \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a030\t\r \u00a02.4.5. \u00a0Influenzaimpfrate \u00a0bei \u00a0Sportlern \u00a0 \u00a0Welche \u00a0 Rolle \u00a0 die \u00a0 Influenza-\u00ad\u00e4hnlichen \u00a0 Erkrankungen \u00a0 spielen, \u00a0 zeigen \u00a0 die \u00a0Olympischen \u00a0 Winterspiele \u00a0 2002. \u00a0 12% \u00a0 aller \u00a0 Arztbesuche \u00a0 waren \u00a0Atemwegsinfektionen \u00a0 geschuldet. \u00a0 188 \u00a0 von \u00a0 diesen \u00a0wurden \u00a0 auf \u00a0 Influenza \u00a0gescreent, \u00a0wobei \u00a0in \u00a0fast \u00a020% \u00a0der \u00a0F\u00e4lle \u00a0eine \u00a0Influenza \u00a0nachgewiesen \u00a0werden \u00a0konnte. \u00a0Die \u00a0Rate \u00a0der \u00a0Teilnehmer, \u00a0die \u00a0zuvor \u00a0eine \u00a0Immunisierung \u00a0erhalten \u00a0hatte \u00a0wurde \u00a0als \u00a0gering \u00a0beschrieben \u00a0(Gundlapalli \u00a0et \u00a0al. \u00a02006). \u00a0Auch \u00a0bei \u00a0einer \u00a0aktuellen \u00a0Erhebung \u00a0 in \u00a0 die \u00a0 20 \u00a0 Fu\u00dfballmannschaften \u00a0 der \u00a0 italienischen \u00a0 Serie \u00a0 A \u00a0eingeschlossen \u00a0waren, \u00a0zeigte \u00a0sich \u00a0nur \u00a0eine \u00a0m\u00e4\u00dfige \u00a0Resonanz \u00a0bez\u00fcglich \u00a0der \u00a0Influenzaimpfung. \u00a0 Nur \u00a0 75% \u00a0 der \u00a0 Teams \u00a0 boten \u00a0 \u00fcberhaupt \u00a0 aktiv \u00a0 eine \u00a0Immunisierung \u00a0an, \u00a0wobei \u00a0im \u00a0Median \u00a0nur \u00a040% \u00a0der \u00a0Athleten \u00a0teilnahm \u00a0(Signorelli \u00a0et \u00a0al. \u00a02016). \u00a0Diese \u00a0niedrigen \u00a0Impfraten \u00a0sind \u00a0zum \u00a0einen \u00a0einer \u00a0generellen \u00a0Verunsicherung \u00a0in \u00a0der \u00a0Gesellschaft \u00a0bez\u00fcglich \u00a0Impfungen \u00a0und \u00a0deren \u00a0Sicherheit \u00a0geschuldet, \u00a0welche \u00a0durch \u00a0Presseberichte \u00a0verst\u00e4rkt \u00a0wird \u00a0(Signorelli \u00a0et \u00a0al. \u00a02015, \u00a0Odone \u00a0et \u00a0al. \u00a02015). \u00a0Zum \u00a0anderen \u00a0spielt \u00a0aber \u00a0auch \u00a0ein \u00a0mangelndes \u00a0Risikobewusstsein \u00a0der \u00a0Sportler \u00a0im \u00a0Hinblick \u00a0auf \u00a0Gefahren \u00a0und \u00a0Konsequenzen \u00a0einer \u00a0echten \u00a0Influenza \u00a0eine \u00a0gro\u00dfe \u00a0Rolle \u00a0(Signorelli \u00a0et \u00a0a. \u00a02016), \u00a0obwohl \u00a0es \u00a0zahlreiche \u00a0Empfehlungen \u00a0zum \u00a0Thema \u00a0Influenza \u00a0 und \u00a0Immunisierung \u00a0 gibt \u00a0 (Constantini \u00a0 et \u00a0 al. \u00a0 2001, \u00a0 G\u00e4rtner&Meyer \u00a02014, \u00a0Trabacchi \u00a0et \u00a0al. \u00a02015). \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a031\t\r \u00a02.5. \u00a0Einfl\u00fcsse \u00a0k\u00f6rperlicher \u00a0Aktivit\u00e4t \u00a0auf \u00a0Impfungen \u00a0 \u00a02.5.1. \u00a0Effekte \u00a0auf \u00a0den \u00a0Impferfolg \u00a0 \u00a0Diverse \u00a0Untersuchungen \u00a0besch\u00e4ftigten \u00a0sich \u00a0mit \u00a0der \u00a0Frage \u00a0inwiefern \u00a0k\u00f6rperliche \u00a0Aktivit\u00e4t \u00a0die \u00a0Serokonversionsrate \u00a0nach \u00a0einer \u00a0Impfung \u00a0beeinflusst \u00a0(Gleeson \u00a0et \u00a0al. \u00a01996, \u00a0 Bruunsgaard \u00a0 et \u00a0 al. \u00a0 1997). \u00a0 Hierbei \u00a0 scheint \u00a0 eine \u00a0 \u00fcber \u00a0 die \u00a0 \u201enormale \u00a0Belastung\u201c \u00a0 nicht \u00a0 hinausgehende \u00a0 k\u00f6rperliche \u00a0 Bet\u00e4tigung \u00a0 sowohl \u00a0 bei \u00a0 Nicht-\u00adSportlern \u00a0als \u00a0auch \u00a0bei \u00a0Leistungssportlern \u00a0keinen \u00a0Einfluss \u00a0auf \u00a0Impfung \u00a0zu \u00a0haben \u00a0(Furian&G\u00e4rtner \u00a0 2014, \u00a0 Grande \u00a0 et \u00a0 al. \u00a0 2016). \u00a0Kommt \u00a0 es \u00a0 vor \u00a0 einer \u00a0 Impfung \u00a0k\u00f6rperlich \u00a0jedoch \u00a0 zu \u00a0 einer \u00a0\u00dcberlastungssituation, \u00a0 kann \u00a0 dies \u00a0 zu \u00a0 einer \u00a0verringerten \u00a0 spezifischen \u00a0 Antik\u00f6rperbildung \u00a0 f\u00fchren \u00a0 (Furian \u00a0et \u00a0 al. \u00a0 1999). \u00a0 So \u00a0konnten \u00a0 Studien \u00a0 zum \u00a0 Beispiel \u00a0zeigen, \u00a0 dass \u00a0 in \u00a0 Folge \u00a0 einer \u00a0 zweiten \u00a0Trainingseinheit \u00a0nach \u00a0einer \u00a0vorangegangen \u00a0ersten \u00a0Trainingseinheit \u00a0die \u00a0Zahlen \u00a0der \u00a0CD4+-\u00ad, \u00a0CD8+-\u00ad \u00a0und \u00a0CD56+-\u00ad \u00a0T-\u00adLymphozyten \u00a0gesunken \u00a0war. \u00a0Zudem \u00a0lies \u00a0sich \u00a0auch \u00a0 eine \u00a0 verringerte \u00a0 Mitogen-\u00adinduzierte \u00a0 Produktion \u00a0 des \u00a0 CD69-\u00adAktivierungsmarker \u00a0auf \u00a0CD56+ \u00a0-\u00adZellen \u00a0erkennen \u00a0(Ronsen \u00a0et \u00a0al. \u00a02001). \u00a0Allerdings \u00a0lassen \u00a0 sich \u00a0 hieraus \u00a0 nicht \u00a0 zwangsweise \u00a0 R\u00fcckschl\u00fcsse \u00a0 auf \u00a0 die \u00a0 Immunantwort \u00a0nach \u00a0 einer \u00a0 Impfung \u00a0 ziehen. \u00a0 So \u00a0 zeigten \u00a0 sich \u00a0 ebenb\u00fcrtige \u00a0 bis \u00a0 hin \u00a0 zu \u00a0 erh\u00f6hte \u00a0Antik\u00f6rpertiter \u00a0f\u00fcr \u00a0Leistungssportler \u00a0im \u00a0Vergleich \u00a0zur \u00a0Kontrollgruppe \u00a0(Rosic \u00a0et \u00a0al. \u00a02008). \u00a0In \u00a0 einer \u00a0 anderen \u00a0 Studie, \u00a0 in \u00a0 der \u00a0 die \u00a0 Probanden \u00a0 physischem \u00a0(anhand \u00a0 eines \u00a0Fahrradergometers) \u00a0oder \u00a0psychischem \u00a0(Kopfrechnen \u00a0unter \u00a0Druck) \u00a0Stress \u00a0vor \u00a0der \u00a0 Influenza-\u00adImpfung \u00a0 ausgesetzt \u00a0 wurden, \u00a0 konnte \u00a0 bei \u00a0 den \u00a0 m\u00e4nnlichen \u00a0Probanden \u00a0keine \u00a0Auswirkung \u00a0auf \u00a0den \u00a0Impferfolg \u00a0festgestellt \u00a0werden. \u00a0Bei \u00a0den \u00a0Frauen \u00a0hingegen \u00a0zeigte \u00a0sich \u00a0anschlie\u00dfend \u00a0eine \u00a0st\u00e4rkere \u00a0Antik\u00f6rperantwort \u00a0als \u00a0in \u00a0 der \u00a0 Kontrollgruppe, \u00a0 die \u00a0 keinem \u00a0 Stress \u00a0 ausgesetzt \u00a0 waren \u00a0 (Edwards \u00a0 et \u00a0 al. \u00a02006). \u00a0Auch \u00a0in \u00a0Tierversuchen \u00a0zeigte \u00a0sich \u00a0eine \u00a0verst\u00e4rkende \u00a0Wirkung \u00a0von \u00a0Stress \u00a0auf \u00a0das \u00a0Immunsystem \u00a0(Dhabhar&McEwen \u00a01998). \u00a0Die \u00a0Auswirkung \u00a0von \u00a0Stress, \u00a0sei \u00a0er \u00a0psychisch, \u00a0physisch \u00a0oder \u00a0medikamenteninduziert, \u00a0auf \u00a0die \u00a0Immunantwort \u00a0h\u00e4ngt \u00a0dabei \u00a0von \u00a0Faktoren \u00a0wie \u00a0Art \u00a0des \u00a0Stressors, \u00a0Intensit\u00e4t \u00a0und \u00a0Dauer \u00a0ab \u00a0(Pruett \u00a0et \u00a0al. \u00a02003). \u00a0Exzentrische \u00a0 \u00dcbungen \u00a0 wie \u00a0 \u201eBizeps \u00a0 Curls\u201c \u00a0 oder \u00a0 \u201eSeitheben\u201c, \u00a0 bei \u00a0 denen \u00a0 der \u00a0Musculus \u00a0 biceps \u00a0 bracchi \u00a0 oder \u00a0 der \u00a0 Musculus \u00a0 deltoideus, \u00a0die \u00a0 nahe \u00a0 des \u00a0\t\r \u00a032\t\r \u00a0Injektionsortes \u00a0 liegen, \u00a0angespannt \u00a0 werden, \u00a0 scheinen \u00a0die \u00a0 Immunreaktion \u00a0 zu \u00a0verst\u00e4rken. \u00a0Im \u00a0Vergleich \u00a0zu \u00a0den \u00a0Kontrollgruppen \u00a0zeigte \u00a0sich \u00a0eine \u00a0verbesserte \u00a0Immunantwort \u00a0bei \u00a0den \u00a0k\u00f6rperlich \u00a0Aktiven \u00a0und \u00a0das \u00a0obwohl \u00a0nur \u00a0die \u00a0halbe \u00a0Dosis \u00a0des \u00a0Influenzaimpfstoffes \u00a0verabreicht \u00a0wurden \u00a0(Edwards \u00a0et \u00a0al. \u00a02007, \u00a0Edwards \u00a0et \u00a0al. \u00a0 2010). \u00a0 Dies \u00a0 l\u00e4sst \u00a0 sich \u00a0 dadurch \u00a0 erkl\u00e4ren, \u00a0 dass \u00a0 nach \u00a0 wiederholten \u00a0Muskelkontraktionen, \u00a0 wie \u00a0 sie \u00a0 in \u00a0 diesen \u00a0 \u00dcbungen \u00a0 stattfinden, \u00a0 ein \u00a0vor\u00fcbergehender \u00a0 Anstieg \u00a0 der \u00a0 lymphatischen \u00a0 Drainage \u00a0 in \u00a0 den \u00a0 betroffenen \u00a0Muskeln \u00a0 vorzufinden \u00a0 ist \u00a0 (Havas \u00a0 et \u00a0 al. \u00a0 1997). \u00a0 Auf \u00a0 diesen \u00a0 folgt \u00a0ein \u00a0 verst\u00e4rkter \u00a0Fluss \u00a0 von \u00a0 lymphatischen \u00a0 Zellen \u00a0 durch \u00a0 den \u00a0 jeweiligen \u00a0 Muskel \u00a0 und \u00a0 somit \u00a0 ein \u00a0intensivierter \u00a0 Transport \u00a0 von \u00a0 der \u00a0 Injektionsstelle \u00a0 zu \u00a0 den \u00a0 nachgeschalteten \u00a0lymphatischen \u00a0 Organen \u00a0 (Swartz \u00a0 et \u00a0 al. \u00a0 2008). \u00a0 Aber \u00a0 auch \u00a0 die \u00a0 Tatsache, \u00a0 dass \u00a0durch \u00a0 den \u00a0 Muskelschaden \u00a0 Mediatoren \u00a0 freigesetzt \u00a0 werden, \u00a0die \u00a0 dendritische \u00a0Zellen \u00a0aktivieren \u00a0sollen, \u00a0l\u00e4sst \u00a0den \u00a0Schluss \u00a0zu, \u00a0dass \u00a0in \u00a0einem \u00a0Muskel \u00a0nach \u00a0einer \u00a0Trainingseinheit \u00a0eine \u00a0verst\u00e4rkte \u00a0Immunogenit\u00e4t \u00a0vorliegt \u00a0(Shi&Rock \u00a02002). \u00a0 \u00a0Im \u00a0Hinblick \u00a0auf \u00a0den \u00a0zeitlichen \u00a0Abstand \u00a0(6 \u00a0Stunden \u00a0bzw. \u00a048 \u00a0Stunden) \u00a0zwischen \u00a0der \u00a0 Trainingseinheit \u00a0 und \u00a0 einer \u00a0 Influenzaimmunisierung \u00a0 konnten \u00a0 keine \u00a0Unterschiede \u00a0 bez\u00fcglich \u00a0 der \u00a0 Zell-\u00advermittelten \u00a0 Immunit\u00e4t \u00a0 erhoben \u00a0 werden \u00a0(Campbell \u00a0et \u00a0al. \u00a02010). \u00a0Auch \u00a0die \u00a0Intensit\u00e4t \u00a0(50%, \u00a085%, \u00a0110%) \u00a0der \u00a0k\u00f6rperlichen \u00a0Bet\u00e4tigung \u00a0scheint \u00a0f\u00fcr \u00a0den \u00a0Impferfolg \u00a0irrelevant \u00a0zu \u00a0sein \u00a0(Edwards \u00a0et \u00a0al. \u00a02010). \u00a0Bei \u00a0 \u00e4lteren, \u00a0 ansonsten \u00a0 nicht-\u00adsportlich \u00a0 aktiven \u00a0 Menschen \u00a0 lie\u00df \u00a0 sich \u00a0durch \u00a0Ausdauertraining \u00a0 \u00fcber \u00a0 drei \u00a0 Monate \u00a0eine \u00a0 verbesserte \u00a0 Seroprotekion \u00a0 \u00fcber \u00a0 die \u00a0gesamte \u00a0 Influenzasaison \u00a0 hinweg \u00a0 beobachten \u00a0 (Woods \u00a0 et \u00a0 al. \u00a0 2009). \u00a0 Eine \u00a0verbesserte \u00a0 Immunantwort \u00a0 wurde \u00a0 auch \u00a0 in \u00a0 Studien \u00a0beobachtet, \u00a0 in \u00a0 der \u00a0 \u00e4ltere \u00a0Personen \u00a0 \u00fcber \u00a0 10 \u00a0 Monate \u00a0 ein \u00a0 moderates \u00a0 Aerobic \u00a0 Programm \u00a0 oder \u00a0 \u00fcber \u00a0 5 \u00a0Monate \u00a0Taiji \u00a0und \u00a0Qigong \u00a0absolvierten \u00a0(Kohut \u00a0et \u00a0al. \u00a02004, \u00a0Yang \u00a0et \u00a0al. \u00a02007). \u00a0Es \u00a0gibt \u00a0insgesamt \u00a0Hinweise \u00a0darauf, \u00a0dass \u00a0sowohl \u00a0kurzfristiges \u00a0als \u00a0auch \u00a0best\u00e4ndiges \u00a0Training \u00a0 eine \u00a0 verbesserte \u00a0 Immunreaktion \u00a0 bei \u00a0 Menschen \u00a0 bewirken \u00a0 kann, \u00a0 die \u00a0sonst \u00a0 eine \u00a0suboptimale \u00a0 Immunantwort \u00a0 zeigen \u00a0 (Pascoe \u00a0 et \u00a0 al. \u00a0 2014). \u00a0 Diese \u00a0Strategie \u00a0k\u00f6nnte \u00a0man \u00a0sich \u00a0dann \u00a0zu \u00a0Nutzen \u00a0machen, \u00a0wenn \u00a0im \u00a0Rahmen \u00a0einer \u00a0Pandemie \u00a0Impfstoff \u00a0eingespart \u00a0werden \u00a0muss \u00a0oder \u00a0auch \u00a0in \u00a0Entwicklungsl\u00e4ndern, \u00a0in \u00a0denen \u00a0Impfstoffe \u00a0generell \u00a0knapp \u00a0sind \u00a0(Edwards \u00a0et \u00a0al. \u00a02010). \u00a0Auch \u00a0f\u00fcr \u00a0\u00e4ltere \u00a0Menschen, \u00a0immunsupprimierte \u00a0oder \u00a0HIV-\u00adpositive \u00a0Patienten \u00a0sowie \u00a0f\u00fcr \u00a0Patienten \u00a0mit \u00a0einem \u00a0erh\u00f6hten \u00a0Risiko \u00a0einer \u00a0Infektion, \u00a0w\u00e4re \u00a0dies \u00a0eine \u00a0kosteng\u00fcnstige \u00a0und \u00a0\t\r \u00a033\t\r \u00a0sichere \u00a0 Ma\u00dfnahme \u00a0 um \u00a0 die \u00a0 Erfolgsaussichten \u00a0 der \u00a0 Impfung \u00a0 zu \u00a0 erh\u00f6hen \u00a0(Edwards&Booy \u00a02013). \u00a0Andererseits \u00a0stellte \u00a0es \u00a0sich \u00a0so \u00a0dar, \u00a0dass \u00a0weniger \u00a0intensive \u00a0Bet\u00e4tigungen \u00a0wie \u00a0ein \u00a0flotter \u00a0 Spaziergang \u00a0 nicht \u00a0 ausreichten \u00a0 um \u00a0 eine \u00a0 verbesserte \u00a0 Immunantwort \u00a0 zu \u00a0bewirken \u00a0(Long \u00a0et \u00a0al. \u00a02012). \u00a0 \u00a0 \u00a02.5.2. \u00a0Effekte \u00a0auf \u00a0das \u00a0Nebenwirkungsprofil \u00a0 \u00a0In \u00a0 der \u00a0 Literatur \u00a0 gibt \u00a0 es \u00a0 nicht \u00a0 ausreichend \u00a0 Hinweise \u00a0 daf\u00fcr, \u00a0 dass \u00a0 k\u00f6rperliche \u00a0Aktivit\u00e4t \u00a0vor \u00a0der \u00a0Impfung \u00a0die \u00a0Rate \u00a0an \u00a0Nebenwirkungen \u00a0erh\u00f6ht. \u00a0Auch \u00a0 in \u00a0 einem \u00a0 Review \u00a0 konnte \u00a0 keine \u00a0 nachteilige \u00a0 Wirkung \u00a0 von \u00a0 Sport \u00a0 auf \u00a0 die \u00a0Impfung \u00a0 festgestellt \u00a0 werden. \u00a0 Die \u00a0 k\u00f6rperlich \u00a0 Aktiven \u00a0 hatten \u00a0 in \u00a0 diesem \u00a0Zusammenhang \u00a0 zudem \u00a0 nicht \u00a0 mehr \u00a0 Nebenwirkungen \u00a0 als \u00a0 die \u00a0 Kontrollgruppe \u00a0(Grande \u00a0et \u00a0al. \u00a02016). \u00a0Etwas \u00a0 anders \u00a0 verh\u00e4lt \u00a0 es \u00a0 sich \u00a0 bei \u00a0 exzentrischen \u00a0 \u00dcbungen, \u00a0 die \u00a0 direkt \u00a0 den \u00a0 zu \u00a0impfenden \u00a0 Muskel \u00a0 beanspruchen. \u00a0 Hier \u00a0 gab \u00a0 die \u00a0 k\u00f6rperlich \u00a0 aktive \u00a0 Gruppe \u00a0unabh\u00e4ngig \u00a0vom \u00a0Geschlecht \u00a0vermehrte \u00a0Schmerzen \u00a0an \u00a0(Edwards \u00a0et \u00a0al. \u00a02007). \u00a0Zudem \u00a0 k\u00f6nnen \u00a0 auch \u00a0 leichte \u00a0 Entz\u00fcndungserscheinungen \u00a0 auftreten \u00a0(Furian&Rolirad \u00a0 2009). \u00a0 Mit \u00a0 zunehmender \u00a0 Intensit\u00e4t \u00a0der \u00a0 \u00dcbung \u00a0 und \u00a0zunehmender \u00a0Mikrosch\u00e4digung \u00a0der \u00a0Muskulatur \u00a0scheinen \u00a0auch \u00a0die \u00a0Schmerzen \u00a0zuzunehmen \u00a0(Edwards \u00a0et \u00a0al. \u00a02010). \u00a0Auch \u00a0der \u00a0Zeitpunkt \u00a0physischer \u00a0Bet\u00e4tigung \u00a0k\u00f6nnte \u00a0eine \u00a0Rolle \u00a0spielen. \u00a0So \u00a0konnte \u00a0bei \u00a0Probanden, \u00a0die \u00a0direkt \u00a0nach \u00a0dem \u00a0Sport \u00a0geimpft \u00a0wurden \u00a0ein \u00a0gr\u00f6\u00dferer \u00a0Schmerz \u00a0erhoben \u00a0werden \u00a0als \u00a0einer \u00a0Kontrollgruppe \u00a0und \u00a0einer \u00a0Gruppe, \u00a0die \u00a0erst \u00a06 \u00a0Stunden \u00a0nach \u00a0dem \u00a0Sport \u00a0geimpft \u00a0wurde \u00a0(Campbell \u00a0et \u00a0al. \u00a02010). \u00a0Auch \u00a0 f\u00fcr \u00a0 Training \u00a0 nach \u00a0 einer \u00a0 Impfung \u00a0bestehen \u00a0 bislang \u00a0keine \u00a0 Hinweise \u00a0 auf \u00a0nachteilige \u00a0 Effekte, \u00a0 obwohl \u00a0 in \u00a0 der \u00a0 Praxis \u00a0 h\u00e4ufig \u00a0 Bedenken \u00a0 diesbez\u00fcglich \u00a0ge\u00e4u\u00dfert \u00a0 werden. \u00a0 Ebenso \u00a0 wird \u00a0 nicht \u00a0 generell \u00a0 eine \u00a0 Sportpause \u00a0 empfohlen \u00a0(Furian \u00a02000, \u00a0Furian&Rolirad \u00a02009). \u00a0 \u00a0  \t\r \u00a034\t\r \u00a02.6. \u00a0Studienziel \u00a0und \u00a0Hypothesen \u00a0 \u00a0Ziel \u00a0dieser \u00a0Studie \u00a0ist \u00a0es \u00a0vor \u00a0allem \u00a0praktisch-\u00adangewandte, \u00a0aber \u00a0auch \u00a0theoretisch-\u00adgrundlagenorientierte \u00a0Fragen \u00a0zur \u00a0Impfung \u00a0von \u00a0Leistungssportlern \u00a0am \u00a0Beispiel \u00a0der \u00a0j\u00e4hrlichen \u00a0Influenza-\u00adImpfung \u00a0zu \u00a0untersuchen. \u00a0Diese \u00a0gliedern \u00a0sich \u00a0folgenderma\u00dfen: \u00a0 \u00a01. \u00a0Ist \u00a0bei \u00a0Leistungssportlern \u00a0ein \u00a0zeitlicher \u00a0Abstand \u00a0zu \u00a0ber\u00fccksichtigen, \u00a0wenn \u00a0ein \u00a0Impfzeitpunkt \u00a0nach \u00a0einer \u00a0k\u00f6rperlichen \u00a0Bet\u00e4tigung \u00a0festgelegt \u00a0wird? \u00a02. \u00a0F\u00fchrt \u00a0 physische \u00a0 Belastung \u00a0 vor \u00a0 einer \u00a0 Impfung \u00a0 zu \u00a0 einer \u00a0 eingeschr\u00e4nkten \u00a0Immunantwort \u00a0auf \u00a0Impfantigene? \u00a03. \u00a0Hat \u00a0 der \u00a0 Impfzeitpunkt \u00a0bei \u00a0 Leistungssportlern \u00a0Einfluss \u00a0 auf \u00a0 die \u00a0Nebenwirkungen? \u00a0 \u00a0Zu \u00a0diesen \u00a0Fragen \u00a0werden \u00a0folgende \u00a0Arbeitshypothesen \u00a0verfolgt: \u00a0 \u00a01. \u00a0Leistungssportliches \u00a0 Training \u00a0 unmittelbar \u00a0 vor \u00a0 einer \u00a0 Influenzaimpfung \u00a0 hat \u00a0keinen \u00a0negativen \u00a0Einfluss \u00a0auf \u00a0die \u00a0Induktion \u00a0der \u00a0humoralen \u00a0und \u00a0zellul\u00e4ren \u00a0Immunantwort \u00a02. \u00a0Leistungssportliches \u00a0Training \u00a0unmittelbar \u00a0vor \u00a0einer \u00a0Influenzaimpfung \u00a0f\u00fchrt \u00a0nicht \u00a0zu \u00a0vermehrten \u00a0Impfnebenwirkungen. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a035\t\r \u00a03. \u00a0Material \u00a0und \u00a0Methoden \u00a0 \u00a03.1. \u00a0Studiendesign \u00a0 \u00a0Bei \u00a0der \u00a0vorliegenden \u00a0Arbeit \u00a0handelt \u00a0es \u00a0sich \u00a0um \u00a0eine \u00a0randomisierte, \u00a0kontrollierte \u00a0Studie. \u00a0Von \u00a0einem \u00a0cross-\u00adover \u00a0Design \u00a0wurde \u00a0Abstand \u00a0genommen, \u00a0da \u00a0eine \u00a0Impfung \u00a0gegen \u00a0die \u00a0Influenza \u00a0nur \u00a0einmal \u00a0j\u00e4hrlich \u00a0erfolgt \u00a0und \u00a0nach \u00a0dieser \u00a0mit \u00a0relativ \u00a0hoher \u00a0Wahrscheinlichkeit \u00a0ein \u00a0Impfschutz \u00a0besteht. \u00a0Ein \u00a0im \u00a0Folgejahr \u00a0identischer \u00a0Impfstoff \u00a0ist \u00a0nicht \u00a0zu \u00a0erwarten. \u00a0Ziel \u00a0dieser \u00a0Erhebung \u00a0war \u00a0es \u00a0die \u00a0Kinetik \u00a0der \u00a0Influenza-\u00adspezifischen \u00a0humoralen \u00a0und \u00a0zellul\u00e4ren \u00a0 Immunantwort \u00a0 auf \u00a0 eine \u00a0 Influenza-\u00adImpfung \u00a0 bei \u00a0 Leistungssportlern \u00a0darzulegen \u00a0und \u00a0Unterschiede \u00a0bez\u00fcglich \u00a0der \u00a0Nebenwirkungen \u00a0zu \u00a0erfassen. \u00a0Die \u00a0eingeschlossenen \u00a0Athleten \u00a0wurden \u00a0in \u00a0zwei \u00a0Subgruppen \u00a0unterteilt: \u00a0 \u00a0\u2022 \u00a0Leistungssportler, \u00a0 die \u00a0 innerhalb \u00a0 von \u00a0 zwei \u00a0 Stunden \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 ein \u00a0intensives \u00a0Training \u00a0absolviert \u00a0hatten \u00a0(n=24) \u00a0\u2022 \u00a0Leistungssportler, \u00a0 die \u00a0 in \u00a0 den \u00a0 vorausgegangenen \u00a0 26 \u00a0 Stunden \u00a0 keiner \u00a0k\u00f6rperlichen \u00a0Belastung \u00a0ausgesetzt \u00a0waren \u00a0(n=21) \u00a0 \u00a0Die \u00a0oben \u00a0genannten \u00a0Sportlergruppen \u00a0wurden \u00a0vor \u00a0und \u00a0im \u00a0Verlauf \u00a0nach \u00a0der \u00a0Impfung \u00a0klinisch \u00a0 und \u00a0 immunologisch \u00a0 nachverfolgt. \u00a0Da \u00a0 es \u00a0 aktuell \u00a0 noch \u00a0 kein \u00a0 messbares \u00a0Korrelat \u00a0der \u00a0Protektion \u00a0im \u00a0Sinne \u00a0eines \u00a0Titers \u00a0gibt, \u00a0orientieren \u00a0sich \u00a0die \u00a0Zielparameter \u00a0an \u00a0messbaren \u00a0Faktoren \u00a0der \u00a0humoralen \u00a0und \u00a0zellul\u00e4ren \u00a0immunologischen \u00a0Antwort. \u00a0Zur \u00a0 Darstellung \u00a0 der \u00a0 impfinduzierten \u00a0 Immunreaktion \u00a0 scheint, \u00a0 aufgrund \u00a0 der \u00a0Kreuzreaktivit\u00e4ten \u00a0 auf \u00a0 T-\u00adZell-\u00adEbene \u00a0 eine \u00a0 Stimulation \u00a0 mit \u00a0 Gesamtantigen \u00a0 bei \u00a0Auswertung \u00a0der \u00a0T-\u00adZell-\u00adAntwort \u00a0ausreichend. \u00a0Durch \u00a0diese \u00a0Vorgehensweise \u00a0sollte \u00a0der \u00a0unmittelbare \u00a0(\u201eakute\u201c) \u00a0Einfluss \u00a0von \u00a0k\u00f6rperlicher \u00a0Aktivit\u00e4t \u00a0auf \u00a0die \u00a0Immunantwort \u00a0untersucht \u00a0 werden. \u00a0 Des \u00a0 Weiteren \u00a0 wurden \u00a0 die \u00a0 Sportler \u00a0 dazu \u00a0 angehalten \u00a0 ihren \u00a0Trainingsaufwand \u00a0im \u00a0Zeitraum \u00a0der \u00a0Impfung \u00a0sowie \u00a0durch \u00a0die \u00a0Impfung \u00a0entstandene \u00a0Beschwerden \u00a0im \u00a0Folgezeitraum \u00a0detailliert \u00a0zu \u00a0dokumentieren. \u00a0Die \u00a0Datenerfassung \u00a0erfolgte \u00a0von \u00a0September \u00a02016 \u00a0bis \u00a0Juni \u00a02017 \u00a0sowohl \u00a0am \u00a0Institut \u00a0f\u00fcr \u00a0 Sport-\u00ad \u00a0und \u00a0 Pr\u00e4ventivmedizin \u00a0 der \u00a0 Universit\u00e4t \u00a0 des \u00a0 Saarlandes \u00a0 als \u00a0 auch \u00a0am \u00a0\t\r \u00a036\t\r \u00a0Universit\u00e4tsklinikum \u00a0 des \u00a0 Saarlandes \u00a0 in \u00a0Homburg. \u00a0 Die \u00a0 Studie \u00a0wurde \u00a0 von \u00a0der \u00a0Ethikkommission \u00a0 der \u00a0 \u00c4rztekammer \u00a0 des \u00a0 Saarlandes \u00a0 unter \u00a0 der \u00a0 Registriernummer \u00a0149/16 \u00a0genehmigt. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a037\t\r \u00a03.2. \u00a0Probanden \u00a0und \u00a0Probandenrekrutierung \u00a0 \u00a0Eingeschlossen \u00a0wurden \u00a0gesunde \u00a0Leistungssportler \u00a0(n=45) \u00a0beiderlei \u00a0Geschlechts, \u00a0die \u00a0sich \u00a0mindestens \u00a0auf \u00a0nationalem \u00a0Niveau \u00a0im \u00a0Wettkampfprozess \u00a0befanden. \u00a0In \u00a0der \u00a02h-\u00adGruppe \u00a0befanden \u00a0sich \u00a024 \u00a0Sportler \u00a0im \u00a0Alter \u00a0von \u00a016 \u00a0bis \u00a032 \u00a0Jahren \u00a0(21,9\u00b14,6), \u00a0darunter \u00a05 \u00a0Frauen \u00a0und \u00a019 \u00a0M\u00e4nner. \u00a0In \u00a0der \u00a026h-\u00adGruppe \u00a021 \u00a0Sportler \u00a0im \u00a0Alter \u00a0von \u00a016 \u00a0bis \u00a052 \u00a0Jahren \u00a0(25,6\u00b19,8), \u00a0darunter \u00a04 \u00a0Frauen \u00a0und \u00a017 \u00a0M\u00e4nner. \u00a0Weder \u00a0bez\u00fcglich \u00a0des \u00a0Geschlechts \u00a0 (p=1,00) \u00a0 noch \u00a0 bez\u00fcglich \u00a0 des \u00a0 Alters \u00a0 (p=0,36) \u00a0 waren \u00a0 statistisch \u00a0signifikante \u00a0Unterschiede \u00a0vorhanden. \u00a0Die \u00a0anthropometrischen \u00a0Daten \u00a0sind \u00a0in \u00a0der \u00a0untenstehenden \u00a0Tabelle \u00a03 \u00a0aufgef\u00fchrt. \u00a0Ein \u00a0leistungssportlich \u00a0orientiertes \u00a0Training \u00a0wurde \u00a0als \u00a0Durchf\u00fchrung \u00a0an \u00a0mindestens \u00a0f\u00fcnf \u00a0Tagen \u00a0in \u00a0der \u00a0Woche \u00a0definiert. \u00a0Die \u00a0 Akquisition \u00a0 der \u00a0 meisten \u00a0 Athleten \u00a0 erfolgte \u00a0 am \u00a0 nahegelegenen \u00a0Olympiast\u00fctzpunkt \u00a0 Rheinland-\u00adPfalz/Saarland. \u00a0 Die \u00a0 meisten \u00a0 Probanden \u00a0 wurden \u00a0telefonisch, \u00a0selten \u00a0auch \u00a0per \u00a0E-\u00adMail, \u00a0konsultiert \u00a0und \u00a0\u00fcber \u00a0die \u00a0Rahmenbedingungen, \u00a0Terminwahl \u00a0sowie \u00a0die \u00a0Zuteilung \u00a0zu \u00a0den \u00a0Subgruppen \u00a0informiert. \u00a0Bei \u00a0einigen \u00a0erfolgte \u00a0dies \u00a0auch \u00a0indirekt \u00a0\u00fcber \u00a0die \u00a0jeweils \u00a0zust\u00e4ndigen \u00a0Trainer \u00a0oder \u00a0Betreuer. \u00a0Hierbei \u00a0wurden \u00a0die \u00a0Teilnehmer \u00a0aus \u00a0verschiedenen \u00a0Sportarten \u00a0rekrutiert. \u00a0Diese \u00a0sind \u00a0im \u00a0Folgenden \u00a0aufgelistet. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a038\t\r \u00a0SPORTART \u00a0ANZAHL/N\u00c4HERE \u00a0KLASSIFIKATION \u00a0BADMINTON \u00a05 \u00a0Bundeskaderathleten \u00a01 \u00a0weitere \u00a0Athletin \u00a0BASKETBALL \u00a01 \u00a0Oberligaspieler \u00a0FU\u00dfBALL \u00a03 \u00a0Regionalligaspieler \u00a0HAMMERWURF \u00a03 \u00a0Bundeskaderathleten/-\u00adinnen \u00a0MOUNTAINBIKE \u00a02 \u00a0C-\u00adKlasse \u00a0Athleten \u00a0RINGEN \u00a03 \u00a0Bundeskaderathleten \u00a01 \u00a0Landeskaderathlet \u00a07 \u00a0weitere \u00a0Athleten \u00a0RUDERN \u00a01 \u00a0Bundeskaderathletin \u00a0 \u00a05 \u00a0Landeskaderathleten/-\u00adinnen \u00a0SCHWIMMEN \u00a05 \u00a0Bundeskaderathleten \u00a02 \u00a0Landeskaderathleten \u00a0TRIATHLON \u00a04 \u00a0Bundeskaderathleten \u00a0ULTRAMARATHONLAUF \u00a02 \u00a0Athleten/-\u00adinnen \u00a0GESAMT \u00a045 \u00a0Athleten/-\u00adinnen \u00a0 \u00a0Tabelle \u00a02: \u00a0Auflistung \u00a0der \u00a0der \u00a0Athleten \u00a0nach \u00a0Sportart \u00a0und \u00a0Kaderstatus \u00a0 \u00a0Es \u00a0wurden \u00a0insbesondere \u00a0Personen \u00a0eingeschlossen, \u00a0die \u00a0nicht \u00a0vorimmunisiert \u00a0waren. \u00a0Ob \u00a0 Teilnehmer \u00a0 vorgeimpft \u00a0 waren, \u00a0 wurde \u00a0 zus\u00e4tzlich \u00a0erfasst. \u00a0In \u00a0 einigen \u00a0 F\u00e4llen \u00a0 lag \u00a0jedoch \u00a0keine \u00a0genaue \u00a0Impfdokumentation \u00a0vor, \u00a0so \u00a0dass \u00a0die \u00a0Erinnerung \u00a0der \u00a0Probanden \u00a0herangezogen \u00a0werden \u00a0musste. \u00a0In \u00a0diesen \u00a0F\u00e4llen \u00a0bleibt \u00a0naturgem\u00e4\u00df \u00a0eine \u00a0Unsicherheit, \u00a0was \u00a0 den \u00a0 genauen \u00a0 Impfzeitpunkt \u00a0 angeht. \u00a0Zwar \u00a0 ist \u00a0 ein \u00a0 ausreichender \u00a0 Schutz \u00a0 der \u00a0Impfung \u00a0in \u00a0der \u00a0Praxis \u00a0sowohl \u00a0f\u00fcr \u00a0Vorimmunisierte \u00a0als \u00a0auch \u00a0f\u00fcr \u00a0Impfnaive \u00a0von \u00a0gro\u00dfer \u00a0Bedeutung, \u00a0 aber \u00a0 ein \u00a0 Unterschied \u00a0 in \u00a0 der \u00a0 Induktion \u00a0 der \u00a0 dadurch \u00a0 ausgel\u00f6sten \u00a0Immunantwort \u00a0 ist \u00a0 nicht \u00a0 ausgeschlossen. \u00a0Eine \u00a0 im \u00a0 Vorjahr \u00a0 durchgef\u00fchrte \u00a0Immunisierung \u00a0wurde \u00a0in \u00a0diesem \u00a0Rahmen \u00a0noch \u00a0als \u00a0akzeptabel \u00a0angesehen. \u00a0Es \u00a0wurden \u00a0Patienten \u00a0 mit \u00a0 einer \u00a0 akuten \u00a0 Infektion \u00a0aufgrund \u00a0 der \u00a0m\u00f6glicherweise \u00a0 verf\u00e4lschten \u00a0Laborparameter \u00a0 nicht \u00a0 in \u00a0 die \u00a0 Studie \u00a0 eingeschlossen. \u00a0 Auch \u00a0eine \u00a0 Schwangerschaft, \u00a0eine \u00a0 Erkrankung \u00a0 aus \u00a0 dem \u00a0 rheumatischen \u00a0 Formenkreis \u00a0sowie \u00a0 eine \u00a0Immunsuppression \u00a0jedweder \u00a0Genese \u00a0galten \u00a0als \u00a0Ausschlusskriterien. \u00a0\t\r \u00a039\t\r \u00a0\u00dcberdies \u00a0erfolgte \u00a0eine \u00a0Aufkl\u00e4rung \u00a0in \u00a0puncto \u00a0bekannter \u00a0Allergien \u00a0gegen \u00a0H\u00fchnereiwei\u00df \u00a0oder \u00a0anderer \u00a0Komponenten \u00a0des \u00a0Impfstoffes. \u00a0Bei \u00a0Vorliegen \u00a0ebensolcher \u00a0wurde \u00a0die \u00a0Impfung \u00a0nicht \u00a0vollzogen. \u00a0Initial \u00a0 wurden \u00a0 46 \u00a0Sportler \u00a0 geimpft. \u00a0 Eine \u00a0 Ablehnung \u00a0 aufgrund \u00a0 einer \u00a0 der \u00a0 oben \u00a0genannten \u00a0Ausschlusskriterien \u00a0war \u00a0nicht \u00a0n\u00f6tig. \u00a0Ein \u00a0Proband \u00a0beendete \u00a0die \u00a0Teilnahme \u00a0an \u00a0der \u00a0Studie \u00a0nach \u00a0einer \u00a0Woche \u00a0aufgrund \u00a0eines \u00a0Wohnortwechsels \u00a0und \u00a0wurde \u00a0aus \u00a0der \u00a0 Studie \u00a0 ausgeschlossen. \u00a0Ein \u00a0 weiterer \u00a0 Proband \u00a0 verweigerte \u00a0 aus \u00a0 pers\u00f6nlichen \u00a0Gr\u00fcnden \u00a0die \u00a0Blutentnahme \u00a0nach \u00a0sechs \u00a0Monaten. \u00a0Durch \u00a0Extrapolation \u00a0der \u00a0fehlenden \u00a0Messwerte \u00a0 (siehe \u00a0 3.5 \u00a0 Statistische \u00a0 Analyse) \u00a0 konnte \u00a0 in \u00a0 diesem \u00a0 Fall \u00a0 ein \u00a0kompletter \u00a0Studienausschluss \u00a0vermieden \u00a0werden. \u00a0Alle \u00a0Probanden \u00a0nahmen \u00a0unentgeltlich \u00a0an \u00a0der \u00a0Studie \u00a0teil. \u00a0 \u00a0GRUPPE \u00a0N \u00a0M \u00a0W \u00a0 \u00a0ALTER \u00a0(MW\u00b1SD) \u00a02 \u00a0H \u00a024 \u00a019 \u00a05 \u00a021,5 \u00a0\u00b1 \u00a04,5 \u00a026 \u00a0H \u00a021 \u00a017 \u00a04 \u00a025,2 \u00a0\u00b1 \u00a09,9 \u00a0 \u00a0Tabelle \u00a03: \u00a0Anthropometrische \u00a0Daten \u00a0f\u00fcr \u00a0alle \u00a0Probanden \u00a0(n=46), \u00a0MW \u00a0= \u00a0Mittelwert, \u00a0SD \u00a0= \u00a0Standardabweichungen \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a040\t\r \u00a03.3. \u00a0Testdurchf\u00fchrung \u00a0 \u00a03.3.1. \u00a0Standardisierung \u00a0 \u00a0Um \u00a0personenbezogene \u00a0St\u00f6rgr\u00f6\u00dfen \u00a0zu \u00a0vermeiden, \u00a0fand \u00a0eine \u00a0Randomisierung \u00a0der \u00a0Sportler \u00a0im \u00a0Sinne \u00a0einer \u00a0zufallsgebundenen \u00a0Zuordnung \u00a0zu \u00a0einer \u00a0der \u00a0beiden \u00a0Subgruppen \u00a0 statt. \u00a0 Dabei \u00a0 wurde \u00a0 im \u00a0 Vorfeld \u00a0 des \u00a0 Impftermins \u00a0 per \u00a0 M\u00fcnzwurf \u00a0festgelegt, \u00a0ob \u00a0der \u00a0Sportler \u00a0in \u00a0die \u00a0Gruppe, \u00a0die \u00a0innerhalb \u00a0von \u00a0zwei \u00a0Stunden \u00a0vor \u00a0der \u00a0Impfung \u00a0intensiv \u00a0trainiert, \u00a0oder \u00a0in \u00a0die \u00a0Gruppe, \u00a0die \u00a0in \u00a0den \u00a026 \u00a0Stunden \u00a0vor \u00a0Impfung \u00a0 keinen \u00a0 Sport \u00a0 betreibt, \u00a0 zugeteilt \u00a0 wird. \u00a0 Die \u00a0 Impfungen \u00a0 und \u00a0Blutentnahmen \u00a0 fanden \u00a0 bei \u00a0 Raumtemperatur \u00a0 (22\u00b0C) \u00a0 unter \u00a0 gleichen \u00a0Bedingungen \u00a0statt. \u00a0 \u00a0An \u00a0den \u00a0Kontrollterminen \u00a0gab \u00a0es \u00a0keine \u00a0Vorgabe \u00a0bez\u00fcglich \u00a0physischer \u00a0Aktivit\u00e4t \u00a0vor \u00a0der \u00a0Blutentnahme. \u00a0 \u00a0 \u00a03.3.2. \u00a0Zeitpunkte \u00a0der \u00a0Impfungen \u00a0und \u00a0Nachkontrollen \u00a0 \u00a0Im \u00a0Zuge \u00a0dieser \u00a0Studie \u00a0wurde \u00a0Ende \u00a0September \u00a0der \u00a0erste \u00a0Proband \u00a0geimpft. \u00a0Das \u00a0Gros \u00a0 der \u00a0 Sportler \u00a0 wurde \u00a0 im \u00a0 Oktober \u00a0 (n=9) \u00a0 und \u00a0 November \u00a0 (n=34) \u00a0 gegen \u00a0 die \u00a0Influenza \u00a0immunisiert. \u00a0Zwei \u00a0Teilnehmer \u00a0wurden \u00a0im \u00a0Dezember \u00a0geimpft. \u00a0Die \u00a0 exakten \u00a0 Impftermine \u00a0 wurden \u00a0 in \u00a0 Absprache \u00a0 mit \u00a0 den \u00a0 Sportlern \u00a0beziehungsweise \u00a0deren \u00a0Trainern \u00a0so \u00a0gew\u00e4hlt, \u00a0dass \u00a0es \u00a0zumeist \u00a0zu \u00a0keiner \u00a0oder \u00a0nur \u00a0einer \u00a0sehr \u00a0geringf\u00fcgigen \u00a0Beeintr\u00e4chtigung \u00a0des \u00a0gewohnten \u00a0oder \u00a0geplanten \u00a0Tagesprogramms \u00a0 kam. \u00a0So \u00a0 wurden \u00a0 die \u00a0 Termine \u00a0 der \u00a0 Gruppe, \u00a0 die \u00a0 am \u00a0 Vortag \u00a0pausieren \u00a0 sollten, \u00a0 auf \u00a0 den \u00a0 Morgen \u00a0 nach \u00a0 trainingsfreien \u00a0 Tagen \u00a0 oder \u00a0 auf \u00a0 freie \u00a0Tage \u00a0 in \u00a0 Folge \u00a0 eines \u00a0 Wettkampfes \u00a0 gelegt. \u00a0 Zudem \u00a0 wurden \u00a0 ausstehende \u00a0Wettkampfphasen \u00a0abgewartet, \u00a0um \u00a0eine \u00a0eventuelle \u00a0Leistungsminderung \u00a0durch \u00a0eventuelle \u00a0Nebenwirkungen \u00a0zu \u00a0vermeiden. \u00a0 \u00a0Die \u00a0 darauffolgenden \u00a0 Untersuchungen \u00a0 wurden \u00a0 sieben \u00a0 Tage, \u00a0 14 \u00a0 Tage \u00a0 und \u00a0 6 \u00a0Monate \u00a0nach \u00a0der \u00a0Impfung \u00a0durchgef\u00fchrt. \u00a0 \u00a0Die \u00a0Wahl \u00a0dieser \u00a0Zeitpunkte \u00a0liegt \u00a0in \u00a0bereits \u00a0durchgef\u00fchrten \u00a0Studien \u00a0im \u00a0Bereich \u00a0der \u00a0Influenza-\u00adImpfung \u00a0begr\u00fcndet. \u00a0Dabei \u00a0kommt \u00a0es \u00a0nach \u00a01-\u00ad2 \u00a0Wochen \u00a0zu \u00a0einem \u00a0\t\r \u00a041\t\r \u00a0Maximum \u00a0 der \u00a0 humoralen \u00a0 und \u00a0 zellul\u00e4ren \u00a0 Immunantwort, \u00a0 die \u00a0 in \u00a0 der \u00a0 Folgezeit \u00a0absinkt \u00a0und \u00a0ein \u00a0Grundniveau \u00a0an \u00a0messbaren \u00a0Effektor-\u00adT-\u00adZellen \u00a0erreicht \u00a0(Schmidt \u00a0et \u00a0al. \u00a02012). \u00a0 \u00a0Um \u00a0 die \u00a0 Unterschiede \u00a0 der \u00a0 Kinetik \u00a0 und \u00a0 Funktionalit\u00e4t \u00a0 der \u00a0 T-\u00adZellen \u00a0 detailliert \u00a0herauszuarbeiten, \u00a0 wurden \u00a0 diese \u00a0 Mehrfachmessungen \u00a0 mit \u00a0 oben \u00a0 genannten \u00a0zeitlichen \u00a0Abst\u00e4nden \u00a0als \u00a0notwendig \u00a0erachtet. \u00a0 \u00a0 \u00a03.3.3. \u00a0Probenmaterial \u00a0und \u00a0Erfassungsb\u00f6gen \u00a0 \u00a0Allen \u00a0Probanden \u00a0wurde \u00a0im \u00a0Vorfeld \u00a0der \u00a0Impfung \u00a0ein \u00a0Informationsbogen \u00a0sowie \u00a0eine \u00a0zu \u00a0unterzeichnende \u00a0Einverst\u00e4ndniserkl\u00e4rung \u00a0ausgeteilt \u00a0(siehe \u00a0Anhang). \u00a0\u00dcberdies \u00a0wurde \u00a0auch \u00a0ein \u00a0\u201eTagebuch\u201c \u00a0zur \u00a0Erfassung \u00a0der \u00a0Nebenwirkungen \u00a0an \u00a0die \u00a0einzelnen \u00a0Teilnehmer \u00a0verteilt. \u00a0Hierbei \u00a0orientierte \u00a0man \u00a0sich \u00a0an \u00a0Vorlagen \u00a0der \u00a0\u201eBrighton \u00a0Collaberation\u201c \u00a0(Gold \u00a0et \u00a0al. \u00a02010). \u00a0In \u00a0 diesem \u00a0 konnten \u00a0 die \u00a0 Beschwerden \u00a0 der \u00a0 ersten \u00a0 sieben \u00a0 Tage \u00a0 nach \u00a0 Impfung \u00a0schriftlich \u00a0festgehalten \u00a0werden, \u00a0und \u00a0falls \u00a0sie \u00a0l\u00e4nger \u00a0anhielten \u00a0auch \u00a0das \u00a0Datum \u00a0des \u00a0 letzten \u00a0 Beschwerdetages. \u00a0 Der \u00a0 Bogen \u00a0 wurde \u00a0 unterteilt \u00a0 in \u00a0 \u201elokale \u00a0Beschwerden \u00a0an \u00a0der \u00a0Einstichstelle\u201c \u00a0und \u00a0\u201eAllgemeinreaktionen\u201c. \u00a0Zu \u00a0den \u00a0lokalen \u00a0Nebenwirkungen \u00a0wurden \u00a0unter \u00a0anderem \u00a0Schmerzen, \u00a0R\u00f6tung \u00a0und \u00a0Schwellung \u00a0gez\u00e4hlt. \u00a0 Zu \u00a0 den \u00a0 allgemeinen \u00a0 Reaktionen \u00a0 M\u00fcdigkeit, \u00a0 \u00dcbelkeit, \u00a0 Sch\u00fcttelfrost \u00a0sowie \u00a0 Kopf-\u00ad \u00a0und \u00a0 Muskelschmerzen. \u00a0 Obendrein \u00a0 wurde \u00a0 noch \u00a0 ein \u00a0 Freiraum \u00a0gelassen \u00a0um \u00a0individuelle, \u00a0nicht \u00a0aufgef\u00fchrte \u00a0Beschwerden \u00a0zu \u00a0erg\u00e4nzen. \u00a0Alle \u00a0auftretenden \u00a0Reaktionen \u00a0sollten \u00a0t\u00e4glich \u00a0anhand \u00a0ihres \u00a0Schweregrades \u00a0neu \u00a0bewertet \u00a0werden. \u00a0Mit \u00a0\u201e1\u201c \u00a0wurden \u00a0milde \u00a0Reaktionen \u00a0bezeichnet, \u00a0bei \u00a0denen \u00a0die \u00a0t\u00e4gliche \u00a0Aktivit\u00e4t \u00a0nicht \u00a0beeintr\u00e4chtigt \u00a0wurde, \u00a0mit \u00a0\u201e2\u201c \u00a0moderate \u00a0Reaktionen, \u00a0die \u00a0die \u00a0 t\u00e4glichen \u00a0 Aktivit\u00e4ten \u00a0 beeintr\u00e4chtigen. \u00a0 Der \u00a0 maximale \u00a0 Schweregrad \u00a0\u201e3\u201c \u00a0(\u201eschwer\u201c) \u00a0 bedeutete, \u00a0 dass \u00a0 durch \u00a0 die \u00a0 betroffene \u00a0 Nebenwirkung \u00a0 die \u00a0 t\u00e4glichen \u00a0Aktivit\u00e4ten \u00a0nicht \u00a0mehr \u00a0ausgef\u00fchrt \u00a0werden \u00a0konnten. \u00a0Die \u00a0Parameter \u00a0R\u00f6tung \u00a0und \u00a0Schwellung \u00a0 wurden \u00a0 anhand \u00a0 ihrer \u00a0 Gr\u00f6\u00dfe \u00a0 in \u00a0 Millimeter \u00a0 \u00fcber \u00a0 diesen \u00a0 Zeitraum \u00a0quantifiziert. \u00a0Ferner \u00a0wurde \u00a0in \u00a0dem \u00a0Bogen \u00a0die \u00a0t\u00e4glich \u00a0gemessene \u00a0K\u00f6rpertemperatur \u00a0erfasst. \u00a0Die \u00a0 Messungen \u00a0 sollten \u00a0 dabei \u00a0etwa \u00a0 zur \u00a0 gleichen \u00a0 Uhrzeit \u00a0 erfolgen, \u00a0 um \u00a0 eine \u00a0bessere \u00a0 Vergleichbarkeit \u00a0 zu \u00a0 gew\u00e4hrleisten. \u00a0 Die \u00a0 zuvor \u00a0 ausgeteilten, \u00a0\t\r \u00a042\t\r \u00a0handels\u00fcblichen \u00a0 Thermometer \u00a0 eignen \u00a0 sich \u00a0 zur \u00a0 oralen, \u00a0 axill\u00e4ren \u00a0 und \u00a0 rektalen \u00a0Messung \u00a0 und \u00a0 konnten \u00a0 von \u00a0 den \u00a0 Teilnehmern \u00a0 behalten \u00a0 werden. \u00a0Die \u00a0K\u00f6rpertemperatur \u00a0 sollte \u00a0 oral \u00a0 gemessen \u00a0 werden. \u00a0 Bei \u00a0 mehreren \u00a0 Messungen \u00a0wurde \u00a0 die \u00a0 h\u00f6chste \u00a0 Temperatur \u00a0des \u00a0 Tages \u00a0notiert. \u00a0Erg\u00e4nzend \u00a0 konnte, \u00a0 falls \u00a0vorhanden, \u00a0 auch \u00a0 die \u00a0 t\u00e4gliche \u00a0 Medikation \u00a0 und \u00a0 die \u00a0 Behandlung \u00a0 von \u00a0unerw\u00fcnschten \u00a0 Wirkungen \u00a0 durch \u00a0 die \u00a0 Impfung \u00a0 dokumentiert \u00a0 werden. \u00a0 Und \u00a0 es \u00a0bestand \u00a0die \u00a0M\u00f6glichkeit \u00a0dem \u00a0Bogen \u00a0erg\u00e4nzende \u00a0Bemerkungen \u00a0hinzuzuf\u00fcgen \u00a0(siehe \u00a0Anhang \u00a0Nebenwirkungsbogen). \u00a0Auch \u00a0ein \u00a0Fragebogen \u00a0zur \u00a0Erhebung \u00a0der \u00a0Trainingsinhalte \u00a0und \u00a0\u2013umf\u00e4nge \u00a0wurde \u00a0an \u00a0 jeden \u00a0 Leistungssportler \u00a0 im \u00a0 Rahmen \u00a0 der \u00a0 Impfung \u00a0 verteilt. \u00a0 Anhand \u00a0 dieses \u00a0Bogens \u00a0 wurde \u00a0 der \u00a0 Aufwand \u00a0 der \u00a0 sportlichen \u00a0 Bet\u00e4tigung \u00a0 quantifiziert. \u00a0 Dabei \u00a0wurde \u00a0 der \u00a0zeitliche \u00a0Umfang \u00a0der \u00a0 Trainingseinheit, \u00a0 aber \u00a0 auch \u00a0 die \u00a0 Art \u00a0 des \u00a0Trainings \u00a0 in \u00a0 den \u00a0 beiden \u00a0 Tagen \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0sowie \u00a0 in \u00a0 den \u00a0 zwei \u00a0darauffolgenden \u00a0 Wochen \u00a0 dokumentiert. \u00a0 Zus\u00e4tzlich \u00a0 wurde \u00a0 nach \u00a0 jeder \u00a0Trainingseinheit \u00a0 aufgezeichnet, \u00a0 ob \u00a0 es \u00a0 w\u00e4hrend \u00a0 der \u00a0 k\u00f6rperlichen \u00a0 Bet\u00e4tigung \u00a0subjektiv \u00a0 zu \u00a0 einer \u00a0 Leistungseinschr\u00e4nkung \u00a0 durch \u00a0 die \u00a0 Impfung \u00a0 und \u00a0 deren \u00a0Nebenwirkungen \u00a0kam \u00a0(siehe \u00a0Anhang \u00a0Trainingsbogen). \u00a0 \u00a0Bei \u00a0den \u00a0 Blutentnahmen \u00a0 wurden \u00a0 jedem \u00a0 Teilnehmer \u00a0 jeweils \u00a0 4,7 \u00a0 ml \u00a0Lithiumheparinblut, \u00a0 zwei \u00a0 R\u00f6hrchen \u00a0 \u00e0 \u00a07,5 \u00a0 ml \u00a0 Serum \u00a0 und \u00a0 2,7 \u00a0ml \u00a0 EDTA-\u00adBlut \u00a0entnommen. \u00a0 Das \u00a0 Lithiumheparinblut \u00a0 wurde \u00a0 f\u00fcr \u00a0 die \u00a0 T-\u00adZellanalyse \u00a0 verwendet, \u00a0das \u00a0Serum \u00a0f\u00fcr \u00a0die \u00a0Antik\u00f6rpermessung \u00a0und \u00a0die \u00a0Messung \u00a0des \u00a0CRP. \u00a0Mithilfe \u00a0des \u00a0EDTA-\u00adBlutes \u00a0 wurde \u00a0 ein \u00a0 Differentialblutbild \u00a0 erstellt. \u00a0 Somit \u00a0 wurden \u00a0 jedem \u00a0Probanden \u00a0 zu \u00a0 jedem \u00a0 der \u00a0 vier \u00a0 Entnahmezeitpunkte \u00a0 jeweils \u00a0 22,4 \u00a0 ml \u00a0 Blut \u00a0entnommen. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a043\t\r \u00a03.3.4. \u00a0Studienablauf \u00a0 \u00a0Nach \u00a0Vereinbarung \u00a0der \u00a0Termine \u00a0wurde \u00a0aufgrund \u00a0der \u00a0g\u00fcnstigeren \u00a0Infrastruktur \u00a0der \u00a0Gro\u00dfteil \u00a0der \u00a0Impfungen \u00a0an \u00a0der \u00a0Sportmedizin \u00a0in \u00a0Saarbr\u00fccken \u00a0durchgef\u00fchrt. \u00a0 \u00a0Zu \u00a0 Beginn \u00a0 wurden \u00a0 alle \u00a0 Teilnehmer \u00a0 noch \u00a0 einmal \u00a0 \u00fcber \u00a0 den \u00a0 Studienablauf, \u00a0 die \u00a0Verwendung \u00a0 der \u00a0 Daten \u00a0sowie \u00a0 die \u00a0 Komplikationsrisiken \u00a0 und \u00a0 die \u00a0Kontraindikationen \u00a0der \u00a0 Impfung \u00a0 aufgekl\u00e4rt. \u00a0 Infolgedessen \u00a0 sollte \u00a0 auch \u00a0 die \u00a0Einverst\u00e4ndniserkl\u00e4rung \u00a0 unterzeichnet \u00a0 beziehungsweise \u00a0 bei \u00a0 Minderj\u00e4hrigen, \u00a0die \u00a0 von \u00a0 den \u00a0 Erziehungsberechtigten \u00a0 unterschriebene \u00a0 Erkl\u00e4rung \u00a0vorgezeigt \u00a0werden. \u00a0Daraufhin \u00a0 erfolgte \u00a0 die \u00a0 erste \u00a0 Blutentnahme, \u00a0die \u00a0immer \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0durchgef\u00fchrt \u00a0wurde. \u00a0Nachdem \u00a0die \u00a0Entnahmestelle \u00a0lege \u00a0artis \u00a0desinfiziert \u00a0wurde, \u00a0erfolgte \u00a0mithilfe \u00a0einer \u00a0Multifly-\u00adKan\u00fcle \u00a0eine \u00a0ven\u00f6se \u00a0Blutentnahme \u00a0(Vena \u00a0mediana \u00a0cubiti). \u00a0 \u00a0Im \u00a0 Anschluss \u00a0wurde \u00a0die \u00a0 Impfung \u00a0 nach \u00a0 einem \u00a0 standardisierten \u00a0 Schema \u00a0durchgef\u00fchrt \u00a0(s. \u00a0u.). \u00a0Als \u00a0Impfstoff \u00a0wurde \u00a0ein \u00a0tetravalenter \u00a0Totimpfstoff \u00a0(\u201eInfluSplit \u00a0Tetra \u00a0 2016/17\u201c;\u037e \u00a0GlaxoSmithKline \u00a0 GmbH \u00a0 & \u00a0 Co. \u00a0 KG, \u00a0 Charge: \u00a0 AFLBA \u00a0152AB) \u00a0gew\u00e4hlt. \u00a0Der \u00a0Impfstoff \u00a0wurde \u00a0zuvor \u00a0im \u00a0K\u00fchlschrank \u00a0gelagert. \u00a0Nach \u00a0Entnahme \u00a0des \u00a0 Impfstoffes, \u00a0der \u00a0sich \u00a0 bereits \u00a0 in \u00a0 einer \u00a0 Fertigspritze \u00a0 befand, \u00a0 wurden \u00a0Chargenaufkleber \u00a0sowohl \u00a0in \u00a0der \u00a0Patientenakte \u00a0als \u00a0auch \u00a0im \u00a0Impfpass \u00a0hinterlegt. \u00a0Danach \u00a0wurde \u00a0der \u00a0Impfstoff \u00a0in \u00a0der \u00a0Hand \u00a0angew\u00e4rmt \u00a0und \u00a0mit \u00a0einer \u00a0Nadel \u00a0f\u00fcr \u00a0i.m. \u00a0Injektionen \u00a0versehen. \u00a0Hierzu \u00a0wurden \u00a0Kan\u00fclen \u00a0mit \u00a00,5 \u00a0mm \u00a0x \u00a025 \u00a0mm \u00a0bzw. \u00a025 \u00a0g \u00a0x \u00a01 \u00a0verwendet. \u00a0Die \u00a0Spritzen \u00a0wurden \u00a0vor \u00a0der \u00a0Injektion \u00a0nicht \u00a0entl\u00fcftet, \u00a0so \u00a0dass, \u00a0kein \u00a0Impfstoff \u00a0 nach \u00a0 au\u00dfen \u00a0 an \u00a0 die \u00a0 Kan\u00fcle \u00a0 kommen \u00a0 konnte. \u00a0Geimpft \u00a0 wurde \u00a0 am \u00a0sitzenden \u00a0 oder \u00a0 liegenden \u00a0 Patienten \u00a0 in \u00a0 den \u00a0 Musculus \u00a0deltoideus \u00a0 des \u00a0 nicht \u00a0dominanten \u00a0Armes. \u00a0Der \u00a0Oberarm \u00a0sollte \u00a0dabei \u00a0locker \u00a0herunterh\u00e4ngen \u00a0um \u00a0ein \u00a0Anspannen \u00a0 der \u00a0 Muskeln \u00a0 zu \u00a0 vermeiden. \u00a0Nach \u00a0 Orientierung \u00a0 an \u00a0 den \u00a0anatomischen \u00a0Gegebenheiten \u00a0und \u00a0Auffinden \u00a0einer \u00a0geeigneten \u00a0Injektionsstelle, \u00a0erfolgte \u00a0 die \u00a0 Desinfektion \u00a0 der \u00a0 entsprechenden \u00a0 Stelle. \u00a0 Nach \u00a0 erstmaligem \u00a0Aufspr\u00fchen \u00a0des \u00a0Desinfektionsmittels \u00a0und \u00a0Abwischen \u00a0mittels \u00a0Tupfer, \u00a0wurde \u00a0die \u00a0Stelle \u00a0erneut \u00a0desinfiziert. \u00a0Um \u00a0eine \u00a0Verschleppung \u00a0des \u00a0Desinfektionsmittels \u00a0in \u00a0den \u00a0 Stichkanal \u00a0 und \u00a0 dadurch \u00a0 entstehende \u00a0 Lokalrealreaktionen \u00a0 zu \u00a0 vermeiden, \u00a0wurde \u00a0mindestens \u00a030 \u00a0Sekunden \u00a0gewartet, \u00a0bis \u00a0die \u00a0Haut \u00a0komplett \u00a0getrocknet \u00a0war. \u00a0Danach \u00a0 erfolgte \u00a0 der \u00a0 Einstich \u00a0 in \u00a0 die \u00a0 betreffende \u00a0 Stelle \u00a0 in \u00a0 einem \u00a0 90\u00b0 \u00a0 Winkel \u00a0\t\r \u00a044\t\r \u00a0(Cook&Murtagh \u00a02005) \u00a0und \u00a0aufgrund \u00a0der \u00a0schmerzreduzierenden \u00a0Wirkung \u00a0eine \u00a0z\u00fcgige \u00a0 Injektion \u00a0 des \u00a0 Impfstoffes \u00a0 (Ipp \u00a0 et \u00a0 al. \u00a0 2007). \u00a0 Auf \u00a0 eine \u00a0 Aspiration \u00a0 wurde \u00a0entsprechend \u00a0 der \u00a0 Leitlinien \u00a0 der \u00a0 STIKO \u00a0 2016/17 \u00a0 verzichtet. \u00a0 \u00a0Um \u00a0 allergische \u00a0Reaktionen \u00a0und \u00a0Synkopen \u00a0fr\u00fchzeitig \u00a0zu \u00a0erkennen \u00a0und \u00a0behandeln \u00a0zu \u00a0k\u00f6nnen, \u00a0wurde \u00a0eine \u00a0Nachbeobachtungszeit \u00a0von \u00a030 \u00a0Minuten \u00a0eingehalten. \u00a0Nach \u00a0 der \u00a0 Impfung \u00a0 wurden \u00a0den \u00a0 Studienteilnehmern \u00a0die \u00a0 Frageb\u00f6gen \u00a0 zur \u00a0Trainingsanamnese \u00a0und \u00a0den \u00a0Nebenwirkungen \u00a0erl\u00e4utert. \u00a0Ein \u00a0 Teil \u00a0 der \u00a0 entnommenen \u00a0 Blutproben \u00a0 verblieb \u00a0 im \u00a0 Anschluss \u00a0 in \u00a0 der \u00a0Sportmedizin. \u00a0Dort \u00a0erfolgte \u00a0im \u00a0institutseigenen \u00a0klinisch-\u00adchemischen \u00a0Labor \u00a0die \u00a0sp\u00e4ter \u00a0 erl\u00e4uterte \u00a0 Routinediagnostik. \u00a0 Ein \u00a0 Serumr\u00f6hrchen \u00a0 und \u00a0 das \u00a0Lithiumheparinr\u00f6hrchen \u00a0 wurden \u00a0 an \u00a0 das \u00a0 immunologische \u00a0 Labor \u00a0 der \u00a0Transplantations-\u00ad \u00a0und \u00a0Infektionsimmunologie \u00a0nach \u00a0Homburg \u00a0transportiert. \u00a0Dort \u00a0fanden \u00a0 die \u00a0 laborexperimentellen \u00a0 Analysen \u00a0 der \u00a0 Blutproben \u00a0 statt. \u00a0Nach \u00a0 einer \u00a0Woche, \u00a0zwei \u00a0Wochen \u00a0und \u00a0sechs \u00a0Monaten \u00a0wurden \u00a0die \u00a0Kontrollblutentnahmen \u00a0nach \u00a0 dem \u00a0 gleichen, \u00a0 oben \u00a0 genannten \u00a0 Schema, \u00a0 durchgef\u00fchrt. \u00a0Zudem \u00a0 wurden \u00a0innerhalb \u00a0der \u00a0 ersten \u00a0 beiden \u00a0 Wochen \u00a0 nach \u00a0 Impfung \u00a0 die \u00a0 \u201eTageb\u00fccher\u201c \u00a0 zur \u00a0Erfassung \u00a0 der \u00a0 Nebenwirkungen \u00a0sowie \u00a0 die \u00a0 Frageb\u00f6gen \u00a0 zur \u00a0 Erfassung \u00a0 des \u00a0Trainingsinhaltes \u00a0und \u00a0\u2013umfanges \u00a0eingesammelt \u00a0und \u00a0weitere \u00a0Beschwerden \u00a0und \u00a0Einschr\u00e4nkungen \u00a0nach \u00a0dieser \u00a0Zeit \u00a0erfragt. \u00a0 \u00a0\n \u00a0 \u00a0Abbildung \u00a03: \u00a0Schematische \u00a0Darstellung \u00a0des \u00a0Studienverlaufs. \u00a0nach\t\r \u00a06\t\r \u00a0Monaten\t\r \u00a0Letzte\t\r \u00a0BETag\t\r \u00a014Dritte\t\r \u00a0BEEnde\t\r \u00a0TrainingserfassungTag\t\r \u00a07Zweite\t\r \u00a0BEEnde\t\r \u00a0NebenwirkungserfassungTag\t\r \u00a00Erste\t\r \u00a0BEImpfungBeginn\t\r \u00a0Datenerfassung\t\r \u00a045\t\r \u00a03.4. \u00a0Messmethodik \u00a0 \u00a03.4.1. \u00a0Anthropometrische \u00a0Daten \u00a0 \u00a0Die \u00a0anthropometrischen \u00a0Daten \u00a0der \u00a0Teilnehmer \u00a0wurden \u00a0anamnestisch \u00a0erhoben. \u00a0 \u00a0 \u00a03.4.2. \u00a0Routine \u00a0Laborparameter \u00a0 \u00a0Die \u00a0 Bestimmung \u00a0 der \u00a0 Routinediagnostik \u00a0 erfolgte \u00a0 direkt \u00a0 im \u00a0 Anschluss \u00a0 an \u00a0 die \u00a0Blutentnahme. \u00a0Dabei \u00a0 wurde \u00a0 in \u00a0 jedem \u00a0 Zyklus \u00a0 eine \u00a0 h\u00e4matologische \u00a0 Diagnostik \u00a0 (H\u00e4moglobin, \u00a0H\u00e4matokrit, \u00a0 Erythrozyten, \u00a0 Leukozyten, \u00a0 Thrombozyten, \u00a0 MCV) \u00a0 und \u00a0 ein \u00a0Differentialblutbild \u00a0 (Neutrophile, \u00a0 Eosinophile, \u00a0 Basophile, \u00a0 Lymphozyten, \u00a0Monozyten) \u00a0erstellt. \u00a0Auch \u00a0der \u00a0CRP-\u00adWert \u00a0wurde \u00a0bei \u00a0jeder \u00a0Untersuchung \u00a0erfasst. \u00a0Bei \u00a0 der \u00a0 ersten \u00a0 Blutuntersuchung \u00a0 wurden \u00a0 additiv \u00a0 zur \u00a0 \u00dcberpr\u00fcfung \u00a0 des \u00a0Gesundheitszustandes \u00a0 noch \u00a0 Leberwerte \u00a0 (GOT, \u00a0 GPT, \u00a0 Gamma-\u00adGT), \u00a0Nierenwerte \u00a0(Harnstoff, \u00a0Kreatinin), \u00a0Elektrolyte \u00a0(Kalium, \u00a0Natrium) \u00a0und \u00a0Glukose \u00a0mitbestimmt. \u00a0Eine \u00a0 statistische \u00a0 Auswertung \u00a0 dieser \u00a0 einmalig \u00a0 erhobenen \u00a0 Werte \u00a0erfolgte \u00a0nicht. \u00a0Das \u00a0 Blutbild \u00a0 wurde \u00a0 anhand \u00a0 eines \u00a0 gut \u00a0 durchmischten \u00a0 EDTA-\u00adR\u00f6hrchens \u00a0 am \u00a0\u201eACT5diff\u201c \u00a0 von \u00a0 Beckman \u00a0Coulter, \u00a0 einem \u00a0 vollautomatischen \u00a0 H\u00e4matologie-\u00adAnalysator, \u00a0bestimmt. \u00a0F\u00fcr \u00a0die \u00a0aus \u00a0der \u00a0Serumchemie \u00a0zu \u00a0bestimmenden \u00a0Werte \u00a0lie\u00df \u00a0man \u00a0das \u00a0Blut \u00a0in \u00a0einer \u00a0Serum-\u00adMonovette \u00a0gerinnen. \u00a0Danach \u00a0wurde \u00a0dieses \u00a0f\u00fcr \u00a0f\u00fcnf \u00a0 Minuten \u00a0 bei \u00a0 4000 \u00a0 rpm \u00a0 zentrifugiert. \u00a0 Der \u00a0 Serum\u00fcberstand \u00a0 wurde \u00a0 im \u00a0Anschluss \u00a0zur \u00a0Messung \u00a0im \u00a0\u201eUniCel \u00a0DXC \u00a0600\u201c \u00a0von \u00a0Beckmann \u00a0Coulter \u00a0eingesetzt \u00a0und \u00a0vollautomatisiert \u00a0gemessen. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a046\t\r \u00a03.4.3. \u00a0Immunologische \u00a0laboranalytische \u00a0Methoden \u00a0 \u00a0Die \u00a0laboranalytischen \u00a0Verfahren \u00a0wurden \u00a0im \u00a0Rahmen \u00a0einer \u00a0weiteren \u00a0Dissertation \u00a0am \u00a0Universit\u00e4tsklinikum \u00a0des \u00a0Saarlandes \u00a0in \u00a0Homburg \u00a0durchgef\u00fchrt. \u00a0Es \u00a0soll \u00a0hier \u00a0nur \u00a0ein \u00a0\u00dcberblick \u00a0\u00fcber \u00a0die \u00a0Vorgehensweise \u00a0gegeben \u00a0werden. \u00a0 \u00a0Zuerst \u00a0wurden \u00a0zwei \u00a0verschiedene \u00a0Oberfl\u00e4chenf\u00e4rbungen \u00a0durchgef\u00fchrt. \u00a0Eine \u00a0T-\u00adZell-\u00ad \u00a0und \u00a0eine \u00a0B-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung. \u00a0F\u00fcr \u00a0 die \u00a0 T-\u00adZell-\u00adF\u00e4rbung \u00a0 wurden \u00a0 100 \u00a0\u00b5l \u00a0 Vollblut \u00a0 mit \u00a0 18,25 \u00a0\u00b5l \u00a0eines \u00a0Antik\u00f6rpergemisches \u00a0 (Tbl. \u00a0 3) \u00a0 vermischt \u00a0 und \u00a0 20-\u00ad30 \u00a0 Minuten \u00a0 im \u00a0 Dunkeln \u00a0 bei \u00a0Raumtemperatur \u00a0 inkubiert. \u00a0 Danach \u00a0 wurden \u00a0 900 \u00a0\u00b5l \u00a0 einer \u00a0 \u201eLysing-\u00adL\u00f6sung\u201c \u00a0hinzugegeben, \u00a0 die \u00a0 zu \u00a0 einer \u00a0 Zelllyse \u00a0 f\u00fchrt. \u00a0 Nach \u00a0 erneuter \u00a0 zehnmin\u00fctiger \u00a0Inkubation \u00a0im \u00a0Dunkeln, \u00a0wurde \u00a0das \u00a0Gemisch \u00a0bei \u00a01300 \u00a0rpm \u00a0f\u00fcr \u00a0sieben \u00a0Minuten \u00a0zentrifugiert \u00a0und \u00a0bis \u00a0auf \u00a0einen \u00a0kleinen \u00a0Bodensatz \u00a0abgesaugt. \u00a0Zu \u00a0diesem \u00a0wurden \u00a0dann \u00a02 \u00a0ml \u00a0eines \u00a0sogenannten \u00a0\u201eFACS-\u00adPuffers\u201c \u00a0hinzugef\u00fcgt \u00a0und \u00a0es \u00a0erfolgte \u00a0eine \u00a0erneute \u00a0 siebenmin\u00fctige \u00a0 Zentrifugierung \u00a0 bei \u00a0 1300 \u00a0 rpm. \u00a0 Die \u00a0 \u00fcbersch\u00fcssige \u00a0Fl\u00fcssigkeit \u00a0wurde \u00a0ebenfalls \u00a0wieder \u00a0abgesaugt. \u00a0Die \u00a0Probe \u00a0wurde \u00a0dann \u00a0in \u00a0150 \u00a0\u00b5l \u00a01%igem \u00a0Paraformaldehyd \u00a0konserviert. \u00a0 \u00a0CD4 \u00a0APC-\u00adH7 \u00a01 \u00a0\u00b5l \u00a0CD8 \u00a0V500 \u00a01 \u00a0\u00b5l \u00a0CD45RO \u00a0PE-\u00adCy7 \u00a01,25 \u00a0\u00b5l \u00a0CD27 \u00a0FITC \u00a04 \u00a0\u00b5l \u00a0CXCR5 \u00a0PerCP-\u00adCy5.5 \u00a01 \u00a0\u00b5l \u00a0ICOS/CD278 \u00a0PE \u00a05 \u00a0\u00b5l \u00a0PDI \u00a0APC \u00a05 \u00a0\u00b5l \u00a0 \u00a0Tabelle \u00a04: \u00a0 \u00dcbersicht \u00a0 \u00fcber \u00a0 die \u00a0 Handelsnamen \u00a0 der \u00a0 bei \u00a0 der \u00a0 T-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung \u00a0 eingesetzten \u00a0 Antik\u00f6rper \u00a0 (Mitte)und \u00a0 die \u00a0 zugeh\u00f6rigen \u00a0Oberfl\u00e4chenstrukturen \u00a0 (Links). \u00a0 Zudem \u00a0 die \u00a0 jeweiligen \u00a0 Volumenangaben \u00a0(Rechts). \u00a0 \u00a0Im \u00a0 Rahmen \u00a0 der \u00a0 B-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung \u00a0 wurden \u00a0 100 \u00a0\u00b5l \u00a0 Vollblut \u00a0 mit \u00a0 15 \u00a0\u00b5l \u00a0einer \u00a0Antik\u00f6rpermischung \u00a0vermengt \u00a0(Tbl. \u00a04). \u00a0Die \u00a0folgenden \u00a0Schritte \u00a0sind \u00a0identisch \u00a0mit \u00a0der \u00a0T-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung. \u00a0\t\r \u00a047\t\r \u00a0 \u00a0CD19 \u00a0FITC \u00a02,5 \u00a0\u00b5l \u00a0IgD \u00a0PE-\u00adCy7 \u00a03 \u00a0\u00b5l \u00a0CD27 \u00a0APC \u00a00,5 \u00a0\u00b5l \u00a0CD38 \u00a0PE \u00a05 \u00a0\u00b5l \u00a0CD3 \u00a0PerCP \u00a04 \u00a0\u00b5l \u00a0 \u00a0Tabelle \u00a05: \u00a0 \u00dcbersicht \u00a0 \u00fcber \u00a0 die \u00a0 Handelsnamen \u00a0 der \u00a0 bei \u00a0 der \u00a0 B-\u00adZell-\u00adOberfl\u00e4chenf\u00e4rbung \u00a0 eingesetzten \u00a0 Antik\u00f6rper \u00a0 (Mitte)und \u00a0 die \u00a0 zugeh\u00f6rigen \u00a0Oberfl\u00e4chenstrukturen \u00a0 (Links). \u00a0 Zudem \u00a0 die \u00a0 jeweiligen \u00a0 Volumenangaben \u00a0(Rechts). \u00a0 \u00a0Anschlie\u00dfend \u00a0 wurde \u00a0 die \u00a0 Oberfl\u00e4chenzusammensetzung \u00a0durchflusszytometrisch \u00a0gemessen. \u00a0In \u00a0einem \u00a0weiteren \u00a0Schritt \u00a0erfolgte \u00a0eine \u00a0Stimulation \u00a0der \u00a0Zellen. \u00a0Dazu \u00a0 wurden \u00a0 je \u00a0 450 \u00a0\u00b5l \u00a0 Vollblut \u00a0 mit \u00a0 8 \u00a0\u00b5l \u00a0 einer \u00a0 Phosphat-\u00adgepufferten \u00a0Kochsalz\u00f6sung \u00a0(PBS), \u00a0mit \u00a01,125 \u00a0\u00b5l \u00a0Staphylococcus \u00a0aureus \u00a0Enterotoxin \u00a0B \u00a0(SEB) \u00a0oder \u00a0 mit \u00a0 8 \u00a0\u00b5l \u00a0 des \u00a0 in \u00a0 der \u00a0 Studie \u00a0 verwendeten \u00a0 Impfstoffes \u00a0 (\u201eInfluSplit \u00a0 Tetra\u201c) \u00a0versetzt. \u00a0Zudem \u00a0wurde \u00a0pro \u00a0Antigen \u00a0auch \u00a01,35 \u00a0\u00b5l \u00a0Stim-\u00adMix \u00a0vorgelegt, \u00a0um \u00a0die \u00a0Stimulation \u00a0der \u00a0Zellen \u00a0zu \u00a0verst\u00e4rken. \u00a0Das \u00a0PBS \u00a0diente \u00a0als \u00a0Negativkontrolle, \u00a0bei \u00a0SEB \u00a0 ist \u00a0 unabh\u00e4ngig \u00a0 von \u00a0 der \u00a0 Impfung \u00a0 eine \u00a0 sehr \u00a0 ausgepr\u00e4gte \u00a0 Zellreaktion \u00a0 zu \u00a0erwarten. \u00a0Nach \u00a0einer \u00a0Inkubationszeit \u00a0von \u00a0zwei \u00a0Stunden \u00a0wurden \u00a0je \u00a00,9 \u00a0\u00b5l \u00a0Brefeldin \u00a0A \u00a0(BFA) \u00a0zugesetzt \u00a0 und \u00a0 weitere \u00a0 vier \u00a0 Stunden \u00a0 inkubiert. \u00a0 Nach \u00a0 Ablauf \u00a0 der \u00a0 Zeit \u00a0 wurden \u00a0jeweils \u00a045 \u00a0\u00b5l \u00a0EDTA \u00a0zugef\u00fcgt \u00a0und \u00a0f\u00fcr \u00a0zehn \u00a0Sekunden \u00a0gevortext. \u00a0Nach \u00a0einer \u00a0Inkubation \u00a0von \u00a015 \u00a0Minuten \u00a0bei \u00a0Raumtemperatur \u00a0wurden \u00a04ml \u00a0einer \u00a0Lysing-\u00adL\u00f6sung \u00a0 zu \u00a0 dem \u00a0 Gemisch \u00a0 hinzugegeben \u00a0 und \u00a0 es \u00a0 erfolgte \u00a0 eine \u00a0 erneute \u00a0Inkubation \u00a0 f\u00fcr \u00a0 zehn \u00a0 Minuten \u00a0 bei \u00a0 Raumtemperatur. \u00a0 Nach \u00a0 siebenmin\u00fctigem \u00a0zentrifugieren \u00a0 (bei \u00a0 1300 \u00a0 rpm) \u00a0 und \u00a0 absaugen \u00a0 des \u00a0 \u00dcberstandes \u00a0 wurden \u00a0 2 \u00a0ml \u00a0FACS-\u00adPuffer \u00a0hinzugegeben \u00a0und \u00a0erneut \u00a0zentrifugiert \u00a0(7 \u00a0Minuten, \u00a01300 \u00a0rpm) \u00a0und \u00a0abgesaugt. \u00a0Das \u00a0restliche \u00a0Pr\u00e4parat \u00a0wurde \u00a0in \u00a0400 \u00a0\u00b5L \u00a0FACS-\u00adPuffer \u00a0aufgenommen. \u00a0Danach \u00a0erfolgte \u00a0die \u00a0intrazellul\u00e4re \u00a0F\u00e4rbung. \u00a0Dazu \u00a0 wurden \u00a0 je \u00a0 200 \u00a0\u00b5l \u00a0 auf \u00a0 FACS-\u00adR\u00f6hrchen \u00a0 verteilt \u00a0 und \u00a0 2 \u00a0ml \u00a0 eines \u00a0 5%igen \u00a0Saponin-\u00adPuffers \u00a0 hinzugef\u00fcgt. \u00a0 Dann \u00a0 wurden \u00a0 die \u00a0 Proben \u00a0 f\u00fcr \u00a0 zehn \u00a0 Minuten \u00a0 bei \u00a0\t\r \u00a048\t\r \u00a0Raumtemperatur \u00a0inkubiert, \u00a0zentrifugiert \u00a0(7 \u00a0Minuten, \u00a01300 \u00a0rpm) \u00a0und \u00a0abgesaugt. \u00a0Im \u00a0Anschluss \u00a0wurden \u00a0die \u00a0intrazellul\u00e4ren \u00a0Antik\u00f6rper \u00a0zu \u00a0je \u00a050 \u00a0\u00b5l \u00a0Probenvolumen \u00a0(Tbl. \u00a05 \u00a0und \u00a06) \u00a0zugegeben. \u00a0Nach \u00a0erneuter \u00a0drei\u00dfigmin\u00fctiger \u00a0Inkubation \u00a0bei \u00a0Raumtemperatur \u00a0wurden \u00a03 \u00a0ml \u00a0eines \u00a0FACS-\u00adPuffers \u00a0gemischt, \u00a0zentrifugiert \u00a0(7 \u00a0Minuten \u00a01300 \u00a0rpm), \u00a0abgesaugt \u00a0und \u00a0in \u00a0150 \u00a0\u00b5l \u00a0Paraformaldehyd \u00a0aufgenommen. \u00a0 \u00a0CD4 \u00a0PE-\u00adCy7 \u00a01 \u00a0\u00b5l \u00a0CD \u00a069 \u00a0PerCP \u00a02 \u00a0\u00b5l \u00a0IFNg\uf067 \u00a0FITC \u00a00,5 \u00a0\u00b5l \u00a0IL-\u00ad2 \u00a0PE \u00a02 \u00a0\u00b5l \u00a0TNFa\uf061 \u00a0V450 \u00a01 \u00a0\u00b5l \u00a0IL-\u00ad21 \u00a0AlexaFlour647 \u00a05 \u00a0\u00b5l \u00a0SAP \u00a05% \u00a0 \u00a01 \u00a0\u00b5l \u00a0FACS \u00a0Puffer \u00a0 \u00a037,5 \u00a0\u00b5l \u00a0 \u00a0Tabelle \u00a06: \u00a0Zusammensetzung \u00a0der \u00a050 \u00a0\u00b5l \u00a0des \u00a0Probenvolumens \u00a0der \u00a01. \u00a0F\u00e4rbung \u00a0der \u00a0Stimulation. \u00a0Die \u00a0vier \u00a0anzuf\u00e4rbenden \u00a0Zytokine \u00a0sind \u00a0hervorgehoben. \u00a0In \u00a0der \u00a0Mitte \u00a0der \u00a0Tabelle \u00a0der \u00a0Handelsname \u00a0der \u00a0eingesetzten \u00a0Antik\u00f6rper. \u00a0 \u00a0 \u00a0CD4 \u00a0PE-\u00adCy7 \u00a01 \u00a0\u00b5l \u00a0CD69 \u00a0PerCP \u00a02 \u00a0\u00b5l \u00a0IFNg\uf067 \u00a0FITC \u00a00,5 \u00a0\u00b5l \u00a0CD27 \u00a0PE \u00a02 \u00a0\u00b5l \u00a0CTLA4 \u00a0APC \u00a02 \u00a0\u00b5l \u00a0SAP \u00a05% \u00a0 \u00a01 \u00a0\u00b5l \u00a0FACS \u00a0Puffer \u00a0 \u00a041,4 \u00a0\u00b5l \u00a0 \u00a0Tabelle \u00a07: \u00a0 Zusammensetzung \u00a0 der \u00a0 50 \u00a0\u00b5l \u00a0der \u00a0 2. \u00a0 F\u00e4rbung \u00a0 der \u00a0 Stimulation. \u00a0 Die \u00a0anzuf\u00e4rbenden \u00a0Influenza-\u00adCluster \u00a0sind \u00a0hervorgehoben. \u00a0In \u00a0der \u00a0Mitte \u00a0der \u00a0Tabelle \u00a0die \u00a0Handelsnamen \u00a0der \u00a0eingesetzten \u00a0Antik\u00f6rper. \u00a0 \u00a0\t\r \u00a049\t\r \u00a0Auch \u00a0 im \u00a0 Anschluss \u00a0 an \u00a0 diese \u00a0 F\u00e4rbungen \u00a0 erfolgte \u00a0 eine \u00a0 Messung \u00a0 mittels \u00a0Durchflusszytometrie. \u00a0Zu \u00a0den \u00a0Influenza-\u00adspezifischen-\u00adCD4+-\u00adT-\u00adZellen \u00a0z\u00e4hlen \u00a0CD4+-\u00adT-\u00adZellen, \u00a0die \u00a0nach \u00a0sechs \u00a0Stunden \u00a0Stimulation \u00a0mit \u00a0dem \u00a0Impfantigen \u00a0das \u00a0Zytokin \u00a0IFNg\uf067 \u00a0exprimieren \u00a0und \u00a0 auf \u00a0 deren \u00a0 Zelloberfl\u00e4che \u00a0 zudem \u00a0 das \u00a0 Molek\u00fcl \u00a0 CD69, \u00a0 als \u00a0 ein \u00a0Aktivierungsmarker, \u00a0 nachweisbar \u00a0 ist. \u00a0 Der \u00a0 tats\u00e4chliche \u00a0 Anteil \u00a0 Influenza-\u00adspezifischer-\u00adCD4+-\u00adT-\u00adZellen \u00a0 wird \u00a0 dabei \u00a0 berechnet, \u00a0 indem \u00a0 man \u00a0 von \u00a0 dem \u00a0prozentualen \u00a0Anteil \u00a0der \u00a0CD69+-\u00ad \u00a0und \u00a0IFNg\uf067+-\u00adCD4+-\u00adT-\u00adZellen \u00a0nach \u00a0Stimulation \u00a0mit \u00a0dem \u00a0Impfstoff \u00a0den \u00a0Anteil \u00a0der \u00a0CD69+-\u00adund \u00a0IFNg\uf067+-\u00adCD4+-\u00adT-\u00adZellen \u00a0nach \u00a0Stimulation \u00a0mit \u00a0der \u00a0Negativkontrolle/\u201eHintergrundaktivit\u00e4t\u201c \u00a0(PBS) \u00a0subtrahiert. \u00a0Die \u00a0Plasma-\u00adR\u00f6hrchen \u00a0wurden \u00a0abgesert. \u00a0Unter \u00a0Verwendung \u00a0der \u00a0ELISA-\u00adTechnologie \u00a0wurden \u00a0die \u00a0IgG-\u00adLevel \u00a0sowie \u00a0IgM-\u00ad \u00a0und \u00a0 IgA-\u00adRatio \u00a0gegen \u00a0 die \u00a0 zugeh\u00f6rigen \u00a0 Impfantigene \u00a0 gemessen \u00a0(ELISA \u00a0 der \u00a0Firma \u00a0Euroimmun \u00a0AG: \u00a0Anti \u00a0Influenza-\u00adA/B-\u00adViren \u00a0Pool \u00a0ELISA). \u00a0Da in dem verwendeten IgG-Elisa-KIT drei Kalibratoren mit definierten Konzentrationen (2/ 20/ 200 RE/ml) vorlagen, war es m\u00f6glich anhand dieser Werte eine Standardkurve zu erstellen und mithilfe dieser Standardkurve war eine quantitative Auswertung der IgG-Level der Probandenproben m\u00f6glich. In dem IgM-und IgA-Elisa-Kit lag jeweils nur ein Kalibrator vor, anhand dessen nur eine semiquantitative Auswertung m\u00f6glich war. Daher wurde bei diesen die Ratio angegeben. Zudem gab es f\u00fcr jedes Kit eine Positiv- sowie eine Negativkontrolle, die jeweils in den entsprechenden Bereichen liegen m\u00fcssen, um die Messung zu validieren (IgG-Level: negativ <16IE/L, grenzwertig 16-22 IE/L, positiv >22 IE/L; IgA- und IgM-Ratio: negativ <0,8, grenzwertig 0,8-1,1, positiv >1,1) \u00a0Die \u00a0 Messung \u00a0 der \u00a0 Antik\u00f6rpertiter \u00a0 erfolgte \u00a0 durch \u00a0 Analyse \u00a0 neutralisierender \u00a0Antik\u00f6rper \u00a0 in \u00a0 einem \u00a0ausw\u00e4rtigen \u00a0 Labor. \u00a0 Durch \u00a0 diese \u00a0 Mikroneutralisations-\u00adAssays \u00a0konnten \u00a0dabei \u00a0spezifisch \u00a0die \u00a0im \u00a0Impfstoff \u00a0enthalten \u00a0St\u00e4mme \u00a0bestimmt \u00a0werden. \u00a0 \u00a0Hierzu \u00a0wurden \u00a0 die \u00a0 Proben \u00a0 zuerst \u00a0mit \u00a0 einem \u00a0 Rezeptor-\u00adzerst\u00f6renden \u00a0 Enzym \u00a0(RDE;\u037e \u00a0Denkan-\u00adSeiken, \u00a0Tokyo, \u00a0Japan) \u00a0inkubiert, \u00a0um \u00a0unspezifische \u00a0Inhibitoren \u00a0zu \u00a0zerst\u00f6ren. \u00a0Danach \u00a0wurden \u00a0die \u00a0Seren \u00a0f\u00fcr \u00a030 \u00a0Minuten \u00a0bei \u00a056\u00b0C \u00a0hitzeinaktiviert \u00a0und \u00a0mit \u00a0einem \u00a0 Verd\u00fcnnungsmittel \u00a0 (EMEM+0,1% \u00a0 Antibiotika \u00a0 + \u00a0 2%FBS, \u00a0Biochrom, \u00a0 Deutschland) \u00a0 zur \u00a0 Produktion \u00a0von \u00a0 Verd\u00fcnnungsreihen \u00a0 mit \u00a0 einem \u00a0\t\r \u00a050\t\r \u00a0Verh\u00e4ltnis \u00a0von \u00a01:10 \u00a0bis \u00a01:20480 \u00a0verwendet. \u00a0Diese \u00a0Seruml\u00f6sungen \u00a0wurden \u00a0mit \u00a0demselben \u00a0Volumen \u00a0eines \u00a0Virusverd\u00fcnnungsmittels \u00a0gemischt, \u00a0welches \u00a0200 \u00a0bis \u00a0400 \u00a0 fokusbildende \u00a0 Einheiten \u00a0 (FFU) \u00a0des \u00a0 Influenza \u00a0A-\u00ad \u00a0oder \u00a0 B-\u00adVirus \u00a0[A/California/7/2009 \u00a0(H1N1) \u00a0pdm09-\u00ad\u00e4hnlicher \u00a0Stamm \u00a0(A/Christchurch/16/2010, \u00a0NIB-\u00ad74xp);\u037e \u00a0 A/Hong \u00a0 Kong/4801/2014;\u037e \u00a0 B/Brisbane/60/08 \u00a0 und \u00a0B/Phuket/3073/2013 \u00a0enthielt. \u00a0Im \u00a0Anschluss \u00a0wurde \u00a0das \u00a0Gemisch \u00a0f\u00fcr \u00a090 \u00a0Minuten \u00a0bei \u00a037\u00b0C \u00a0und \u00a05% \u00a0CO2-\u00adGehalt \u00a0in \u00a0einer \u00a0feuchten \u00a0Kammer \u00a0inkubiert. \u00a0 \u00a0Danach \u00a0wurden \u00a0hiervon \u00a0100 \u00a0Mikroliter \u00a0zu \u00a0Mardin-\u00adDarby \u00a0 Hundenierenzellen \u00a0 (MDCK)-\u00adMonolayer \u00a0 (ECCC, \u00a0 Salisbury,UK) \u00a0zusammen \u00a0mit \u00a0geeigneten \u00a0Kontrollen \u00a0auf \u00a096-\u00adWell-\u00adPlatten \u00a0gegeben. \u00a0Nach \u00a0einer \u00a0einst\u00fcndigen \u00a0Inkubation \u00a0wurden \u00a0in \u00a0jede \u00a0Vertiefung \u00a0f\u00fcr \u00a024 \u00a0bis \u00a048 \u00a0Stunden \u00a0100 \u00a0Mikroliter \u00a0 eines \u00a0 Overlay-\u00adMediums \u00a0 (1:1 \u00a0 Virusverd\u00fcnnungsmittel \u00a0 / \u00a0 3,2% \u00a0Carboxymethylzellulose, \u00a0 Sigma) \u00a0 zugesetzt. \u00a0 Diese \u00a0 Monolayer \u00a0wurden \u00a0anschlie\u00dfend \u00a0f\u00fcr \u00a0zehn \u00a0Minuten \u00a0mit \u00a0einem \u00a0eiskalten \u00a0Gemisch \u00a0(40% \u00a0Aceton/ \u00a060% \u00a0Methanol) \u00a0fixiert. \u00a0Nach \u00a0dem \u00a0Blockieren \u00a0mit \u00a01% \u00a0Rinderserumalbumin \u00a0und \u00a00,1% \u00a0Thimoseral \u00a0 (Sigma) \u00a0 in \u00a0 Waschpuffer \u00a0 f\u00fcr \u00a0 30 \u00a0 Minuten \u00a0 bei \u00a0 37\u00b0C, \u00a0 erfolgte \u00a0 eine \u00a0erneute \u00a0 Inkubation \u00a0 mit \u00a0 monoklonalen \u00a0 Maus-\u00adAnti-\u00adInfluenza \u00a0 A \u00a0(MAB8251 \u00a0Millipore) \u00a0oder \u00a0Maus-\u00adAnti-\u00adInfluenza \u00a0B \u00a0(MAB8661Millipore) \u00a0Antik\u00f6rpern. \u00a0Durch \u00a0Meerrettich-\u00adPeroxidase-\u00admarkierte \u00a0 Kaninchen-\u00adAnti-\u00adMaus-\u00adIgG \u00a0konnten \u00a0 die \u00a0 Foki \u00a0gezeigt \u00a0und \u00a0mittels \u00a0automatisiertem \u00a0ELISPOT-\u00adGer\u00e4t \u00a0(AID \u00a0Diagnostika \u00a0GmbH, \u00a0Stra\u00df, \u00a0Deutschland) \u00a0gez\u00e4hlt \u00a0werden. \u00a0Der \u00a0Neutralisationstiter \u00a0dr\u00fcckt \u00a0dabei \u00a0den \u00a0reziproken \u00a0Wert \u00a0der \u00a0h\u00f6chsten \u00a0Verd\u00fcnnungsstufe \u00a0aus, \u00a0der \u00a0eine \u00a0Verringerung \u00a0der \u00a0Foki \u00a0um \u00a075% \u00a0im \u00a0Vergleich \u00a0zur \u00a0Viruskontrolle \u00a0ergab. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a051\t\r \u00a03.5. \u00a0Statistische \u00a0Analysen \u00a0 \u00a0Nach \u00a0Pr\u00fcfung \u00a0auf \u00a0Plausibilit\u00e4t \u00a0wurden \u00a0alle \u00a0Daten \u00a0mit \u00a0der \u00a0Computersoftware \u00a0SPSS \u00a0(Version \u00a023, \u00a0IBM \u00a0Corporation, \u00a0Armonk, \u00a0USA) \u00a0statistisch \u00a0ausgewertet \u00a0und \u00a0graphisch \u00a0dargestellt. \u00a0Auf \u00a0 eine \u00a0 formale \u00a0 Fallzahlberechnung \u00a0 wurde \u00a0 im \u00a0 Rahmen \u00a0 der \u00a0 Studienplanung \u00a0verzichtet. \u00a0Aufgrund \u00a0des \u00a0 Mangels \u00a0 an \u00a0Vorinformationen \u00a0zum \u00a0 Thema \u00a0 Influenza-\u00adImpfung \u00a0im \u00a0Leistungssport \u00a0und \u00a0des \u00a0Fehlens \u00a0klinisch \u00a0etablierter \u00a0Zielparameter \u00a0war \u00a0eine \u00a0Absch\u00e4tzung \u00a0der \u00a0Effektgr\u00f6\u00dfe \u00a0sowie \u00a0der \u00a0Gr\u00f6\u00dfe \u00a0der \u00a0Streuung \u00a0nicht \u00a0m\u00f6glich. \u00a0Nachdem \u00a0die \u00a0Datenerfassung \u00a0der \u00a0Nebenwirkungen \u00a0und \u00a0anthropometrischen \u00a0Daten \u00a0vollzogen \u00a0war, \u00a0wurde \u00a0mit \u00a0dem \u00a0Shapiro-\u00adWilks-\u00adTest \u00a0auf \u00a0Normalverteilung \u00a0gepr\u00fcft. \u00a0Da \u00a0lediglich \u00a0das \u00a0Alter \u00a0das \u00a0Kriterium \u00a0der \u00a0Normalverteilung \u00a0erf\u00fcllte, \u00a0wurde \u00a0bei \u00a0diesem \u00a0der \u00a0Chi-\u00adQuadrat-\u00adTest \u00a0angewandt. \u00a0Die \u00a0\u00fcbrigen \u00a0der \u00a0ordinal \u00a0oder \u00a0metrisch \u00a0skalierten \u00a0Variablen \u00a0erf\u00fcllten \u00a0dieses \u00a0Kriterium \u00a0nicht, \u00a0weshalb \u00a0eine \u00a0Auswertung \u00a0anhand \u00a0des \u00a0Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0als \u00a0nonparametrisches-\u00adTestverfahren \u00a0f\u00fcr \u00a0metrisch \u00a0skalierte \u00a0Variablen \u00a0erfolgte. \u00a0F\u00fcr \u00a0 nominale \u00a0 und \u00a0 kategoriale \u00a0Variablen \u00a0 wurde \u00a0der \u00a0 Vergleich \u00a0zwischen \u00a0 beiden \u00a0 Gruppen \u00a0mithilfe \u00a0des \u00a0 exakten \u00a0 Test \u00a0 nach \u00a0 Fisher \u00a0durchgef\u00fchrt. \u00a0Auch \u00a0 erfolgte \u00a0 eine \u00a0 prozentuale \u00a0 Darstellung \u00a0 der \u00a0 H\u00e4ufigkeiten \u00a0 der \u00a0 jeweils \u00a0aufgetretenen \u00a0Impfbeschwerden. \u00a0 \u00a0Zur \u00a0Bestimmung \u00a0der \u00a0Unterschiede \u00a0bez\u00fcglich \u00a0der \u00a0Trainingsdauer \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0wurde, \u00a0bei \u00a0fehlender \u00a0Normalverteilung, \u00a0ebenfalls \u00a0der \u00a0Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0herangezogen, \u00a0zum \u00a0Vergleich \u00a0der \u00a0Einschr\u00e4nkungen \u00a0durch \u00a0die \u00a0Impfung \u00a0beim \u00a0Training \u00a0der \u00a0exakte \u00a0Test \u00a0nach \u00a0Fisher. \u00a0Auch \u00a0 bei \u00a0 der \u00a0Auswertung \u00a0 der \u00a0 Antik\u00f6rperlevel, \u00a0der \u00a0 Neutralisationstiter \u00a0und \u00a0der \u00a0CD4+-\u00adT-\u00adZellen \u00a0wurde \u00a0mittels \u00a0Shapiro-\u00adWilks-\u00adTest \u00a0auf \u00a0Normalverteilung \u00a0gepr\u00fcft \u00a0und \u00a0darauf \u00a0geachtet, \u00a0ob \u00a0Ausrei\u00dfer \u00a0vorliegen. \u00a0Da \u00a0eine \u00a0Normalverteilung \u00a0in \u00a0den \u00a0meisten \u00a0F\u00e4llen \u00a0nicht \u00a0erf\u00fcllt \u00a0wurde \u00a0und \u00a0zudem \u00a0auch \u00a0teilweise \u00a0Ausrei\u00dfer \u00a0vorlagen, \u00a0entschied \u00a0man \u00a0 sich \u00a0 f\u00fcr \u00a0 nonparametrische \u00a0 Verfahren. \u00a0Der \u00a0 Vergleich \u00a0 der \u00a0 Werte \u00a0 zwischen \u00a0beiden \u00a0Gruppen \u00a0\u00fcber \u00a0alle \u00a0Messzeitpunkte \u00a0hinweg \u00a0als \u00a0auch \u00a0an \u00a0jedem \u00a0einzelnen \u00a0Testzeitpunkt \u00a0erfolgte \u00a0mit \u00a0Hilfe \u00a0des \u00a0Mann-\u00adWhitney-\u00adU-\u00adTest. \u00a0Ob \u00a0beim \u00a0 Vergleich \u00a0 der \u00a0 Werte \u00a0 an \u00a0 den \u00a0 Messzeitpunkten \u00a0innerhalb \u00a0 der \u00a0 jeweiligen \u00a0Gruppe \u00a0signifikante \u00a0 Unterschiede \u00a0vorlagen, \u00a0 wurde \u00a0 mittels \u00a0 Friedmann-\u00adTest \u00a0 als \u00a0nonparametrisches \u00a0Verfahren \u00a0f\u00fcr \u00a0gepaarte \u00a0Variablen \u00a0gepr\u00fcft. \u00a0War \u00a0das \u00a0Ergebnis \u00a0\t\r \u00a052\t\r \u00a0dieses \u00a0Tests \u00a0signifikant, \u00a0wurde \u00a0der \u00a0Dunn-\u00adBonferroni-\u00adpost-\u00adhoc \u00a0Test \u00a0durchgef\u00fchrt, \u00a0um \u00a0festzustellen, \u00a0an \u00a0welchen \u00a0Messzeitpunkten \u00a0sich \u00a0die \u00a0Werte \u00a0unterschieden. \u00a0Da \u00a0bei \u00a0einem \u00a0Probanden \u00a0die \u00a0Sechsmonatswerte \u00a0nicht \u00a0erhoben \u00a0werden \u00a0konnten, \u00a0wurden \u00a0diese \u00a0Werte \u00a0extrapoliert \u00a0um \u00a0einen \u00a0\u201edrop-\u00adout\u201c \u00a0zu \u00a0vermeiden. \u00a0Hierzu \u00a0wurde \u00a0als \u00a0Verfahren \u00a0der \u00a0\u201esingle \u00a0imputation\u201c, \u00a0also \u00a0dem \u00a0Ersetzen \u00a0eines \u00a0Fehlenden \u00a0Wertes, \u00a0eine \u00a0Mischung \u00a0aus dem \"nearest neighbor imputation\"-Verfahren und dem \"mean imputation\"-Verfahren angewendet. Dabei wurde der \u00a0jeweilige \u00a0Rang \u00a0des \u00a0Sportlers \u00a0mit \u00a0dem \u00a0fehlenden \u00a0Wert \u00a0in \u00a0der \u00a0Blutentnahme \u00a0nach \u00a0zwei \u00a0Wochen \u00a0herangezogen \u00a0(z. \u00a0B. \u00a0 Rang \u00a0 17). \u00a0 Denselben \u00a0Rang \u00a0 sollte \u00a0 er \u00a0 in \u00a0 seinem \u00a0 Sechsmonatswert \u00a0 wieder \u00a0einnehmen, \u00a0weshalb \u00a0der \u00a0Mittelwert \u00a0aus \u00a0den \u00a0Werten \u00a0des \u00a0Sportlers \u00a0der \u00a0diesen \u00a0Rang \u00a0nach \u00a0sechs \u00a0Monaten \u00a0einnahm \u00a0(Rang \u00a017) \u00a0und \u00a0des \u00a0Sportlers \u00a0des \u00a0n\u00e4chst \u00a0niedrigeren \u00a0Ranges \u00a0(Rang \u00a016) \u00a0errechnet \u00a0wurde. \u00a0Dieser \u00a0Mittelwert \u00a0ersetzt \u00a0den \u00a0fehlenden \u00a0Wert. \u00a0So \u00a0 ist \u00a0 der \u00a0 \u201efehlende \u00a0 Proband\u201c \u00a0 an \u00a0 seinem \u00a0 urspr\u00fcnglichen \u00a0 Rang \u00a0 und \u00a0 alle \u00a0nachfolgenden \u00a0Teilnehmer \u00a0steigen \u00a0jeweils \u00a0um \u00a0einen \u00a0Rang. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a053\t\r \u00a04. \u00a0Ergebnisse \u00a0 \u00a04.1. \u00a0Immunologische \u00a0Auswertung \u00a0 \u00a04.1.1. \u00a0Blutbildver\u00e4nderungen \u00a0 \u00a0Unterschiede \u00a0im \u00a0 Differentialblutbild \u00a0 lie\u00dfen \u00a0sich \u00a0bei \u00a0 den \u00a0 Probanden \u00a0erwartungsgem\u00e4\u00df \u00a0an \u00a0 den \u00a0 Leukozyten \u00a0erkennen. \u00a0Es \u00a0zeigten \u00a0 sich \u00a0 in \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 mit \u00a0 p<0,01 \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 signifikant \u00a0 h\u00f6here \u00a0 Neutrophilenzahlen. \u00a0Dementsprechend \u00a0waren \u00a0auch \u00a0die \u00a0Leukozytenzahlen \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0mit \u00a0im \u00a0Mittel \u00a07665\u00b12342 \u00a0Leukozyten/\u00b5L \u00a0und \u00a0nur \u00a05605\u00b11222 \u00a0Leukozyten/\u00b5L \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0mit \u00a0p<0,01, \u00a0signifikant \u00a0h\u00f6her. \u00a0W\u00e4hrend \u00a0ein \u00a0und \u00a0zwei \u00a0Wochen \u00a0nach \u00a0der \u00a0Impfung \u00a0die \u00a0Leukozyten \u00a0nicht \u00a0signifikant \u00a0unterschiedlich \u00a0waren, \u00a0zeigte \u00a0sich \u00a0mit \u00a0p<0,01 \u00a0nach \u00a0sechs \u00a0Monaten \u00a0erneut \u00a0ein \u00a0signifikanter \u00a0h\u00f6herer \u00a0Wert \u00a0in \u00a0der \u00a02h-\u00adGruppe. \u00a0Folglich \u00a0waren \u00a0die \u00a0prozentualen \u00a0Lymphozytenzahlen \u00a0vor \u00a0der \u00a0Impfung \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0mit \u00a0p<0,01 \u00a0signifikant \u00a0niedriger \u00a0als \u00a0in \u00a0der \u00a026h-\u00adGruppe. \u00a0Ebenso \u00a0zeigten \u00a0die \u00a0Basophilen \u00a0mit \u00a0p=0,03 \u00a0vor \u00a0der \u00a0Impfung \u00a0signifikant \u00a0h\u00f6here \u00a0Werte \u00a0 in \u00a0 der \u00a0 2h-\u00adGruppe, \u00a0 wobei \u00a0 sich \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0 keine \u00a0 signifikanten \u00a0Unterschiede \u00a0mehr \u00a0zeigten. \u00a0 \u00a0 \u00a0\t\r \u00a054\t\r \u00a0  Abbildung \u00a04: \u00a0 Darstellung \u00a0 des \u00a0Medians \u00a0 des \u00a0Lymphozytenverlaufs \u00a0in \u00a0 Prozent \u00a0(Woche \u00a00 \u00a0entspricht \u00a0dem \u00a0Zeitpunkt \u00a0vor \u00a0der \u00a0Impfung). \u00a0  \n \u00a0Abbildung \u00a05: \u00a0Darstellung \u00a0des \u00a0Medians \u00a0des \u00a0Leukozytenverlaufs \u00a0(103/L). \u00a0 Der \u00a0 Median \u00a0 des \u00a0 C-\u00adreaktiven \u00a0 Proteins \u00a0 lag \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 stets \u00a0 unter \u00a00,5mg/dl. \u00a0 Es \u00a0 lie\u00dfen \u00a0 sich \u00a0 keine \u00a0 Unterschiede \u00a0 in \u00a0Abh\u00e4ngigkeit \u00a0 zur \u00a0Gruppenzugeh\u00f6rigkeit \u00a0feststellen \u00a0(p>0,5). \u00a0Ebenfalls \u00a0 bez\u00fcglich \u00a0 der \u00a0 weiteren \u00a0 erhobenen \u00a0 Routineparameter \u00a0 zeigten \u00a0 sich \u00a0keine \u00a0Unterschiede \u00a0zwischen \u00a0beiden \u00a0Gruppen. \u00a0Auf \u00a0eine \u00a0detaillierte \u00a0Darstellung \u00a0wird \u00a0aufgrund \u00a0der \u00a0fehlenden \u00a0Relevanz \u00a0f\u00fcr \u00a0das \u00a0Ergebnis \u00a0der \u00a0Studie \u00a0verzichtet. \u00a0Woche 26Woche 2Woche 1Woche 0%40383634323026h-Gruppe2h-GruppeLymphozyten\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum GMEDIAN(leuko)[name=\"GMEDIAN_leuko\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: GMEDIAN_leuko=col(source(s), name(\"GMEDIAN_leuko\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Gruppenmedian leuko\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Seite 48\nWoche 26Woche 2Woche 1Woche 0119753126h-Gruppe2h-GruppeLeukozyten\nSeite 51\t\r \u00a055\t\r \u00a04.1.2. \u00a0CD4+-\u00adT-\u00adZell-\u00adFrequenzen \u00a0 \u00a0Vor \u00a0 der \u00a0 Impfung \u00a0 lag \u00a0 der \u00a0 Median \u00a0 des \u00a0 Anteils \u00a0 Influenza-\u00adspezifischer-\u00adCD4+-\u00adT-\u00adZellen \u00a0in \u00a0beiden \u00a0Gruppen \u00a0bei \u00a0kleiner \u00a0oder \u00a0gleich \u00a00,1%. \u00a0H\u00f6here \u00a0Werte \u00a0zeigten \u00a0sich \u00a0dabei \u00a0fast \u00a0immer \u00a0in \u00a0der \u00a02h-\u00adGruppe. \u00a0Im \u00a0Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0lie\u00dfen \u00a0sich \u00a0keine \u00a0 signifikanten \u00a0 Unterschiede \u00a0 bez\u00fcglich \u00a0 der \u00a0 prozentualen \u00a0Lymphozytenwerte \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0feststellen \u00a0(p=0,59). \u00a0Die \u00a0Werte \u00a0an \u00a0den \u00a0einzelnen \u00a0Messzeitpunkten \u00a0sind \u00a0in \u00a0Tabelle \u00a08 \u00a0dargestellt. \u00a0 \u00a0 \u00a0 \u00a0WOCHE \u00a00 \u00a0WOCHE \u00a01 \u00a0WOCHE \u00a02 \u00a0WOCHE \u00a026 \u00a0 \u00a025%-\u00adPerzentile \u00a00,05 \u00a00,28 \u00a00,21 \u00a00,085 \u00a02H-\u00adGRUPPE \u00a0Median \u00a00,01 \u00a00,44 \u00a00,27 \u00a00,14 \u00a0 \u00a075%-\u00adPerzentile \u00a00,19 \u00a00,57 \u00a00,37 \u00a00,18 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a025%-\u00adPerzentile \u00a00,06 \u00a00,26 \u00a00,19 \u00a00,08 \u00a026H-\u00adGRUPPE \u00a0Median \u00a00,09 \u00a00,38 \u00a00,34 \u00a00,10 \u00a0 \u00a075%-\u00adPerzentile \u00a00,14 \u00a00,74 \u00a00,48 \u00a00,15 \u00a0MANN-\u00adWHITNEY-\u00adU-\u00adTEST \u00a0 \u00a0p=0,47 \u00a0p=0,98 \u00a0p=0,47 \u00a0p=0,27 \u00a0 \u00a0Tabelle \u00a08: \u00a0Auflistung \u00a0 des \u00a0prozentualen \u00a0 Medians \u00a0sowie \u00a0 der \u00a0 25%-\u00ad \u00a0und \u00a0 75%-\u00adPerzentile \u00a0der \u00a0Influenza-\u00adspezifischen-\u00adCD4+-\u00adT-\u00adLymphozyten \u00a0in \u00a0beiden \u00a0Gruppen. \u00a0Anhand \u00a0 Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0 wurde \u00a0 Gruppenvergleich \u00a0 zu \u00a0 den \u00a0 jeweiligen \u00a0Zeitpunkten \u00a0 durchgef\u00fchrt. \u00a0 Der \u00a0 Messzeitpunkt \u00a0 \u201eWoche \u00a0 0\u201c \u00a0 entspricht \u00a0 der \u00a0Blutentnahme \u00a0direkt \u00a0vor \u00a0der \u00a0Impfung. \u00a0 \u00a0Sowohl \u00a0in \u00a0der \u00a02h-\u00adGruppe, \u00a0als \u00a0auch \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0lie\u00df \u00a0sich \u00a0im \u00a0Friedmann-\u00adTest \u00a0 im \u00a0 Vergleich \u00a0 der \u00a0 vier \u00a0 Messzeitpunkte \u00a0 miteinander \u00a0 mit \u00a0 p<0,01 \u00a0 ein \u00a0signifikanter \u00a0 Unterschied \u00a0 der \u00a0 Influenza-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten \u00a0feststellen. \u00a0 Aufgrund \u00a0 dessen \u00a0 wurde \u00a0 der \u00a0 Dunn-\u00adBonferroni-\u00adpost-\u00adhoc-\u00adTest \u00a0durchgef\u00fchrt. \u00a0 Hier \u00a0zeigte \u00a0 sich, \u00a0 dass \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 die \u00a0 Anstiege \u00a0 der \u00a0Lymphozyten \u00a0vom \u00a0Zeitpunkt \u00a0vor \u00a0der \u00a0Impfung \u00a0zu \u00a0den \u00a0Messzeitpunkten \u00a0nach \u00a0ein \u00a0und \u00a0zwei \u00a0Wochen \u00a0signifikant \u00a0waren \u00a0(p<0,01). \u00a0Auch \u00a0der \u00a0anschlie\u00dfende \u00a0Abfall \u00a0der \u00a0 Influenza-\u00adspezifischen-\u00adCD4+-\u00adT-\u00adZellen \u00a0 im \u00a0 Vergleich \u00a0 zum \u00a0 Status \u00a0 nach \u00a0 ein \u00a0und \u00a0zwei \u00a0Wochen \u00a0auf \u00a0sechs \u00a0Monate \u00a0war \u00a0im \u00a0post-\u00adhoc-\u00adTest \u00a0in \u00a0beiden \u00a0Kollektiven \u00a0signifikant \u00a0(p<0,01). \u00a0 \u00a0\t\r \u00a056\t\r \u00a0 \u00a0\n \u00a0 \u00a0Abbildung \u00a06: \u00a0Verlauf \u00a0des \u00a0prozentualen \u00a0Anteils \u00a0der \u00a0Influenza-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten \u00a0in \u00a0 Abh\u00e4ngigkeit \u00a0 vom \u00a0 Zeitpunkt \u00a0 der \u00a0 Impfung. \u00a0 Es \u00a0 l\u00e4sst \u00a0 sich \u00a0 ein \u00a0signifikanter \u00a0Anstieg \u00a0des \u00a0Anteils \u00a0der \u00a0reaktiven \u00a0T-\u00adLymphozyten \u00a0nach \u00a0der \u00a0Impfung \u00a0erkennen, \u00a0 welcher \u00a0 nach \u00a0 sechs \u00a0 Monaten \u00a0 nahe \u00a0 wieder \u00a0 den \u00a0 Ausgangswert \u00a0erreichte \u00a0(* \u00a0= \u00a0p<0,05;\u037e \u00a0** \u00a0p<0,01). \u00a0 \u00a0Im \u00a0 Hinblick \u00a0 auf \u00a0 die \u00a0 SEB-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten, \u00a0 welche \u00a0 als \u00a0Positivkontrolle \u00a0 dienten, \u00a0 zeigten \u00a0 sich \u00a0 stets \u00a0 h\u00f6here \u00a0 Werte. \u00a0 Erwartungsgem\u00e4\u00df \u00a0wurden \u00a0 keine \u00a0 signifikanten \u00a0 Unterschiede \u00a0 im \u00a0 Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0 zwischen \u00a0beiden \u00a0Gruppen \u00a0dokumentiert \u00a0(p=0,44). \u00a0Auch \u00a0im \u00a0Friedmann-\u00adTest \u00a0konnte \u00a0im \u00a0Vergleich \u00a0der \u00a0vier \u00a0Messzeitpunkte \u00a0weder \u00a0in \u00a0der \u00a0 2h-\u00adGruppe \u00a0 (p=0,54) \u00a0 noch \u00a0 in \u00a0 der \u00a0 26h-\u00adGruppe \u00a0 (p=0,47) \u00a0 ein \u00a0 signifikanter \u00a0Unterschied \u00a0 festgestellt \u00a0 werden. \u00a0 Aus \u00a0 diesem \u00a0 Grund \u00a0 konnte \u00a0 auf \u00a0 den \u00a0 Dunn-\u00adBonferroni-\u00adpost-\u00adhoc \u00a0verzichtet \u00a0werden. \u00a0 \u00a0Woche 26Woche 2Woche 1Woche 00,80,70,60,50,40,30,20,10,026h-Gruppe2h-GruppeInfluenza-reaktive-CD4+-T-Zellen________________________________________________________________________________________________________________________________________________****************\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum MEDIAN(STC)[name=\"MEDIAN_STC\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: MEDIAN_STC=col(source(s), name(\"MEDIAN_STC\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Median SEB-reaktive-T-Zellen\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Page 25\t\r \u00a057\t\r \u00a0 \u00a0 \u00a0Abbildung \u00a07: \u00a0Darstellung \u00a0des \u00a0Verlaufs \u00a0der \u00a0SEB-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten \u00a0in \u00a0Abh\u00e4ngigkeit \u00a0vom \u00a0Zeitpunkt \u00a0der \u00a0Impfung. \u00a0Bei \u00a0der \u00a0Positivkontrolle \u00a0lie\u00dfen \u00a0sich \u00a0wie \u00a0erwartet \u00a0keine \u00a0signifikanten \u00a0Anstiege \u00a0oder \u00a0Abf\u00e4lle \u00a0verzeichnen. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Woche 26Woche 2Woche 1Woche 07654321026h-Gruppe2h-GruppeSEB-reaktive-CD4+-T-Zellen\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum MEDIAN(H1N1)[name=\"MEDIAN_H1N1\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: MEDIAN_H1N1=col(source(s), name(\"MEDIAN_H1N1\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Median H1N1\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Seite 29\t\r \u00a058\t\r \u00a04.1.3. \u00a0Antik\u00f6rpertiter \u00a0 \u00a0Im \u00a0Hinblick \u00a0auf \u00a0die \u00a0Influenza-\u00adspezifischen \u00a0Antik\u00f6rper \u00a0wurden \u00a0sowohl \u00a0das \u00a0IgG-\u00adLevel, \u00a0als \u00a0auch \u00a0die \u00a0IgM-\u00adund \u00a0die \u00a0IgA-\u00adRatio \u00a0bestimmt \u00a0(Erl\u00e4uterung \u00a0Level/Ratio \u00a0siehe \u00a0Kapitel \u00a03.4.3 \u00a0immunologische \u00a0laboranalytische \u00a0Methoden). \u00a0Der \u00a0Verlauf \u00a0der \u00a0IgG-\u00adAntik\u00f6rpertiter \u00a0in \u00a0IE/L \u00a0\u00e4hnelte \u00a0hierbei \u00a0dem \u00a0der \u00a0Influenza-\u00adreaktiven-\u00adCD4+-\u00adT-\u00adLymphozyten. \u00a0Insgesamt \u00a0war \u00a0im \u00a0Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0kein \u00a0signifikanter \u00a0Unterschied \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0feststellbar \u00a0(p=0,49). \u00a0 \u00a0 \u00a0 \u00a0WOCHE \u00a00 \u00a0WOCHE \u00a01 \u00a0WOCHE \u00a02 \u00a0WOCHE \u00a026 \u00a0 \u00a025%-\u00adPerzentile \u00a077,7 \u00a0152,1 \u00a0151,4 \u00a0139,7 \u00a02H-\u00adGRUPPE \u00a0Median \u00a0133,6 \u00a0170,7 \u00a0169,7 \u00a0155,0 \u00a0 \u00a075%-\u00adPerzentile \u00a0157,2 \u00a0282,3 \u00a0267,3 \u00a0179,8 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a025%-\u00adPerzentile \u00a0103,0 \u00a0162,7 \u00a0161,7 \u00a0124,3 \u00a026H-\u00adGRUPPE \u00a0Median \u00a0129,6 \u00a0183,0 \u00a0183,8 \u00a0157,1 \u00a0 \u00a075%-\u00adPerzentile \u00a0166,0 \u00a0212,0 \u00a0220,1 \u00a0185,2 \u00a0MANN-\u00adWHITNEY-\u00adU-\u00adTEST \u00a0 \u00a0p=0,75 \u00a0p=0,38 \u00a0p=0,50 \u00a0p=0,96 \u00a0 \u00a0Tabelle \u00a09: \u00a0Darstellung \u00a0des \u00a0Medians \u00a0und \u00a0der \u00a025%-\u00adund \u00a075%-\u00ad \u00a0Perzentile \u00a0des \u00a0Influenza-\u00adspezifischen-\u00adIgG-\u00adLevels \u00a0in \u00a0IE/L. \u00a0Darunter \u00a0das \u00a0Ergebnis \u00a0des \u00a0MWU-\u00adTest \u00a0im \u00a0Vergleich \u00a0beider \u00a0Gruppen \u00a0zu \u00a0dem \u00a0jeweiligen \u00a0Zeitpunkt. \u00a0 \u00a0Im \u00a0Vergleich \u00a0der \u00a0vier \u00a0Messzeitpunkte \u00a0miteinander \u00a0konnten \u00a0im \u00a0Friedmann-\u00adTest \u00a0sowohl \u00a0 in \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 (p<0,01), \u00a0 als \u00a0 auch \u00a0 in \u00a0 der \u00a0 26h-\u00adGruppe \u00a0 (p<0,01) \u00a0signifikante \u00a0 Unterschiede \u00a0 festgestellt \u00a0 werden, \u00a0 weshalb \u00a0 der \u00a0 Dunn-\u00adBonferroni-\u00adpost-\u00adhoc-\u00adTest \u00a0 durchgef\u00fchrt \u00a0 wurde. \u00a0 Hier \u00a0 zeigten \u00a0 sich \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0signifikante \u00a0Anstiege \u00a0vom \u00a0Zeitpunkt \u00a0vor \u00a0der \u00a0Impfung \u00a0auf \u00a0die \u00a0Messzeitpunkte \u00a0nach \u00a0ein \u00a0und \u00a0zwei \u00a0Wochen \u00a0(p<0,01). \u00a0W\u00e4hrend \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0nur \u00a0der \u00a0Abfall \u00a0des \u00a0Levels \u00a0von \u00a0einer \u00a0Woche \u00a0auf \u00a0sechs \u00a0Monate \u00a0eine \u00a0Signifikanz \u00a0aufwies \u00a0(p<0,05), \u00a0war \u00a0der \u00a0Levelabfall \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0von \u00a0einer \u00a0und \u00a0zwei \u00a0Wochen \u00a0auf \u00a0sechs \u00a0Monate \u00a0signifikant \u00a0(p<0,01). \u00a0 \u00a0\t\r \u00a059\t\r \u00a0 \u00a0Abbildung \u00a08: \u00a0Graphische \u00a0Darstellung \u00a0des \u00a0Verlaufs \u00a0des \u00a0IgG-\u00adLevels \u00a0in \u00a0IE/L \u00a0(* \u00a0= \u00a0p<0,05;\u037e \u00a0** \u00a0p<0,01). \u00a0 \u00a0\u00c4hnlich \u00a0wie \u00a0bei \u00a0dem \u00a0IgG-\u00adLevel \u00a0verhielt \u00a0es \u00a0sich \u00a0auch \u00a0mit \u00a0der \u00a0IgM-\u00adRatio. \u00a0Auch \u00a0hier \u00a0war \u00a0 der \u00a0 Unterschied \u00a0 im \u00a0 Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0 statistisch \u00a0 nicht \u00a0 signifikant \u00a0(p=0,77). \u00a0Eine \u00a0\u00dcbersicht \u00a0\u00fcber \u00a0die \u00a0Werte \u00a0liefert \u00a0Tabelle \u00a010. \u00a0 \u00a0 \u00a0 \u00a0WOCHE \u00a00 \u00a0WOCHE \u00a01 \u00a0WOCHE \u00a02 \u00a0WOCHE \u00a026 \u00a0 \u00a025%-\u00adPerzentile \u00a00,19 \u00a02,04 \u00a02,20 \u00a00,85 \u00a02H-\u00adGRUPPE \u00a0Median \u00a00,26 \u00a04,58 \u00a03,57 \u00a01,22 \u00a0 \u00a075%-\u00adPerzentile \u00a00,69 \u00a07,40 \u00a06,70 \u00a02,08 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a025%-\u00adPerzentile \u00a00,16 \u00a01,76 \u00a01,75 \u00a00,60 \u00a026H-\u00adGRUPPE \u00a0Median \u00a00,38 \u00a04,80 \u00a04,13 \u00a01,03 \u00a0 \u00a075%-\u00adPerzentile \u00a00,58 \u00a019,18 \u00a013,19 \u00a01,91 \u00a0MANN-\u00adWHITNEY-\u00adU-\u00adTEST \u00a0 \u00a0p=0,73 \u00a0p=0,55 \u00a0p=0,79 \u00a0p=0,26 \u00a0 \u00a0Tabelle \u00a010: \u00a0Darstellung \u00a0des \u00a0Medians, \u00a0der \u00a025%-\u00adund \u00a075%-\u00adPerzentile \u00a0der \u00a0IgM-\u00adRatio \u00a0sowie \u00a0der \u00a0statistische \u00a0Vergleich \u00a0beider \u00a0Gruppen \u00a0zum \u00a0jeweiligen \u00a0Zeitpunkt. \u00a0Eine \u00a0deutlich \u00a0h\u00f6here \u00a075%-\u00adPerzentile \u00a0nach \u00a0ein \u00a0und \u00a0zwei \u00a0Wochen \u00a0zeigte \u00a0sich \u00a0hierbei \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0bei \u00a0ansonsten \u00a0\u00e4hnlichen \u00a0Werten. \u00a0 Woche 26Woche 2Woche 1Woche 030025020015010026h-Gruppe2h-GruppeIgG-Level\n_____________**_______________________**_____________________________*______________________________________________________________________________********\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum MEDIAN(IgM)[name=\"MEDIAN_IgM\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: MEDIAN_IgM=col(source(s), name(\"MEDIAN_IgM\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Median IgM\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Page 14\t\r \u00a060\t\r \u00a0Nachdem \u00a0im \u00a0Friedmann-\u00adTest \u00a0mit \u00a0jeweils \u00a0p<0,01 \u00a0signifikante \u00a0Unterschiede \u00a0im \u00a0Vergleich \u00a0 der \u00a0 jeweiligen \u00a0 Entnahmezeitpunkte \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 festgestellt \u00a0wurden, \u00a0wurde \u00a0auch \u00a0hier \u00a0ein \u00a0post-\u00adhoc-\u00adTest \u00a0durchgef\u00fchrt. \u00a0Die \u00a0Anstiege \u00a0der \u00a0Ratio \u00a0vom \u00a0 Zeitpunkt \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 auf \u00a0 die \u00a0 Nachkontrollen \u00a0 nach \u00a0 ein \u00a0und \u00a0 zwei \u00a0Wochen \u00a0 waren \u00a0 mit \u00a0 p<0,01 \u00a0 sowohl \u00a0 in \u00a0 der \u00a0 2h-\u00ad \u00a0als \u00a0 auch \u00a0 in \u00a0 der \u00a0 26h-\u00adGruppe \u00a0signifikant. \u00a0Idem \u00a0zu \u00a0dem \u00a0IgG-\u00adTiter \u00a0war \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0nur \u00a0der \u00a0Abfall \u00a0der \u00a0Ratio \u00a0von \u00a0einer \u00a0Woche \u00a0auf \u00a0sechs \u00a0Monate \u00a0signifikant \u00a0(p<0,01), \u00a0w\u00e4hrend \u00a0dies \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0von \u00a0einer \u00a0(p<0,01) \u00a0und \u00a0zwei \u00a0Wochen \u00a0(p<0,05) \u00a0auf \u00a0sechs \u00a0Monate \u00a0der \u00a0Fall \u00a0war. \u00a0Nach \u00a0sechs \u00a0Monaten \u00a0war \u00a0die \u00a0Ratio \u00a0mit \u00a0p<0,05 \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0und \u00a0p<0,01 \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0h\u00f6her \u00a0als \u00a0der \u00a0Ausgangswert. \u00a0 \u00a0 \u00a0\n \u00a0Abbildung \u00a09: \u00a0 \u00a0Verlauf \u00a0der \u00a0IgM-\u00adRatio \u00a0\u00fcber \u00a0sechs \u00a0Monate \u00a0(* \u00a0= \u00a0p<0,05;\u037e \u00a0** \u00a0p<0,01). \u00a0 Analog \u00a0zu \u00a0den \u00a0oben \u00a0genannten \u00a0Antik\u00f6rpern \u00a0verhielt \u00a0sich \u00a0auch \u00a0die \u00a0IgA-\u00adRatio. \u00a0Mit \u00a0p=0,79 \u00a0war \u00a0insgesamt \u00a0kein \u00a0statistisch \u00a0zu \u00a0sichernder \u00a0Unterschied \u00a0feststellbar \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Woche 26Woche 2Woche1Woche 0108642026h-Gruppe2h-GruppeIgM-Ratio__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________****************\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum MEDIAN(IgA)[name=\"MEDIAN_IgA\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: MEDIAN_IgA=col(source(s), name(\"MEDIAN_IgA\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Median IgA\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Page 17\t\r \u00a061\t\r \u00a0 \u00a0 \u00a0WOCHE \u00a00 \u00a0WOCHE \u00a01 \u00a0WOCHE \u00a02 \u00a0WOCHE \u00a026 \u00a0 \u00a025%-\u00adPerzentile \u00a00,20 \u00a00,44 \u00a00,42 \u00a00,22 \u00a02H-\u00adGRUPPE \u00a0Median \u00a00,38 \u00a00,68 \u00a00,68 \u00a00,52 \u00a0 \u00a075%-\u00adPerzentile \u00a00,70 \u00a01,39 \u00a01,22 \u00a00,86 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a025%-\u00adPerzentile \u00a00,21 \u00a00,46 \u00a00,34 \u00a00,28 \u00a026H-\u00adGRUPPE \u00a0Median \u00a00,40 \u00a00,75 \u00a00,89 \u00a00,56 \u00a0 \u00a075%-\u00adPerzentile \u00a00,74 \u00a01,33 \u00a01,29 \u00a00,89 \u00a0MANN-\u00adWHITNEY-\u00adU-\u00adTEST \u00a0 \u00a0p=0,84 \u00a0p=1,0 \u00a0p=0,93 \u00a0p=0,67 \u00a0 \u00a0Tabelle \u00a011: \u00a0Median \u00a0und \u00a0Perzentilen \u00a0der \u00a0IgA-\u00adRatio. \u00a0In \u00a0der \u00a026h-\u00adGruppe \u00a0zeigte \u00a0sich \u00a0hierbei \u00a0stets \u00a0ein \u00a0h\u00f6herer \u00a0Median \u00a0als \u00a0in \u00a0der \u00a02h-\u00adGruppe. \u00a0 Auch \u00a0bei \u00a0der \u00a0IgA-\u00adRatio \u00a0wurde \u00a0der \u00a0Dunn-\u00adBonferroni-\u00adpost-\u00adhoc-\u00adTest \u00a0durchgef\u00fchrt, \u00a0nachdem \u00a0 sich \u00a0 im \u00a0 Vergleich \u00a0 der \u00a0 Messwerte \u00a0 an \u00a0 den \u00a0 verschiedenen \u00a0Entnahmezeitpunkten \u00a0 im \u00a0 Friedmann-\u00adTest \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 signifikante \u00a0Unterschiede \u00a0zeigten \u00a0(p<0,01). \u00a0In \u00a0beiden \u00a0Sportlergruppen \u00a0stieg \u00a0die \u00a0Ratio \u00a0vom \u00a0Zeitpunkt \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 auf \u00a0 eine \u00a0 und \u00a0 zwei \u00a0 Wochen \u00a0 an \u00a0 (p<0,01). \u00a0 W\u00e4hrend \u00a0jedoch \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0ein \u00a0signifikanter \u00a0Abfall \u00a0der \u00a0Ratio \u00a0von \u00a0ein \u00a0(p<0,01) \u00a0und \u00a0zwei \u00a0Wochen \u00a0(p<0,05) \u00a0nach \u00a0Impfung \u00a0auf \u00a0sechs \u00a0Monate \u00a0vorlagen, \u00a0war \u00a0dieser \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0nur \u00a0von \u00a0einer \u00a0Woche \u00a0auf \u00a0sechs \u00a0Monate \u00a0signifikant \u00a0(p<0,01). \u00a0 \u00a0 \u00a0\n \u00a0Abbildung \u00a010: \u00a0Graphische \u00a0Darstellung \u00a0des \u00a0Verlaufs \u00a0der \u00a0IgA-\u00adRatio \u00a0(* \u00a0= \u00a0p<0,05;\u037e \u00a0** \u00a0p<0,01). \u00a0Woche 26Woche 2Woche 1Woche 01,51,21,00,70,50,226h-Gruppe2h-GruppeIgA-Ratio\n______________________________________________________________________________________________________________________________________*************\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum MEDIAN(ITC)[name=\"MEDIAN_ITC\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: MEDIAN_ITC=col(source(s), name(\"MEDIAN_ITC\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Median Influenza-reaktive T-Zellen\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200)) Page 20\t\r \u00a062\t\r \u00a04.1.4. \u00a0Neutralisationstests \u00a0 Zuletzt \u00a0 wurden \u00a0 noch \u00a0 Neutralisationstiter \u00a0 gegen \u00a0 die \u00a0 Influenza-\u00adSt\u00e4mme \u00a0 H1N1, \u00a0H3N2, \u00a0Brisbane \u00a0und \u00a0Phuket \u00a0bestimmt. \u00a0Die \u00a0 Einschr\u00e4nkung \u00a0 des \u00a0 Wertebereichs \u00a0 der \u00a0 Titer \u00a0 ergibt \u00a0 sich \u00a0 aus \u00a0 den \u00a0Verd\u00fcnnungsreihen \u00a0 der \u00a0 Proben \u00a0 (siehe \u00a0 Kapitel \u00a0 3.4.3 \u00a0 immunologische \u00a0laboranalytische \u00a0Methoden). \u00a0 \u00a0Im \u00a0 Mann-\u00adWhitney-\u00adU-\u00adTest \u00a0 zeigten \u00a0 sich \u00a0 insgesamt \u00a0 f\u00fcr \u00a0 keinen \u00a0 dieser \u00a0 vier \u00a0 Titer \u00a0signifikante \u00a0 Unterschiede \u00a0 (H1N1: \u00a0 p=0,51/ \u00a0 H2N3: \u00a0 p=0,94/ \u00a0 Brisbane: \u00a0 p=0,20/ \u00a0Phuket: \u00a0p=0,52). \u00a0Die \u00a0Titer \u00a0gegen \u00a0den \u00a0Influenza-\u00adB-\u00adStamm \u00a0\u201eBrisbane\u201c \u00a0waren \u00a0im \u00a0Median \u00a0am \u00a0niedrigsten, \u00a0gegen \u00a0H1N1 \u00a0am \u00a0h\u00f6chsten. \u00a0 \u00a0  \u00a0 \u00a0WOCHE \u00a00 \u00a0WOCHE \u00a01 \u00a0WOCHE \u00a02 \u00a0WOCHE \u00a026 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a02H-\u00adGRUPPE \u00a0H1N1 \u00a0160(140/560) \u00a05120(1600/10240) \u00a05120(2560/10240) \u00a01280(640/2560) \u00a0H2N3 \u00a060(20/160) \u00a0640(160/1280) \u00a0960(640/2560) \u00a0640(160/2240) \u00a0Brisbane \u00a020(9/40) \u00a0160(40/320) \u00a0160(50/560) \u00a080(40/160) \u00a0Phuket \u00a030(10/160) \u00a0320(200/640) \u00a0640(320/640) \u00a0160(80/320) \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a026H-\u00adGRUPPE \u00a0H1N1 \u00a0320(40/960) \u00a05120(2560/15360) \u00a010240(2560/10240) \u00a01280(960/2560) \u00a0H2N3 \u00a080(30/160) \u00a0640(160/2560) \u00a0640(480/3840) \u00a0640(120/1600) \u00a0Brisbane \u00a010(9/40) \u00a0160(60/640) \u00a0320(160/640) \u00a080(80/240) \u00a0 \u00a0Phuket \u00a040(10/160) \u00a0640(120/640) \u00a0640(160/1280) \u00a0160(80/640) \u00a0 Tabelle \u00a012: \u00a0\u00dcberblick \u00a0\u00fcber \u00a0Median \u00a0und \u00a0Perzentilen \u00a0der \u00a0Neutralisationstiter. \u00a0Der \u00a0Median \u00a0ist \u00a0fett \u00a0gedruckt \u00a0und \u00a0in \u00a0Klammern \u00a0dahinter \u00a0erst \u00a0die \u00a025%-\u00adPerzentile \u00a0und \u00a0dann \u00a0die \u00a075%-\u00adPerzentile). \u00a0  \u00a0WOCHE \u00a00 \u00a0WOCHE \u00a01 \u00a0WOCHE \u00a02 \u00a0WOCHE \u00a026 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0H1N1 \u00a0p=0,40 \u00a0p=0,68 \u00a0p=0,58 \u00a0p=0,35 \u00a0H2N3 \u00a0p=0,60 \u00a0p=0,90 \u00a0p=0,96 \u00a0p=0,71 \u00a0BRISBANE \u00a0p=0,56 \u00a0p=0,25 \u00a0p=0,15 \u00a0p=0,21 \u00a0PHUKET \u00a0p=0,80 \u00a0p=0,74 \u00a0p=0,62 \u00a0p=0,75 \u00a0 \u00a0Tabelle \u00a013: \u00a0Vergleich \u00a0der \u00a0beiden \u00a0Gruppen \u00a0zu \u00a0den \u00a0jeweiligen \u00a0Messzeitpunkten \u00a0mittels \u00a0Mann-\u00adWhitney-\u00adU-\u00adTest. \u00a0Auch \u00a0hier \u00a0waren \u00a0keine \u00a0signifikanten \u00a0Unterschiede \u00a0zwischen \u00a0den \u00a0Kollektiven \u00a0feststellbar. \u00a0 \t\r \u00a063\t\r \u00a0Auch \u00a0bei \u00a0den \u00a0Neutralisationstitern \u00a0wurde \u00a0prim\u00e4r \u00a0ein \u00a0Friedmann-\u00adTest \u00a0zum \u00a0Vergleich \u00a0der \u00a0 vier \u00a0 Messzeitpunkte \u00a0 jeweils \u00a0 f\u00fcr \u00a0 die \u00a0 2h-\u00ad \u00a0als \u00a0 auch \u00a0 f\u00fcr \u00a0 die \u00a0 26h-\u00adGruppe \u00a0durchgef\u00fchrt. \u00a0F\u00fcr \u00a0beide \u00a0Gruppen \u00a0waren \u00a0bei \u00a0allen \u00a0St\u00e4mmen \u00a0die \u00a0Messwerte \u00a0an \u00a0den \u00a0vier \u00a0Zeitpunkten \u00a0mit \u00a0p<0,01 \u00a0signifikant \u00a0unterschiedlich. \u00a0Im \u00a0Dunn-\u00adBonferroni-\u00adpost-\u00adhoc-\u00adTest \u00a0 zeigten \u00a0 sich \u00a0 f\u00fcr \u00a0 den \u00a0 H1N1-\u00adStamm \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 mit \u00a0 p<0,01 \u00a0signifikante \u00a0Anstiege \u00a0vom \u00a0Ausgangswert \u00a0auf \u00a0die \u00a0Messungen \u00a0nach \u00a0einer \u00a0und \u00a0zwei \u00a0Wochen, \u00a0ebenso \u00a0wie \u00a0ein \u00a0signifikanter \u00a0Abfall \u00a0der \u00a0Werte \u00a0von \u00a0Woche \u00a0auf \u00a0Woche \u00a026 \u00a0(2h-\u00adGruppe: \u00a0p<0,01;\u037e \u00a026h-\u00adGruppe: \u00a0p<0,05). \u00a0In \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 war \u00a0 der \u00a0 Wert \u00a0 nach \u00a0 sechs \u00a0 Monaten \u00a0 p<0,05 \u00a0 zudem \u00a0 signifikant \u00a0h\u00f6her \u00a0als \u00a0der \u00a0Ausgangswert. \u00a0 \u00a0\n \u00a0Abbildung \u00a011: \u00a0Verlauf \u00a0der \u00a0H1N1-\u00adTiter \u00a0vom \u00a0Zeitpunkt \u00a0der \u00a0Impfung \u00a0bis \u00a0zur \u00a0letzten \u00a0Kontrolle \u00a0nach \u00a0sechs \u00a0Monaten \u00a0(*=p<0,05;\u037e \u00a0**=p<0,01). \u00a0 \u00a0F\u00fcr \u00a0 den \u00a0 H3N2-\u00adTiter \u00a0 konnten \u00a0 im \u00a0 post-\u00adhoc-\u00adTest \u00a0 ebenfalls \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0signifikante \u00a0 Anstiege \u00a0 auf \u00a0 die \u00a0 Messzeitpunkte \u00a0 nach \u00a0 einer \u00a0 und \u00a0 zwei \u00a0 Wochen \u00a0beobachtet \u00a0werden \u00a0(p<0,01). \u00a0Hier \u00a0lagen \u00a0in \u00a0beiden \u00a0Gruppen \u00a0die \u00a0Sechsmonatswerte \u00a0signifikant \u00a0\u00fcber \u00a0den \u00a0Ausgangswerten \u00a0(p<0,01). \u00a0Woche 26Woche 2Woche 1Woche 014.00012.00010.0008.0006.0004.0002.000026h-Gruppe2h-GruppeH1N1_________________________________________________________________________________________________________________________________________________________________*************\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum GMEDIAN(H2N3)[name=\"GMEDIAN_H2N3\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: GMEDIAN_H2N3=col(source(s), name(\"GMEDIAN_H2N3\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Gruppenmedian H2N3\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Page 35\t\r \u00a064\t\r \u00a0 \u00a0Abbildung \u00a012: \u00a0Verlauf \u00a0des \u00a0H3N2-\u00adTiters \u00a0(*=p<0,05;\u037e \u00a0**=p<0,01). \u00a0 Sowohl \u00a0f\u00fcr \u00a0den \u00a0Brisbane-\u00ad \u00a0als \u00a0auch \u00a0f\u00fcr \u00a0den \u00a0Phuket-\u00adStamm \u00a0lie\u00dfen \u00a0sich \u00a0in \u00a0beiden \u00a0Gruppen \u00a0signifikante \u00a0Anstiege \u00a0der \u00a0Titer \u00a0nach \u00a0einer \u00a0und \u00a0zwei \u00a0Wochen \u00a0feststellen. \u00a0Zudem \u00a0zeigte \u00a0sich \u00a0f\u00fcr \u00a0beide \u00a0St\u00e4mme \u00a0nur \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0ein \u00a0signifikanter \u00a0Abfall \u00a0von \u00a0Woche \u00a0zwei \u00a0auf \u00a0Woche \u00a026. \u00a0Auch \u00a0f\u00fcr \u00a0den \u00a0Brisbane-\u00ad \u00a0und \u00a0den \u00a0Phuket-\u00adStamm \u00a0galt, \u00a0dass \u00a0in \u00a0beiden \u00a0Gruppen \u00a0der \u00a0Endwert \u00a0mit \u00a0p<0,05 \u00a0nach \u00a0sechs \u00a0Monaten \u00a0signifikant \u00a0\u00fcber \u00a0dem \u00a0Ausgangwert \u00a0lag \u00a0(Ausnahme: \u00a0p<0,01 \u00a0f\u00fcr \u00a0den \u00a0Brisbane-\u00adStamm \u00a026h-\u00adGruppe). \u00a0 \u00a0\n \u00a0Abbildung \u00a013: \u00a0Graphische \u00a0Darstellung \u00a0des \u00a0Titerverlaufs \u00a0des \u00a0Brisbane-\u00adStammes \u00a0(*=p<0,05;\u037e \u00a0**=p<0,01). \u00a0Woche 26Woche 2Woche 1Woche 03.0002.5002.0001.5001.000500026h-Gruppe2h-GruppeH3N2\n______________________________________________________________________________________________________________________________________________________******\n******\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum     GMEDIAN(Brisbane)[name=\"GMEDIAN_Brisbane\"] Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: GMEDIAN_Brisbane=col(source(s), name(\"GMEDIAN_Brisbane\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Gruppenmedian Brisbane\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Page 38\nWoche 26Woche 2Woche 1Woche 01.200900600300026h-Gruppe2h-GruppeBrisbane_______________________________________________________________________________________________________________________________________________________************\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Entnahmedatum GMEDIAN(Phuket)[name=\"GMEDIAN_Phuket\"]     Sportlergruppe MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Entnahmedatum=col(source(s), name(\"Entnahmedatum\"), notIn(\"4\"), unit.category())   DATA: GMEDIAN_Phuket=col(source(s), name(\"GMEDIAN_Phuket\"))   DATA: Sportlergruppe=col(source(s), name(\"Sportlergruppe\"), unit.category())   GUIDE: axis(dim(1), label(\"Entnahmedatum\"))   GUIDE: axis(dim(2), delta(10), label(\"Gruppenmedian Phuket\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Sportlergruppe\"))   SCALE: cat(dim(1), include(\"0\", \"1\", \"2\", \"3\"))   SCALE: linear(dim(2), min(1), max(200))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"1\", \"2\")) Page 41\t\r \u00a065\t\r \u00a0 \u00a0 \u00a0Abbildung \u00a014: \u00a0Graphische \u00a0Darstellung \u00a0des \u00a0Titerverlaufs \u00a0des \u00a0Phuket-\u00adStammes \u00a0(*=p<0,05;\u037e \u00a0**=p<0,01). \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Woche 26Woche 2Woche 1Woche 02.0001.5001.000500026h-Gruppe2h-GruppePhuket\n_________________________________________________________________________________________________________________________________________________________________************\n       DATASET ACTIVATE DataSet1.  SAVE OUTFILE='/Users/clemensziller/Dokumente/Immunoneu!.sav'   /COMPRESSED. GET   FILE='/Users/clemensziller/Dokumente/Entwurf Fragebogen.sav'. DATASET NAME DataSet3 WINDOW=FRONT. DATASET ACTIVATE DataSet1. DATASET ACTIVATE DataSet1.  SAVE OUTFILE='/Users/clemensziller/Dokumente/Immunoneu!.sav'   /COMPRESSED. DATASET ACTIVATE DataSet1. DATASET CLOSE DataSet3. DATASET ACTIVATE DataSet1.  SAVE OUTFILE='/Users/clemensziller/Dokumente/Immunoneu!.sav'   /COMPRESSED. * Diagrammerstellung. GGRAPH Page 44\t\r \u00a066\t\r \u00a04.2. \u00a0Nebenwirkungen \u00a0 \u00a0Insgesamt \u00a0gaben \u00a080% \u00a0(n=36) \u00a0der \u00a0Probanden \u00a0irgendeine \u00a0Form \u00a0von \u00a0unerw\u00fcnschten \u00a0Wirkungen \u00a0oder \u00a0Nebenwirkungen \u00a0an. \u00a0 \u00a0In \u00a0der \u00a02h-\u00adGruppe \u00a0betraf \u00a0dies \u00a087% \u00a0(n=21) \u00a0der \u00a0Probanden, \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0nur \u00a071% \u00a0(n=15) \u00a0der \u00a0Probanden. \u00a0Ein \u00a0statistisch \u00a0signifikanter \u00a0Unterschied \u00a0zwischen \u00a0den \u00a0beiden \u00a0Gruppen \u00a0zeigte \u00a0sich \u00a0dennoch \u00a0nicht \u00a0(p=0,27). \u00a0Im \u00a0 Folgenden \u00a0 wird \u00a0 unterschieden \u00a0 zwischen \u00a0 lokalen \u00a0 Nebenwirkungen \u00a0 an \u00a0 der \u00a0Einstichstelle \u00a0und \u00a0allgemeinen \u00a0Reaktionen \u00a0auf \u00a0die \u00a0Impfung. \u00a0 \u00a0 \u00a04.2.1. \u00a0Lokale \u00a0Reaktionen \u00a0 \u00a0Die \u00a0h\u00e4ufigste \u00a0lokale \u00a0Nebenwirkung \u00a0war \u00a0der \u00a0Schmerz. \u00a0Dieser \u00a0wurde \u00a0von \u00a073% \u00a0(n=33) \u00a0der \u00a0Probanden \u00a0angegeben. \u00a0Auch \u00a0hier \u00a0gaben \u00a0mehr \u00a0Probanden \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0(83%) \u00a0an, \u00a0lokale \u00a0Schmerzen \u00a0an \u00a0der \u00a0Einstichstelle \u00a0versp\u00fcrt \u00a0zu \u00a0haben, \u00a0als \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0(62%). \u00a0Es \u00a0ergaben \u00a0sich \u00a0keine \u00a0signifikanten \u00a0Unterschiede \u00a0bez\u00fcglich \u00a0 maximaler \u00a0 Intensit\u00e4t \u00a0 (p=0,72) \u00a0 und \u00a0 Dauer \u00a0 (p=0,38) \u00a0 des \u00a0 lokalen \u00a0Schmerzes. \u00a0 \u00a0\n \u00a0Abbildung \u00a015: \u00a0Vergleich \u00a0der \u00a0Intensit\u00e4t \u00a0\u00fcber \u00a07 \u00a0Tagen \u00a0der \u00a0Angabe \u00a0\u201eSchmerz \u00a0an \u00a0der \u00a0Einstichstelle\u201c. \u00a0Es \u00a0zeigte \u00a0sich \u00a0sowohl \u00a0eine \u00a0etwas \u00a0l\u00e4ngere \u00a0Dauer, \u00a0h\u00f6here \u00a0maximale \u00a0Intensit\u00e4t \u00a0und \u00a0h\u00f6here \u00a07-\u00adTages-\u00adIntensit\u00e4t \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0(0=keine \u00a0Symptome, \u00a01=mild, \u00a02=bei \u00a0Ber\u00fchrung, \u00a03=bei \u00a0Bewegung, \u00a04=spontan). \u00a026h-Gruppe2h-GruppeIntensit\u00e4t des lokalen Schmerzes (d0-d7)8,006,004,002,00,00p=0,10\n0       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Gruppe R\u00f6tungsmaximum MISSING=LISTWISE     REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Gruppe=col(source(s), name(\"Gruppe\"), notIn(\"0\", \"3\"), unit.category())   DATA: R\u00f6tungsmaximum=col(source(s), name(\"R\u00f6tungsmaximum\"))   DATA: id=col(source(s), name(\"$CASENUM\"), unit.category())   GUIDE: axis(dim(1), label(\"Zugeh\u00f6rigkeit zu Gruppe\"))   GUIDE: axis(dim(2), label(\"Maximale Gr\u00f6\u00dfe der R\u00f6tung\"))   SCALE: cat(dim(1), include(\"1\", \"2\"))   SCALE: linear(dim(2), include(0))   ELEMENT: schema(position(bin.quantile.letter(Gruppe*R\u00f6tungsmaximum)), label(id)) END GPL.GGraphPage 84\t\r \u00a067\t\r \u00a0 Eine \u00a0 R\u00f6tung \u00a0 der \u00a0 Einstichstelle \u00a0 wurde \u00a0 nur \u00a0 von \u00a0 4% \u00a0 (n=2) \u00a0 der \u00a0 Probanden \u00a0angegeben, \u00a0 diese \u00a0 befanden \u00a0 sich \u00a0 beide \u00a0 in \u00a0 der \u00a0 26h-\u00adGruppe, \u00a0 eine \u00a0 Schwellung \u00a0gaben \u00a0ebenfalls \u00a0nur \u00a07% \u00a0(n=3) \u00a0der \u00a0Probanden \u00a0an, \u00a0welche \u00a0sich \u00a0alle \u00a0drei \u00a0in \u00a0der \u00a02h-\u00adGruppe \u00a0befanden. \u00a0Die \u00a0Unterschiede \u00a0waren \u00a0nicht \u00a0signifikant. \u00a0 \u00a0\n \u00a0 \u00a0Abbildung \u00a016: \u00a0Gr\u00f6\u00dfe \u00a0und \u00a0Dauer \u00a0der \u00a0R\u00f6tung \u00a0an \u00a0der \u00a0Einstichstelle. \u00a0 \n Abbildung \u00a017: \u00a0Gr\u00f6\u00dfe \u00a0und \u00a0Dauer \u00a0der \u00a0Schwellung \u00a0an \u00a0der \u00a0Einstichstelle. \u00a0 \u00a0 Dar\u00fcber \u00a0hinaus \u00a0wurden \u00a0auch \u00a0andere \u00a0lokale \u00a0Beschwerden \u00a0erfasst, \u00a0die \u00a0bei \u00a022% \u00a0(n=10) \u00a0 der \u00a0 Probanden \u00a0 auftraten. \u00a0 Sie \u00a0 traten \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 bei \u00a0 je \u00a0 f\u00fcnf \u00a0Probanden \u00a0auf. \u00a0Hierzu \u00a0z\u00e4hlten \u00a0ein \u00a0Stechen \u00a0an \u00a0der \u00a0Einstichstelle \u00a0(n=8), \u00a0Juckreiz \u00a0(n=1) \u00a0 und \u00a0 geschwollene \u00a0 Lymphknoten \u00a0 am \u00a0 betroffenen \u00a0 Arm \u00a0(n=1). \u00a0Auch \u00a0 hier \u00a0\n26h-Gruppe2h-Gruppe100,0%80,0%60,0%40,0%20,0%0,0%0 Tage1 Tag2 TageDauer der R\u00f6tungp=0,21\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Gruppe COUNT()[name=\"COUNT\"] Schwellungsdauer     MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Gruppe=col(source(s), name(\"Gruppe\"), notIn(\"0\", \"3\"), unit.category())   DATA: COUNT=col(source(s), name(\"COUNT\"))   DATA: Schwellungsdauer=col(source(s), name(\"Schwellungsdauer\"), unit.category())   GUIDE: axis(dim(1), label(\"Zugeh\u00f6rigkeit zu Gruppe\"))   GUIDE: axis(dim(2), label(\"Anzahl\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Schwellungsdauer\"))   SCALE: cat(dim(1), include(\"1\", \"2\"))   SCALE: linear(dim(2), include(0))   SCALE: cat(aesthetic(aesthetic.color.interior), include(\"0\", \"1\", \"2\", \"3Page 47\n\t\r \u00a068\t\r \u00a0konnte \u00a0kein \u00a0signifikanter \u00a0Unterschied \u00a0bez\u00fcglich \u00a0maximaler \u00a0Intensit\u00e4t \u00a0(p=0,92) \u00a0und \u00a0Dauer \u00a0(p=0,93) \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0gezeigt \u00a0werden. \u00a0 \u00a0 \u00a04.2.2. \u00a0Allgemeine \u00a0Reaktionen \u00a0 \u00a0Die \u00a0 h\u00e4ufigste \u00a0 allgemeine \u00a0 unerw\u00fcnschte \u00a0 Wirkung \u00a0 war \u00a0 der \u00a0 Muskelschmerz, \u00a0welcher \u00a0als \u00a0prim\u00e4r \u00a0nicht \u00a0an \u00a0der \u00a0Impfstelle \u00a0auftretende \u00a0Myalgien \u00a0definiert \u00a0wurde. \u00a0Dieser \u00a0 wurde \u00a0 von \u00a0 42% \u00a0 (19) \u00a0 der \u00a0 Sportler \u00a0 angegeben. \u00a0In \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 hielt \u00a0dieser \u00a0im \u00a0Schnitt \u00a02,4 \u00a0Tage \u00a0an \u00a0und \u00a0wurde \u00a0bis \u00a0zum \u00a0dritten \u00a0Tag \u00a0nach \u00a0der \u00a0Impfung \u00a0angegeben, \u00a0wohingegen \u00a0er \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0nur \u00a0am \u00a0Tag \u00a0der \u00a0Impfung \u00a0und \u00a0am \u00a0ersten \u00a0 Tag \u00a0 danach \u00a0 angegeben \u00a0 wurde \u00a0 und \u00a0 im \u00a0 Schnitt \u00a0 1,6 \u00a0 Tage \u00a0 anhielt. \u00a0 Der \u00a0Unterschied \u00a0im \u00a0Hinblick \u00a0auf \u00a0die \u00a0Dauer \u00a0war \u00a0statistisch \u00a0nicht \u00a0signifikant \u00a0(p=0,39). \u00a0 \u00a0\n \u00a0Abbildung \u00a018: \u00a0Maximale \u00a0Intensit\u00e4t \u00a0des \u00a0Muskelschmerzes. \u00a0  \u00a026h-Gruppe2h-Gruppe100,0%80,0%60,0%40,0%20,0%0,0%keine SymptomeMildModeratSchwerMaximale Intensit\u00e4t der Muskelschmerzenp=0,57\n       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Gruppe COUNT()[name=\"COUNT\"] Sch\u00fcttelfrostmaximum     MISSING=LISTWISE REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Gruppe=col(source(s), name(\"Gruppe\"), notIn(\"0\", \"3\"), unit.category())   DATA: COUNT=col(source(s), name(\"COUNT\"))   DATA: Sch\u00fcttelfrostmaximum=col(source(s), name(\"Sch\u00fcttelfrostmaximum\"), unit.category())   GUIDE: axis(dim(1), label(\"Zugeh\u00f6rigkeit zu Gruppe\"))   GUIDE: axis(dim(2), label(\"Anzahl\"))   GUIDE: legend(aesthetic(aesthetic.color.interior), label(\"Maximaler Schweregad des \",     \"Sch\u00fcttelfrostes\"))   SCALE: cat(dim(1), include(\"1\", \"2\"))   SCALE: linear(dim(2), include(0)) Page 29\t\r \u00a069\t\r \u00a0 \u00a0Abbildung \u00a019: \u00a0Summe \u00a0der \u00a0Intensit\u00e4t \u00a0des \u00a0Muskelschmerzes \u00a0\u00fcber \u00a0sieben \u00a0Tage \u00a0(0=keine \u00a0Symptome, \u00a01=mild, \u00a02=moderat, \u00a03=schwer). \u00a0 \u00a0Als \u00a0 zweith\u00e4ufigste \u00a0 allgemeine \u00a0 unerw\u00fcnschte \u00a0 Nebenwirkung \u00a0 wurde \u00a0 von \u00a0 40% \u00a0(n=18) \u00a0 der \u00a0 Athleten \u00a0 M\u00fcdigkeit \u00a0 angegeben. \u00a0 Unter \u00a0 diesen \u00a0 befanden \u00a0 sich \u00a0 acht \u00a0Personen \u00a0aus \u00a0der \u00a02h-\u00adGruppe \u00a0(33%) \u00a0und \u00a0zehn \u00a0Personen \u00a0aus \u00a0der \u00a026h-\u00adGruppe \u00a0(43%). \u00a0 Hier \u00a0 lie\u00df \u00a0sich \u00a0 ebenfalls \u00a0 kein \u00a0 statistisch \u00a0 signifikanter \u00a0 Unterschied \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0feststellen \u00a0(p=0,56). \u00a0Insgesamt \u00a0betrachtet \u00a0war \u00a0die \u00a0M\u00fcdigkeit \u00a0von \u00a0milder \u00a0Intensit\u00e4t, \u00a0hielt \u00a0im \u00a0Schnitt \u00a0drei \u00a0Tage \u00a0an \u00a0und \u00a0wurde \u00a0ohne \u00a0erkennbaren \u00a0zeitlichen \u00a0Zusammenhang \u00a0\u00fcber \u00a0alle \u00a0sieben \u00a0im \u00a0Bogen \u00a0erfassten \u00a0Tage \u00a0hinweg \u00a0und \u00a0dar\u00fcber \u00a0hinaus \u00a0angegeben. \u00a0Kopfschmerz \u00a0wurde \u00a0von \u00a022% \u00a0(n=10) \u00a0der \u00a0Probanden \u00a0angegeben. \u00a025% \u00a0(n=6) \u00a0in \u00a0der \u00a0 2h-\u00adGruppe \u00a0 und \u00a0 19% \u00a0 (n=4) \u00a0 in \u00a0 der \u00a0 26h-\u00adGruppe. \u00a0 Auch \u00a0 hier \u00a0war \u00a0 der \u00a0Unterschied \u00a0nicht \u00a0signifikant \u00a0(p=0,73). \u00a0Ferner \u00a0gaben \u00a0noch \u00a09% \u00a0(n=4) \u00a0\u00dcbelkeit \u00a0an. \u00a0Jeweils \u00a0zwei \u00a0Personen \u00a0jeder \u00a0Gruppe. \u00a0 \u00a0Sch\u00fcttelfrost \u00a0wurde \u00a0von \u00a0je \u00a0einer \u00a0Person \u00a0jeder \u00a0Gruppe \u00a0angegeben. \u00a0Dieser \u00a0trat \u00a0in \u00a0beiden \u00a0F\u00e4llen \u00a0am \u00a0ersten \u00a0Tag \u00a0nach \u00a0der \u00a0Impfung \u00a0auf. \u00a0Bei \u00a0 der \u00a0 t\u00e4glichen \u00a0 Temperaturmessung \u00a0 trat \u00a0 bei \u00a0 einem \u00a0 Probanden \u00a0in \u00a0 der \u00a0 2h-\u00adGruppe \u00a0am \u00a0zweiten \u00a0und \u00a0am \u00a0dritten \u00a0Tag \u00a0nach \u00a0der \u00a0Impfung \u00a0Fieber \u00a0auf, \u00a0welches \u00a0hier \u00a0als \u00a0oral \u00a0gemessene \u00a0Temperatur \u00a0\u00fcber \u00a038,5\u00b0C \u00a0definiert \u00a0ist \u00a0(Herold \u00a02015). \u00a0Hierbei \u00a0ist \u00a0jedoch \u00a0zu \u00a0ber\u00fccksichtigen, \u00a0dass \u00a0vier \u00a0Probanden \u00a0an \u00a0einem \u00a0Tag \u00a0und \u00a0sieben \u00a0Probanden \u00a0\u00fcber \u00a0mehrere \u00a0Tage \u00a0oder \u00a0die \u00a0gesamte \u00a0Woche \u00a0diese \u00a0Messung \u00a0nicht \u00a0durchgef\u00fchrt \u00a0hatten. \u00a026h-Gruppe2h-GruppeIntensit\u00e4t des Muskelschmerzes (d0-d7)6,005,004,003,002,001,00,001p=0,81\n0       * Diagrammerstellung. GGRAPH   /GRAPHDATASET NAME=\"graphdataset\" VARIABLES=Gruppe Sch\u00fcttelfrostintensit\u00e4t MISSING=LISTWISE     REPORTMISSING=NO   /GRAPHSPEC SOURCE=INLINE. BEGIN GPL   SOURCE: s=userSource(id(\"graphdataset\"))   DATA: Gruppe=col(source(s), name(\"Gruppe\"), notIn(\"0\", \"3\"), unit.category())   DATA: Sch\u00fcttelfrostintensit\u00e4t=col(source(s), name(\"Sch\u00fcttelfrostintensit\u00e4t\"))   DATA: id=col(source(s), name(\"$CASENUM\"), unit.category())   GUIDE: axis(dim(1), label(\"Zugeh\u00f6rigkeit zu Gruppe\"))   GUIDE: axis(dim(2), label(\"Sch\u00fcttelfrostintensit\u00e4t\"))   SCALE: cat(dim(1), include(\"1\", \"2\"))   SCALE: linear(dim(2), include(0))   ELEMENT: schema(position(bin.quantile.letter(Gruppe*Sch\u00fcttelfrostintensit\u00e4t)), label(id)) END GPL.GGraphPage 94\t\r \u00a070\t\r \u00a0Von \u00a0 insgesamt \u00a0 acht \u00a0Probanden \u00a0 wurden \u00a0 zudem \u00a0 noch \u00a0 andere \u00a0Allgemeinreaktionen \u00a0nach \u00a0der \u00a0Impfung \u00a0festgestellt. \u00a0 \u00a0Bez\u00fcglich \u00a0Dauer \u00a0(p=0,84) \u00a0und \u00a0maximaler \u00a0Intensit\u00e4t \u00a0(p=0,33) \u00a0zeigten \u00a0sich \u00a0keine \u00a0signifikanten \u00a0Unterschiede. \u00a0 \u00a0 \u00a02h-\u00adGruppe \u00a026h-\u00adGruppe \u00a0keine \u00a021 \u00a016 \u00a0Schw\u00e4chegef\u00fchl \u00a01 \u00a0-\u00ad \u00a0Schnupfen \u00a01 \u00a02 \u00a0Hautsensibilit\u00e4t \u00a01 \u00a0 \u00a0Schwindel \u00a0-\u00ad \u00a01 \u00a0Juckreiz \u00a0-\u00ad \u00a01 \u00a0Mamillenschmerz/-\u00adverh\u00e4rtung \u00a0-\u00ad \u00a01 \u00a0 \u00a0Tabelle \u00a014: \u00a0\u00dcberblick \u00a0\u00fcber \u00a0die \u00a0Art \u00a0anderer \u00a0Allgemeinreaktionen. \u00a0 \u00a0 \u00a04.2.3. \u00a0Besonderheiten \u00a0im \u00a0Trainingsablauf \u00a0 \u00a0Die \u00a0 durchschnittliche \u00a0 Trainingszeit \u00a0 der \u00a0 Probanden \u00a0 war \u00a0 im \u00a0 Mittel \u00a014,7\u00b14,9 \u00a0Stunden \u00a0in \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 und \u00a013,1\u00b14,4 \u00a0Stunden \u00a0in \u00a0 der \u00a0 26h-\u00adGruppe. \u00a0 Die \u00a0Unterschiede \u00a0in \u00a0der \u00a0Trainingszeit \u00a0waren \u00a0mit \u00a0p=0,25 \u00a0nicht \u00a0signifikant. \u00a0Mit \u00a0p<0,01 \u00a0gab \u00a0 es \u00a0 erwartungsgem\u00e4\u00df \u00a0 entsprechend \u00a0 der \u00a0 Gruppendefinition \u00a0 jedoch \u00a0Unterschiede \u00a0in \u00a0der \u00a0Trainingsdauer \u00a0vor \u00a0Impfung. \u00a0So \u00a0trainierten \u00a0die \u00a0Sportler \u00a0der \u00a02h-\u00adGruppe \u00a0in \u00a0den \u00a0beiden \u00a0Tagen \u00a0pr\u00e4 \u00a0Vakzination \u00a05,5h \u00a0Stunden, \u00a0wohingegen \u00a0die \u00a026h-\u00adGruppe \u00a0im \u00a0Mittel \u00a0nur \u00a0auf \u00a02,9 \u00a0Stunden \u00a0Training \u00a0kam. \u00a0In \u00a0der \u00a02h-\u00adGruppe \u00a0traten \u00a0bei \u00a010 \u00a0Sportlern \u00a0(42%) \u00a0Einschr\u00e4nkungen \u00a0im \u00a0Training \u00a0auf, \u00a0davon \u00a0bei \u00a0einem \u00a0Athleten \u00a0(4%) \u00a0nur \u00a0am \u00a0Tag \u00a0der \u00a0Impfung, \u00a0bei \u00a0acht \u00a0Athleten \u00a0(33%) \u00a0am \u00a0 ersten \u00a0 Tag \u00a0 nach \u00a0 der \u00a0 Impfung, \u00a0 wobei \u00a0 bei \u00a0 einem \u00a0dieser \u00a0 die \u00a0Einschr\u00e4nkung \u00a0 am \u00a0 zweiten \u00a0Tag \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0 anhielt. \u00a0Und \u00a0 bei \u00a0einem \u00a0Probanden \u00a0traten \u00a0diese \u00a0am \u00a0zweiten \u00a0Tag \u00a0nach \u00a0der \u00a0Impfung \u00a0auf \u00a0und \u00a0hielten \u00a0noch \u00a0einen \u00a0weiteren \u00a0Tag \u00a0an. \u00a0\t\r \u00a071\t\r \u00a0In \u00a0 der \u00a0 26h-\u00adGruppe \u00a0 gaben \u00a0 vier \u00a0(19%) \u00a0 Probanden \u00a0 eine \u00a0 Einschr\u00e4nkung \u00a0 der \u00a0Trainingsleistung \u00a0an. \u00a0Zwei \u00a0(9%) \u00a0der \u00a0Sportler \u00a0stellten \u00a0diese \u00a0am \u00a0Tag \u00a0der \u00a0Impfung \u00a0und \u00a0zwei \u00a0(9%) \u00a0Sportler \u00a0ab \u00a0dem \u00a0ersten \u00a0Tag \u00a0nach \u00a0der \u00a0Impfung \u00a0fest. \u00a0Bei \u00a0 einer \u00a0 Probandin \u00a0 dieses \u00a0 Kollektivs \u00a0 hielt \u00a0 die \u00a0 Einschr\u00e4nkung \u00a0im \u00a0 Sinne \u00a0 von \u00a0M\u00fcdigkeit \u00a0und \u00a0eines \u00a0grippalen \u00a0Infekts \u00a0die \u00a0nachfolgenden \u00a0sieben \u00a0Tage \u00a0an. \u00a0Auch \u00a0hierbei \u00a0ergaben \u00a0sich \u00a0keine \u00a0statistisch \u00a0signifikanten \u00a0Unterschiede \u00a0zwischen \u00a0den \u00a0Subgruppen. \u00a0Die \u00a0 Sportler \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 hatten \u00a0 im \u00a0 Schnitt \u00a0 eine \u00a0subjektive \u00a0Minderung \u00a0 der \u00a0Trainingsleistung \u00a0von \u00a01,8 \u00a0Tagen, \u00a0die \u00a0Sportler \u00a0der \u00a026h-\u00adGruppe \u00a0von \u00a02,5 \u00a0Tagen. \u00a0Der \u00a0Unterschied \u00a0war \u00a0nicht \u00a0signifikant. \u00a0Es \u00a0kam \u00a0impfbedingt \u00a0hierbei \u00a0zu \u00a0keinem \u00a0Trainingsausfall \u00a0 und \u00a0 in \u00a0 lediglich \u00a0 einem \u00a0 Fall \u00a0 war \u00a0 eine \u00a0 leichte \u00a0 Modifikation \u00a0 der \u00a0Trainingseinheit \u00a0notwendig. \u00a0 \u00a0Gruppe \u00a0Gesamtzahl \u00a0Sportart \u00a0Anzahl \u00a0Leistungsminderung \u00a0(Tage \u00a0/ \u00a0Person) \u00a02h-\u00adGruppe \u00a0n=10 \u00a0Schwimmen \u00a01 \u00a01,5 \u00a0Rudern \u00a02 \u00a01 \u00a0Ringen \u00a03 \u00a02,3 \u00a0Triathlon \u00a02 \u00a01 \u00a0Badminton \u00a01 \u00a01 \u00a0Hammerwurf \u00a01 \u00a03 \u00a026h-\u00adGruppe \u00a0n=4 \u00a0Schwimmen \u00a01 \u00a02 \u00a0Badminton \u00a01 \u00a07 \u00a0Rudern \u00a01 \u00a01 \u00a0Mountainbike \u00a01 \u00a02 \u00a0 \u00a0Tabelle \u00a015: \u00a0Trainingsausf\u00e4lle \u00a0in \u00a0Abh\u00e4ngigkeit \u00a0von \u00a0der \u00a0Sportart. \u00a0 \u00a0Als \u00a0 Gr\u00fcnde \u00a0 f\u00fcr \u00a0 die \u00a0 verringerte \u00a0 Trainingsleistung \u00a0 wurden \u00a0 unter \u00a0 anderem \u00a0Muskelschmerzen \u00a0und \u00a0Stechen \u00a0bzw. \u00a0\u201eZiehen\u201c \u00a0im \u00a0betroffenen \u00a0Arm, \u00a0aber \u00a0auch \u00a0M\u00fcdigkeit \u00a0 angegeben. \u00a0 Eine \u00a0 Probandin \u00a0der \u00a0 26h-\u00adGruppe \u00a0versp\u00fcrte \u00a0 Schwindel \u00a0und \u00a0\u00dcbelkeit \u00a0im \u00a0Training \u00a0und \u00a0entwickelte \u00a0im \u00a0Anschluss \u00a0einen \u00a0grippalen \u00a0Infekt, \u00a0der \u00a0 ein \u00a0 weiteres \u00a0 Training \u00a0 in \u00a0 der \u00a0 zweiten \u00a0 Woche \u00a0 nach \u00a0 Impfung \u00a0 unm\u00f6glich \u00a0machte. \u00a0\t\r \u00a072\t\r \u00a05. \u00a0Diskussion \u00a0 \u00a05.1. \u00a0Ergebnisbewertung \u00a0 \u00a0Zusammenfassend \u00a0l\u00e4sst \u00a0sich \u00a0feststellen, \u00a0dass \u00a0sich \u00a0in \u00a0dieser \u00a0Studie \u00a0keine \u00a0Hinweise \u00a0auf \u00a0 eine \u00a0 eingeschr\u00e4nkte \u00a0 Immunantwort \u00a0 bei \u00a0 Sportlern, \u00a0 welche \u00a0 in \u00a0 einem \u00a0 engen \u00a0zeitlichen \u00a0Zusammenhang \u00a0nach \u00a0einer \u00a0Trainingseinheit \u00a0geimpft \u00a0wurden, \u00a0feststellen \u00a0lie\u00df. \u00a0 Ebenso \u00a0 scheint \u00a0 die \u00a0 sportliche \u00a0 Bet\u00e4tigung \u00a0 keinen \u00a0 Einfluss \u00a0 auf \u00a0 das \u00a0Nebenwirkungsprofil \u00a0zu \u00a0haben. \u00a0 \u00a05.1.1. \u00a0Abh\u00e4ngigkeit \u00a0des \u00a0Impferfolges \u00a0vom \u00a0Impfzeitpunkt \u00a0 \u00a0Entsprechend \u00a0 der \u00a0 \u201eopen \u00a0window\u201c-\u00adTheorie \u00a0 soll \u00a0 es \u00a0 nach \u00a0 k\u00f6rperlicher \u00a0 Aktivit\u00e4t \u00a0innerhalb \u00a0 eines \u00a0 gewissen \u00a0 Zeitfensters \u00a0 zu \u00a0 einer \u00a0 erh\u00f6hten \u00a0 Infektanf\u00e4lligkeit \u00a0kommen, \u00a0 die \u00a0 sich \u00a0 immunologisch \u00a0 unter \u00a0 anderem \u00a0an \u00a0 einer \u00a0 verringerten \u00a0Gesamtzahl \u00a0zirkulierender \u00a0Lymphozyten \u00a0zeigen \u00a0l\u00e4sst \u00a0(Kakanis \u00a0et \u00a0al. \u00a02010). \u00a0Inwieweit \u00a0 dies \u00a0 die \u00a0 zellul\u00e4re \u00a0 und \u00a0 humorale \u00a0 Immunantwort \u00a0 auf \u00a0 eine \u00a0 Impfung \u00a0beeinflusst, \u00a0sollte \u00a0unter \u00a0anderem \u00a0in \u00a0dieser \u00a0Studie \u00a0erhoben \u00a0werden. \u00a0Im \u00a0Rahmen \u00a0des \u00a0belastungsindizierten \u00a0Kortisolanstieges \u00a0(Scharhag \u00a0et \u00a0al. \u00a02002) \u00a0trat \u00a0 bei \u00a0 den \u00a0 Probanden, \u00a0 die \u00a0 innerhalb \u00a0 von \u00a0 zwei \u00a0 Stunden \u00a0 nach \u00a0 der \u00a0 letzten \u00a0Trainingseinheit \u00a0 geimpft \u00a0 wurden, \u00a0 erwartungsgem\u00e4\u00df \u00a0 eine \u00a0 Neutrophilie \u00a0 und \u00a0Leukozytose \u00a0 auf. \u00a0 Dementsprechend \u00a0 waren \u00a0 auch \u00a0 die \u00a0 prozentualen \u00a0Lymphozytenzahlen \u00a0 mit \u00a0 p<0,1 \u00a0 in \u00a0 der \u00a0 2h-\u00adGruppe \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 signifikant \u00a0niedriger \u00a0als \u00a0in \u00a0der \u00a026h-\u00adGruppe. \u00a0Im \u00a0 Hinblick \u00a0 auf \u00a0 die \u00a0 Influenza-\u00adspezifischen-\u00adCD4+-\u00adLymphozyten \u00a0war \u00a0 das \u00a0Ansprechen \u00a0auf \u00a0die \u00a0Impfung \u00a0und \u00a0die \u00a0Effektivit\u00e4t \u00a0der \u00a0Immuninduktion \u00a0im \u00a0Sinne \u00a0eines \u00a0 Anstieges \u00a0 dieser \u00a0 spezifischen \u00a0 Abwehrzellen \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0signifikant, \u00a0 wobei \u00a0 die \u00a0 Werte \u00a0 nach \u00a0 einer \u00a0 Woche \u00a0 ihren \u00a0 H\u00f6hepunkt \u00a0 erreichten. \u00a0 \u00a0Zudem \u00a0 waren \u00a0 weder \u00a0 insgesamt, \u00a0 \u00fcber \u00a0 alle \u00a0 Messungen \u00a0 hinweg, \u00a0 noch \u00a0 an \u00a0 den \u00a0einzelnen \u00a0Messzeitpunkten \u00a0sowohl \u00a0vor \u00a0als \u00a0auch \u00a0nach \u00a0der \u00a0Impfung \u00a0statistisch \u00a0zu \u00a0sichernde \u00a0Unterschiede \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0feststellbar. \u00a0Dies \u00a0spricht \u00a0f\u00fcr \u00a0eine \u00a0 gleichwertige \u00a0 immunogene \u00a0 Reaktion \u00a0 auf \u00a0 die \u00a0 Impfung \u00a0 und \u00a0stellt \u00a0eine \u00a0\t\r \u00a073\t\r \u00a0abgeschw\u00e4chte \u00a0 zellul\u00e4re \u00a0 Impfreaktion \u00a0 im \u00a0 Rahmen \u00a0 des \u00a0 \u201eopen \u00a0windows\u201c \u00a0in \u00a0Frage. \u00a0 \u00a0\u00c4hnliches \u00a0wurde \u00a0auch \u00a0in \u00a0einer \u00a0Studie \u00a0 aus \u00a0 dem \u00a0 Jahr \u00a0 2010 \u00a0berichtet. \u00a0 Dabei \u00a0wurden \u00a0junge \u00a0 gesunde \u00a0 M\u00e4nner \u00a0 zu \u00a0 verschiedenen \u00a0 Zeitpunkten \u00a0nach \u00a0 einem \u00a0exzentrischen \u00a0 Training \u00a0 gegen \u00a0 Influenza \u00a0 geimpft. \u00a0Es \u00a0 zeigten \u00a0 sich \u00a0keine \u00a0Unterschiede \u00a0 in \u00a0 der \u00a0zell-\u00advermittelten \u00a0Immunit\u00e4t \u00a0zwischen \u00a0 den \u00a0 Gruppen \u00a0in \u00a0Abh\u00e4ngigkeit \u00a0vom \u00a0Abstand \u00a0der \u00a0Impfung \u00a0zur \u00a0Trainingseinheit \u00a0(Campbell \u00a0et \u00a0al. \u00a02010). \u00a0 \u00a0Analog \u00a0hierzu \u00a0verhielten \u00a0sich \u00a0die \u00a0Titer \u00a0der \u00a0Influenza-\u00adspezifischen \u00a0Antik\u00f6rper. \u00a0Es \u00a0waren \u00a0zu \u00a0keinem \u00a0Zeitpunkt \u00a0Unterschiede \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0feststellbar, \u00a0wohingegen \u00a0sich \u00a0im \u00a0Vergleich \u00a0der \u00a0Messzeitpunkte \u00a0des \u00a0jeweiligen \u00a0Kollektivs \u00a0eine \u00a0identische \u00a0Induktion \u00a0der \u00a0immunologischen \u00a0Reaktion \u00a0beobachten \u00a0lie\u00df. \u00a0Sowohl \u00a0das \u00a0 IgG-\u00ad \u00a0Level, \u00a0 als \u00a0 auch \u00a0 die \u00a0 IgM-\u00ad \u00a0und \u00a0 IgA-\u00adRatio \u00a0 stiegen \u00a0 im \u00a0 Vergleich \u00a0 der \u00a0Messzeitpunkte \u00a0 in \u00a0 beiden \u00a0 Gruppen \u00a0 signifikant \u00a0 an \u00a0 und \u00a0 fielen \u00a0 dann \u00a0 bis \u00a0 zur \u00a0Blutentnahme \u00a0nach \u00a0sechs \u00a0Monaten \u00a0wieder \u00a0signifikant \u00a0ab. \u00a0 \u00a0Die \u00a0 Gleichwertigkeit \u00a0 der \u00a0 immunogenen \u00a0 Reaktion \u00a0 beider \u00a0 Gruppen \u00a0 zeigte \u00a0 sich \u00a0zuletzt \u00a0auch \u00a0anhand \u00a0der \u00a0Neutralisationstiter. \u00a0Es \u00a0konnte \u00a0auch \u00a0hier \u00a0zu \u00a0keinem \u00a0Zeitpunkt \u00a0ein \u00a0Unterschied \u00a0zwischen \u00a0beiden \u00a0Sportlergruppen \u00a0erhoben \u00a0werden. \u00a0Immunologisch \u00a0zeigte \u00a0sich \u00a0der \u00a0Impferfolg \u00a0auch \u00a0hier \u00a0im \u00a0Sinne \u00a0eines \u00a0signifikanten \u00a0Anstieges \u00a0der \u00a0Titer \u00a0innerhalb \u00a0der \u00a0ersten \u00a0beiden \u00a0Wochen, \u00a0mit \u00a0darauffolgendem \u00a0signifikanten \u00a0Abfall \u00a0der \u00a0Werte. \u00a0Die \u00a0 k\u00f6rperliche \u00a0 Aktivit\u00e4t \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 scheint \u00a0 also \u00a0 weder \u00a0 einen \u00a0immunsuppressiven \u00a0 Effekt \u00a0 auf \u00a0 die \u00a0 Impfantwort \u00a0 im \u00a0 Sinne \u00a0 eines \u00a0verminderten \u00a0Anstieges \u00a0 dieser \u00a0 Titer \u00a0 gehabt \u00a0 zu \u00a0 haben, \u00a0 noch \u00a0 auf \u00a0 die \u00a0 Dauer \u00a0 der \u00a0 protektiven \u00a0Wirkung. \u00a0W\u00e4hrend \u00a0bei \u00a0den \u00a0Antik\u00f6rpertitern \u00a0im \u00a0Vergleich \u00a0zum \u00a0Ausgangswert \u00a0lediglich \u00a0f\u00fcr \u00a0die \u00a0 IgM-\u00adRatio \u00a0 sechs \u00a0 Monate \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0 signifikant \u00a0 h\u00f6here \u00a0 Werte \u00a0vorlagen, \u00a0war \u00a0dies \u00a0bei \u00a0den \u00a0Neutralisationstitern \u00a0f\u00fcr \u00a0alle \u00a0vier \u00a0St\u00e4mme \u00a0der \u00a0Fall. \u00a0Ein \u00a0Unterschied \u00a0zwischen \u00a0beiden \u00a0Gruppen \u00a0lie\u00df \u00a0sich \u00a0auch \u00a0hier \u00a0nicht \u00a0erkennen. \u00a0 \u00a0Die \u00a0 akute \u00a0 Auswirkung \u00a0 einer \u00a0 vorangegangenen \u00a0 Trainingseinheit \u00a0 auf \u00a0 den \u00a0Impferfolg \u00a0untersuchte \u00a0lediglich \u00a0eine \u00a0Studie, \u00a0in \u00a0der \u00a0moderat \u00a0trainierte \u00a0M\u00e4nner \u00a0mit \u00a0 Triathleten \u00a0 verglichen \u00a0 wurden. \u00a0 Die \u00a0 Triathleten \u00a0 wurden \u00a0 in \u00a0 zwei \u00a0 Gruppen \u00a0aufgeteilt, \u00a0 wobei \u00a0 eine \u00a0 Gruppe \u00a0 direkt \u00a0 nach \u00a0 einem \u00a0 Halb-\u00adIronman-\u00adWettbewerb \u00a0geimpft \u00a0 wurde \u00a0 und \u00a0 die \u00a0 andere \u00a0 Gruppe \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 keine \u00a0 sportliche \u00a0\t\r \u00a074\t\r \u00a0Bet\u00e4tigung \u00a0absolvierte. \u00a0Es \u00a0zeigten \u00a0sich \u00a0keine \u00a0Unterschiede \u00a0zwischen \u00a0den \u00a0drei \u00a0Gruppen \u00a0 in \u00a0 Hinblick \u00a0 auf \u00a0 die \u00a0 Antik\u00f6rper \u00a0 gegen \u00a0 Diphterie-\u00ad, \u00a0 Tetanustoxid-\u00ad \u00a0und \u00a0Pneumokokken-\u00adAntigene \u00a0(Bruunsgard \u00a0et \u00a0al. \u00a01997). \u00a0Whitham \u00a0et \u00a0al. \u00a0hingegen \u00a0impften \u00a0ihre \u00a0Probanden \u00a0nach \u00a0einer \u00a0Trainingszeit \u00a0von \u00a0zwei \u00a0Wochen. \u00a0W\u00e4hrend \u00a0eine \u00a0Gruppe \u00a0ihr \u00a0gewohntes \u00a0leichtes \u00a0Training \u00a0(VO2max \u00a041,1 \u00a0 \u00b1 \u00a0 1,5 \u00a0 ml\u22c5kg-\u00ad1\u22c5min-\u00ad1) \u00a0 fortsetzte, \u00a0 erh\u00f6hten \u00a0 die \u00a0 Probanden \u00a0 der \u00a0 schweren \u00a0Trainingsgruppe \u00a0 (VO2max \u00a0 53,1 \u00a0\u00b1 \u00a03,7 \u00a0ml\u22c5kg-\u00ad1\u22c5min-\u00ad1) \u00a0 f\u00fcr \u00a0 die \u00a0 Dauer \u00a0 des \u00a0Protokolls \u00a0ihre \u00a0Leistung. \u00a0Zwar \u00a0konnten \u00a0nach \u00a014 \u00a0Tagen \u00a0keine \u00a0unterschiedlichen \u00a0Antik\u00f6rperkonzentrationen \u00a0 festgestellt \u00a0 werden, \u00a0 nach \u00a0 einem \u00a0 Jahr \u00a0 hingegen \u00a0waren \u00a0die \u00a0Werte \u00a0in \u00a0der \u00a0Gruppe \u00a0mit \u00a0dem \u00a0schweren \u00a0Training \u00a0signifikant \u00a0h\u00f6her \u00a0(Whitham \u00a0et \u00a0al. \u00a02003). \u00a0Ob \u00a0tats\u00e4chlich \u00a0ein \u00a0immunverst\u00e4rkender \u00a0Effekt \u00a0vorliegt \u00a0oder \u00a0 ob \u00a0 dieser \u00a0 Befund \u00a0 mit \u00a0 einer \u00a0 h\u00e4ufigeren \u00a0 Virusexposition \u00a0 korreliert \u00a0 konnte \u00a0nicht \u00a0abschlie\u00dfend \u00a0gekl\u00e4rt \u00a0werden. \u00a0Auch \u00a0 in \u00a0 dem \u00a0 bereits \u00a0 weiter \u00a0 oben \u00a0 erw\u00e4hnten \u00a0 Review \u00a0 konnte \u00a0 kein \u00a0 eindeutiger \u00a0Einfluss \u00a0 von \u00a0 l\u00e4ngerfristiger \u00a0 k\u00f6rperlicher \u00a0 Aktivit\u00e4t \u00a0 auf \u00a0 die \u00a0 Serokonversionsrate \u00a0festgestellt \u00a0werden \u00a0(Grande \u00a0et \u00a0al. \u00a02016). \u00a0Eine \u00a0verbesserte \u00a0Immunogenit\u00e4t \u00a0nach \u00a0vorangehenden \u00a0Trainingseinheiten \u00a0hingegen, \u00a0 welche \u00a0 in \u00a0 einigen \u00a0 bisher \u00a0durchgef\u00fchrten \u00a0Studien \u00a0postuliert \u00a0wurde \u00a0(Shi&Rock \u00a02002, \u00a0Edwards \u00a0et \u00a0al. \u00a02007), \u00a0konnte \u00a0 in \u00a0 dieser \u00a0 Studie \u00a0 jedoch \u00a0 auch \u00a0 nicht \u00a0 erhoben \u00a0 werden. \u00a0 Dabei \u00a0 soll \u00a0 die \u00a0Verst\u00e4rkung \u00a0der \u00a0Immunreaktion \u00a0vor \u00a0allem \u00a0durch \u00a0\u00dcbungen \u00a0die \u00a0dem \u00a0Injektionsort \u00a0naheliegen \u00a0 (Edwards \u00a0 et \u00a0 al. \u00a0 2007) \u00a0 und \u00a0insbesondere \u00a0 bei \u00a0 \u00e4lteren \u00a0 Menschen \u00a0bewirkt \u00a0 werden \u00a0 (Woods \u00a0 et \u00a0 al. \u00a0 2009, \u00a0 Campbell \u00a0 et \u00a0 al. \u00a0 2010). \u00a0Inwieweit \u00a0 solche \u00a0\u00dcbungen \u00a0 vor \u00a0 der \u00a0 Impfung \u00a0 praktiziert \u00a0 wurden, \u00a0 wurde \u00a0 in \u00a0 dieser \u00a0 Studie \u00a0 nicht \u00a0erhoben \u00a0 und \u00a0mit \u00a0 der \u00a0 Wahl \u00a0 des \u00a0 nichtdominanten \u00a0 Armes \u00a0 als \u00a0 Injektionsstelle \u00a0wurde \u00a0 die \u00a0 Distanz \u00a0zudem \u00a0erh\u00f6ht. \u00a0Diese \u00a0Studien \u00a0wurden \u00a0 au\u00dferdem \u00a0nicht \u00a0 an \u00a0Leistungssportlern \u00a0durchgef\u00fchrt. \u00a0Zudem \u00a0 war \u00a0 denjenigen \u00a0Erhebungen, \u00a0 die \u00a0 einen \u00a0 verst\u00e4rkenden \u00a0 Effekt \u00a0kurzfristiger \u00a0 k\u00f6rperlicher \u00a0 Aktivit\u00e4t \u00a0 feststellten, \u00a0 eine \u00a0 Kontrollgruppe \u00a0 mit \u00a0 einer \u00a0relativ \u00a0schlechten \u00a0Immunantwort \u00a0gemeinsam \u00a0(Campbell \u00a0et \u00a0al. \u00a02010). \u00a0 \u00a0Ferner \u00a0konnte \u00a0keine \u00a0generell \u00a0eingeschr\u00e4nkte \u00a0Immunkompetenz, \u00a0wie \u00a0sie \u00a0in \u00a0der \u00a0\u201ej-\u00adshaped-\u00adcurve\u201c-\u00adTheorie \u00a0 beschrieben \u00a0 wird \u00a0(Niemann \u00a0et \u00a0 al. \u00a0 1990), \u00a0 ermittelt \u00a0werden. \u00a0Im \u00a0 Vergleich \u00a0 mit \u00a0 einem \u00a0Kontrollkollektiv, \u00a0 zeigte \u00a0 sich \u00a0 bei \u00a0 den \u00a0Sportlergruppen \u00a0 nach \u00a0 einer \u00a0 und \u00a0 zwei \u00a0 Wochen \u00a0immunologisch \u00a0sogar \u00a0 ein \u00a0\t\r \u00a075\t\r \u00a0besseres \u00a0 Ansprechen \u00a0 auf \u00a0 die \u00a0 Influenzaimpfung \u00a0(BISP \u00a0 2016;\u037e \u00a0Manuskript \u00a0 in \u00a0Arbeit) \u00a0 \u00a0Zu \u00a0beachten \u00a0ist \u00a0weiterhin, \u00a0dass \u00a0all \u00a0diese \u00a0Ergebnisse \u00a0vor \u00a0dem \u00a0Hintergrund \u00a0der \u00a0Problematik \u00a0 des \u00a0 \u201eMultiplen \u00a0 Testens\u201c \u00a0 zu \u00a0 betrachten \u00a0 sind. \u00a0 So \u00a0 wurden \u00a0 auch \u00a0 in \u00a0dieser \u00a0 Erhebung \u00a0 verschiedene \u00a0 Hypothesen \u00a0 an \u00a0 derselben \u00a0 Studiengruppe \u00a0getestet, \u00a0wobei \u00a0man \u00a0bei \u00a0der \u00a0Interpretation \u00a0von \u00a0einem \u00a0Fehler \u00a0der \u00a01. \u00a0Art \u00a0von \u00a0a\uf061=5% \u00a0ausgegangen \u00a0ist. \u00a0Es \u00a0reichen \u00a0also \u00a0schon \u00a020 \u00a0Untersuchungen \u00a0aus, \u00a0dass \u00a0davon \u00a0ausgegangen \u00a0 werden \u00a0 kann, \u00a0 das \u00a0 einer \u00a0 der \u00a0 p-\u00adWerte \u00a0 f\u00e4lschlicherweise \u00a0 als \u00a0signifikanter \u00a0p-\u00adWert \u00a0angesehen \u00a0wurde \u00a0(Victor \u00a0et \u00a0al. \u00a02010). \u00a0 \u00a0 \u00a05.1.2. \u00a0Abh\u00e4ngigkeit \u00a0der \u00a0Nebenwirkungen \u00a0vom \u00a0Impfzeitpunkt \u00a0 \u00a0Die \u00a0 Hypothese, \u00a0 dass \u00a0 leistungssportliches \u00a0 Training \u00a0 unmittelbar \u00a0 vor \u00a0 einer \u00a0Impfung \u00a0 zu \u00a0 einem \u00a0 vermehrten \u00a0 Auftreten \u00a0 von \u00a0 Impfnebenwirkungen \u00a0 f\u00fchrt, \u00a0best\u00e4tigte \u00a0sich \u00a0in \u00a0dieser \u00a0Erhebung \u00a0nicht. \u00a0Auch \u00a0in \u00a0einem \u00a0Review \u00a0aus \u00a0dem \u00a0Jahr \u00a02016 \u00a0 kam \u00a0 man \u00a0 zu \u00a0 der \u00a0 Einsch\u00e4tzung, \u00a0 dass \u00a0 k\u00f6rperliche \u00a0 Aktivit\u00e4t \u00a0 vor \u00a0 der \u00a0 der \u00a0Influenzaimpfung \u00a0 keine \u00a0 nachteilige \u00a0 Wirkung \u00a0 auf \u00a0 das \u00a0 Nebenwirkungsprofil \u00a0 hat \u00a0(Grande \u00a0et \u00a0al.). \u00a0Zwar \u00a0gaben \u00a0nominell \u00a0mehr \u00a0Probanden \u00a0der \u00a02h-\u00adGruppe \u00a0an, \u00a0irgendeine \u00a0Form \u00a0von \u00a0unerw\u00fcnschter \u00a0Wirkung \u00a0nach \u00a0der \u00a0Impfung \u00a0gehabt \u00a0zu \u00a0haben, \u00a0jedoch \u00a0waren \u00a0die \u00a0Unterschiede \u00a0nicht \u00a0signifikant. \u00a0\u00c4hnliche \u00a0Werte \u00a0zeigten \u00a0sich \u00a0auch \u00a0bei \u00a0lokalem \u00a0Schmerz \u00a0 an \u00a0 der \u00a0 Einstichstelle. \u00a0Bei \u00a0 der \u00a0 Summe \u00a0 der \u00a0 Intensit\u00e4ten \u00a0 \u00fcber \u00a0 sieben \u00a0Tage \u00a0zeigte \u00a0sich \u00a0mit \u00a0p=0,10 \u00a0ein \u00a0Trend \u00a0zuungunsten \u00a0der \u00a02h-\u00adGruppe. \u00a0 \u00a0In \u00a0einer \u00a0Studie \u00a0aus \u00a0dem \u00a0Jahr \u00a02010 \u00a0zeigte \u00a0sich \u00a0ebenfalls \u00a0ein \u00a0gr\u00f6\u00dferer \u00a0Schmerz \u00a0in \u00a0der \u00a0direkt \u00a0nach \u00a0dem \u00a0Sport \u00a0geimpften \u00a0Gruppe, \u00a0als \u00a0in \u00a0der \u00a0Kontrollgruppe, \u00a0die \u00a0zuvor \u00a0eine \u00a0sechsst\u00fcndige \u00a0Pause \u00a0einlegte \u00a0(Campbell \u00a0et \u00a0al. \u00a02010). \u00a0 \u00a0Allerdings \u00a0handelte \u00a0es \u00a0sich \u00a0in \u00a0dieser \u00a0Erhebung \u00a0um \u00a0Nicht-\u00adLeistungssportler, \u00a0die \u00a0\u00dcbungen \u00a0absolvieren \u00a0 mussten, \u00a0 die \u00a0 die \u00a0 Schulter \u00a0 miteinschlossen, \u00a0 wohingegen \u00a0 die \u00a0Leistungssportler \u00a0in \u00a0unserer \u00a0Studie \u00a0ihr \u00a0gewohntes \u00a0Training \u00a0absolvierten. \u00a0Im \u00a0Hinblick \u00a0auf \u00a0die \u00a0weiteren \u00a0lokalen \u00a0und \u00a0auch \u00a0die \u00a0allgemeinen \u00a0Beschwerden \u00a0lie\u00dfen \u00a0sich \u00a0keine \u00a0signifikanten \u00a0Unterschiede \u00a0feststellen. \u00a0Dies \u00a0wurde \u00a0auch \u00a0auch \u00a0in \u00a0einer \u00a0 Studie \u00a0von \u00a0 Nichol \u00a0 et \u00a0 al. \u00a0erhoben, \u00a0 in \u00a0 der \u00a0 keine \u00a0 h\u00f6here \u00a0\t\r \u00a076\t\r \u00a0Auftretenswahrscheinlichkeit \u00a0 von \u00a0 systemischen \u00a0 Nebenwirkungen \u00a0 wie \u00a0 Fieber, \u00a0Kopfschmerz \u00a0 oder \u00a0 M\u00fcdigkeit \u00a0 bei \u00a0 Influenzageimpften \u00a0 im \u00a0 Vergleich \u00a0 zu \u00a0 einer \u00a0Placebo-\u00adGruppe \u00a0festgestellt \u00a0wurde \u00a0(Nichol \u00a0et \u00a0al. \u00a01996). \u00a0Zudem \u00a0 scheinen \u00a0 die \u00a0 Nebenwirkungen \u00a0 auch \u00a0 von \u00a0 geringerer \u00a0 Relevanz \u00a0 zu \u00a0gewesen \u00a0sein, \u00a0da \u00a0es \u00a0impfbedingt \u00a0zu \u00a0keinen \u00a0Trainingsausf\u00e4llen \u00a0kam \u00a0und \u00a0nur \u00a0in \u00a0einem \u00a0 Fall \u00a0 eine \u00a0Modifikation \u00a0der \u00a0 Einheiten \u00a0 von \u00a0 N\u00f6ten \u00a0 war. \u00a0 Dass \u00a0 sich \u00a0Einschr\u00e4nkungen \u00a0der \u00a0Trainingsleistung \u00a0am \u00a0Impftag \u00a0h\u00e4ufiger \u00a0in \u00a0der \u00a026h-\u00adGruppe \u00a0zeigten, \u00a0erscheint \u00a0in \u00a0Anbetracht \u00a0der \u00a0Tatsache, \u00a0dass \u00a0sich \u00a0diese \u00a0aufgrund \u00a0der \u00a0Studienteilnahme \u00a0 erst \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0 ins \u00a0 Training \u00a0 begeben \u00a0konnten \u00a0 als \u00a0logisch. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a077\t\r \u00a05.2. \u00a0Methodenkritik \u00a0 \u00a05.2.1. \u00a0Timing \u00a0der \u00a0Impfung \u00a0und \u00a0der \u00a0Blutentnahmen \u00a0 \u00a0Um \u00a0den \u00a0Einfluss \u00a0k\u00f6rperlicher \u00a0Bet\u00e4tigung \u00a0auf \u00a0die \u00a0Rate \u00a0an \u00a0Nebenwirkungen \u00a0und \u00a0den \u00a0Erfolg \u00a0einer \u00a0Impfung \u00a0zu \u00a0eruieren, \u00a0wurde \u00a0eine \u00a0Sportlergruppe \u00a0innerhalb \u00a0von \u00a0zwei \u00a0 Stunden \u00a0 nach \u00a0 dem \u00a0 Training \u00a0 geimpft, \u00a0 wohingegen \u00a0 das \u00a0 andere \u00a0 Kollektiv \u00a0nach \u00a026-\u00adst\u00fcndiger \u00a0Pause \u00a0die \u00a0Vakzination \u00a0erhalten \u00a0hatte, \u00a0um \u00a0einen \u00a0zeitlichen \u00a0Abstand \u00a0 von \u00a0 mindestens \u00a0 24 \u00a0 Stunden \u00a0 zwischen \u00a0 beiden \u00a0 Gruppen \u00a0 zu \u00a0gew\u00e4hrleisten. \u00a0Eine \u00a0l\u00e4ngere \u00a0Trainingspause \u00a0w\u00e4re \u00a0hierbei \u00a0f\u00fcr \u00a0viele \u00a0Athleten \u00a0nicht \u00a0m\u00f6glich \u00a0gewesen. \u00a0Nicht \u00a0ber\u00fccksichtigt \u00a0wurde \u00a0im \u00a0Rahmen \u00a0dieses \u00a0Studiendesigns \u00a0jedoch, \u00a0ob \u00a0sich \u00a0die \u00a0 Athleten \u00a0 direkt \u00a0 oder \u00a0 kurz \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0 k\u00f6rperlich \u00a0 bet\u00e4tigten. \u00a0Hierzu \u00a0w\u00e4ren \u00a0mehr \u00a0Probanden \u00a0notwendig \u00a0gewesen, \u00a0was \u00a0zu \u00a0Rekrutierungsproblemen \u00a0oder \u00a0einer \u00a0Reduktion \u00a0der \u00a0statistischen \u00a0Power \u00a0gef\u00fchrt \u00a0h\u00e4tte. \u00a0 \u00a0Ein \u00a0 Gro\u00dfteil \u00a0 der \u00a0 Probanden \u00a0 des \u00a0 26h-\u00adKollektivs \u00a0 begab \u00a0 sich \u00a0vermutlich \u00a0nach \u00a0einem \u00a0 trainingsfreien \u00a0 Tag \u00a0 im \u00a0 Anschluss \u00a0 nach \u00a0 der \u00a0 Impfung \u00a0 ins \u00a0 Training, \u00a0wohingegen \u00a0 die \u00a0 Sportler \u00a0 der \u00a0 anderen \u00a0Studiengruppe \u00a0 sich \u00a0 zumeist \u00a0nach \u00a0 der \u00a0Einheit \u00a0 k\u00f6rperlich \u00a0 schonten. \u00a0 Somit \u00a0 ist \u00a0 auch \u00a0 das \u00a0 Ergebnis \u00a0 der \u00a0Trainingseinschr\u00e4nkung \u00a0am \u00a0Tag \u00a0der \u00a0Impfung \u00a0nur \u00a0begrenzt \u00a0beurteilbar, \u00a0da \u00a0nur \u00a0Sportler, \u00a0die \u00a0sich \u00a0nach \u00a0der \u00a0Impfung \u00a0k\u00f6rperlich \u00a0bet\u00e4tigten, \u00a0eine \u00a0Einschr\u00e4nkung \u00a0versp\u00fcren \u00a0 konnten. \u00a0Der \u00a0 Abstand \u00a0 zur \u00a0 n\u00e4chsten \u00a0 Trainingseinheit \u00a0 wurde \u00a0 nicht \u00a0eruiert. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a078\t\r \u00a05.2.2. \u00a0Einschlusskriterien \u00a0der \u00a0Probanden \u00a0und \u00a0Probandenzahlen \u00a0 \u00a0Bei \u00a0der \u00a0Wahl \u00a0der \u00a0Probanden \u00a0wurde \u00a0leistungssportlich \u00a0orientiertes \u00a0Training \u00a0an \u00a0mindestens \u00a0f\u00fcnf \u00a0Tagen \u00a0die \u00a0Woche \u00a0als \u00a0ausreichend \u00a0angesehen, \u00a0sofern \u00a0sich \u00a0die \u00a0Athleten \u00a0 auf \u00a0 nationalem \u00a0 Niveau \u00a0 im \u00a0 Wettkampfprozess \u00a0 befanden. \u00a0So \u00a0 wurden \u00a0Sportler \u00a0 aus \u00a0 zehn \u00a0 verschiedenen \u00a0 Sportarten \u00a0 mit \u00a0 teils \u00a0 unterschiedlichen \u00a0Ambitionen \u00a0 in \u00a0 die \u00a0 Studie \u00a0 eingeschlossen. \u00a0Obwohl \u00a0 die \u00a0 individuellen \u00a0Trainingszeiten \u00a0 teils \u00a0 stark \u00a0 variierten, \u00a0 konnte \u00a0 bei \u00a0 im \u00a0 Mittel \u00a0 nicht \u00a0 signifikant \u00a0unterschiedlichen \u00a0 Werten \u00a0 eine \u00a0 Vergleichbarkeit \u00a0 der \u00a0 Gruppen \u00a0 gew\u00e4hrleistet \u00a0werden. \u00a0Aus \u00a0 den \u00a0 verschiedenen \u00a0 Sportarten \u00a0ergab \u00a0sich \u00a0 hierbei \u00a0eine \u00a0 unterschiedliche \u00a0Beanspruchung \u00a0 der \u00a0 Muskelgruppen. \u00a0Da \u00a0 die \u00a0 Impfung \u00a0 in \u00a0 den \u00a0 Musculus \u00a0deltoideus \u00a0des \u00a0nicht \u00a0dominanten \u00a0Armes \u00a0erfolgte, \u00a0haben \u00a0Sportarten \u00a0wie \u00a0L\u00e4ufer \u00a0oder \u00a0Fu\u00dfballer \u00a0eine \u00a0geringere \u00a0Belastung \u00a0des \u00a0durch \u00a0die \u00a0Nadel \u00a0l\u00e4dierten \u00a0Muskel, \u00a0wohingegen \u00a0Schwimmer \u00a0oder \u00a0Ruderer \u00a0diesen \u00a0in \u00a0der \u00a0Regel \u00a0direkt \u00a0belasten. \u00a0Des \u00a0Weiteren \u00a0 konnte \u00a0 gezeigt \u00a0 werden, \u00a0dass \u00a0insbesondere \u00a0 exzentrische \u00a0 \u00dcbungen, \u00a0wie \u00a0 sie \u00a0 zum \u00a0 Beispiel \u00a0 ausgiebig \u00a0 im \u00a0 Krafttraining \u00a0 der \u00a0 Ringer \u00a0 zum \u00a0 Einsatz \u00a0kommen, \u00a0 eine \u00a0 geh\u00e4uft \u00a0 auftretende \u00a0 Schmerzreaktion \u00a0 hervorrufen \u00a0 k\u00f6nnen \u00a0(Edwards \u00a0et \u00a0al. \u00a02007). \u00a0Wie \u00a0 bereits \u00a0 erw\u00e4hnt \u00a0 wurde \u00a0bei \u00a0 der \u00a0 Planung \u00a0 der \u00a0 Studie \u00a0auf \u00a0 eine \u00a0 formale \u00a0Fallzahlberechnung \u00a0 verzichtet. \u00a0Zwar \u00a0 kann \u00a0 bei \u00a0 einer \u00a0 zu \u00a0 geringen \u00a0 Anzahl \u00a0 an \u00a0Probanden \u00a0ein \u00a0statistisch \u00a0signifikantes \u00a0Ergebnis \u00a0nicht \u00a0signifikant \u00a0sein, \u00a0eine \u00a0zu \u00a0hohe \u00a0 Fallzahl \u00a0 wiederum \u00a0 kann \u00a0 ein \u00a0 unbedeutendes \u00a0 Ergebnis \u00a0 signifikant \u00a0erscheinen \u00a0lassen. \u00a0Neben \u00a0fehlender \u00a0etablierter \u00a0Zielparameter \u00a0zur \u00a0Berechnung \u00a0der \u00a0 Effektst\u00e4rke \u00a0waren \u00a0auch \u00a0 die \u00a0 begrenzte \u00a0 Rekrutierungsphase \u00a0 und \u00a0die \u00a0beschr\u00e4nkte \u00a0Anzahl \u00a0an \u00a0Hochleistungssportlern, \u00a0die \u00a0sich \u00a0zu \u00a0solch \u00a0einer \u00a0Studie \u00a0bereit \u00a0 erkl\u00e4ren, \u00a0limitierend \u00a0(R\u00f6hrig \u00a0 et \u00a0 al. \u00a0 2010). \u00a0Auch \u00a0 wurde \u00a0 zu \u00a0 Beginn \u00a0 der \u00a0Studie \u00a0die \u00a0Anwesenheit \u00a0der \u00a0Probanden \u00a0nach \u00a0sechs \u00a0Monaten \u00a0erfragt, \u00a0sodass \u00a0bei \u00a0der \u00a0Planung \u00a0nicht \u00a0von \u00a0einem \u00a0\u201edrop-\u00adout \u00a0auszugehen \u00a0war. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a079\t\r \u00a05.2.3. \u00a0Verst\u00e4ndlichkeit \u00a0und \u00a0Zuverl\u00e4ssigkeit \u00a0der \u00a0Nebenwirkungserhebung \u00a0 \u00a0Um \u00a0 zeitaufw\u00e4ndige \u00a0 t\u00e4gliche \u00a0 Untersuchungen \u00a0 der \u00a0 Probanden \u00a0 innerhalb \u00a0 der \u00a0ersten \u00a0zwei \u00a0Wochen \u00a0zu \u00a0vermeiden, \u00a0erfolgte \u00a0die \u00a0Erhebung \u00a0der \u00a0Nebenwirkung \u00a0anhand \u00a0 von \u00a0 B\u00f6gen, \u00a0 die \u00a0 sich \u00a0 an \u00a0 den \u00a0 Standards \u00a0 der \u00a0 \u201eBrighton \u00a0 Collaberation\u201c \u00a0orientierten. \u00a0Sie \u00a0dienen \u00a0dazu, \u00a0anhand \u00a0von \u00a0standardisierten \u00a0Falldefinitionen \u00a0eine \u00a0bessere \u00a0 Vergleichbarkeit \u00a0 f\u00fcr \u00a0 die \u00a0 Erfassung \u00a0 unerw\u00fcnschter \u00a0 Wirkungen \u00a0 bei \u00a0Impfungen \u00a0zu \u00a0gew\u00e4hrleisten \u00a0(Kohl \u00a0et \u00a0al. \u00a02007). \u00a0 \u00a0Jedoch \u00a0 lie\u00dfen \u00a0 diese \u00a0 B\u00f6gen \u00a0 einigen \u00a0 Spielraum \u00a0 f\u00fcr \u00a0 Interpretationen. \u00a0So \u00a0 ist \u00a0beispielsweise \u00a0unklar, \u00a0ob \u00a0Sch\u00fcttelfrost \u00a0im \u00a0eigentlichen \u00a0Sinne \u00a0vorgelegen \u00a0hatte. \u00a0Auch \u00a0 wurde \u00a0 bei \u00a0 den \u00a0 weiteren \u00a0 Nebenwirkungen \u00a0 von \u00a0 einem \u00a0 Probanden \u00a0 eine \u00a0Lymphknotenschwellung \u00a0in \u00a0der \u00a0Axilla \u00a0angegeben, \u00a0die \u00a0im \u00a0Rahmen \u00a0der \u00a0Studie \u00a0nicht \u00a0objektiviert \u00a0werden \u00a0konnte. \u00a0Die \u00a0 t\u00e4glichen \u00a0 oralen \u00a0 Temperaturmessungen \u00a0 wurden \u00a0nach \u00a0 einer \u00a0 kurzen \u00a0Schulung \u00a0 der \u00a0 Probanden \u00a0 am \u00a0 Impftag \u00a0ebenso \u00a0selbstst\u00e4ndig \u00a0 durchgef\u00fchrt. \u00a0Inwieweit \u00a0 diese \u00a0 korrekt \u00a0 ausgef\u00fchrt \u00a0 wurden \u00a0bleibt \u00a0 offen. \u00a0Wie \u00a0 bereits \u00a0 oben \u00a0erw\u00e4hnt \u00a0wurde \u00a0diese \u00a0jedoch \u00a0von \u00a0elf \u00a0Athleten \u00a0teilweise \u00a0oder \u00a0\u00fcber \u00a0die \u00a0gesamte \u00a0Woche \u00a0nicht \u00a0gemessen. \u00a0Auch \u00a0 w\u00e4re \u00a0 ein \u00a0 Beginn \u00a0 der \u00a0 Nebenwirkungserhebung \u00a0 einige \u00a0 Tage \u00a0 vor \u00a0 der \u00a0Impfung \u00a0sinnvoll. \u00a0Anhand \u00a0einer \u00a0Art \u00a0\u201eNulllinie\u201c \u00a0der \u00a0Begleitsymptomatik \u00a0lie\u00dfe \u00a0sich \u00a0besser \u00a0feststellen, \u00a0ob \u00a0ein \u00a0zeitlicher \u00a0Zusammenhang \u00a0zwischen \u00a0Impfung \u00a0und \u00a0der \u00a0Symptomatik \u00a0besteht \u00a0oder \u00a0ob \u00a0dies \u00a0bereits \u00a0zuvor \u00a0bestehende \u00a0Beschwerden \u00a0wie \u00a0beispielsweise \u00a0M\u00fcdigkeit \u00a0oder \u00a0Kopfschmerzen \u00a0sind. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a080\t\r \u00a05.2.4. \u00a0Probentransport \u00a0 \u00a0Eine \u00a0 weitere \u00a0 Schwierigkeit \u00a0 bot \u00a0 der \u00a0 Transport \u00a0 der \u00a0 Proben \u00a0 zu \u00a0 dem \u00a0 jeweiligen \u00a0Labor. \u00a0 Um \u00a0 eine \u00a0 zu \u00a0 rasche \u00a0 H\u00e4molyse \u00a0 und \u00a0Ver\u00e4nderung \u00a0 der \u00a0 Blutproben \u00a0 zu \u00a0vermeiden, \u00a0wurden \u00a0diese \u00a0stets \u00a0in \u00a0einem \u00a0K\u00fchlschrank \u00a0gelagert. \u00a0W\u00e4hrend \u00a0des \u00a0Transportes \u00a0 zum \u00a0 zust\u00e4ndigen \u00a0 Labor \u00a0 wurden \u00a0 K\u00fchlboxen \u00a0 verwendet, \u00a0 um \u00a0 eine \u00a0Erw\u00e4rmung \u00a0 bzw. \u00a0 zu \u00a0 ausgepr\u00e4gte \u00a0 Temperaturschwankungen \u00a0 zu \u00a0 vermeiden. \u00a0Erleichternd \u00a0war \u00a0zudem \u00a0der \u00a0Umstand, \u00a0dass \u00a0das \u00a0Gros \u00a0der \u00a0Studie \u00a0in \u00a0den \u00a0Winter-\u00ad \u00a0und \u00a0 Fr\u00fchjahrsmonaten \u00a0 stattfand, \u00a0 weshalb \u00a0 die \u00a0 Witterungsbedingungen \u00a0 einem \u00a0\u00dcberw\u00e4rmen \u00a0der \u00a0Proben \u00a0entgegenkamen. \u00a0Nichtsdestotrotz \u00a0verz\u00f6gerte \u00a0sich \u00a0der \u00a0Transport \u00a0insofern \u00a0teilweise \u00a0um \u00a0Stunden, \u00a0da \u00a0aus \u00a0organisatorischen \u00a0Gr\u00fcnden \u00a0nicht \u00a0jede \u00a0Probe \u00a0gesondert \u00a0von \u00a0Homburg \u00a0nach \u00a0Saarbr\u00fccken \u00a0oder \u00a0umgekehrt \u00a0transportiert \u00a0werden \u00a0konnte \u00a0und \u00a0somit \u00a0die \u00a0Proben \u00a0 teilweise \u00a0 im \u00a0 Laufe \u00a0 eines \u00a0 Tages \u00a0 zuerst \u00a0 gesammelt \u00a0 werden \u00a0 mussten, \u00a0bevor \u00a0 sie \u00a0 weiterverschickt \u00a0 werden \u00a0 konnten. \u00a0Aufgrund \u00a0 des \u00a0 zeitaufw\u00e4ndigen \u00a0Laborverfahrens \u00a0 konnten \u00a0 die \u00a0 Proben \u00a0 in \u00a0manchen \u00a0F\u00e4llen \u00a0 erst \u00a0 am \u00a0 n\u00e4chsten \u00a0Morgen \u00a0verarbeitet \u00a0werden. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a081\t\r \u00a05.3. \u00a0Schlussfolgerung \u00a0 \u00a0In \u00a0 Anlehnung \u00a0 an \u00a0 die \u00a0 Ausgangshypothesen \u00a0 lassen \u00a0 sich \u00a0 die \u00a0 Ergebnisse \u00a0 dieser \u00a0Studie \u00a0wie \u00a0folgt \u00a0zusammenfassen: \u00a0Im \u00a0Gegensatz \u00a0zu \u00a0den \u00a0Bef\u00fcrchtungen \u00a0vieler \u00a0Praktiker, \u00a0aufgrund \u00a0der \u00a0\u201eopen \u00a0window\u201c-\u00adTheorie \u00a0(Kakanis \u00a0et \u00a0al. \u00a02010), \u00a0konnte \u00a0in \u00a0dieser \u00a0Erhebung \u00a0kein \u00a0negativer \u00a0Einfluss \u00a0einer \u00a0vorangehenden \u00a0Trainingseinheit \u00a0auf \u00a0den \u00a0Impferfolg \u00a0dokumentiert \u00a0werden. \u00a0Sowohl \u00a0im \u00a0Hinblick \u00a0auf \u00a0die \u00a0zellul\u00e4re \u00a0Immunantwort, \u00a0als \u00a0auch \u00a0im \u00a0Hinblick \u00a0auf \u00a0die \u00a0humorale \u00a0Immunantwort \u00a0konnten \u00a0sowohl \u00a0in \u00a0der \u00a0Summe \u00a0als \u00a0auch \u00a0im \u00a0Vergleich \u00a0der \u00a0einzelnen \u00a0 Messzeitpunkte \u00a0 keine \u00a0 signifikanten \u00a0 Unterschiede \u00a0zwischen \u00a0 beiden \u00a0Gruppen \u00a0erhoben \u00a0werden. \u00a0Bez\u00fcglich \u00a0der \u00a0zellul\u00e4ren \u00a0Immunantwort \u00a0\u00e4u\u00dferte \u00a0sich \u00a0die \u00a0Effektivit\u00e4t \u00a0der \u00a0Impfung \u00a0in \u00a0einem \u00a0signifikanten \u00a0Anstieg \u00a0Influenza-\u00adspezifischer-\u00adCD4+-\u00adT-\u00adZellen \u00a0in \u00a0 beiden \u00a0 Gruppen, \u00a0bez\u00fcglich \u00a0der \u00a0 humoralen \u00a0 Immunantwort \u00a0in \u00a0 einem \u00a0signifikanten \u00a0 Anstieg \u00a0 der \u00a0 Neutralisationsantik\u00f6rper \u00a0 und \u00a0 der \u00a0IgG-\u00ad, \u00a0 IgM-\u00ad \u00a0und \u00a0 IgA-\u00adAntik\u00f6rper. \u00a0Im \u00a0 Gegensatz \u00a0 zur \u00a0 zellul\u00e4ren \u00a0 Immunantwort \u00a0lagen \u00a0die \u00a0 Werte \u00a0 der \u00a0Neutralisationstiter \u00a0und \u00a0der \u00a0IgM-\u00adRatio \u00a0am \u00a0Ende \u00a0der \u00a0Studie \u00a0signifikant \u00a0\u00fcber \u00a0dem \u00a0Ausgangswert. \u00a0 \u00a0Unabh\u00e4ngig \u00a0von \u00a0der \u00a0k\u00f6rperlichen \u00a0Aktivit\u00e4t \u00a0vor \u00a0einer \u00a0Impfung \u00a0gegen \u00a0Influenza \u00a0sind \u00a0lokale \u00a0 Nebenwirkungen \u00a0 wie \u00a0 Schmerzen, \u00a0 R\u00f6tung \u00a0 und \u00a0 Schwellung \u00a0 mit \u00a0 der \u00a0Vakzination \u00a0assoziiert. \u00a0Hierbei \u00a0kann \u00a0es \u00a0durch \u00a0eine \u00a0erh\u00f6hte \u00a0Muskelaktivit\u00e4t \u00a0zu \u00a0einer \u00a0verst\u00e4rkten \u00a0 lokalen \u00a0 Reaktion \u00a0 auf \u00a0 den \u00a0 Impfstoff \u00a0 an \u00a0 der \u00a0 Injektionsstelle \u00a0 kommen \u00a0(Havas \u00a0et \u00a0al. \u00a01997, \u00a0Swartz \u00a0et \u00a0al. \u00a02008). \u00a0Dies \u00a0best\u00e4tigte \u00a0sich \u00a0in \u00a0dieser \u00a0Erhebung \u00a0nicht. \u00a0 Sowohl \u00a0 im \u00a0 Hinblick \u00a0 auf \u00a0 die \u00a0 lokalen \u00a0 als \u00a0 auch \u00a0 auf \u00a0 die \u00a0 allgemeinen \u00a0Nebenwirkungen \u00a0 zeigten \u00a0 sich \u00a0 keine \u00a0statistisch \u00a0 zu \u00a0 sichernden \u00a0Unterschiede \u00a0zwischen \u00a0 beiden \u00a0 Gruppen. \u00a0Zudem \u00a0 stellt \u00a0 es \u00a0 sich \u00a0so \u00a0 dar, \u00a0 als \u00a0 w\u00e4ren \u00a0 diese \u00a0Nebenwirkungen \u00a0 von \u00a0 untergeordneter \u00a0Relevanz, \u00a0 da \u00a0 es \u00a0 zu \u00a0 keinem \u00a0Trainingsabbruch \u00a0oder \u00a0\u2013ausfall \u00a0kam. \u00a0Ebenso \u00a0wie \u00a0die \u00a0Nebenwirkungen \u00a0waren \u00a0auch \u00a0die \u00a0Unterschiede \u00a0der \u00a0Trainingseinschr\u00e4nkung \u00a0nicht \u00a0signifikant. \u00a0Insofern \u00a0 erscheint \u00a0 eine \u00a0 Anpassung \u00a0 des \u00a0 leistungssportlichen \u00a0 Trainings \u00a0 an \u00a0 eine \u00a0anstehende \u00a0Impfung \u00a0in \u00a0Anbetracht \u00a0dieser \u00a0Studie \u00a0als \u00a0nicht \u00a0notwendig. \u00a0Weder \u00a0eine \u00a0eingeschr\u00e4nkte \u00a0Effektivit\u00e4t \u00a0der \u00a0Immuninduktion \u00a0noch \u00a0ein \u00a0vermehrtes \u00a0Auftreten \u00a0von \u00a0Impfnebenwirkungen \u00a0konnten \u00a0nachgewiesen \u00a0werden. \u00a0Eine \u00a0Beurteilung, \u00a0inwieweit \u00a0sportliche \u00a0Bet\u00e4tigung \u00a0als \u00a0Adjuvans \u00a0f\u00fcr \u00a0eine \u00a0Impfung \u00a0wirken \u00a0kann, \u00a0ist \u00a0anhand \u00a0dieser \u00a0Erhebung \u00a0nicht \u00a0m\u00f6glich. \u00a0\t\r \u00a082\t\r \u00a0Literaturverzeichnis \u00a0 \u00a0 Ambrose \u00a0CS, \u00a0Luke \u00a0C, \u00a0Coelingh \u00a0K \u00a0(2008) \u00a0Current \u00a0status \u00a0of \u00a0live \u00a0attenuated \u00a0influenza \u00a0vaccines \u00a0in \u00a0the \u00a0United \u00a0States \u00a0for \u00a0seasonal \u00a0and \u00a0pandemic \u00a0influenza. \u00a0Influenza \u00a0Resp \u00a0Viruses \u00a02(6): \u00a0193-\u00ad202 \u00a0 \u00a0Black \u00a0 S \u00a0 (2013) \u00a0 The \u00a0 role \u00a0 of \u00a0 health \u00a0 economic \u00a0 analysis \u00a0 in \u00a0 vaccine \u00a0 decision \u00a0 making. \u00a0Vaccine \u00a031: \u00a06046-\u00ad49 \u00a0 \u00a0Banzhoff \u00a0 A, \u00a0 Nacci \u00a0 P, \u00a0 Podda \u00a0 A \u00a0 (2003) \u00a0 A \u00a0 new \u00a0 MF59-\u00adadjuvanted \u00a0 influenza \u00a0vaccine \u00a0enhances \u00a0the \u00a0immune \u00a0response \u00a0in \u00a0the \u00a0elderly \u00a0with \u00a0chronic \u00a0disease: \u00a0Results \u00a0from \u00a0an \u00a0immunogenicity \u00a0meta-\u00adanalysis. \u00a0Gerontology \u00a049(3): \u00a0177-\u00ad84 \u00a0 \u00a0Baum \u00a0M, \u00a0Liesen \u00a0H \u00a0(1997) \u00a0Sports \u00a0and \u00a0the \u00a0immune \u00a0system. \u00a0Orthopade \u00a026(11): \u00a0976-\u00ad80 \u00a0 \u00a0Belshe \u00a0 RB \u00a0 (2010) \u00a0 The \u00a0 need \u00a0 for \u00a0 quadrivalent \u00a0 vaccine \u00a0 against \u00a0 seasonal \u00a0 influenza. \u00a0Vaccine \u00a028S: \u00a045-\u00ad53 \u00a0 \u00a0Beran \u00a0 J, \u00a0Peeters \u00a0 M, \u00a0 Dew\u00e9 \u00a0 W, \u00a0 Raupachov\u00e1 \u00a0 J, \u00a0 Hobzov\u00e1 \u00a0 L, \u00a0 Devaster \u00a0 JM \u00a0 (2013) \u00a0Immunogenicity \u00a0 and \u00a0 safety \u00a0 of \u00a0 quadrivalent \u00a0 versus \u00a0 trivalent \u00a0 inactivated \u00a0 influenza \u00a0vaccine: \u00a0a \u00a0randomized \u00a0controlled \u00a0trial \u00a0in \u00a0adults. \u00a0BMC \u00a0Infect \u00a0Dis \u00a013: \u00a0224:1-\u00ad10 \u00a0 \u00a0Braun \u00a0MM, \u00a0Patriarca \u00a0PA, \u00a0Ellenberg \u00a0SS \u00a0(1997) \u00a0Syncope \u00a0after \u00a0vaccination. \u00a0Arch \u00a0Pediatr \u00a0Adolesc \u00a0Med \u00a0151(3): \u00a0255-\u00ad59 \u00a0 \u00a0Bruunsgaard \u00a0H, \u00a0Hartkopp \u00a0A, \u00a0Mohr \u00a0T, \u00a0Konradsen \u00a0H, \u00a0Heron \u00a0I, \u00a0Mordhorst \u00a0CH, \u00a0Pedersen \u00a0BK \u00a0 (1997) \u00a0 In \u00a0 vivo \u00a0cell-\u00admediated \u00a0 immunity \u00a0 and \u00a0 vaccination \u00a0 response \u00a0 following \u00a0prolonged, \u00a0intense \u00a0exercise. \u00a0Med \u00a0Sci \u00a0Sports \u00a0Exerc \u00a029(9):1176-\u00ad81 \u00a0 \u00a0Bundesinstitut \u00a0 f\u00fcr \u00a0 Sportwissenschaft \u00a0 (2016) \u00a0 Impfungen \u00a0 im \u00a0 leistungssportlichen \u00a0Training. BMI/BISp \u00a0(Aktenzeichen: \u00a0072026/16-\u00ad17) \u00a0 \u00a0[Online \u00a0im \u00a0Internet:] \u00a0https://www.bisp-\u00adsurf.de/Record/PR020160800131/Solr#tabnav \u00a0\t\r \u00a083\t\r \u00a0[Stand: \u00a015.9.18, \u00a020:27] \u00a0 \u00a0Campbell \u00a0 JP, \u00a0 Edwards \u00a0 KM, \u00a0 Ring \u00a0 C, \u00a0 Drayson \u00a0 MT, \u00a0 Bosch \u00a0 JA, \u00a0 Inskip \u00a0 A, \u00a0 Long \u00a0 JE, \u00a0Pulsford \u00a0D, \u00a0Burns \u00a0VE \u00a0(2010) \u00a0The \u00a0effects \u00a0of \u00a0vaccine \u00a0timing \u00a0on \u00a0the \u00a0efficacy \u00a0of \u00a0an \u00a0acute \u00a0eccentric \u00a0 exercise \u00a0 intervention \u00a0 on \u00a0 the \u00a0 immune \u00a0 response \u00a0 to \u00a0 an \u00a0 influenza \u00a0 vaccine \u00a0 in \u00a0young \u00a0adults. \u00a0Brain \u00a0Behav \u00a0Immun \u00a024(2): \u00a0236-\u00ad42 \u00a0Caseris \u00a0M, \u00a0Houhou \u00a0N, \u00a0Longuet \u00a0P, \u00a0Rioux \u00a0C, \u00a0Lepeule \u00a0R, \u00a0Choquet \u00a0C, \u00a0Yazdanpanah \u00a0Y, \u00a0Yeni \u00a0P, \u00a0Joly \u00a0V \u00a0(2014) \u00a0French \u00a02010-\u00ad2011 \u00a0measles \u00a0outbreak \u00a0in \u00a0adults: \u00a0report \u00a0vom \u00a0a \u00a0Parisian \u00a0teaching \u00a0hospital. \u00a0Clin \u00a0Microbiol \u00a0Infect \u00a020(4): \u00a0242-\u00ad44 \u00a0Centers \u00a0 for \u00a0 Disease \u00a0 Control \u00a0 and \u00a0 Prevention \u00a0 (CDC) \u00a0 (2008). \u00a0 Syncope \u00a0 after \u00a0vaccination\u2014United \u00a0States, \u00a0January \u00a02005\u2013July \u00a02007. \u00a0MMWR \u00a0Morb \u00a0Mortal \u00a0Wkly \u00a0Rep \u00a057:457\u201360 \u00a0Centers \u00a0for \u00a0disease \u00a0controll \u00a0and \u00a0prevention \u00a0(2017) \u00a0Possible \u00a0side \u00a0effects \u00a0from \u00a0vaccines. \u00a0Influenza \u00a0vaccine \u00a0side \u00a0effects. \u00a0[Online \u00a0im \u00a0Internet:] \u00a0https://www.cdc.gov/vaccines/vac-\u00adgen/side-\u00adeffects.htm \u00a0[Stand: \u00a010.4.17, \u00a015:26] \u00a0 \u00a0Constantini \u00a0 N, \u00a0 Ken-\u00adDror \u00a0 A, \u00a0 Eliakim \u00a0A, \u00a0 Galatzkia \u00a0 L, \u00a0 Morag \u00a0 A, \u00a0 Mann \u00a0 G, \u00a0 Volach \u00a0 B, \u00a0Asharov \u00a0 J, \u00a0 Shoval \u00a0 D \u00a0 (2001) \u00a0 Vaccination \u00a0 in \u00a0 sports \u00a0 and \u00a0 recommendations \u00a0 for \u00a0immunizations \u00a0against \u00a0flu \u00a0hepatitis \u00a0A \u00a0und \u00a0hepatitis \u00a0B. \u00a0Harefuah \u00a0140(12): \u00a01191-\u00ad95 \u00a0 \u00a0Cook \u00a0IF, \u00a0Murtagh \u00a0J \u00a0(2005) \u00a0Optimal \u00a0technique \u00a0for \u00a0intramuscular \u00a0injection \u00a0of \u00a0infants \u00a0and \u00a0toddlers: \u00a0a \u00a0randomised \u00a0trial. \u00a0MJA \u00a0183(2): \u00a060-\u00ad63 \u00a0 \u00a0Davenport \u00a0JM \u00a0(2004) \u00a0A \u00a0systematic \u00a0review \u00a0to \u00a0ascertain \u00a0whether \u00a0the \u00a0standard \u00a0needle \u00a0is \u00a0more \u00a0effective \u00a0than \u00a0a \u00a0longer \u00a0or \u00a0wider \u00a0needle \u00a0in \u00a0reducing \u00a0the \u00a0incidence \u00a0of \u00a0local \u00a0reaction \u00a0in \u00a0children \u00a0receiving \u00a0primary \u00a0immunization. \u00a0J \u00a0Adv \u00a0Nurs \u00a046(1): \u00a066-\u00ad77 \u00a0 \u00a0Demicheli \u00a0V, \u00a0Jefferson \u00a0T, \u00a0Al-\u00adAnsary \u00a0LA, \u00a0Ferroni \u00a0E, \u00a0Rivetti \u00a0A, \u00a0Di \u00a0Pietrantonj \u00a0C \u00a0(2014) \u00a0Vaccines \u00a0for \u00a0preventing \u00a0influenza \u00a0in \u00a0healthy \u00a0adults. \u00a0Cochrane \u00a0Database \u00a0Syst \u00a0Rev \u00a03: \u00a01-\u00ad263 \u00a0 \u00a0\t\r \u00a084\t\r \u00a0Dhabhar \u00a0 FS,McEwen \u00a0 BS \u00a0 (1998) \u00a0 Enhancing \u00a0 versus \u00a0 supressive \u00a0 effects \u00a0 of \u00a0 stress \u00a0hormones \u00a0on \u00a0skin \u00a0immune \u00a0function. \u00a0Proc \u00a0Nat \u00a0lAcad \u00a0Sci \u00a096(3): \u00a01059-\u00ad64 \u00a0 \u00a0DiazGranados \u00a0CA, \u00a0Denis \u00a0M, \u00a0Plotkin \u00a0S \u00a0(2012) \u00a0Seasonal \u00a0influenza \u00a0vaccine \u00a0efficacy \u00a0and \u00a0its \u00a0 determinants \u00a0 in \u00a0 children \u00a0 and \u00a0 non-\u00adelderly \u00a0adults: \u00a0 a \u00a0 systematic \u00a0 review \u00a0 with \u00a0 meta-\u00adanalyses \u00a0of \u00a0controlled \u00a0trials. \u00a0Vaccine \u00a031: \u00a049-\u00ad57 \u00a0 \u00a0Doed\u00e9e \u00a0AMCM, \u00a0Boland \u00a0GJ, \u00a0Pennings \u00a0JLA, \u00a0de \u00a0Klerk \u00a0A, \u00a0Berbers \u00a0GAM, \u00a0van \u00a0der \u00a0Klis \u00a0FRM, \u00a0de \u00a0Melker \u00a0HE, \u00a0van \u00a0Loveren \u00a0H, \u00a0Janssen \u00a0R \u00a0(2014) \u00a0Effects \u00a0of \u00a0prophylactic \u00a0and \u00a0therapeutic \u00a0Paracetamol \u00a0treatment \u00a0during \u00a0vaccination \u00a0on \u00a0Hepatitis \u00a0B \u00a0antibody \u00a0levels \u00a0in \u00a0adults: \u00a0two \u00a0open-\u00adlabel, \u00a0randomized \u00a0controlled \u00a0trials. \u00a0PLos \u00a0One \u00a09(4): \u00a01-\u00ad8 \u00a0 \u00a0Edwards \u00a0KM, \u00a0Burns \u00a0VE, \u00a0Reynolds \u00a0T, \u00a0Caroll \u00a0D, \u00a0Drayson \u00a0M, \u00a0Ring \u00a0C \u00a0(2006) \u00a0Acute \u00a0stress \u00a0exposure \u00a0prior \u00a0to \u00a0influenza \u00a0vaccination \u00a0enhances \u00a0antibody \u00a0response \u00a0in \u00a0women. \u00a0Brain \u00a0Behav \u00a0Immun \u00a020(2): \u00a0159-\u00ad68 \u00a0 \u00a0Edwards \u00a0KM, \u00a0Burns \u00a0VE, \u00a0Allen \u00a0LM, \u00a0McPhee \u00a0JS, \u00a0Bosh \u00a0JA, \u00a0Caroll \u00a0D, \u00a0Drayson \u00a0M, \u00a0Ring \u00a0C \u00a0(2007) \u00a0 Eccentric \u00a0 exercise \u00a0 as \u00a0 an \u00a0 adjuvant \u00a0 to \u00a0 influenza \u00a0 vaccination \u00a0 in \u00a0 human. \u00a0 Brain \u00a0Behav \u00a0Immun \u00a021(2): \u00a0209-\u00ad17 \u00a0 \u00a0Edwards \u00a0KM, \u00a0Campbell \u00a0JP, \u00a0Ring \u00a0C, \u00a0Drayson \u00a0MT, \u00a0Bosch \u00a0JA, \u00a0Downes \u00a0C, \u00a0Long \u00a0JE, \u00a0Lumb \u00a0JA, \u00a0 Merry \u00a0 A, \u00a0 Paine \u00a0 NJ, \u00a0 Burns \u00a0 VE \u00a0 (2010) \u00a0 Exercise \u00a0 intensity \u00a0 does \u00a0 not \u00a0 influence \u00a0 the \u00a0efficacy \u00a0of \u00a0eccenticic \u00a0exercise \u00a0as \u00a0a \u00a0behavioural \u00a0adjuvant \u00a0to \u00a0vaccination. \u00a0Brain \u00a0Behav \u00a0Immun \u00a024(7): \u00a0623-\u00ad30 \u00a0 \u00a0Edwards \u00a0 KM, \u00a0 Booy \u00a0 R \u00a0 (2013) \u00a0 Effects \u00a0 of \u00a0 exercise \u00a0 on \u00a0 vaccine \u00a0induced \u00a0 immune \u00a0responses. \u00a0Hum \u00a0Vaccin \u00a0Immunother \u00a09(4): \u00a0907-\u00ad10 \u00a0 \u00a0Furian \u00a0TC, \u00a0Wagner \u00a0D, \u00a0Hart \u00a0E, \u00a0Ritthaler \u00a0F \u00a0(1999) \u00a0Suppression \u00a0of \u00a0seroconversion \u00a0rate \u00a0and \u00a0 specific \u00a0 antibody-\u00adtiter \u00a0 after \u00a0 vaccination \u00a0 against \u00a0 hepatitis \u00a0 A \u00a0 during \u00a0 an \u00a0 intensive \u00a0work-\u00adout \u00a0phase. \u00a0Int \u00a0J \u00a0Sports \u00a0Med \u00a0(S1): \u00a046 \u00a0 \u00a0Furian \u00a0TC \u00a0(2000) \u00a0Impfen \u00a0und \u00a0Leistungssport. \u00a0Dtsch \u00a0Z \u00a0Sportmed \u00a051: \u00a0211-\u00ad12 \u00a0 \u00a0\t\r \u00a085\t\r \u00a0Furian \u00a0TC, \u00a0Rolirad \u00a0KD \u00a0(2009) \u00a0Impfungen \u00a0und \u00a0k\u00f6rperliche \u00a0Aktivit\u00e4t. \u00a0Dtsch \u00a0Z \u00a0Sportmed \u00a012: \u00a0406-\u00ad10 \u00a0 \u00a0Furian \u00a0TC, \u00a0G\u00e4rtner \u00a0BC \u00a0(2014) \u00a0Impfungen \u00a0bei \u00a0Sportlern. \u00a0Dtsch \u00a0Z \u00a0Sportmed \u00a012: \u00a0333-\u00ad36 \u00a0 \u00a0Gabriel \u00a0H, \u00a0Kindermann \u00a0W \u00a0(1994) \u00a0The \u00a0acute \u00a0immune \u00a0response \u00a0to \u00a0exercise: \u00a0What \u00a0does \u00a0it \u00a0mean. \u00a0Int \u00a0J \u00a0Sports \u00a0Med \u00a018(1): \u00a028-\u00ad45 \u00a0 \u00a0Gabriel \u00a0 H \u00a0 (2004) \u00a0 II \u00a0 Sport \u00a0 und \u00a0 Immunsystem. \u00a0 In: \u00a0 Pokan \u00a0 R, \u00a0 F\u00f6rster \u00a0 H, \u00a0 Hofmann \u00a0 P, \u00a0H\u00f6rtnagel \u00a0 H, \u00a0 Ledl-\u00adKurskowski \u00a0 E, \u00a0 Wonisch \u00a0 M \u00a0 (eds) \u00a0 Kompendium \u00a0 der \u00a0 Sportmedizin. \u00a0Springer, \u00a0Vienna, \u00a0pp \u00a0227-\u00ad50 \u00a0 \u00a0Gatmaitan \u00a0BG, \u00a0Chason \u00a0JL, \u00a0Lerner \u00a0AM \u00a0(1970) \u00a0Augmentation \u00a0of \u00a0the \u00a0virulence \u00a0of \u00a0murine \u00a0coxsackie-\u00advirus \u00a0B-\u00ad3 \u00a0myocardiopathy \u00a0by \u00a0exercise. \u00a0J \u00a0Exp \u00a0Med \u00a0131(6): \u00a01121-\u00ad36 \u00a0 \u00a0Gleeson \u00a0M, \u00a0Pyne \u00a0DB, \u00a0McDonald \u00a0WA, \u00a0Clancy \u00a0RL, \u00a0Cripps \u00a0AW, \u00a0Horn \u00a0PL, \u00a0Fricker \u00a0PA \u00a0(1996) \u00a0Pneumococcal \u00a0antibody \u00a0responses \u00a0in \u00a0elite \u00a0swimmers. \u00a0Clin \u00a0Exp \u00a0Immunol \u00a0105: \u00a0238-\u00ad44 \u00a0 \u00a0Gold \u00a0MS, \u00a0Gidudu \u00a0J, \u00a0Erlewyn-\u00adLajeunesse \u00a0M, \u00a0Law \u00a0B;\u037eThe \u00a0Brighton \u00a0Collaberation \u00a0(2010) \u00a0Can \u00a0 the \u00a0 Brighton \u00a0 Collaboration \u00a0 case \u00a0 definitions \u00a0 be \u00a0 used \u00a0 to \u00a0 improve \u00a0 the \u00a0 quality \u00a0 of \u00a0Adverse \u00a0Event \u00a0Following \u00a0Immunization \u00a0(AEFI) \u00a0reporting? \u00a0Anaphylaxis \u00a0as \u00a0a \u00a0case \u00a0study. \u00a0Vaccine \u00a028: \u00a04487-\u00ad98 \u00a0 \u00a0Govaert \u00a0ME, \u00a0Dinant \u00a0MJ, \u00a0Aretz \u00a0K, \u00a0Masurel \u00a0N, \u00a0Sprenger \u00a0MJW, \u00a0Knottnerus \u00a0JA \u00a0(1993) \u00a0Adverse \u00a0reactions \u00a0to \u00a0influenza \u00a0vaccine \u00a0in \u00a0elderly \u00a0people: \u00a0a \u00a0randomised \u00a0double \u00a0blind \u00a0placebo \u00a0controlled \u00a0trial. \u00a0BMJ \u00a0307: \u00a0988-\u00ad90 \u00a0 \u00a0Grande \u00a0AJ, \u00a0Reid \u00a0H, \u00a0Thomas \u00a0EE, \u00a0Nunan \u00a0D, \u00a0Foster \u00a0C \u00a0(2016) \u00a0Exercise \u00a0prior \u00a0to \u00a0influenza \u00a0vaccination \u00a0 for \u00a0 limiting \u00a0 influenza \u00a0 incidence \u00a0 and \u00a0 it\u00b4s \u00a0 related \u00a0 complications \u00a0 in \u00a0 adults \u00a0(Review). \u00a0Cochrane \u00a0Database \u00a0Syst \u00a0Review \u00a08: \u00a01-\u00ad46 \u00a0 \u00a0Greenberg \u00a0 DP, \u00a0 Robertson \u00a0 CA, \u00a0 Noss \u00a0 MJ, \u00a0 Blatter \u00a0 MM, \u00a0 Biedenbender \u00a0 R, \u00a0 Decker \u00a0 D \u00a0(2013) \u00a0 Safety \u00a0 and \u00a0 immunogenicity \u00a0 of \u00a0 a \u00a0 quadrivalent \u00a0 inactivated \u00a0 influenza \u00a0 vaccine \u00a0\t\r \u00a086\t\r \u00a0compared \u00a0 to \u00a0 licensed \u00a0 trivalent \u00a0 inactivated \u00a0 influenza \u00a0 vaccines \u00a0 in \u00a0 adults. \u00a0 Vaccine \u00a0 \u00a0 \u00a031:770-\u00ad76 \u00a0Gross \u00a0PA, \u00a0Lewandowski \u00a0RA, \u00a0Russo \u00a0C, \u00a0Weksler \u00a0M, \u00a0Bonelli \u00a0J, \u00a0Dran \u00a0Sandra, \u00a0Munk \u00a0G, \u00a0Deichmiller \u00a0S, \u00a0Hilsen \u00a0R, \u00a0Panush \u00a0RF \u00a0(1993) \u00a0Vaccine \u00a0immune \u00a0response \u00a0and \u00a0side \u00a0effects \u00a0with \u00a0 the \u00a0 use \u00a0 of \u00a0 Acetaminophen \u00a0 with \u00a0 influenza \u00a0 vaccine. \u00a0 Clin \u00a0Diagn \u00a0Lab \u00a0Immunol \u00a01(2):134-\u00ad38 \u00a0Guiterrez \u00a0RL, \u00a0Decker \u00a0CF \u00a0(2010) \u00a0Blood-\u00adborne \u00a0infections \u00a0and \u00a0the \u00a0athlete. \u00a0Disease-\u00ada-\u00admonth \u00a056: \u00a0436-\u00ad42 \u00a0Gundlapalli \u00a0AV, \u00a0Rubin \u00a0MA, \u00a0Samore \u00a0MH, \u00a0Lopansri \u00a0B, \u00a0Lathey \u00a0T, \u00a0McGuire \u00a0HL, \u00a0Wintrhop \u00a0KL, \u00a0 Dunn \u00a0 JJ, \u00a0 Willick \u00a0 SE, \u00a0 Vosters \u00a0 RL, \u00a0 Waeckerle \u00a0 JF, \u00a0 Carroll \u00a0 KC, \u00a0 Gwaltney \u00a0 JM \u00a0 Jr., \u00a0Hayden \u00a0 GF, \u00a0 Elstad \u00a0 MR, \u00a0 Sande \u00a0 MA \u00a0 (2006) \u00a0 Influenza, \u00a0 Winter, \u00a0 Olympiad,2002. \u00a0Emerging \u00a0Infect \u00a0Diseases \u00a012(1): \u00a0144-\u00ad46 \u00a0Gysling \u00a0E \u00a0(2007) \u00a0Influenza-\u00adImpfstoff \u00a0mit \u00a0MF59-\u00adAdjuvans. \u00a0pharma-\u00adkritik \u00a029: \u00a061-\u00ad62 \u00a0 \u00a0G\u00e4rtner \u00a0BC, \u00a0Meyer \u00a0T \u00a0(2014) \u00a0Vaccination \u00a0in \u00a0Elite \u00a0Athletes. \u00a0Sports \u00a0Med \u00a044: \u00a01361-\u00ad76 \u00a0 \u00a0Halsey \u00a0 NA, \u00a0 Griffioen \u00a0 M, \u00a0 Dreskin \u00a0 SC, \u00a0 Dekker \u00a0 CL, \u00a0 Wood \u00a0 R, \u00a0 Sharma \u00a0 D, \u00a0 Jones \u00a0 JF, \u00a0LaRussa \u00a0PS, \u00a0Garner \u00a0J, \u00a0Berger \u00a0M, \u00a0Proveaux \u00a0T, \u00a0Velozzi \u00a0C, \u00a0Broder \u00a0K, \u00a0Setse \u00a0R, \u00a0Pahud \u00a0B, \u00a0Hrncir \u00a0D, \u00a0Choi \u00a0H, \u00a0Sparks \u00a0R, \u00a0Williams \u00a0SE, \u00a0Engler \u00a0RJ, \u00a0Gidudu \u00a0J, \u00a0Baxter \u00a0R, \u00a0Klein \u00a0N \u00a0Edwards \u00a0K, \u00a0Cano \u00a0M, \u00a0Kelso \u00a0JM \u00a0(2013) \u00a0Immediate \u00a0hypersensitivity \u00a0reactions \u00a0following \u00a0monovalent \u00a02009 \u00a0pandemic \u00a0Influenza \u00a0A(H1N1) \u00a0vaccines: \u00a0Report \u00a0to \u00a0VAERS. \u00a0Vaccine \u00a031: \u00a06107-\u00ad12 \u00a0 \u00a0Hastings \u00a0JL, \u00a0Levine \u00a0BD \u00a0(2012) \u00a0Syncope \u00a0in \u00a0atheltic \u00a0patient. \u00a0Prog \u00a0Cardiovasc \u00a0Dis \u00a054(5): \u00a0438-\u00ad44 \u00a0 \u00a0Havas \u00a0E, \u00a0Parvainen \u00a0T, \u00a0Vuorela \u00a0J, \u00a0Toivanen \u00a0J, \u00a0Nikula \u00a0T, \u00a0Vihko \u00a0V \u00a0(1997) \u00a0Lymph \u00a0flow \u00a0dynamics \u00a0in \u00a0exercising \u00a0human \u00a0skeletal \u00a0muscle \u00a0as \u00a0detectet \u00a0by \u00a0scintigraphy.J \u00a0Physiol \u00a0504 \u00a0(PT1): \u00a0233-\u00ad39 \u00a0 \u00a0Heikkinen \u00a0T, \u00a0Heinonen \u00a0S \u00a0(2011) \u00a0Effectiveness \u00a0and \u00a0safety \u00a0of \u00a0influenza \u00a0vaccination \u00a0in \u00a0children: \u00a0European \u00a0perspective. \u00a0Vaccine \u00a029: \u00a07529-\u00ad34 \u00a0\t\r \u00a087\t\r \u00a0 \u00a0Herold \u00a0G \u00a0(2015) \u00a0Innere \u00a0Medizin. \u00a0Eine \u00a0vorlesungsorientierte \u00a0Darstellung. \u00a0Herold, \u00a0Gerd, \u00a0K\u00f6ln \u00a0 \u00a0Hoebe \u00a0 CJPA, \u00a0 Vermeiren \u00a0 APA, \u00a0 Dukers-\u00adMuijrers \u00a0 NHTM \u00a0 (2012) \u00a0 Revaccination \u00a0 with \u00a0Fendrix \u00a0or \u00a0HBVaxPro \u00a0results \u00a0in \u00a0better \u00a0response \u00a0rate \u00a0than \u00a0does \u00a0revaccination \u00a0with \u00a0three \u00a0doses \u00a0of \u00a0EngerixB \u00a0in \u00a0previous \u00a0non-\u00adresponders. \u00a0Vaccine \u00a030: \u00a06434-\u00ad37 \u00a0 \u00a0Illb\u00e4ck \u00a0 NG, \u00a0 Fohlmann \u00a0 J, \u00a0 Friman \u00a0 G \u00a0 (1989) \u00a0 Exercise \u00a0 in \u00a0 cocksackie \u00a0 B3 \u00a0 myocarditis: \u00a0Effects \u00a0on \u00a0heart \u00a0and \u00a0lymphocyte \u00a0subpopulations \u00a0and \u00a0the \u00a0inflammatory \u00a0reaction. \u00a0AHJ \u00a0117(6): \u00a01298-\u00ad1302 \u00a0 \u00a0Ipp \u00a0M, \u00a0Sam \u00a0J, \u00a0Parkin \u00a0PC \u00a0(2006) \u00a0Needle \u00a0aspiration \u00a0and \u00a0intramuscular \u00a0vaccination. \u00a0Arch \u00a0Pediatr \u00a0Adolesc \u00a0Med \u00a0160(4): \u00a0451 \u00a0 \u00a0Ipp \u00a0 M, \u00a0 Taddio \u00a0 A, \u00a0 Sam \u00a0 J, \u00a0 Goldbach \u00a0 M, \u00a0 Parkin \u00a0 PC \u00a0 (2007) \u00a0 Vaccine \u00a0 related \u00a0 pain: \u00a0randomised \u00a0controlled \u00a0trial \u00a0oft \u00a0wo \u00a0injection \u00a0techniques. \u00a0Arch \u00a0Dis \u00a0Child \u00a092: \u00a01105-\u00ad08 \u00a0 \u00a0Kakanis \u00a0 MW, \u00a0 Peake \u00a0 J, \u00a0 Brenu \u00a0 EW, \u00a0 Simmonds \u00a0 M, \u00a0 Gray \u00a0 B, \u00a0Hooper \u00a0 SL, \u00a0 Marshall-\u00adGradisnik \u00a0SM \u00a0(2010) \u00a0The \u00a0open \u00a0window \u00a0of \u00a0susceptibility \u00a0to \u00a0infection \u00a0after \u00a0acute \u00a0exercise \u00a0in \u00a0healthy \u00a0young \u00a0male \u00a0elite \u00a0athletes. \u00a0Exerc \u00a0Immunol \u00a0Rev \u00a016: \u00a0119-\u00ad37 \u00a0Kata \u00a0A \u00a0(2010) \u00a0A \u00a0postmodern \u00a0pandora\u00b4s \u00a0box: \u00a0Anti-\u00advaccination \u00a0misinformation \u00a0on \u00a0the \u00a0internet. \u00a0Vaccine \u00a028(7): \u00a01709-\u00ad16 \u00a0Kohl \u00a0KS, \u00a0Gidudu \u00a0J, \u00a0Bonhoeffer \u00a0J, \u00a0Braun \u00a0MM, \u00a0Buettcher \u00a0M, \u00a0Chen \u00a0RT, \u00a0Duclos \u00a0P, \u00a0Harald \u00a0Heijbel \u00a0H, \u00a0Heininger \u00a0U \u00a0Loupi \u00a0E, \u00a0Marcy \u00a0SM;\u037e \u00a0The \u00a0Brighton \u00a0Collaboration \u00a0(2007) \u00a0The \u00a0development \u00a0 of \u00a0 standardized \u00a0 case \u00a0 definitions \u00a0 and \u00a0 guidelines \u00a0for \u00a0 adverse \u00a0 events \u00a0following \u00a0immunization. \u00a0Vaccine \u00a025:5671\u201374. \u00a0 \u00a0Kohut \u00a0 ML, \u00a0 Arntson \u00a0 BA, \u00a0 Lee \u00a0 W, \u00a0 Rozeboom \u00a0 K, \u00a0 Yoon \u00a0 KJ, \u00a0 Cunnick \u00a0 JE, \u00a0 McElhaney \u00a0 J \u00a0(2004) \u00a0Moderate \u00a0exercise \u00a0improves \u00a0antibody \u00a0response \u00a0to \u00a0influenza \u00a0immunization \u00a0in \u00a0older \u00a0adults. \u00a0Vaccine \u00a022(17-\u00ad18): \u00a02298-\u00ad306 \u00a0 \u00a0\t\r \u00a088\t\r \u00a0Kordi \u00a0 R, \u00a0 Wallace \u00a0 WA \u00a0 (2004) \u00a0 Blood \u00a0 borne \u00a0 infections \u00a0 in \u00a0 sport: \u00a0 risks \u00a0 of \u00a0 transmission, \u00a0methods \u00a0of \u00a0prevention, \u00a0and \u00a0recommendations \u00a0for \u00a0hepatitis \u00a0B \u00a0vaccination. \u00a0Br \u00a0J \u00a0Sports \u00a0Med \u00a038(6): \u00a0678-\u00ad84 \u00a0 \u00a0Kroger \u00a0AT, \u00a0Atkinson \u00a0WL, \u00a0Marcuse \u00a0EK, \u00a0Pickering \u00a0LK \u00a0(2006) \u00a0General \u00a0recommendations \u00a0on \u00a0 immunization: \u00a0 Recommendations \u00a0 on \u00a0 the \u00a0 Advisory \u00a0 Committee \u00a0 on \u00a0 Immunization \u00a0Practices(ACIP). \u00a0MMWR \u00a0Recomm \u00a0Rep \u00a055: \u00a01-\u00ad48 \u00a0 \u00a0Lidholm \u00a0 AG, \u00a0 Bergfors \u00a0 E, \u00a0 Inerot \u00a0 A, \u00a0 Blomgren \u00a0 U, \u00a0 Gillstedt \u00a0 M, \u00a0 Trollfors \u00a0 B \u00a0 (2013) \u00a0Unexpected \u00a0 loss \u00a0 of \u00a0 contact \u00a0 allergy \u00a0 to \u00a0 alluminium \u00a0 induced \u00a0 by \u00a0 vaccine. \u00a0 Contact \u00a0Dermatitis \u00a068(5): \u00a0286-\u00ad92 \u00a0 \u00a0Long \u00a0JE, \u00a0Ring \u00a0C, \u00a0Drayson \u00a0M, \u00a0Bosch \u00a0J, \u00a0Campbell \u00a0JP, \u00a0Bhabra \u00a0J, \u00a0Browne \u00a0D, \u00a0Dawson \u00a0J, \u00a0Harding \u00a0S, \u00a0Lau \u00a0J, \u00a0Burns \u00a0VE \u00a0(2012) \u00a0Vaccination \u00a0response \u00a0following \u00a0aerobic \u00a0exercise: \u00a0Can \u00a0 a \u00a0 brisk \u00a0 walk \u00a0 enhance \u00a0 antibosy \u00a0response \u00a0 to \u00a0 pneumococcal \u00a0 and \u00a0 influenza \u00a0vaccinations? \u00a0Brain \u00a0Behav \u00a0Immun \u00a026(4): \u00a0680-\u00ad87 \u00a0 \u00a0Martin \u00a0A, \u00a0Lemon \u00a0SM \u00a0(2006) \u00a0Hepatitis \u00a0A \u00a0virus: \u00a0From \u00a0discovery \u00a0to \u00a0vaccines. \u00a0Hepatology \u00a043(2 \u00a0Suppl \u00a01): \u00a0146-\u00ad72 \u00a0 \u00a0McCulers \u00a0 JA, \u00a0 Saito \u00a0 T, \u00a0 Iverson \u00a0 AR \u00a0 (2004) \u00a0 Multiple \u00a0 Genotypes \u00a0 of \u00a0 influenza \u00a0 B \u00a0 virus \u00a0circulated \u00a0between \u00a01979 \u00a0and \u00a02003.J \u00a0Virol \u00a078(23): \u00a012817-\u00ad28 \u00a0 \u00a0Nichol \u00a0KL, \u00a0Margolis \u00a0KL, \u00a0Lind \u00a0A, \u00a0Murdoch \u00a0Maureem, \u00a0McFadden \u00a0R, \u00a0Hauge \u00a0M, \u00a0Magnan \u00a0S, \u00a0 Drake \u00a0 M \u00a0 (1996) \u00a0 Side \u00a0 effects \u00a0 associated \u00a0 with \u00a0 influenza \u00a0 vaccination \u00a0 in \u00a0 healthy \u00a0working \u00a0adults. \u00a0A \u00a0randomized \u00a0placebo \u00a0controlled \u00a0trial. \u00a0Arch \u00a0Intern \u00a0Med \u00a0156(14): \u00a01546-\u00ad50 \u00a0 \u00a0Niemann \u00a0DC, \u00a0Nielsen-\u00adCanarella \u00a0SL, \u00a0Markoff \u00a0PA, \u00a0Balk-\u00adLamberton \u00a0AJ, \u00a0Yang \u00a0H, \u00a0Chritton \u00a0DBW, \u00a0Lee \u00a0JW, \u00a0Arabatzis \u00a0K \u00a0(1990) \u00a0The \u00a0effects \u00a0of \u00a0moderate \u00a0exercise \u00a0training \u00a0on \u00a0natural \u00a0killer \u00a0cells \u00a0and \u00a0acute \u00a0upper \u00a0respiratory \u00a0tract \u00a0infections. \u00a0Int \u00a0J \u00a0Sports \u00a0Med \u00a011(6): \u00a0467-\u00ad73 \u00a0 \u00a0Niemann \u00a0 DC \u00a0 (1994) \u00a0 Exercise, \u00a0 upper \u00a0 respiratory \u00a0 tract \u00a0 infection, \u00a0 and \u00a0 the \u00a0 immune \u00a0system. \u00a0Med \u00a0Sci \u00a0Sports \u00a0Exerc \u00a026(2): \u00a0128-\u00ad39 \u00a0\t\r \u00a089\t\r \u00a0 \u00a0Niemann \u00a0 DC, \u00a0 Pedersen \u00a0 BK \u00a0 (1999) \u00a0 Exercise \u00a0 and \u00a0 immune \u00a0 function. \u00a0 Recent \u00a0developments. \u00a0Sports \u00a0Med \u00a027(2): \u00a073-\u00ad80 \u00a0 \u00a0Niemann \u00a0DC \u00a0(2007) \u00a0Marathon \u00a0training \u00a0and \u00a0immune \u00a0function. \u00a0Sports \u00a0Med \u00a037 \u00a0(4-\u00ad5): \u00a0412-\u00ad15 \u00a0 \u00a0Odone \u00a0A, \u00a0Chiesa \u00a0V,Ciorba \u00a0V, \u00a0Cella \u00a0P, \u00a0Pasquarella \u00a0C, \u00a0Signorelli \u00a0C \u00a0(2015) \u00a0Influenza \u00a0and \u00a0immunization: \u00a0a \u00a0quantitative \u00a0study \u00a0of \u00a0media \u00a0coverage \u00a0in \u00a0the \u00a0season \u00a0oft \u00a0he \u00a0\u201eFluad \u00a0case\u201c. \u00a0Epidemiol \u00a0Prev \u00a039(4): \u00a0139-\u00ad45 \u00a0 \u00a0O\u00b4Hagan \u00a0 DT \u00a0 (2007) \u00a0 MF-\u00ad59 \u00a0 is \u00a0 a \u00a0 safe \u00a0 and \u00a0 potent \u00a0 vaccine \u00a0 adjuvant \u00a0 that \u00a0 enhances \u00a0protection \u00a0against \u00a0influenza \u00a0virus \u00a0infection. \u00a0Expert \u00a0Rev \u00a0Vaccines \u00a06(5): \u00a0699-\u00ad710 \u00a0 \u00a0Pascoe \u00a0AR, \u00a0Singh \u00a0MAF, \u00a0Edwards \u00a0KM \u00a0(2014) \u00a0The \u00a0effects \u00a0of \u00a0exercise \u00a0on \u00a0vaccination \u00a0responses: \u00a0 A \u00a0 review \u00a0 of \u00a0 chronic \u00a0 and \u00a0 acute \u00a0 exercise \u00a0 interventions \u00a0 in \u00a0 humans. \u00a0 Brain \u00a0Behav \u00a0Immun \u00a039: \u00a033-\u00ad41 \u00a0 \u00a0Pedersen \u00a0 BK, \u00a0 Ullum \u00a0 H \u00a0 (1994) \u00a0 NK \u00a0 cell \u00a0 response \u00a0 to \u00a0 physical \u00a0 activity: \u00a0 possible \u00a0mechanisms \u00a0of \u00a0action. \u00a0Med \u00a0Sci \u00a0Sports \u00a0Exerc \u00a026(2): \u00a0140-\u00ad46 \u00a0 \u00a0Petousis-\u00adHarris \u00a0H \u00a0(2008) \u00a0Vaccine \u00a0injection \u00a0technique \u00a0and \u00a0reactogenicity-\u00adEvidence \u00a0for \u00a0practice. \u00a0Vaccine \u00a026(50): \u00a06299-\u00ad304 \u00a0 \u00a0Pileggi \u00a0C, \u00a0Lotito \u00a0F, \u00a0Bianco \u00a0A, \u00a0Nobile \u00a0CGA, \u00a0Pavia \u00a0M \u00a0(2015) \u00a0Immunogenicity \u00a0and \u00a0safety \u00a0of \u00a0intradermal \u00a0influenza \u00a0vaccine \u00a0in \u00a0Immunocompromized \u00a0patients: \u00a0a \u00a0meta-\u00adanalysis \u00a0of \u00a0randomized \u00a0controlled \u00a0trials. \u00a0BMC \u00a0Infectious \u00a0Diseases \u00a015: \u00a0427-\u00ad37 \u00a0 \u00a0Pruett \u00a0SB \u00a0(2003) \u00a0Stress \u00a0and \u00a0the \u00a0immune \u00a0system \u00a0(Review). \u00a0Pathophysiology \u00a09(3): \u00a0133-\u00ad53 \u00a0 \u00a0Prymula \u00a0R, \u00a0Siegrist \u00a0CA, \u00a0Chlibek \u00a0R, \u00a0Zemlickova \u00a0H, \u00a0Vackova \u00a0M, \u00a0Smetana \u00a0J, \u00a0Lammel \u00a0P, \u00a0Kaliskova \u00a0 E, \u00a0 Borys \u00a0 D, \u00a0 Schuermann \u00a0 L \u00a0 (2009) \u00a0 Effect \u00a0 of \u00a0 prophylactic \u00a0 Paracetamol \u00a0\t\r \u00a090\t\r \u00a0administration \u00a0 at \u00a0 time \u00a0 of \u00a0 vaccination \u00a0 on \u00a0 febrile \u00a0 reactions \u00a0 and \u00a0 antibody \u00a0 respones \u00a0 in \u00a0children: \u00a0two \u00a0open-\u00adlabel \u00a0randomised \u00a0controlled \u00a0trials. \u00a0Lancet \u00a0374: \u00a01339-\u00ad50 \u00a0 \u00a0Pyne \u00a0 DB, \u00a0 Gleeson \u00a0 M \u00a0 (1998) \u00a0 Effects \u00a0 of \u00a0 intensive \u00a0 exercise \u00a0 training \u00a0 on \u00a0 immunity \u00a0 in \u00a0athletes. \u00a0Int \u00a0J \u00a0Sports \u00a0Med \u00a019: \u00a0183-\u00ad94 \u00a0 \u00a0P\u00f6hlmann \u00a0S, \u00a0Schmitt \u00a0C \u00a0(2016) \u00a0Orthomyxoviren: \u00a0Influenza. \u00a0In: \u00a0Suerbaum \u00a0S, \u00a0Burchard \u00a0GD, \u00a0Kaufmann \u00a0SHE, \u00a0Schulz \u00a0TF \u00a0(eds) \u00a0Medizinische \u00a0Mikrobiologie \u00a0und \u00a0Infektiologie. \u00a0Springer, \u00a0Berlin \u00a0Heidelberg, \u00a0pp \u00a0483-\u00ad87 \u00a0 \u00a0Robert-\u00adKoch-\u00adInstitut \u00a0(2012) \u00a0H\u00e4ufig \u00a0gestellte \u00a0Fragen \u00a0zur \u00a0FSME \u00a0Impfung \u00a0[Online \u00a0 im \u00a0 Internet:] \u00a0https://www.rki.de/SharedDocs/FAQ/FSME/FSME-\u00adImpfung/FSME-\u00adImpfung.html \u00a0[Stand: \u00a022.3.17, \u00a09:27] \u00a0 \u00a0Robert-\u00adKoch-\u00adInstitut \u00a0 (2017) \u00a0 Bericht \u00a0 zur \u00a0 Epidemiologie \u00a0 der \u00a0 Influenza \u00a0 in \u00a0 Deutschland \u00a0Saison \u00a02016/17 \u00a0[Online \u00a0im \u00a0Internet:] \u00a0https://influenza.rki.de/Saisonberichte/2016.pdf \u00a0[Stand: \u00a030.3.18, \u00a013:16] \u00a0 \u00a0Robert-\u00adKoch-\u00adInstitut \u00a0(2018) \u00a0Influenza \u00a0Wochenbericht. \u00a0Kalenderwoche \u00a012 \u00a0(17.03 \u00a0bis \u00a023.03.18) \u00a0[Online \u00a0im \u00a0Internet:] \u00a0https://influenza.rki.de/Wochenberichte/2017_2018/2018-\u00ad12.pdf \u00a0[Stand: \u00a030.3.18, \u00a016:21] \u00a0 \u00a0Ronsen \u00a0O, \u00a0Pedersen \u00a0BK, \u00a0Oritsland \u00a0TR, \u00a0Bahr \u00a0R, \u00a0Kjieldsen-\u00adKragh \u00a0J \u00a0(2001) \u00a0Leukocyte \u00a0counts \u00a0and \u00a0lymphocyte \u00a0responsiveness \u00a0associated \u00a0with \u00a0repeated \u00a0bouts \u00a0of \u00a0strenuous \u00a0endurance \u00a0exercise. \u00a0J \u00a0Appl \u00a0Physiol \u00a091: \u00a0425-\u00ad34 \u00a0 \u00a0Rosic \u00a0 I, \u00a0 Mallicevic \u00a0 S, \u00a0 Medic \u00a0 S, \u00a0 Vlasich \u00a0 C \u00a0 (2008) \u00a0 Immune \u00a0 response \u00a0 by \u00a0 athletes \u00a0 to \u00a0hepatitis \u00a0b \u00a0vaccination. \u00a0Vaccine \u00a026: \u00a0 \u00a0 \u00a03190-\u00ad91 \u00a0 \u00a0R\u00f6hrig \u00a0B, \u00a0du \u00a0Pres \u00a0JB, \u00a0Wachtlin \u00a0D, \u00a0Kwiecien \u00a0R, \u00a0Blettner \u00a0M \u00a0(2010) \u00a0Fallzahlplanung \u00a0in \u00a0klinischen \u00a0Studien. \u00a0Dtsch \u00a0Arztebl \u00a0Int \u00a0107(31-\u00ad32): \u00a0552-\u00ad56 \u00a0\t\r \u00a091\t\r \u00a0 \u00a0Scharhag \u00a0J, \u00a0Meyer \u00a0T, \u00a0Gabriel \u00a0HHW, \u00a0Auracher \u00a0M, \u00a0Kindermann \u00a0W \u00a0(2002) \u00a0Mobilization \u00a0and \u00a0 oxidative \u00a0 burst \u00a0 of \u00a0 neutrophils \u00a0 are \u00a0 influenced \u00a0 by \u00a0 carbohydrate \u00a0 supplementation \u00a0during \u00a0prolonged \u00a0cycling \u00a0in \u00a0humans. \u00a0Eur \u00a0J \u00a0Appl \u00a0Physiol87: \u00a0584-\u00ad87 \u00a0 \u00a0Schmidt \u00a0T, \u00a0Dirks \u00a0J, \u00a0Enders \u00a0M, \u00a0G\u00e4rtner \u00a0BC, \u00a0Uhlmann-\u00adSchiffler \u00a0H, \u00a0Sester \u00a0U, \u00a0Sester \u00a0M \u00a0(2012) \u00a0 CD4+T-\u00adcell \u00a0 immunity \u00a0 after \u00a0 pandemic \u00a0 influenza \u00a0 vaccination \u00a0 cross \u00a0 reacts \u00a0 with \u00a0seasonal \u00a0 antigens \u00a0 and \u00a0 functionally \u00a0 differs \u00a0 from \u00a0 active \u00a0 influenza \u00a0 infection. \u00a0Eur \u00a0J \u00a0Immunol \u00a042(7):1755-\u00ad66 \u00a0 \u00a0Schmolz \u00a0G, \u00a0Ley-\u00adK\u00f6llstadt \u00a0S, \u00a0H\u00fcl\u00dfe \u00a0C \u00a0(2016) \u00a0Invasive \u00a0Meningokokkenerkrankungen-\u00ad \u00a0Epidemiologie, \u00a0 reisemedizinische \u00a0 Relevanz, \u00a0 Impfstoffe \u00a0 und \u00a0 Impfregime. \u00a0Flug \u00a0und \u00a0Reisemed \u00a023(2):79-\u00ad86 \u00a0 \u00a0Shi \u00a0 Y, \u00a0 Rock \u00a0 KL \u00a0 (2002) \u00a0Cell \u00a0 death \u00a0 releases \u00a0 endogenous \u00a0 adjuvants \u00a0 that \u00a0 selectively \u00a0enhance \u00a0immune \u00a0surveillance \u00a0of \u00a0particulate \u00a0antigens. \u00a0Eur \u00a0J \u00a0Immunol \u00a032: \u00a0155-\u00ad62 \u00a0 \u00a0Signorelli \u00a0C, \u00a0Odone \u00a0A, \u00a0Conversano \u00a0M, \u00a0Bonanni \u00a0P \u00a0(2015) \u00a0Deaths \u00a0after \u00a0Fluad \u00a0flu \u00a0vaccine \u00a0and \u00a0the \u00a0epidemic \u00a0of \u00a0panic \u00a0in \u00a0Italy. \u00a0BMJ \u00a0350: \u00a0h116 \u00a0 \u00a0Signorelli \u00a0C, \u00a0Odone \u00a0A, \u00a0Miduri \u00a0A, \u00a0Cella \u00a0P, \u00a0Pasquarella \u00a0C, \u00a0Gozzini \u00a0A, \u00a0Tamburrino \u00a0P, \u00a0Castellacci \u00a0E \u00a0(2016) \u00a0Flu \u00a0Vaccination \u00a0in \u00a0elite \u00a0athletes: \u00a0a \u00a0survery \u00a0among \u00a0Serie \u00a0A \u00a0soccer \u00a0teams. \u00a0Acta \u00a0Biomed \u00a087(2): \u00a0117-\u00ad20 \u00a0 \u00a0St\u00e4ndige \u00a0 Impfkommission \u00a0 (STIKO) \u00a0 (2017) \u00a0 Empfehlungen \u00a0 der \u00a0 st\u00e4ndigen \u00a0Impfkommission \u00a0am \u00a0Robert-\u00adKoch-\u00adInstitut \u00a0\u2013 \u00a02017/2018. \u00a0Epi \u00a0Bull \u00a034: \u00a0333-\u00ad80 \u00a0 \u00a0St\u00e4ndige \u00a0 Impfkommission \u00a0 (STIKO) \u00a0 (2018) \u00a0 Wissenschaftliche \u00a0 Begr\u00fcndung \u00a0 f\u00fcr \u00a0 die \u00a0Empfehlung \u00a0des \u00a0quadrivalenten \u00a0saisonalen \u00a0Influnzaimpfstoffes. \u00a0Epi \u00a0Bull \u00a02: \u00a019-\u00ad34 \u00a0 \u00a0St\u00f6hr \u00a0K \u00a0(2002) \u00a0Influenza-\u00adWHO \u00a0cares. \u00a0Lancet \u00a0Infect \u00a0Dis \u00a02:517 \u00a0 \u00a0\t\r \u00a092\t\r \u00a0Swartz \u00a0 MA, \u00a0 Hubbel \u00a0 JA, \u00a0 Reddy \u00a0 ST \u00a0 (2008) \u00a0 Lymphatic \u00a0 drainage \u00a0 function \u00a0 and \u00a0 it\u00b4s \u00a0immunological \u00a0implications: \u00a0From \u00a0dendritic \u00a0cell \u00a0homing \u00a0to \u00a0vaccine \u00a0design \u00a0(Review). \u00a0Semin \u00a0Immunol \u00a020: \u00a0147-\u00ad56 \u00a0 \u00a0Takla \u00a0 A, \u00a0 Wichmann \u00a0 O, \u00a0 Rieck \u00a0 T, \u00a0 Matysiak-\u00adKlose \u00a0 D \u00a0 (2014) \u00a0 Measles \u00a0 incidence \u00a0 and \u00a0reporting \u00a0trends \u00a0in \u00a0Germany, \u00a02007-\u00ad2011. \u00a0Bull \u00a0World \u00a0Health \u00a0Organ \u00a092:742-\u00ad49 \u00a0 \u00a0Toback \u00a0 SL, \u00a0 Levin \u00a0 MJ, \u00a0 Block \u00a0 SL, \u00a0 Belshe \u00a0 RB, \u00a0 Ambrose \u00a0 CS, \u00a0 Falloon \u00a0 J \u00a0 (2012) \u00a0Quadrivalent \u00a0 Ann \u00a0 Arbour \u00a0 Strain \u00a0 live-\u00adattenuated \u00a0 influenza \u00a0 vaccine. \u00a0 Expert \u00a0Rev \u00a0Vaccines \u00a011(11): \u00a01293-\u00ad303 \u00a0 \u00a0Trabacchi \u00a0 V, \u00a0 Odone \u00a0 A, \u00a0 Lillo \u00a0 L, \u00a0 Pasquarella \u00a0 C, \u00a0 Signorelli \u00a0 C \u00a0 (2015) \u00a0 Immunization \u00a0practices \u00a0in \u00a0athletes. \u00a0Acta \u00a0Biomed \u00a086: \u00a0181-\u00ad88 \u00a0 \u00a0Vesikari \u00a0T, \u00a0Karvonen \u00a0A, \u00a0Korhonen \u00a0T, \u00a0Edelman \u00a0K, \u00a0Vainonp\u00e4\u00e4 \u00a0R, \u00a0Salmi \u00a0A, \u00a0Saville \u00a0MK, \u00a0Cho \u00a0I, \u00a0Razmpour \u00a0A, \u00a0Rappaport \u00a0R, \u00a0O\u00b4Neill \u00a0R, \u00a0Georgiu \u00a0A, \u00a0Gruber \u00a0W, \u00a0Mendelman \u00a0PM, \u00a0Forrest \u00a0B, \u00a0CAIV-\u00adT \u00a0Transmission \u00a0Study \u00a0Group \u00a0(2006) \u00a0A \u00a0randomized, \u00a0double-\u00adblind \u00a0study \u00a0of \u00a0the \u00a0safety, \u00a0transmissibility \u00a0and \u00a0phenotypic \u00a0and \u00a0genotypic \u00a0stability \u00a0of \u00a0cold-\u00adadapted \u00a0influenza \u00a0virus \u00a0vaccine. \u00a0Pediatr \u00a0Dis \u00a0Infect \u00a0J \u00a025: \u00a0590-\u00ad95 \u00a0 \u00a0Victor \u00a0A, \u00a0Els\u00e4sser \u00a0A, \u00a0Hommel \u00a0G, \u00a0Blettner \u00a0M \u00a0(2010) \u00a0How \u00a0to \u00a0contend \u00a0with \u00a0the \u00a0problem \u00a0of \u00a0multiple \u00a0testing-\u00ad \u00a0Part \u00a010 \u00a0of \u00a0a \u00a0series \u00a0on \u00a0evaluation \u00a0of \u00a0scientific \u00a0publications. \u00a0Dtsch \u00a0Arztebl \u00a0Int \u00a0107(4): \u00a050-\u00ad56 \u00a0 \u00a0Vilella \u00a0 A, \u00a0 Dal-\u00adRe \u00a0 R, \u00a0 Simo \u00a0 D, \u00a0 Garcia-\u00adCorbeira \u00a0 P, \u00a0 Diego \u00a0 P, \u00a0 Bayas \u00a0 JM \u00a0 (2000) \u00a0Reactogenicity \u00a0profile \u00a0of \u00a0tetanus-\u00addiphteria \u00a0(adult-\u00adtype) \u00a0vaccine: \u00a0results \u00a0of \u00a0a \u00a0naturalisitc \u00a0study \u00a0performed \u00a0at \u00a0an \u00a0adult \u00a0vaccination \u00a0center. \u00a0J \u00a0Clin \u00a0Pharmacol \u00a040: \u00a01267-\u00ad73 \u00a0 \u00a0Whitham \u00a0M, \u00a0Blannin \u00a0AK \u00a0(2003) \u00a0The \u00a0effect \u00a0of \u00a0exercise \u00a0training \u00a0on \u00a0the \u00a0kinetics \u00a0oft \u00a0he \u00a0antibody \u00a0response \u00a0to \u00a0influenza \u00a0vaccination. \u00a0J \u00a0Sports \u00a0Sci \u00a021(12): \u00a0991-\u00ad1000 \u00a0 \u00a0Woods \u00a0JA, \u00a0Keylock \u00a0KT, \u00a0Lowder \u00a0T, \u00a0Viera \u00a0Vj, \u00a0Zelkovich \u00a0W, \u00a0Dumich \u00a0S, \u00a0Colantuano \u00a0K, \u00a0Lyons \u00a0 K, \u00a0 Leifheit \u00a0 K, \u00a0 Cook \u00a0 M, \u00a0 Chapman-\u00adNovakofski \u00a0 K, \u00a0 McAuley \u00a0 E \u00a0 (2009) \u00a0Cardiovascular \u00a0exercise \u00a0training \u00a0extends \u00a0influenza \u00a0vaccine \u00a0seroprotection \u00a0in \u00a0sedentary \u00a0\t\r \u00a093\t\r \u00a0older \u00a0adults: \u00a0The \u00a0immune \u00a0function \u00a0intervention \u00a0trial. \u00a0J \u00a0American \u00a0Geriatrics \u00a0Society \u00a057: \u00a02183-\u00ad91 \u00a0 \u00a0Yang \u00a0Y, \u00a0Verkuillen \u00a0J, \u00a0Rosengren \u00a0KS, \u00a0Mariani \u00a0RA, \u00a0Reed \u00a0M, \u00a0Grubisich \u00a0SA,Woods \u00a0JA \u00a0(2007) \u00a0Effects \u00a0of \u00a0Taiji \u00a0and \u00a0Qigong \u00a0intervention \u00a0on \u00a0the \u00a0antibody \u00a0response \u00a0to \u00a0influenza \u00a0vaccine \u00a0in \u00a0older \u00a0adults. \u00a0Am \u00a0J \u00a0Chin \u00a0Med \u00a035(4): \u00a0597-\u00ad607 \u00a0 \u00a0Young \u00a0 F, \u00a0 Marra \u00a0 F \u00a0 (2011) \u00a0 A \u00a0 systematic \u00a0 review \u00a0 of \u00a0 intradermal \u00a0 influenza \u00a0 vaccines. \u00a0Vaccine \u00a029 \u00a0(48): \u00a08788-\u00ad801 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\t\r \u00a094\t\r \u00a0Anhang \u00a0Einverst\u00e4ndniserkl\u00e4rung \u00a0Impftrain: \u00a0\n \n \n28.09.2016 | Seite 1 \nVersion 03 | 22.07.2016 \nImpfungen im leistungssportlichen Training \u2013 \u201eImpftrain\u201c - Aufkl\u00e4rung f\u00fcr erwachsene und jugendliche (>16 Jahre) Probandinnen und Probanden - Liebe Probandin, lieber Proband,  unsere Arbeitsgruppe besch\u00e4ftigt sich schon seit l\u00e4ngerer Zeit mit der menschlichen Immunant-wort auf bestimmte Krankheitserreger sowie deren Beeinflussbarkeit. Zu den zu ber\u00fccksichti-genden Einflussfaktoren z\u00e4hlt m\u00f6glicherweise auch leistungssportliche Aktivit\u00e4t. Die f\u00fcr Leis-tungssportler besonders bedeutsamen Schutzimpfungen e r f o r d e r n  e i n e  a d \u00e4 q u a t e  I m m u n a n t -wort, um voll wirksam zu sein. Daher befasst sich diese wissenschaftliche Studie mit den Aus-wirkungen einer Impfung bei Leistungssportlern.  In diesem Projekt soll beispielhaft die Reaktion auf eine Impfung gegen Grippe (\u201eInfluenza\u201c) un-tersucht werden. Ein Ziel dieser Analyse ist es, herauszufinden, inwieweit Leistungssportler in ihrer Immunfunktion beeintr\u00e4chtigt sind bzw. inwieweit leistungssportliches Training vor Imp-fung zu einer Beeintr\u00e4chtigung der Impfantwort oder der Impfvertr\u00e4glichkeit f\u00fchrt. Zur besseren Beurteilung der Ergebnisse sind auch Vergleichsmessungen an nicht leistungssportlich aktiven Kontrollpersonen notwendig.  Bei Teilnahme an der Studie erhalten Sie eine Grippeschutzimpfung, die f\u00fcr Leistungssportler von Fachgesellschaften als geboten angesehen und auch vom Robert Koch Institut f\u00fcr breite Be-v\u00f6lkerungskreise empfohlen wird. Zur Beschreibung der Immunantwort ben\u00f6tigen wir von Ihnen insgesamt vier Blutproben von je 13 ml (ca. 1,5 Essl\u00f6ffel; keine akute Beeintr\u00e4chtigung denk-bar). Die Blutentnahmen erfolgen vor Impfung sowie 1, 2 und 26 Wochen nach Impfung. Die Entnahme dieser Blutproben ist grunds\u00e4tzlich nur mit einem sehr geringen Risiko verbunden. An der Einstichstelle kann es zu leichten Schmerzen kommen oder es kann ein \"blauer Fleck\" (Blut-erguss) entstehen, der eventuell einige Tage sichtbar ist. In \u00e4u\u00dferst seltenen F\u00e4llen kann auch die Bildung eines Blutgerinnsels (Thrombose), eine \u00f6rtlich begrenzte Entz\u00fcndung oder eine In-fektion an der Einstichstelle auftreten oder es kann zu Sch\u00e4digungen von Blutgef\u00e4\u00dfen oder Ner-ven kommen.  Nebenwirkungen einer Grippeschutzimpfung sind \u00e4u\u00dferst selten. Im Nachgang einer Impfung kann es zu Schmerz an der Impfstelle und/oder zu allgemeinen Nebenwirkungen wie leichtes \t\r \u00a095\t\r \u00a0  \n \n28.09.2016 | Seite 2 \nVersion 03 | 22.07.2016 \nFieber, Ersch\u00f6pfung, Kopfschmerz, Muskelschmerzen oder Lymphknotenschwellungen kommen. Etwaige Nebenwirkungen werden in Form eines Fragebogens erfasst. Die im Rahmen der geplanten Studie erhobenen Daten werden in pseudonymisierter Form, also ohne Namensnennung, gesammelt und ausgewertet. Die Bestimmungen der \u00e4rztlichen Schwei-gepflicht und des Datenschutzes sind in vollem Umfang gew\u00e4hrleistet. Wir weisen jedoch darauf hin, dass zu Kontrollzwecken speziell autorisierten Pe rs one n eine Eins ichtnahm e in S tudie nun-terlagen gestattet wird, ohne dass die Pseudonymisierung aufgehoben wird. Mit Ihrer Einwilli-gung zur Teilnahme an der Studie willigen Sie auch in diese Offenlegung ein. Wir versichern Ih-nen jedoch, dass Ihre personenbezogenen Daten absolut vertraulich behandelt werden und nicht an die \u00d6ffentlichkeit gelangen.  Die Teilnahme an der Studie ist freiwillig. Die Ablehnung ebenso wie der Widerruf der Einwilli-gung ist ohne Nachteile m\u00f6glich. Im letzteren Falle besteht das Recht auf L\u00f6schung der bis dahin erhobenen Daten. F\u00fcr Ihre Mithilfe m\u00f6chten wir uns vorab herzlich bedanken.  \t\r \u00a096\t\r \u00a0    \n \n28.09.2016 | Seite 3 \nVersion 03 | 22.07.2016 \nImpfungen im leistungssportlichen Training \u2013 \u201eImpftrain\u201c -Einwilligungserkl\u00e4rung- Ich, ........................................................., geb. am ........................................., wurde ausrei-chend \u00fcber die aus meinem Blut durchgef\u00fchrten Bestimmungen informiert. Ich erkl\u00e4re meine Einwilligung zur Grippeschutzimpfung, zu den Blutentnahmen, sowie zur Verwendung der Probe und der daraus ermittelten Daten. Ich wurde dar\u00fcber aufgekl\u00e4rt, dass meine pers\u00f6nlichen Da-ten im klinischen Zentrum verbleiben; ihre Archivierung erfolgt nur in verschl\u00fcsselter Form, damit sich f\u00fcr Dritte kein Hinweis auf meine Identit\u00e4t ergeben kann. Ich wei\u00df, dass ich jeder-zeit meine Einwilligung ohne Angabe von Gr\u00fcnden zur\u00fcckziehen kann. Ich habe eine Kopie der Informationen und der Einwilligungserkl\u00e4rung erhalten.  ........................................... ................................................................. Datum  Unterschrift der Probandin/des Probanden  Bei Teilnehmenden <18 Jahren ........................................... ................................................................. Datum  Unterschrift(en) der/des Erziehungsberechtigen oder des/der gesetzlichen Vertreter(s)  ........................................... ................................................................. Datum  Unterschrift des aufkl\u00e4renden Arztes/ der aufkl\u00e4renden \u00c4rztin \t\r \u00a097\t\r \u00a0Nebenwirkungstagebuch: \u00a0 \n  \n  \n \n   \n Medikamente und behandelte Beschwerden bei Nebenwirkungen  Substanz  Dosis Indikation Datum Beginn  Datum Ende                                    Bemerkungen                  Tagebuch    Vertraulich   Name  Geburtsdatum     Datum der Impfung  ____________________   Liebe/r Teilnehmer/in, wir freuen uns, dass Sie an unserer Studie teilnehmen, in der wir untersuchen wollen, ob und ggf. wie leistungssportliches Training die Wirksamkeit und Nebenwirkungen einer Influenza-Impfung beeinflusst. Daher ist es erforderlich, dass Sie beiliegendes Nebenwirkungstagebuch ausf\u00fcllen. In diesem Tagebuch werden einerseits die L o ka lr e a k tio n e n  e r fa sst . D a z u  g e h \u00f6 r t m\u00f6glicherweise ein Schmerz, eine R\u00f6tung oder eine Schwellung an der Injektionsstelle. Im zweiten Teil des Tagebuches werden sog. \u201eAllgemeinreaktionen\u201c erfasst. Hierzu geh\u00f6ren Kopfschmerzen, Muskelschmerzen, Sch\u00fcttelfrost, \u00dcbelkeit und M\u00fcdigkeit. Wenn weitere Symptome auftreten sollten, k\u00f6nnen Sie diese unter \u201eSonstige\u201c ebenfalls eintragen. Bitte tragen Sie alle Beschwerden ein, auch wenn Sie denken, dass sie nicht im Zusammenhang mit der Impfung stehen. Sie bekommen von uns ein Thermometer, um die K\u00f6rpertemperatur zu messen. Bitte messen Sie im Mund \u00fcber 1 Minute. Dabei sollte das Thermometer unter der Zunge (entweder rechts oder links) platziert sein. Bitte messen Sie die Temperatur abends. Wenn Sie mehrmals am Tag messen, tragen Sie bitte die h\u00f6chste Temperatur ein. Wenn Sie den Durchmesser einer R\u00f6tung oder einer Schwellung messen, tragen Sie bitte auch dann den gr\u00f6\u00dften Durchmesser ein.  Bitte tragen Sie auch ein, wenn Sie Medikamente ben\u00f6tigen, um Nebenwirkungen zu behandeln. Wenn Sie keine Symptome haben, tragen Sie bitte eine \u201e0\u201c in die Felder ein.  Bitte lassen Sie uns das Tagebuch zukommen unter einer der folgenden Adressen (gerne auch als Foto per mail, oder gefaxt):   Institut f\u00fcr Sport und Pr\u00e4ventivmedizin   Institut f\u00fcr Mikrobiologie und Hygiene  Universit\u00e4t des Saarlandes    Haus 43 Campus, Geb\u00e4ude B8 2, Raum 0.07   Sekretariat Zimmer  66123 Saarbr\u00fccken    66421 Homburg/Saar Telefon: +49 (0) 681 302 70400   Telefon: +49 (0) 6841 162 3900 Fax: +49 (0) 681 302 4296    Fax:  +49 (0) 6841 162 3985 Tanja.Stenger@uni-saarland.de   Barbara.Gaertner@uks.eu   Wenn schwere oder unerwartete Reaktionen auftreten, kontaktieren Sie uns bitte sofort:  Telefonnummer: 0176-20913240 (Frau Dr. Tanja Stenger).   Vielen Dank f\u00fcr Ihre Hilfe.  \nBitte f\u00fcllen Sie die Tabelle aus   \n Lokale Beschwerden an der Einstichstelle  Tag der Impfung  Tag 1  Tag 2  Tag 3  Tag 4  Tag 5  Tag 6  Tag 7 Symptome nach Tag 7  H\u00e4lt noch nach 7 Tagen an?   Datum Letzter Tag mit Beschwerden   Maximaler Schweregrad Schmerzen  0 = Keine Schmerzen   1 = Schmerz bei Ber\u00fchrung  2 = Schmerz bei Bewegung des Armes  3 = Spontan schmerzhaft            !!!! nein  !!!! ja dd mmm yyyy   R\u00f6tung   Gr\u00f6\u00dfe in  mm Bitte geben Sie den gr\u00f6\u00dften Durchmesser an, wenn sie mehrmals am Tag nachmessen     ______ mm    ______ mm    ______ mm    ______ mm    ______ mm    ______ mm    ______ mm    ______ mm  !!!! nein  !!!! ja dd mmm yyyy  ______ mm Schwellung     ______ mm    ______ mm    ______ mm    ______ mm    ______ mm    ______ mm    ______ mm    ______ mm   !!!! nein  !!!! ja dd mmm yyyy   ______ mm  Andere (z.B. Stechen)     _________________  0 = Keine Symptome 1 = Mild: T\u00e4gliche Aktivit\u00e4ten nicht beeintr\u00e4chtigt  2 = Moderat: T\u00e4gliche Aktivit\u00e4ten beeintr\u00e4chtigt  3 =Schwer: T\u00e4gliche Aktivit\u00e4ten k\u00f6nnen nicht mehr durchgef\u00fchrt werden.                !!!! nein  !!!! ja dd mmm yyyy  Andere    _________________           !!!! nein !!!! ja dd mmm yyyy  Allgemeinreaktionen Schweregrad  Tag der Impfung Tag 1 Tag 2 Tag 3 Tag 4 Tag 5 Tag 6 Tag 7  H\u00e4lt noch nach 7 Tagen an?   Datum Letzter Tag mit Beschwerden   Maximaler Schweregrad K\u00f6rpertemperatur  (Mund) Bitte geben Sie die h\u00f6chste Temperatur an , wenn sie mehrmals am Tag nachmessen          !!!! nein !!!! ja dd mmm yyyy  Kopfschmerzen       0 = Keine Symptome 1 = Mild: T\u00e4gliche Aktivit\u00e4ten nicht beeintr\u00e4chtigt  2 = Moderat: T\u00e4gliche Aktivit\u00e4ten beeintr\u00e4chtigt  3 =Schwer: T\u00e4gliche Aktivit\u00e4ten k\u00f6nnen nicht mehr durchgef\u00fchrt werden.             !!!! nein !!!! ja dd mmm yyyy  Muskleschmerzen           !!!! nein !!!! ja dd mmm yyyy  Sch\u00fcttelfrost           !!!! nein !!!! ja dd mmm yyyy  \u00dcbelkeit           !!!! nein !!!! ja dd mmm yyyy  M\u00fcdigkeit           !!!! nein !!!! ja dd mmm yyyy  Andere  _________________          !!!! nein !!!! ja dd mmm yyyy  Andere   _________________          !!!! nein  !!!! ja dd mmm yyyy  \t\r \u00a098\t\r \u00a0\u201eTrainingstagebuch\u201c: \u00a0\n \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\nName: Training diary   Datum Uhrzeit Training   Trainingsinhalte Beeintr\u00e4chtigungen im Trainings- bzw.Wettkampfprozess (falls ja angekreuzt wird bitte die Probleme genauer beschreiben: Welcher Trainingsinhalt konnte warum nicht durchgef\u00fchrt werden?)           IMPFUNG   \u0000 nein \u0000 ja, und zwar:    \u0000 nein \u0000 ja, und zwar     \u0000 nein \u0000 ja, und zwar     \u0000 nein \u0000 ja, und zwar  \t\r \u00a099\t\r \u00a0Danksagung/ \u00a0Publikation \u00a0 \u00a0Mein \u00a0besonderer \u00a0Dank \u00a0gilt \u00a0meinem \u00a0Doktorvater \u00a0Herrn \u00a0Prof. \u00a0Dr. \u00a0med. \u00a0Tim \u00a0Meyer \u00a0f\u00fcr \u00a0die \u00a0M\u00f6glichkeit \u00a0an \u00a0seiner \u00a0Klinik \u00a0diese \u00a0sehr \u00a0interessante \u00a0Arbeit \u00a0anfertigen \u00a0zu \u00a0d\u00fcrfen \u00a0und \u00a0die \u00a0engagierte \u00a0und \u00a0wohlwollende \u00a0Betreuung \u00a0und \u00a0F\u00f6rderung \u00a0in \u00a0dieser \u00a0Zeit. \u00a0 \u00a0In \u00a0gleichem \u00a0Ma\u00dfe \u00a0m\u00f6chte \u00a0ich \u00a0meiner \u00a0Betreuerin \u00a0Frau \u00a0Dr. \u00a0med. \u00a0Tanja \u00a0Stenger \u00a0f\u00fcr \u00a0ihre \u00a0umfangreiche \u00a0Betreuung \u00a0w\u00e4hrend \u00a0der \u00a0Studie \u00a0als \u00a0auch \u00a0f\u00fcr \u00a0die \u00a0Unterst\u00fctzung \u00a0bei \u00a0der \u00a0Anfertigung \u00a0der \u00a0Arbeit \u00a0danken. \u00a0 \u00a0Des \u00a0Weiteren \u00a0m\u00f6chte \u00a0ich \u00a0mich \u00a0vielmals \u00a0bei \u00a0Frau \u00a0Prof. \u00a0Dr. \u00a0med. \u00a0Barbara \u00a0G\u00e4rtner \u00a0und \u00a0Herrn \u00a0Dr. \u00a0rer. \u00a0nat. \u00a0David \u00a0Schub \u00a0bedanken, \u00a0die \u00a0sich \u00a0die \u00a0Zeit \u00a0genommen \u00a0haben \u00a0um \u00a0mir \u00a0bei \u00a0der \u00a0statistischen \u00a0Auswertung \u00a0der \u00a0Daten \u00a0zu \u00a0helfen. \u00a0 \u00a0Zudem \u00a0Danke \u00a0ich \u00a0allen \u00a0Probanden \u00a0f\u00fcr \u00a0die \u00a0Bereitschaft \u00a0zur \u00a0Teilnahme \u00a0an \u00a0der \u00a0Studie. \u00a0 \u00a0Mein \u00a0 weiterer \u00a0 Dank \u00a0 geb\u00fchrt \u00a0 allen \u00a0 Mitarbeitern \u00a0 des \u00a0 Instituts \u00a0 f\u00fcr \u00a0 Sport-\u00ad \u00a0und \u00a0Pr\u00e4ventivmedizin \u00a0 der \u00a0 Universit\u00e4t \u00a0 des \u00a0 Saarlandes \u00a0 f\u00fcr \u00a0 ihre \u00a0 Unterst\u00fctzung \u00a0 und \u00a0Hilfsbereitschaft. \u00a0 \u00a0Zum \u00a0Schluss \u00a0m\u00f6chte \u00a0ich \u00a0meiner \u00a0Familie \u00a0danken, \u00a0die \u00a0immer \u00a0hinter \u00a0mir \u00a0stand \u00a0und \u00a0mir \u00a0die \u00a0Kraft \u00a0zur \u00a0Durchf\u00fchrung \u00a0dieser \u00a0Arbeit \u00a0gegeben \u00a0hat. \u00a0 \u00a0Eine \u00a0Publikation \u00a0eines \u00a0Manuskripts \u00a0mit \u00a0dem \u00a0Titel \u00a0\u201eImmune \u00a0response \u00a0and \u00a0risk \u00a0of \u00a0side \u00a0effects \u00a0after \u00a0influenza \u00a0vaccination \u00a0in \u00a0athletes\u201d \u00a0ist \u00a0geplant. \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}